CN113121575A - (substituted phenyl) (substituted pyrimidine) amino derivative and preparation method and pharmaceutical application thereof - Google Patents
(substituted phenyl) (substituted pyrimidine) amino derivative and preparation method and pharmaceutical application thereof Download PDFInfo
- Publication number
- CN113121575A CN113121575A CN202110329149.4A CN202110329149A CN113121575A CN 113121575 A CN113121575 A CN 113121575A CN 202110329149 A CN202110329149 A CN 202110329149A CN 113121575 A CN113121575 A CN 113121575A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- methyl
- amino
- pyrimidin
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 (substituted phenyl) (substituted pyrimidine) amino derivative Chemical class 0.000 title claims abstract description 456
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 147
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 34
- 239000013078 crystal Substances 0.000 claims abstract description 25
- 230000003287 optical effect Effects 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 284
- 229910052801 chlorine Inorganic materials 0.000 claims description 182
- 229910052731 fluorine Inorganic materials 0.000 claims description 181
- 229910052794 bromium Inorganic materials 0.000 claims description 148
- 229910052740 iodine Inorganic materials 0.000 claims description 138
- 229910052739 hydrogen Inorganic materials 0.000 claims description 124
- 125000005842 heteroatom Chemical group 0.000 claims description 107
- 125000001424 substituent group Chemical group 0.000 claims description 106
- 125000003545 alkoxy group Chemical group 0.000 claims description 95
- 125000000217 alkyl group Chemical group 0.000 claims description 92
- 150000003254 radicals Chemical class 0.000 claims description 92
- 229910052717 sulfur Inorganic materials 0.000 claims description 88
- 229910052760 oxygen Inorganic materials 0.000 claims description 76
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 67
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 56
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 50
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 32
- 125000002757 morpholinyl group Chemical group 0.000 claims description 32
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 29
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 27
- 125000004193 piperazinyl group Chemical group 0.000 claims description 26
- 125000003386 piperidinyl group Chemical group 0.000 claims description 22
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 claims description 22
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 18
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 125000002837 carbocyclic group Chemical group 0.000 claims description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 125000003277 amino group Chemical class 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
- 229910052698 phosphorus Inorganic materials 0.000 claims description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 7
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 229940077388 benzenesulfonate Drugs 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims 1
- 230000005496 eutectics Effects 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 390
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 223
- 238000006243 chemical reaction Methods 0.000 description 214
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 201
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 149
- 239000000460 chlorine Substances 0.000 description 136
- 239000007787 solid Substances 0.000 description 127
- 239000012074 organic phase Substances 0.000 description 107
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 98
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 98
- 238000004949 mass spectrometry Methods 0.000 description 98
- 239000000243 solution Substances 0.000 description 93
- 238000005160 1H NMR spectroscopy Methods 0.000 description 85
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 83
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 75
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 75
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 69
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 68
- 238000010898 silica gel chromatography Methods 0.000 description 57
- 125000003118 aryl group Chemical group 0.000 description 55
- 125000001072 heteroaryl group Chemical group 0.000 description 52
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 51
- 230000002829 reductive effect Effects 0.000 description 49
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 49
- 239000000203 mixture Substances 0.000 description 47
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 39
- 125000003003 spiro group Chemical group 0.000 description 37
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- 239000011541 reaction mixture Substances 0.000 description 36
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 32
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 32
- 239000012065 filter cake Substances 0.000 description 31
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 31
- 239000003208 petroleum Substances 0.000 description 31
- 238000000605 extraction Methods 0.000 description 29
- 235000019441 ethanol Nutrition 0.000 description 28
- 229960004756 ethanol Drugs 0.000 description 27
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 27
- 235000019270 ammonium chloride Nutrition 0.000 description 25
- 229910052757 nitrogen Inorganic materials 0.000 description 25
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
- 238000004440 column chromatography Methods 0.000 description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 22
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 22
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 21
- 239000000706 filtrate Substances 0.000 description 20
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 19
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- 229940117913 acrylamide Drugs 0.000 description 19
- 229920006395 saturated elastomer Polymers 0.000 description 19
- 239000012312 sodium hydride Substances 0.000 description 19
- 229910000104 sodium hydride Inorganic materials 0.000 description 19
- 150000001299 aldehydes Chemical class 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 18
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 18
- 235000017557 sodium bicarbonate Nutrition 0.000 description 18
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 17
- 239000008346 aqueous phase Substances 0.000 description 17
- 125000001188 haloalkyl group Chemical group 0.000 description 17
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 17
- 230000035772 mutation Effects 0.000 description 17
- 102200048955 rs121434569 Human genes 0.000 description 17
- 150000003573 thiols Chemical class 0.000 description 17
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 16
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 15
- FYSIGSQCZXQTIH-UHFFFAOYSA-N 4-fluoro-2-methoxy-5-nitroaniline Chemical compound COC1=CC(F)=C([N+]([O-])=O)C=C1N FYSIGSQCZXQTIH-UHFFFAOYSA-N 0.000 description 15
- 125000005110 aryl thio group Chemical group 0.000 description 15
- 239000010410 layer Substances 0.000 description 15
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 15
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 15
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 14
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 14
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 14
- 238000000926 separation method Methods 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 13
- 150000001733 carboxylic acid esters Chemical class 0.000 description 13
- 150000002148 esters Chemical class 0.000 description 13
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 13
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 13
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 13
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 13
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 12
- YJGKIMCJZOZIOQ-UHFFFAOYSA-N 3-(2-chloropyrimidin-4-yl)-1h-indole Chemical compound ClC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 YJGKIMCJZOZIOQ-UHFFFAOYSA-N 0.000 description 11
- 238000001035 drying Methods 0.000 description 11
- OLFHYKFISGHKLX-UHFFFAOYSA-N N-[2-[(1-aminocyclopropyl)methoxy]-5-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxyphenyl]prop-2-enamide Chemical compound NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C1=CNC2=CC=CC=C12)Cl)NC(C=C)=O OLFHYKFISGHKLX-UHFFFAOYSA-N 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- MBYZPCLOMQCIEV-UHFFFAOYSA-N 3-(2,5-dichloropyrimidin-4-yl)-1-methylindole Chemical compound C12=CC=CC=C2N(C)C=C1C1=NC(Cl)=NC=C1Cl MBYZPCLOMQCIEV-UHFFFAOYSA-N 0.000 description 9
- IWIIPOFGVHSGJK-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC Chemical compound ClC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC IWIIPOFGVHSGJK-UHFFFAOYSA-N 0.000 description 9
- LSAXAUHMKAFARK-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(CCN1CCCC1)C)OC)C1=CNC2=CC=CC=C12 Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(CCN1CCCC1)C)OC)C1=CNC2=CC=CC=C12 LSAXAUHMKAFARK-UHFFFAOYSA-N 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 229940121647 egfr inhibitor Drugs 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- IIBWXYHPBMUNJP-UHFFFAOYSA-N 3-(2-chloropyrimidin-4-yl)-1-methylindole Chemical compound C12=CC=CC=C2N(C)C=C1C1=CC=NC(Cl)=N1 IIBWXYHPBMUNJP-UHFFFAOYSA-N 0.000 description 8
- NAIQFJQMXDXVRV-UHFFFAOYSA-N 5-chloro-n-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methylindol-3-yl)pyrimidin-2-amine Chemical compound COC1=CC(F)=C([N+]([O-])=O)C=C1NC1=NC=C(Cl)C(C=2C3=CC=CC=C3N(C)C=2)=N1 NAIQFJQMXDXVRV-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- BFBRQEGSKHTTKV-UHFFFAOYSA-N 1-(6-aminoindol-1-yl)ethanone Chemical compound C1=C(N)C=C2N(C(=O)C)C=CC2=C1 BFBRQEGSKHTTKV-UHFFFAOYSA-N 0.000 description 7
- KGDIMUBURADHIJ-UHFFFAOYSA-N 1-(6-nitroindol-1-yl)ethanone Chemical compound C1=C([N+]([O-])=O)C=C2N(C(=O)C)C=CC2=C1 KGDIMUBURADHIJ-UHFFFAOYSA-N 0.000 description 7
- ATOACDJAVYRCKK-UHFFFAOYSA-N 2-ethyl-4-fluoro-5-nitroaniline Chemical compound C(C)C1=C(N)C=C(C(=C1)F)[N+](=O)[O-] ATOACDJAVYRCKK-UHFFFAOYSA-N 0.000 description 7
- FBEYVYDAVBOFOJ-UHFFFAOYSA-N 3-(2,5-dichloropyrimidin-4-yl)-1h-indole Chemical compound ClC1=NC=C(Cl)C(C=2C3=CC=CC=C3NC=2)=N1 FBEYVYDAVBOFOJ-UHFFFAOYSA-N 0.000 description 7
- PJLONOKQQCUQEO-UHFFFAOYSA-N 3-(2,5-dichloropyrimidin-4-yl)pyrazolo[1,5-a]pyridine Chemical compound ClC1=CN=C(Cl)N=C1C1=C2C=CC=CN2N=C1 PJLONOKQQCUQEO-UHFFFAOYSA-N 0.000 description 7
- ZBYUDAVXPCLAMR-UHFFFAOYSA-N 3-(2-chloropyrimidin-4-yl)-7-fluoro-1h-indole Chemical compound C=1NC=2C(F)=CC=CC=2C=1C1=CC=NC(Cl)=N1 ZBYUDAVXPCLAMR-UHFFFAOYSA-N 0.000 description 7
- CDGIWYMFRIJCIR-UHFFFAOYSA-N 4-(1h-indol-6-yl)morpholine Chemical compound C1COCCN1C1=CC=C(C=CN2)C2=C1 CDGIWYMFRIJCIR-UHFFFAOYSA-N 0.000 description 7
- XJVRZKOALGOGJF-UHFFFAOYSA-N 4-(3-iodo-5-nitrophenyl)morpholine Chemical compound [O-][N+](=O)C1=CC(I)=CC(N2CCOCC2)=C1 XJVRZKOALGOGJF-UHFFFAOYSA-N 0.000 description 7
- MCKAZCQKSORSST-GQCTYLIASA-N 4-[(e)-2-butoxyethenyl]-2,5-dichloropyrimidine Chemical compound CCCCO\C=C\C1=NC(Cl)=NC=C1Cl MCKAZCQKSORSST-GQCTYLIASA-N 0.000 description 7
- XXCHECRMFVJARZ-CQSZACIVSA-N 5-chloro-N-[4-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-2-methoxy-5-nitrophenyl]-4-(4-fluoro-1H-indol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)[N+](=O)[O-])N1C[C@@H](CC1)N(C)C)OC)C1=CNC2=CC=CC(=C12)F XXCHECRMFVJARZ-CQSZACIVSA-N 0.000 description 7
- HEPUGCPYBBSLEQ-UHFFFAOYSA-N 5-chloro-N-[4-[2-(dimethylamino)ethoxy]-2-methoxy-5-nitrophenyl]-4-(1-methylindol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)[N+](=O)[O-])OCCN(C)C)OC)C1=CN(C2=CC=CC=C12)C HEPUGCPYBBSLEQ-UHFFFAOYSA-N 0.000 description 7
- KWRKMKVXMRSNSR-UHFFFAOYSA-N CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CC2(CCCN2C)CC1)OC Chemical compound CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CC2(CCCN2C)CC1)OC KWRKMKVXMRSNSR-UHFFFAOYSA-N 0.000 description 7
- OKKMTGLRUTVBPP-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CN(C2=CC(=CC=C12)N1CCOCC1)C)Cl Chemical compound ClC1=NC=C(C(=N1)C1=CN(C2=CC(=CC=C12)N1CCOCC1)C)Cl OKKMTGLRUTVBPP-UHFFFAOYSA-N 0.000 description 7
- UTFXUULHRUUERR-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CNC2=CC(=CC=C12)N1CCOCC1)Cl Chemical compound ClC1=NC=C(C(=N1)C1=CNC2=CC(=CC=C12)N1CCOCC1)Cl UTFXUULHRUUERR-UHFFFAOYSA-N 0.000 description 7
- RXOWLBCAIHPWBD-UHFFFAOYSA-N ClC1=NC=CC(=N1)C1=CN(C2=C(C=CC=C12)F)C Chemical compound ClC1=NC=CC(=N1)C1=CN(C2=C(C=CC=C12)F)C RXOWLBCAIHPWBD-UHFFFAOYSA-N 0.000 description 7
- PRDDMOVIAYJQEH-UHFFFAOYSA-N ClC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C(F)F Chemical compound ClC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C(F)F PRDDMOVIAYJQEH-UHFFFAOYSA-N 0.000 description 7
- NCIQRLKSQDZMEI-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)[N+](=O)[O-])F)OC)C1=CNC2=CC=CC(=C12)F Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)[N+](=O)[O-])F)OC)C1=CNC2=CC=CC(=C12)F NCIQRLKSQDZMEI-UHFFFAOYSA-N 0.000 description 7
- GLXOBMRIYCPWHU-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)[N+](=O)[O-])N(CCN1CCCC1)C)OC)C1=CNC2=CC=CC=C12 Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)[N+](=O)[O-])N(CCN1CCCC1)C)OC)C1=CNC2=CC=CC=C12 GLXOBMRIYCPWHU-UHFFFAOYSA-N 0.000 description 7
- XTHLRMSFLXONCB-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)[N+](=O)[O-])N1CC2(CCCN2C)CC1)OC)C=1C=NN2C=1C=CC=C2 Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)[N+](=O)[O-])N1CC2(CCCN2C)CC1)OC)C=1C=NN2C=1C=CC=C2 XTHLRMSFLXONCB-UHFFFAOYSA-N 0.000 description 7
- QGGWTVXCJCDICX-UHFFFAOYSA-N FC(N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC1=C(C=C(C(=C1)[N+](=O)[O-])F)OC)F Chemical compound FC(N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC1=C(C=C(C(=C1)[N+](=O)[O-])F)OC)F QGGWTVXCJCDICX-UHFFFAOYSA-N 0.000 description 7
- DVBFIBOOYOMVOL-UHFFFAOYSA-N FC(OC1=C(C=C(C(=C1)F)[N+](=O)[O-])N)F Chemical compound FC(OC1=C(C=C(C(=C1)F)[N+](=O)[O-])N)F DVBFIBOOYOMVOL-UHFFFAOYSA-N 0.000 description 7
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 7
- SZTYQQYYIMVETL-UHFFFAOYSA-N n-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methylindol-3-yl)pyrimidin-2-amine Chemical compound COC1=CC(F)=C([N+]([O-])=O)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 SZTYQQYYIMVETL-UHFFFAOYSA-N 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 6
- GAACDHAQGPPAQF-UHFFFAOYSA-N 3-morpholin-4-yl-5-nitroaniline Chemical compound [O-][N+](=O)C1=CC(N)=CC(N2CCOCC2)=C1 GAACDHAQGPPAQF-UHFFFAOYSA-N 0.000 description 6
- CUQVRFYIORCJIJ-UHFFFAOYSA-N 5-chloro-N-(2-ethyl-4-fluoro-5-nitrophenyl)-4-(1-methylindol-3-yl)pyrimidin-2-amine Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)[N+](=O)[O-])F)CC)C1=CN(C2=CC=CC=C12)C CUQVRFYIORCJIJ-UHFFFAOYSA-N 0.000 description 6
- UUSMGTHYILTPJD-UHFFFAOYSA-N 5-chloro-n-(4-fluoro-2-methoxy-5-nitrophenyl)-4-pyrazolo[1,5-a]pyridin-3-ylpyrimidin-2-amine Chemical compound COC1=CC(F)=C([N+]([O-])=O)C=C1NC1=NC=C(Cl)C(C2=C3C=CC=CN3N=C2)=N1 UUSMGTHYILTPJD-UHFFFAOYSA-N 0.000 description 6
- FGKRLLOIOVIBPS-UHFFFAOYSA-N CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC1=CC(=CC(=C1)N1CCOCC1)N Chemical compound CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC1=CC(=CC(=C1)N1CCOCC1)N FGKRLLOIOVIBPS-UHFFFAOYSA-N 0.000 description 6
- RFXWJYQWTVIDQM-UHFFFAOYSA-N CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC1=CC(=CC(=C1)[N+](=O)[O-])N1CCOCC1 Chemical compound CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC1=CC(=CC(=C1)[N+](=O)[O-])N1CCOCC1 RFXWJYQWTVIDQM-UHFFFAOYSA-N 0.000 description 6
- AYZPWKLWWXNKNI-UHFFFAOYSA-N CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(N)C=1)N1CC2(CCCN2C)CC1)OC Chemical compound CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(N)C=1)N1CC2(CCCN2C)CC1)OC AYZPWKLWWXNKNI-UHFFFAOYSA-N 0.000 description 6
- FISDBNOZDIERFT-UHFFFAOYSA-N COC1=C(C=C(C(=C1)N(CCN1CCCC1)C)N)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C Chemical compound COC1=C(C=C(C(=C1)N(CCN1CCCC1)C)N)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C FISDBNOZDIERFT-UHFFFAOYSA-N 0.000 description 6
- OMDAWDQWPVAWJE-UHFFFAOYSA-N COC1=CC(=C(C=C1NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)N)OCCN1CCOCC1 Chemical compound COC1=CC(=C(C=C1NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)N)OCCN1CCOCC1 OMDAWDQWPVAWJE-UHFFFAOYSA-N 0.000 description 6
- QAUDCRIMNLAUBM-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)[N+](=O)[O-])OCCN1CCN(CC1)C)OC)C1=CN(C2=CC=CC=C12)C Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)[N+](=O)[O-])OCCN1CCN(CC1)C)OC)C1=CN(C2=CC=CC=C12)C QAUDCRIMNLAUBM-UHFFFAOYSA-N 0.000 description 6
- DKMXRWUBAHBTIF-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(N)C=1)N1CC2(CCCN2C)CC1)OC)C=1C=NN2C=1C=CC=C2 Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(N)C=1)N1CC2(CCCN2C)CC1)OC)C=1C=NN2C=1C=CC=C2 DKMXRWUBAHBTIF-UHFFFAOYSA-N 0.000 description 6
- PMAHRNDQIALIDN-UHFFFAOYSA-N FC=1C=CC=C2C(=CN(C=12)C)C1=NC(=NC=C1)NC1=C(C=C(C(=C1)[N+](=O)[O-])F)OC Chemical compound FC=1C=CC=C2C(=CN(C=12)C)C1=NC(=NC=C1)NC1=C(C=C(C(=C1)[N+](=O)[O-])F)OC PMAHRNDQIALIDN-UHFFFAOYSA-N 0.000 description 6
- BYLIDULLJGZOBA-UHFFFAOYSA-N N-[4-methoxy-5-[[4-(1-methylindol-3-yl)pyridin-2-yl]amino]-2-[methyl(2-pyrrolidin-1-ylethyl)amino]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=C(C=C(C(=C1)NC1=NC=CC(=C1)C1=CN(C2=CC=CC=C12)C)OC)N(CCN1CCCC1)C BYLIDULLJGZOBA-UHFFFAOYSA-N 0.000 description 6
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical class CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 150000002367 halogens Chemical group 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 6
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- FSUBWLJEAIKUNC-FNORWQNLSA-N 4-[(E)-2-butoxyethenyl]-2-chloro-5-methoxypyrimidine Chemical compound C(CCC)O/C=C/C1=NC(=NC=C1OC)Cl FSUBWLJEAIKUNC-FNORWQNLSA-N 0.000 description 5
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 5
- AMARRLPHSCFJJY-UHFFFAOYSA-N 5-(difluoromethoxy)-1-N-[2-(dimethylamino)ethyl]-1-N-methyl-4-N-[4-(1-methylindol-3-yl)pyrimidin-2-yl]benzene-1,2,4-triamine Chemical compound FC(OC1=C(C=C(C(=C1)N(C)CCN(C)C)N)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)F AMARRLPHSCFJJY-UHFFFAOYSA-N 0.000 description 5
- PNYYRBPFTYDAGC-UHFFFAOYSA-N 5-chloro-n-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1h-indol-3-yl)pyrimidin-2-amine Chemical compound COC1=CC(F)=C([N+]([O-])=O)C=C1NC1=NC=C(Cl)C(C=2C3=CC=CC=C3NC=2)=N1 PNYYRBPFTYDAGC-UHFFFAOYSA-N 0.000 description 5
- AYGZLVYOUQERGX-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1(CC1)CN(C1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C1=CNC2=CC=CC=C12)Cl)NC(C=C)=O)C Chemical compound C(C)(C)(C)OC(=O)NC1(CC1)CN(C1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C1=CNC2=CC=CC=C12)Cl)NC(C=C)=O)C AYGZLVYOUQERGX-UHFFFAOYSA-N 0.000 description 5
- JHJRAXIFPUMADJ-UHFFFAOYSA-N C(C)(C)(C)OC(NC1(CC1)CN(C)C1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C1=CNC2=CC=CC=C12)Cl)N)=O Chemical compound C(C)(C)(C)OC(NC1(CC1)CN(C)C1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C1=CNC2=CC=CC=C12)Cl)N)=O JHJRAXIFPUMADJ-UHFFFAOYSA-N 0.000 description 5
- QFYXRZBYFGYIKX-UHFFFAOYSA-N C(C)(C)(C)OC(NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)Cl)N)=O Chemical compound C(C)(C)(C)OC(NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)Cl)N)=O QFYXRZBYFGYIKX-UHFFFAOYSA-N 0.000 description 5
- UVWKZHYJMKNPIY-UHFFFAOYSA-N C(C)(C)(C)OC(NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)Cl)[N+](=O)[O-])=O Chemical compound C(C)(C)(C)OC(NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)Cl)[N+](=O)[O-])=O UVWKZHYJMKNPIY-UHFFFAOYSA-N 0.000 description 5
- NWFMRSUUZCLJCV-UHFFFAOYSA-N C(C)(C)(C)OC(NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)Cl)N)=O Chemical compound C(C)(C)(C)OC(NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)Cl)N)=O NWFMRSUUZCLJCV-UHFFFAOYSA-N 0.000 description 5
- MBIPGSXETQSIQU-UHFFFAOYSA-N C(C)(C)(C)OC(NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)Cl)[N+](=O)[O-])=O Chemical compound C(C)(C)(C)OC(NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)Cl)[N+](=O)[O-])=O MBIPGSXETQSIQU-UHFFFAOYSA-N 0.000 description 5
- PPKNEKOHHYXDAM-UHFFFAOYSA-N C(C)(C)(C)OC(NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)N)=O Chemical compound C(C)(C)(C)OC(NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)N)=O PPKNEKOHHYXDAM-UHFFFAOYSA-N 0.000 description 5
- QRBBACVXNJPPFD-UHFFFAOYSA-N C(C)(C)(C)OC(NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)=O Chemical compound C(C)(C)(C)OC(NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)=O QRBBACVXNJPPFD-UHFFFAOYSA-N 0.000 description 5
- BMANLRDUYBPMRT-UHFFFAOYSA-N C(C)(C)(C)OC(NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)[N+](=O)[O-])=O Chemical compound C(C)(C)(C)OC(NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)[N+](=O)[O-])=O BMANLRDUYBPMRT-UHFFFAOYSA-N 0.000 description 5
- VUSFMAXJCFESGG-UHFFFAOYSA-N C(C)(C)(C)OC(NC1=C(C=C(C=C1)F)OC(F)F)=O Chemical compound C(C)(C)(C)OC(NC1=C(C=C(C=C1)F)OC(F)F)=O VUSFMAXJCFESGG-UHFFFAOYSA-N 0.000 description 5
- YBLNRULFWIHAQQ-UHFFFAOYSA-N CN(CCN(C1=C(C(=C(C=C1[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OC)F)C)C Chemical compound CN(CCN(C1=C(C(=C(C=C1[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OC)F)C)C YBLNRULFWIHAQQ-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- ZVNAKXHINTUNKN-MRXNPFEDSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1C[C@@H](CC1)N(C)C)OC)C1=CNC2=CC=CC(=C12)F Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1C[C@@H](CC1)N(C)C)OC)C1=CNC2=CC=CC(=C12)F ZVNAKXHINTUNKN-MRXNPFEDSA-N 0.000 description 5
- SXYRQENJPZFCGB-UHFFFAOYSA-N FC(N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C=C(C(=CC=1OC)N(C)CCN(C)C)N)F Chemical compound FC(N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C=C(C(=CC=1OC)N(C)CCN(C)C)N)F SXYRQENJPZFCGB-UHFFFAOYSA-N 0.000 description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 5
- 229960002584 gefitinib Drugs 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- IMULAGMFJNNKJW-UHFFFAOYSA-N tert-butyl 4-(1H-indol-6-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)c1ccc2cc[nH]c2c1 IMULAGMFJNNKJW-UHFFFAOYSA-N 0.000 description 5
- SQWVONNABCKWFG-UHFFFAOYSA-N tert-butyl N-[1-[[4-[(5-chloro-4-pyrazolo[1,5-a]pyridin-3-ylpyrimidin-2-yl)amino]-5-methoxy-2-(prop-2-enoylamino)phenoxy]methyl]cyclopropyl]carbamate Chemical compound C(C)(C)(C)OC(NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)Cl)NC(C=C)=O)=O SQWVONNABCKWFG-UHFFFAOYSA-N 0.000 description 5
- MLIWTUIROTUNPM-UHFFFAOYSA-N tert-butyl N-[1-[[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-5-methoxy-2-(prop-2-enoylamino)phenoxy]methyl]cyclopropyl]carbamate Chemical compound C(C)(C)(C)OC(=O)NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C1=CNC2=CC=CC=C12)Cl)NC(C=C)=O MLIWTUIROTUNPM-UHFFFAOYSA-N 0.000 description 5
- CMYGQTFQGSRGLO-UHFFFAOYSA-N tert-butyl n-(4-fluoro-2-hydroxyphenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(F)C=C1O CMYGQTFQGSRGLO-UHFFFAOYSA-N 0.000 description 5
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 5
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 4
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- WWJBEAQAZRTTDK-UHFFFAOYSA-N C(C)(C)(C)N1C=C(C2=C(C=CC=C12)F)C1=NC(=NC=C1Cl)Cl Chemical compound C(C)(C)(C)N1C=C(C2=C(C=CC=C12)F)C1=NC(=NC=C1Cl)Cl WWJBEAQAZRTTDK-UHFFFAOYSA-N 0.000 description 4
- ZEDUKIYKRFOLQS-UHFFFAOYSA-N C(C)(C)(C)OC(NC1(CC1)CN(C)C1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C1=CNC2=CC=CC=C12)Cl)[N+](=O)[O-])=O Chemical compound C(C)(C)(C)OC(NC1(CC1)CN(C)C1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C1=CNC2=CC=CC=C12)Cl)[N+](=O)[O-])=O ZEDUKIYKRFOLQS-UHFFFAOYSA-N 0.000 description 4
- ZCMZICPSGZFPDJ-UHFFFAOYSA-N C(C=C)(=O)NC=1C=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC(=CC=C12)N1CCN(CC1)C(=O)OC(C)(C)C)C)Cl)OC Chemical compound C(C=C)(=O)NC=1C=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC(=CC=C12)N1CCN(CC1)C(=O)OC(C)(C)C)C)Cl)OC ZCMZICPSGZFPDJ-UHFFFAOYSA-N 0.000 description 4
- FTJALZNAQYVJNB-UHFFFAOYSA-N CN(C1CN(C)CC1)C(C([N+]([O-])=O)=CC1(C2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)N)=CC1OC Chemical compound CN(C1CN(C)CC1)C(C([N+]([O-])=O)=CC1(C2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)N)=CC1OC FTJALZNAQYVJNB-UHFFFAOYSA-N 0.000 description 4
- IBJHNSDFWCXKHF-UHFFFAOYSA-N CN(CCC1(C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=C(C=CC=C12)F)C)N)NC)C Chemical compound CN(CCC1(C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=C(C=CC=C12)F)C)N)NC)C IBJHNSDFWCXKHF-UHFFFAOYSA-N 0.000 description 4
- XHJDSKVMBGRBES-UHFFFAOYSA-N CN(CCN(C1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=C(C=CC=C12)F)C)NC(C=C)=O)C)C Chemical compound CN(CCN(C1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=C(C=CC=C12)F)C)NC(C=C)=O)C)C XHJDSKVMBGRBES-UHFFFAOYSA-N 0.000 description 4
- MIRQZCNDHGBLTG-UHFFFAOYSA-N COC1=C(C=C(C(=C1)OCCN1CCOCC1)[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C Chemical compound COC1=C(C=C(C(=C1)OCCN1CCOCC1)[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C MIRQZCNDHGBLTG-UHFFFAOYSA-N 0.000 description 4
- MVZWHQHOIBEESD-UHFFFAOYSA-N COC1=CC(=C(C=C1NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)N(C1CN(CC1)C)C Chemical compound COC1=CC(=C(C=C1NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)N(C1CN(CC1)C)C MVZWHQHOIBEESD-UHFFFAOYSA-N 0.000 description 4
- BVMLLOALCWDQNN-UHFFFAOYSA-N COC1=CC(=C(C=C1NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)OCCN1CCOCC1 Chemical compound COC1=CC(=C(C=C1NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)OCCN1CCOCC1 BVMLLOALCWDQNN-UHFFFAOYSA-N 0.000 description 4
- YOCQHPYZUFLVGB-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC)C1=CNC2=CC=CC(=C12)F Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC)C1=CNC2=CC=CC(=C12)F YOCQHPYZUFLVGB-UHFFFAOYSA-N 0.000 description 4
- IBAOGBXHZJHYIA-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CC2(CCCN2C)CC1)OC)C=1C=NN2C=1C=CC=C2 Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CC2(CCCN2C)CC1)OC)C=1C=NN2C=1C=CC=C2 IBAOGBXHZJHYIA-UHFFFAOYSA-N 0.000 description 4
- SXLJQIXBDAIJPH-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)OCCN(C)C)OC)C1=CN(C2=CC=CC=C12)C Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)OCCN(C)C)OC)C1=CN(C2=CC=CC=C12)C SXLJQIXBDAIJPH-UHFFFAOYSA-N 0.000 description 4
- LBIRAULBTSKULT-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)OCCN1CCN(CC1)C)OC)C1=CN(C2=CC=CC=C12)C Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)OCCN1CCN(CC1)C)OC)C1=CN(C2=CC=CC=C12)C LBIRAULBTSKULT-UHFFFAOYSA-N 0.000 description 4
- VKHGCOABPWQRBN-MRXNPFEDSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)O[C@H]1CN(CC1)C)OC)C=1C=NN2C=1C=CC=C2 Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)O[C@H]1CN(CC1)C)OC)C=1C=NN2C=1C=CC=C2 VKHGCOABPWQRBN-MRXNPFEDSA-N 0.000 description 4
- XDECVSCXEVTPLB-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C=C(C=CC=1OC)NC(C=C)=O)C1=CN(C2=CC(=CC=C12)N1CCN(CC1)C)C Chemical compound ClC=1C(=NC(=NC=1)NC=1C=C(C=CC=1OC)NC(C=C)=O)C1=CN(C2=CC(=CC=C12)N1CCN(CC1)C)C XDECVSCXEVTPLB-UHFFFAOYSA-N 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 4
- WTHYYRVWMUXGJD-UHFFFAOYSA-N FC(N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC1=C(C=C(C(=C1)[N+](=O)[O-])N(C)CCN(C)C)OC)F Chemical compound FC(N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC1=C(C=C(C(=C1)[N+](=O)[O-])N(C)CCN(C)C)OC)F WTHYYRVWMUXGJD-UHFFFAOYSA-N 0.000 description 4
- XZKGCKLLBHVTQT-UHFFFAOYSA-N FC(OC1=CC(=C(C=C1NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)N(C)CCN(C)C)F Chemical compound FC(OC1=CC(=C(C=C1NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)N(C)CCN(C)C)F XZKGCKLLBHVTQT-UHFFFAOYSA-N 0.000 description 4
- FSUGTZGZVQWFDN-UHFFFAOYSA-N FC1=C(C=C(C=C1)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC)[N+](=O)[O-] Chemical compound FC1=C(C=C(C=C1)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC)[N+](=O)[O-] FSUGTZGZVQWFDN-UHFFFAOYSA-N 0.000 description 4
- STDRQCMGNLAJQZ-UHFFFAOYSA-N FC1=CC(=C(C=C1[N+](=O)[O-])NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC)OC Chemical compound FC1=CC(=C(C=C1[N+](=O)[O-])NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC)OC STDRQCMGNLAJQZ-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 4
- 229910010084 LiAlH4 Inorganic materials 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- QHVVRLXRLQVAMG-UHFFFAOYSA-N NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O Chemical compound NC1(CC1)COC1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O QHVVRLXRLQVAMG-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940043279 diisopropylamine Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229960001433 erlotinib Drugs 0.000 description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- CZGIEJXGCLWRPY-UHFFFAOYSA-N n,1-dimethylpyrrolidin-3-amine Chemical compound CNC1CCN(C)C1 CZGIEJXGCLWRPY-UHFFFAOYSA-N 0.000 description 4
- GYGYDOOXVKDZCF-UHFFFAOYSA-N n-methyl-2-pyrrolidin-1-ylethanamine Chemical compound CNCCN1CCCC1 GYGYDOOXVKDZCF-UHFFFAOYSA-N 0.000 description 4
- 235000011056 potassium acetate Nutrition 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
- 125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 3
- 125000001627 3 membered heterocyclic group Chemical group 0.000 description 3
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 3
- JPKDKYZYDUDPIH-UHFFFAOYSA-N CN(C1CN(C)CC1)C(C=C(C(C1)(C2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)N)OC)=C1N Chemical compound CN(C1CN(C)CC1)C(C=C(C(C1)(C2=NC=CC(C3=CN(C)C4=CC=CC=C34)=N2)N)OC)=C1N JPKDKYZYDUDPIH-UHFFFAOYSA-N 0.000 description 3
- DBFIWCKRIGXQCK-UHFFFAOYSA-N ClC1=NC=C(C(=N1)C1=CNC2=CC=CC(=C12)F)Cl Chemical compound ClC1=NC=C(C(=N1)C1=CNC2=CC=CC(=C12)F)Cl DBFIWCKRIGXQCK-UHFFFAOYSA-N 0.000 description 3
- JQAHSJDTQHKAFZ-UHFFFAOYSA-N ClC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C(C)C Chemical compound ClC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C(C)C JQAHSJDTQHKAFZ-UHFFFAOYSA-N 0.000 description 3
- XCQVNTTWNRALCM-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)[N+](=O)[O-])N(C)CCN(C)C)CC)C1=CN(C2=CC=CC=C12)C Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)[N+](=O)[O-])N(C)CCN(C)C)CC)C1=CN(C2=CC=CC=C12)C XCQVNTTWNRALCM-UHFFFAOYSA-N 0.000 description 3
- AUGWLVWXZLEIKZ-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)CC)C1=CN(C2=CC=CC=C12)C Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)CC)C1=CN(C2=CC=CC=C12)C AUGWLVWXZLEIKZ-UHFFFAOYSA-N 0.000 description 3
- XBWKSABTVIFNKA-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(N)C=1)N(CCN1CCCC1)C)OC)C1=CNC2=CC=CC=C12 Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(N)C=1)N(CCN1CCCC1)C)OC)C1=CNC2=CC=CC=C12 XBWKSABTVIFNKA-UHFFFAOYSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- XYCTYOWOVPXOGU-UHFFFAOYSA-N FC(N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC)F Chemical compound FC(N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC)F XYCTYOWOVPXOGU-UHFFFAOYSA-N 0.000 description 3
- KMAUSBDZCZBLTN-UHFFFAOYSA-N FC=1C(=C(C=C(C=1F)[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OC Chemical compound FC=1C(=C(C=C(C=1F)[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OC KMAUSBDZCZBLTN-UHFFFAOYSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 3
- CQHOBDXHDPNDSA-UHFFFAOYSA-N N-[5-[(5-chloro-4-pyrazolo[1,5-a]pyridin-3-ylpyrimidin-2-yl)amino]-2-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]prop-2-enamide Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)OCCN(C)C)OC)C=1C=NN2C=1C=CC=C2 CQHOBDXHDPNDSA-UHFFFAOYSA-N 0.000 description 3
- UEEJHVSXFDXPFK-UHFFFAOYSA-O N-dimethylethanolamine Chemical compound C[NH+](C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-O 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- VHHPDZDTKZOHTB-UHFFFAOYSA-M [Br-].[Mg+]C.C1CCOC1 Chemical compound [Br-].[Mg+]C.C1CCOC1 VHHPDZDTKZOHTB-UHFFFAOYSA-M 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 229960003121 arginine Drugs 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 3
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical class CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940125833 compound 23 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 229940125846 compound 25 Drugs 0.000 description 3
- 229940125851 compound 27 Drugs 0.000 description 3
- 229940127204 compound 29 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 229960002887 deanol Drugs 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- 239000012972 dimethylethanolamine Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical class C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 239000004323 potassium nitrate Substances 0.000 description 3
- 235000010333 potassium nitrate Nutrition 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 150000003248 quinolines Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 3
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical class CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IOJVEFAZDJENGW-UHFFFAOYSA-N 1-N-[2-(dimethylamino)ethyl]-6-fluoro-5-methoxy-1-N-methyl-4-N-[4-(1-methylindol-3-yl)pyrimidin-2-yl]benzene-1,2,4-triamine Chemical compound CN(CCN(C=1C(=CC(=C(C=1F)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)N)C)C IOJVEFAZDJENGW-UHFFFAOYSA-N 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical group CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- MXPYCSFCKXSPAB-UHFFFAOYSA-N 1-fluoro-3-iodo-5-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=CC(I)=C1 MXPYCSFCKXSPAB-UHFFFAOYSA-N 0.000 description 2
- ADMXMXNXEITSAX-UHFFFAOYSA-N 1-methyl-1,7-diazaspiro[4.4]nonane Chemical compound CN1CCCC11CNCC1 ADMXMXNXEITSAX-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 2
- ZTHHRSBDBPCCMZ-UHFFFAOYSA-N 2,4-dichloro-5-methoxypyrimidine Chemical compound COC1=CN=C(Cl)N=C1Cl ZTHHRSBDBPCCMZ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 2
- AFCGCODEEUFDAF-UHFFFAOYSA-N 2-ethyl-4-fluoroaniline Chemical compound CCC1=CC(F)=CC=C1N AFCGCODEEUFDAF-UHFFFAOYSA-N 0.000 description 2
- 125000006024 2-pentenyl group Chemical group 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- ZWKIJOPJWWZLDI-UHFFFAOYSA-N 4-fluoro-1h-indole Chemical compound FC1=CC=CC2=C1C=CN2 ZWKIJOPJWWZLDI-UHFFFAOYSA-N 0.000 description 2
- BNRRMRUVYDETQC-UHFFFAOYSA-N 4-fluoro-2-methoxyaniline Chemical compound COC1=CC(F)=CC=C1N BNRRMRUVYDETQC-UHFFFAOYSA-N 0.000 description 2
- PSWCIARYGITEOY-UHFFFAOYSA-N 6-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2C=CNC2=C1 PSWCIARYGITEOY-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- OKVPOTDQCYGQGJ-UHFFFAOYSA-N CN(C)CCN(C)C(C([N+]([O-])=O)=CC1(C(N=C2C3=CNC4=CC=CC(F)=C34)=NC=C2Cl)N)=CC1OC Chemical compound CN(C)CCN(C)C(C([N+]([O-])=O)=CC1(C(N=C2C3=CNC4=CC=CC(F)=C34)=NC=C2Cl)N)=CC1OC OKVPOTDQCYGQGJ-UHFFFAOYSA-N 0.000 description 2
- GLDAJVZHHFIMPX-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(C1)(C2=NC=CC(C3=CN(C(F)F)C4=CC=CC=C34)=N2)N)OC)=C1N Chemical compound CN(C)CCN(C)C(C=C(C(C1)(C2=NC=CC(C3=CN(C(F)F)C4=CC=CC=C34)=N2)N)OC)=C1N GLDAJVZHHFIMPX-UHFFFAOYSA-N 0.000 description 2
- ICBBKQIRHYGTCI-UHFFFAOYSA-N CN(CCC1(C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=C(C=CC=C12)F)C)[N+](=O)[O-])NC)C Chemical compound CN(CCC1(C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=C(C=CC=C12)F)C)[N+](=O)[O-])NC)C ICBBKQIRHYGTCI-UHFFFAOYSA-N 0.000 description 2
- AZJYXYVUWLFVII-UHFFFAOYSA-N CN(CCC1(C(C=C(C(=C1F)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)N)NC)C Chemical compound CN(CCC1(C(C=C(C(=C1F)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)N)NC)C AZJYXYVUWLFVII-UHFFFAOYSA-N 0.000 description 2
- YNRKTIZTSGCTSR-UHFFFAOYSA-N CN(CCC1(C(C=C(C=C1)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)N)NC)C Chemical compound CN(CCC1(C(C=C(C=C1)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)N)NC)C YNRKTIZTSGCTSR-UHFFFAOYSA-N 0.000 description 2
- PBEVCAZWBOXPLB-UHFFFAOYSA-N CN(CCC1(CC=C(C=C1[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC)C Chemical compound CN(CCC1(CC=C(C=C1[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC)C PBEVCAZWBOXPLB-UHFFFAOYSA-N 0.000 description 2
- IEFUTXQHOGRHQS-UHFFFAOYSA-N CN(CCN(C1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC)NC(C=C)=O)C)C Chemical compound CN(CCN(C1=C(C=C(C(=C1)OC)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC)NC(C=C)=O)C)C IEFUTXQHOGRHQS-UHFFFAOYSA-N 0.000 description 2
- VLZLGCJMVYDWFX-UHFFFAOYSA-N CN(CCN(C1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C(C)C)NC(C=C)=O)C)C Chemical compound CN(CCN(C1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C(C)C)NC(C=C)=O)C)C VLZLGCJMVYDWFX-UHFFFAOYSA-N 0.000 description 2
- FANFPTOCKNTCMU-UHFFFAOYSA-N CN(CCN(C1=C(C=C(C(=C1F)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)C)C Chemical compound CN(CCN(C1=C(C=C(C(=C1F)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)C)C FANFPTOCKNTCMU-UHFFFAOYSA-N 0.000 description 2
- DXBXETVSORHONS-UHFFFAOYSA-N CN(CCN(C1=C(C=C(C=C1)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC)NC(C=C)=O)C)C Chemical compound CN(CCN(C1=C(C=C(C=C1)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC)NC(C=C)=O)C)C DXBXETVSORHONS-UHFFFAOYSA-N 0.000 description 2
- RWGPGCZDFZHWRH-UHFFFAOYSA-N CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)[N+](=O)[O-])N1CC2(CCCN2C)CC1)OC Chemical compound CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)[N+](=O)[O-])N1CC2(CCCN2C)CC1)OC RWGPGCZDFZHWRH-UHFFFAOYSA-N 0.000 description 2
- ZFUNUYOJIVXNFR-UHFFFAOYSA-N COC1=CC(=C(C=C1NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)N(CCN1CCCC1)C Chemical compound COC1=CC(=C(C=C1NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)N(CCN1CCCC1)C ZFUNUYOJIVXNFR-UHFFFAOYSA-N 0.000 description 2
- KPNWYZJREIKMFI-UHFFFAOYSA-N COc1c(N)cc(c(F)c1F)[N+]([O-])=O Chemical compound COc1c(N)cc(c(F)c1F)[N+]([O-])=O KPNWYZJREIKMFI-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- UWVXSTGBTXZXBC-UHFFFAOYSA-N ClC=1C(=NC(=NC1)C1(C(C=C(C(=C1)[N+](=O)[O-])N(C1CN(CC1)C)C)OC)N)C1=CNC2=CC=CC=C12 Chemical compound ClC=1C(=NC(=NC1)C1(C(C=C(C(=C1)[N+](=O)[O-])N(C1CN(CC1)C)C)OC)N)C1=CNC2=CC=CC=C12 UWVXSTGBTXZXBC-UHFFFAOYSA-N 0.000 description 2
- KZIWJZHAIFEXII-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)[N+](=O)[O-])N(C1CN(CC1)C)C)OC)C1=CNC2=CC=CC=C12 Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)[N+](=O)[O-])N(C1CN(CC1)C)C)OC)C1=CNC2=CC=CC=C12 KZIWJZHAIFEXII-UHFFFAOYSA-N 0.000 description 2
- YMFXYISHSKZGTH-CQSZACIVSA-N ClC=1C(=NC(=NC=1)NC1=CC(=C(C=C1OC)N1C[C@@H](CC1)N(C)C)N)C1=CNC2=CC=CC(=C12)F Chemical compound ClC=1C(=NC(=NC=1)NC1=CC(=C(C=C1OC)N1C[C@@H](CC1)N(C)C)N)C1=CNC2=CC=CC(=C12)F YMFXYISHSKZGTH-CQSZACIVSA-N 0.000 description 2
- NGQDGIPFETXCGQ-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=CC(=C(C=C1OC)OCCN(C)C)N)C1=CN(C2=CC=CC=C12)C Chemical compound ClC=1C(=NC(=NC=1)NC1=CC(=C(C=C1OC)OCCN(C)C)N)C1=CN(C2=CC=CC=C12)C NGQDGIPFETXCGQ-UHFFFAOYSA-N 0.000 description 2
- XVFVCIDEHJSNAN-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C1CN(CC1)C)C)OC)C1=CNC2=CC=CC=C12 Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C1CN(CC1)C)C)OC)C1=CNC2=CC=CC=C12 XVFVCIDEHJSNAN-UHFFFAOYSA-N 0.000 description 2
- IBAOGBXHZJHYIA-GDLZYMKVSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1C[C@@]2(CCCN2C)CC1)OC)C=1C=NN2C=1C=CC=C2 Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1C[C@@]2(CCCN2C)CC1)OC)C=1C=NN2C=1C=CC=C2 IBAOGBXHZJHYIA-GDLZYMKVSA-N 0.000 description 2
- IBAOGBXHZJHYIA-LJAQVGFWSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1C[C@]2(CCCN2C)CC1)OC)C=1C=NN2C=1C=CC=C2 Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1C[C@]2(CCCN2C)CC1)OC)C=1C=NN2C=1C=CC=C2 IBAOGBXHZJHYIA-LJAQVGFWSA-N 0.000 description 2
- DFKMUQUMUHQKCY-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C=C(C(=CC=1OC)N(C1CN(CC1)C)C)N)C1=CNC2=CC=CC=C12 Chemical compound ClC=1C(=NC(=NC=1)NC=1C=C(C(=CC=1OC)N(C1CN(CC1)C)C)N)C1=CNC2=CC=CC=C12 DFKMUQUMUHQKCY-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- JXASPPWQHFOWPL-UHFFFAOYSA-N Tamarixin Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 JXASPPWQHFOWPL-UHFFFAOYSA-N 0.000 description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- UKVJPLBWWFVLSS-UHFFFAOYSA-N aminomethanol Chemical compound N[CH]O UKVJPLBWWFVLSS-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 2
- JSYBAZQQYCNZJE-UHFFFAOYSA-N benzene-1,2,4-triamine Chemical compound NC1=CC=C(N)C(N)=C1 JSYBAZQQYCNZJE-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 150000002169 ethanolamines Chemical class 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229940013688 formic acid Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical class CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000000802 nitrating effect Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003909 protein kinase inhibitor Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- WMJPISFSIKAZTP-UHFFFAOYSA-N tert-butyl n-[1-(methylaminomethyl)cyclopropyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1(CNC)CC1 WMJPISFSIKAZTP-UHFFFAOYSA-N 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical class CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- FLVFPAIGVBQGET-RXMQYKEDSA-N (3r)-1-methylpyrrolidin-3-ol Chemical compound CN1CC[C@@H](O)C1 FLVFPAIGVBQGET-RXMQYKEDSA-N 0.000 description 1
- PRBHEGAFLDMLAL-GQCTYLIASA-N (4e)-hexa-1,4-diene Chemical compound C\C=C\CC=C PRBHEGAFLDMLAL-GQCTYLIASA-N 0.000 description 1
- BWIJLTPDZWUMHT-UHFFFAOYSA-N (6-bromoindol-1-yl)-tri(propan-2-yl)silane Chemical compound C1=C(Br)C=C2N([Si](C(C)C)(C(C)C)C(C)C)C=CC2=C1 BWIJLTPDZWUMHT-UHFFFAOYSA-N 0.000 description 1
- PMJHHCWVYXUKFD-SNAWJCMRSA-N (E)-1,3-pentadiene Chemical compound C\C=C\C=C PMJHHCWVYXUKFD-SNAWJCMRSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- PCGDBWLKAYKBTN-UHFFFAOYSA-N 1,2-dithiole Chemical compound C1SSC=C1 PCGDBWLKAYKBTN-UHFFFAOYSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- TVOBRQYASMSOCI-UHFFFAOYSA-N 1-N-(5-chloro-4-pyrazolo[1,5-a]pyridin-3-ylpyrimidin-2-yl)-4-[2-(dimethylamino)ethoxy]-6-methoxybenzene-1,3-diamine Chemical compound ClC=1C(=NC(=NC=1)NC1=CC(=C(C=C1OC)OCCN(C)C)N)C=1C=NN2C=1C=CC=C2 TVOBRQYASMSOCI-UHFFFAOYSA-N 0.000 description 1
- AQDGDSNYBFOMEE-UHFFFAOYSA-N 1-N-[2-(dimethylamino)ethyl]-5-methoxy-4-N-(5-methoxy-4-pyrazolo[1,5-a]pyridin-3-ylpyrimidin-2-yl)-1-N-methylbenzene-1,2,4-triamine Chemical compound CN(CCN(C=1C(=CC(=C(C=1)OC)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC)N)C)C AQDGDSNYBFOMEE-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- GCJZFEOFDUEOKD-UHFFFAOYSA-N 1-[[bromo(fluoro)methyl]-ethoxyphosphoryl]oxyethane Chemical compound CCOP(=O)(C(F)Br)OCC GCJZFEOFDUEOKD-UHFFFAOYSA-N 0.000 description 1
- FOZVXADQAHVUSV-UHFFFAOYSA-N 1-bromo-2-(2-bromoethoxy)ethane Chemical compound BrCCOCCBr FOZVXADQAHVUSV-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006025 1-methyl-1-butenyl group Chemical group 0.000 description 1
- 125000006044 1-methyl-1-pentenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical class CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 1
- QHTUMQYGZQYEOZ-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)ethanol Chemical compound CN1CCN(CCO)CC1 QHTUMQYGZQYEOZ-UHFFFAOYSA-N 0.000 description 1
- VUZSIOOEQLAKRM-UHFFFAOYSA-N 2-(difluoromethoxy)-4-N-[2-(dimethylamino)ethyl]-4-N-methyl-1-N-[4-(1-methylindol-3-yl)pyrimidin-2-yl]-5-nitrobenzene-1,4-diamine Chemical compound FC(OC1=C(C=C(C(=C1)N(C)CCN(C)C)[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)F VUZSIOOEQLAKRM-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- HMJZIZUOBYJHJH-UHFFFAOYSA-N 2-[(2-amino-4-nitrophenyl)methoxymethyl]-5-nitroaniline Chemical compound [N+](=O)([O-])C1=CC(=C(C=C1)COCC1=C(C=C(C=C1)[N+](=O)[O-])N)N HMJZIZUOBYJHJH-UHFFFAOYSA-N 0.000 description 1
- XARVANDLQOZMMJ-CHHVJCJISA-N 2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-oxo-2-(2-oxoethylamino)ethylidene]amino]oxy-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)O\N=C(/C(=O)NCC=O)C1=CSC(N)=N1 XARVANDLQOZMMJ-CHHVJCJISA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- IIDUNAVOCYMUFB-UHFFFAOYSA-N 2-amino-5-fluorophenol Chemical compound NC1=CC=C(F)C=C1O IIDUNAVOCYMUFB-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006045 2-methyl-1-pentenyl group Chemical group 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000006031 2-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- KHYAYMJCCQLDOA-UHFFFAOYSA-N 2h-pyridin-1-amine;hydroiodide Chemical compound I.NN1CC=CC=C1 KHYAYMJCCQLDOA-UHFFFAOYSA-N 0.000 description 1
- VIRNXZQVWWBWJE-CQSZACIVSA-N 3-N-(5-chloro-4-pyrazolo[1,5-a]pyridin-3-ylpyrimidin-2-yl)-4-methoxy-6-[(3R)-1-methylpyrrolidin-3-yl]oxybenzene-1,3-diamine Chemical compound ClC=1C(=NC(=NC=1)NC1=CC(=C(C=C1OC)O[C@H]1CN(CC1)C)N)C=1C=NN2C=1C=CC=C2 VIRNXZQVWWBWJE-CQSZACIVSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- GMNIJBFUDYETJY-UHFFFAOYSA-N 4-N-[5-chloro-4-(1-methylindol-3-yl)pyrimidin-2-yl]-5-methoxy-1-N-methyl-1-N-(1-methylpyrrolidin-3-yl)benzene-1,2,4-triamine Chemical compound ClC=1C(=NC(=NC=1)NC=1C=C(C(=CC=1OC)N(C1CN(CC1)C)C)N)C1=CN(C2=CC=CC=C12)C GMNIJBFUDYETJY-UHFFFAOYSA-N 0.000 description 1
- LLIOADBCFIXIEU-UHFFFAOYSA-N 4-fluoro-3-nitroaniline Chemical compound NC1=CC=C(F)C([N+]([O-])=O)=C1 LLIOADBCFIXIEU-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- DBEKGKKRMAOZJP-UHFFFAOYSA-N 5-chloro-N-[4-[2-(dimethylamino)ethoxy]-2-methoxy-5-nitrophenyl]-4-pyrazolo[1,5-a]pyridin-3-ylpyrimidin-2-amine Chemical compound COC1=C(NC2=NC=C(Cl)C(=N2)C2=C3C=CC=CN3N=C2)C=C(C(OCCN(C)C)=C1)[N+]([O-])=O DBEKGKKRMAOZJP-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- MAWGHOPSCKCTPA-UHFFFAOYSA-N 6-bromo-1h-indole Chemical compound BrC1=CC=C2C=CNC2=C1 MAWGHOPSCKCTPA-UHFFFAOYSA-N 0.000 description 1
- XONKJZDHGCMRRF-UHFFFAOYSA-N 7-fluoro-1h-indole Chemical compound FC1=CC=CC2=C1NC=C2 XONKJZDHGCMRRF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- YGDSRMHGTXFOQX-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN(CC1)c1ccc2c(c[nH]c2c1)-c1nc(Cl)ncc1Cl Chemical compound CC(C)(C)OC(=O)N1CCN(CC1)c1ccc2c(c[nH]c2c1)-c1nc(Cl)ncc1Cl YGDSRMHGTXFOQX-UHFFFAOYSA-N 0.000 description 1
- GKZFLKIEUSCVFQ-UHFFFAOYSA-N CN(C)CCN(C)C(C([N+]([O-])=O)=CC1(C2=NC=CC(C3=CN(C(F)F)C4=CC=CC=C34)=N2)N)=CC1OC Chemical compound CN(C)CCN(C)C(C([N+]([O-])=O)=CC1(C2=NC=CC(C3=CN(C(F)F)C4=CC=CC=C34)=N2)N)=CC1OC GKZFLKIEUSCVFQ-UHFFFAOYSA-N 0.000 description 1
- SRRDJBNGVKXULV-UHFFFAOYSA-N CN(CCN(C1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=C(C=CC=C12)F)C)[N+](=O)[O-])C)C Chemical compound CN(CCN(C1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=C(C=CC=C12)F)C)[N+](=O)[O-])C)C SRRDJBNGVKXULV-UHFFFAOYSA-N 0.000 description 1
- UMXWDGIUTPCNLQ-UHFFFAOYSA-N CN(CCN(C1=C(C=C(C=C1)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC)[N+](=O)[O-])C)C Chemical compound CN(CCN(C1=C(C=C(C=C1)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC)[N+](=O)[O-])C)C UMXWDGIUTPCNLQ-UHFFFAOYSA-N 0.000 description 1
- RXTUZYDAODDXPQ-UHFFFAOYSA-N CN(CCN(C1=CC(=C(C=C1[N+](=O)[O-])NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC)OC)C)C Chemical compound CN(CCN(C1=CC(=C(C=C1[N+](=O)[O-])NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC)OC)C)C RXTUZYDAODDXPQ-UHFFFAOYSA-N 0.000 description 1
- HIQBYXGMYLNVKO-UHFFFAOYSA-N CN(CCN(C=1C(=CC(=C(C=1)OC)NC1=NC=CC(=N1)C1=CN(C2=C(C=CC=C12)F)C)N)C)C Chemical compound CN(CCN(C=1C(=CC(=C(C=1)OC)NC1=NC=CC(=N1)C1=CN(C2=C(C=CC=C12)F)C)N)C)C HIQBYXGMYLNVKO-UHFFFAOYSA-N 0.000 description 1
- XDWDSKFMIGQIBP-UHFFFAOYSA-N CN(CCN(C=1C(=CC(=CC=1)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC)N)C)C Chemical compound CN(CCN(C=1C(=CC(=CC=1)NC1=NC=C(C(=N1)C=1C=NN2C=1C=CC=C2)OC)N)C)C XDWDSKFMIGQIBP-UHFFFAOYSA-N 0.000 description 1
- OAMAGBXQEBLRIB-UHFFFAOYSA-N CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)C1(CC(=CC(=C1)N1CCOCC1)N)N Chemical compound CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)C1(CC(=CC(=C1)N1CCOCC1)N)N OAMAGBXQEBLRIB-UHFFFAOYSA-N 0.000 description 1
- BRENQBJWDNSLQJ-UHFFFAOYSA-N CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC1=C(C=C(C(=C1)[N+](=O)[O-])N(C1CN(CC1)C)C)OC Chemical compound CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC1=C(C=C(C(=C1)[N+](=O)[O-])N(C1CN(CC1)C)C)OC BRENQBJWDNSLQJ-UHFFFAOYSA-N 0.000 description 1
- WPHBHVPOCSLZKM-UHFFFAOYSA-N CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C=C(C(=CC=1OC)N(C1CN(CC1)C)C)N Chemical compound CN1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C=C(C(=CC=1OC)N(C1CN(CC1)C)C)N WPHBHVPOCSLZKM-UHFFFAOYSA-N 0.000 description 1
- QQBOICIXCSJSAA-UHFFFAOYSA-N COC1=C(C=C(C(=C1)N(CCN1CCCC1)C)[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C Chemical compound COC1=C(C=C(C(=C1)N(CCN1CCCC1)C)[N+](=O)[O-])NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C QQBOICIXCSJSAA-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- QCZSWFUAKIYGMH-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)[N+](=O)[O-])F)OC)C1=CN(C2=CC(=CC=C12)N1CCOCC1)C Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)[N+](=O)[O-])F)OC)C1=CN(C2=CC(=CC=C12)N1CCOCC1)C QCZSWFUAKIYGMH-UHFFFAOYSA-N 0.000 description 1
- OALUZFJBPMGDFV-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)[N+](=O)[O-])N(C)CCN(C)C)OC)C1=CNC2=CC=CC(=C12)F Chemical compound ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)[N+](=O)[O-])N(C)CCN(C)C)OC)C1=CNC2=CC=CC(=C12)F OALUZFJBPMGDFV-UHFFFAOYSA-N 0.000 description 1
- YYFRZVIEQWETEQ-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=CC(=C(C=C1OC)F)N)C1=CN(C2=CC(=CC=C12)N1CCOCC1)C Chemical compound ClC=1C(=NC(=NC=1)NC1=CC(=C(C=C1OC)F)N)C1=CN(C2=CC(=CC=C12)N1CCOCC1)C YYFRZVIEQWETEQ-UHFFFAOYSA-N 0.000 description 1
- JDQOFGCYZCUIRC-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)F)OC)C1=CN(C2=CC(=CC=C12)N1CCOCC1)C Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)F)OC)C1=CN(C2=CC(=CC=C12)N1CCOCC1)C JDQOFGCYZCUIRC-UHFFFAOYSA-N 0.000 description 1
- PIXDHCNTUGNMMB-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C=C(C(=CC=1CC)N(C)CCN(C)C)N)C1=CN(C2=CC=CC=C12)C Chemical compound ClC=1C(=NC(=NC=1)NC=1C=C(C(=CC=1CC)N(C)CCN(C)C)N)C1=CN(C2=CC=CC=C12)C PIXDHCNTUGNMMB-UHFFFAOYSA-N 0.000 description 1
- OFCMUMBYZRNVQT-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC=1C=C(C(=CC=1OC)N(C)CCN(C)C)N)C1=CNC2=CC=CC(=C12)F Chemical compound ClC=1C(=NC(=NC=1)NC=1C=C(C(=CC=1OC)N(C)CCN(C)C)N)C1=CNC2=CC=CC(=C12)F OFCMUMBYZRNVQT-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- YKTNKLCFUMBJBH-UHFFFAOYSA-N FC(OC=1C(=CC(=C(C=1)N(C)CCN(C)C)[N+](=O)[O-])N)F Chemical compound FC(OC=1C(=CC(=C(C=1)N(C)CCN(C)C)[N+](=O)[O-])N)F YKTNKLCFUMBJBH-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- DADDAUPSAXRSAH-UHFFFAOYSA-N N-[5-[[5-chloro-4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]-4-methoxy-2-[methyl-(1-methylpyrrolidin-3-yl)amino]phenyl]prop-2-enamide Chemical compound ClC=1C(=NC(=NC=1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C1CN(CC1)C)C)OC)C1=CN(C2=CC=CC=C12)C DADDAUPSAXRSAH-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 150000008522 N-ethylpiperidines Chemical class 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 150000003946 cyclohexylamines Chemical class 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000003840 hydrochlorides Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N piperylene Natural products CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- PFZCOWLKXHIVII-UHFFFAOYSA-N pyridin-1-ium-1-amine Chemical compound N[N+]1=CC=CC=C1 PFZCOWLKXHIVII-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- NMQPVLFAFAZYKC-UHFFFAOYSA-N tert-butyl 4-(1h-indol-6-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(C=CN2)C2=C1 NMQPVLFAFAZYKC-UHFFFAOYSA-N 0.000 description 1
- HFMAZNJKNNRONT-UHFFFAOYSA-N tert-butyl n-[1-(hydroxymethyl)cyclopropyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1(CO)CC1 HFMAZNJKNNRONT-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provides a (substituted phenyl) (substituted pyrimidine) amino derivative as shown in a general formula (I), an optical isomer, pharmaceutically acceptable salt or eutectic crystal thereof, a preparation method and application in preparing tumor drugs.Wherein the general formula is compound (I).
Description
The application is a divisional application with application number 201580023470.2, application date 2015 08-25, entitled (substituted phenyl) (substituted pyrimidine) amino derivative, and a preparation method and pharmaceutical use thereof.
Technical Field
The invention relates to a (substituted phenyl) (substituted pyrimidine) amino derivative as shown in a general formula (I), an optical isomer, pharmaceutically acceptable salt or eutectic thereof, a preparation method and application in preparing tumor drugs.
Background
With the advent of the industrialized age, environmental pollution and lifestyle changes have led to a continuous rise in the incidence of cancer. Currently, cancer has become a major killer threatening human life and health. According to international research center for cancer (IARC) reports: in 2008, the number of new cancer cases is 1,266 ten thousand and the number of death cases is 756 ten thousand, accounting for 13 percent of all deaths. In the next decades, the number of cancer patients will still increase rapidly, 2136 new cancer cases and 1315 ten thousands death cases are expected to occur in 2030 years all over the world, and the market demand for cancer treatment will continue to increase rapidly.
The receptor tyrosine kinase superfamily of cell surface receptors plays an important role in the regulation of cell signaling by extracellular growth factors. Receptor tyrosine kinases are capable of catalyzing the transfer of phosphate groups from ATP to tyrosine groups on substrates. When no ligand activates receptor tyrosine kinases, these kinases are in an unphosphorylated monomeric state with the kinase domain in an inactive configuration. When ligand is combined with extracellular segment of receptor tyrosine kinase, receptor is oligomerized and autophosphorylated, which increases the catalytic activity of kinase and forms binding site of signal protein, which is combined with it to activate multiple signal paths. These signaling pathways are interconnected to regulate cell proliferation, survival, differentiation, function, migration and apoptosis. When the receptor tyrosine kinase is out of regulation and abnormally activated, the cells are transformed into tumor cells, and the proliferation, growth and drug resistance of the cells are improved, and the cells have stronger hemangiogenic ability, invasiveness and transfer ability (Yarden and Sliwkowski,2001, Nat Rev Mol Cell Biol,2, 127-.
The ErbB family belongs to receptor tyrosine kinases and comprises four members: epidermal growth factor receptor (EGFR/HER1/ErbB1), HER2(neu/ErbB2), HER3(ErbB3) and HER4(ErbB4) (Olayioye, Neve et al, 2000, EMBO J,19, 3159-. They all contain an extracellular ligand binding domain, a single transmembrane domain and an intracellular tyrosine kinase and regulatory domain. Its function is to catalyze the transfer of the phosphate group of ATP to the tyrosine group of the substrate protein. Ligand-dependent receptor oligomerization leads to autophosphorylation of the receptor regulatory domain, resulting in intracellular signal transduction, ultimately leading to cell proliferation. This signaling pathway is closely related to the development and progression of tumors. In many tumors, hyperactivated ErbB receptors, particularly EGFR, can lead to deregulation of growth factor signaling. Activation of EGFR is usually either sustained activation due to overexpression or mutation or autocrine expression of the ligand. Overexpression or mutation of EGFR is detected in various cancers such as head and neck cancer, ovarian cancer, bladder cancer, cervical cancer, esophageal cancer, gastric cancer, breast cancer, intimal cancer, colon cancer, lung cancer, and brain tumor, and is generally indicative of poor prognosis. Thus, inhibition of EGFR is a highly interesting anti-tumor strategy. Many small molecule inhibitors targeting EGFR have been developed in succession, some of which have been used in clinical therapy.
The first generation of EGFR kinase inhibitors such as gefitinib and erlotinib were clinically effective in the treatment of non-small cell lung cancer, especially those containing activating mutations in the EGFR kinase domain (Mok, Wu et al, 2009, N Engl J Med,361, 947-containing 957; Rosell, Moran et al, 2009, N Engl J Med,361, 958-containing 967). The most common EGFR activating mutations are L858R and delE746_ A750, which are capable of increasing the receptor affinity for gefitinib and erlotinib, but decreasing the receptor affinity for ATP, relative to wild-type EGFR (Carey, Garton et al, 2006, Cancer Res,66, 8163-. However, clinically, the use of gefitinib and erlotinib is eventually limited due to the emergence of acquired resistance. Acquired resistance occurs in more than 50% of lung cancer patients, with more than 90% containing the T790M gatekeeper residue mutation of EGFR (Kobayashi, Boggon et al, 2005, N Engl J Med,352,786 792; Pao, Miller et al, 2005, PLoS Med,2, e 73). The T790M mutation does not sterically hinder drug binding, but restores the receptor affinity for ATP, comparable to wild-type (Yun, Mengwasser et al, 2008, Proc Natl Acad Sci U S A,105, 2070-.
Second generation EGFR kinase inhibitors generally have a quinoline structure and are irreversible EGFR inhibitors. Unlike gefitinib, they contain electrophilic ability and are capable of michael addition reactions with the conserved cysteine group (Cys 797) in EGFR. The covalent nature of these compounds makes them more capable of occupying the ATP site than reversible inhibitors, and thus, although the T790M mutation can increase the affinity for ATP, such inhibitors are sufficient to inhibit EGFR T790M in preclinical models (Engelman, Zejnullahu et al, 2007, Cancer Res,67, 11924. sup. 11932; Li, Ambrogio et al, 2008, Oncogene,27, 4702. sup. 4711). However, the ability of existing irreversible inhibitors to inhibit EGFR T790M mutation was still lower than the ability to inhibit EGFR activating mutation alone in cell line models, and at clinically useful concentrations, such compounds failed to inhibit EGFR T790M in vitro (Yuza, Glatt et al, 2007, Cancer Biol Ther,6,661-667; Godin-Heymann, Ulnus et al, 2008, Mol Cancer Ther her,7,874-879). Since the affinity of EGFR T790M to ATP is similar to that of wild-type EGFR, quinazoline EGFR inhibitors inhibit wild-type EGFR while inhibiting EGFR T790M. Clinically, simultaneous inhibition of wild-type EGFR results in patients with rash and diarrhea, which limits the dosage of second generation EGFR inhibitors, such that the plasma concentration of the drug is insufficient to inhibit T790M, resulting in a greater limitation in the clinical effectiveness of such drugs. For example, CI-1033, HKI-272 and PF00299804, have very limited clinical treatment for Gefitinib and erlotinib resistant non-small cell lung cancer and can develop dose-dependent diarrhea and skin rash (Janne, von Pawel et al, 2007, J Clin Oncol,25, 3936-.
In order to be able to specifically inhibit EGFR T790M, third generation EGFR mutation selective inhibitors were developed. Compared with the second generation quinoline compounds, the irreversible inhibitor has higher selectivity on EGFR T790M, and may have higher activity and better tolerance clinically. For example, the covalent pyrimidine EGFR inhibitor WZ4002 has 30-100 times higher selectivity for EGFR T790M and 100 times lower inhibition for wild type EGFR in vitro than quinoline compounds. Better efficacy was also demonstrated in the EGFR T790M-derived animal lung cancer model (Zhou, Ercan et al, 2009, Nature,462, 1070-. Another mutation selective inhibitor, co-1686, is 10-25 fold more selective for EGFR T790M in vitro than for wild-type EGFR. Mutations that selectively inhibit EGFR, including the drug resistance mutation T790M and the activating mutation (L858R, del19), were not inhibitory to wild-type EGFR. In vitro, oral co-1686 was able to cause tumor regression of the T790M mutation without mediating further drug resistance mutations in tumor cells (Walter, Sjin et al, 2013, Cancer Discov,3, 1404-. To meet clinical needs, there is a continuing need to develop EGFR inhibitors that do not produce significant toxic side effects at concentrations effective to overcome the T790M mutation.
At present, various documents report protein kinase inhibitors and anti-tumor application thereof. Such as:
WO2009051822 discloses pyrimidine derivatives useful as EGFR inhibitors, and their use in the treatment of cancer. Wherein A, B is selected from carbocycle or heterocycle, etc., and the structure is shown as follows:
WO2011140338 describes heterocyclic derivatives that are useful as EGFR inhibitors, and their use as antitumor agents. Wherein B is selected from 6 to 10 membered mono-or bis-heteroaryl containing at least one N atom, X1 is selected from O, S or N, R29、R29aAnd R29b are each independently selected from H, 5-to 6-membered non-heteroaryl, 5-to 6-membered non-heteroarylmethylene, or 5-to 6-membered non-heteroarylcarbonyl, as shown in the following structure:
WO2011090760, WO2009158571 describe pyrimidine derivatives useful as protein kinase inhibitors and as medicaments for the treatment of various diseases, wherein A, B is independently selected from heterocyclic or carbocyclic rings, and the structures are as follows:
WO2013014448 discloses pyrimidine derivatives useful as EGFR inhibitors, and their use in the treatment of cancer. Wherein G is selected from 4,5,6, 7-tetrahydropyrazolo [ l,5-a ] pyridin-3-yl, lH-indol-3-yl, 1-methyl-lH-indol-3-yl or pyrazolo [ l,5-a ] pyridin-3-yl, R3 is N-dimethylaminoethyl-N-methylamino, and the like, and has the following structure:
The invention aims to provide an EGFR inhibitor with good effect, good tolerance, high selectivity or low toxic and side effects, and application thereof in preparing medicaments related to cancer treatment. The cancer comprises head and neck cancer, ovarian cancer, bladder cancer, cervical cancer, esophageal cancer, gastric cancer, breast cancer, intimal cancer, colon cancer, lung cancer, brain tumor, non-small cell lung cancer, pancreatic cancer, solid tumor, colorectal tumor or malignant glioma and the like.
Disclosure of Invention
The invention relates to a compound shown in a general formula (I) and an optical isomer, pharmaceutically acceptable salt or eutectic thereof, wherein:
b is selected from 6 to 15 membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O, S or P;
R1each independently selected from F, Cl, Br, I, hydroxy, cyano, C1-10Alkyl radical, C1-10Alkoxy, -NR1aR1b、 -C(=O)C1-10Alkyl, -S (═ O)2-C1-10Alkyl, -C (═ O) -3 to 15 membered heterocycle, -C (═ O) -C3-15Carbocyclic ring, - (CH)2)n-3 to 15 membered heterocycle, - (CH)2)n-C3-15Carbocyclic ring, -O- (CH)2)n-C3-15Carbocyclic ring, -O- (CH)2)n-3 to 15 membered heterocycle, -O- (CH)2)n-C(=O)C1-6Alkyl, -O- (CH)2)n-O-C(=O)C1-6Alkyl or-O- (CH)2)n-O-C1-10Alkyl, said CH2Alkyl, alkoxy, carbocyclic or heterocyclic ring optionally further substituted by 0 to 5 substituents selected from F, Cl, Br, I,Is O, hydroxy, amino, cyano, nitro, C 1-6Alkyl radical, C1-6Alkoxy, - (CH)2)n-OH、-(CH2)n-F、 -C(=O)C1-6Alkyl, -O-C (═ O) C1-6Alkyl, -C (═ O) C1-6Alkoxy, -C (═ O) C3-15Carbocyclic ring, - (CH)2)n-C3-10Carbocyclic ring or- (CH)2)n-3 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from N, O, S or P;
R1aand R1bSelected from H or C1-10An alkyl group;
R2selected from H, F, Cl, Br, I, cyano, C1-10Alkyl or C1-10Alkoxy, said alkyl or alkoxy being optionally further substituted by 0 to 4 substituents selected from F, Cl, Br, I, C1-6Alkyl or C1-6Substituted by a substituent of alkoxy;
R3selected from H, C2-10Alkenyl radical, C3-15Cycloalkyl radical, C1-10Alkyl or C1-10Alkoxy, said alkenyl, cycloalkyl, alkyl or alkoxy being optionally further 0 to 4 selected from F, Cl, Br, I, C1-6Alkyl or C1-6Substituted by a substituent of alkoxy;
R4selected from H, F, Cl, Br, I, nitro, amino, C1-10Alkyl, 5-to 15-membered spirocyclic, 4-to 15-membered fused cyclic, 3-to 10-membered heterocyclic, -NR4cR4d、-Z-(CH2)nR4a、-O-(CH2)nR4b、-Z-(CH2)nNR4cR4dor-O- (CH)2)nNR4cR4dSaid CH2Spiro, fused or heterocyclic ring optionally further substituted by 0 to 4 groups selected from F, Cl, Br, I, hydroxy, amino, C1-6Alkyl radical, C1-6Alkoxy, - (CH)2)n-C(=O)-R4e、-(CH2)n-O-C(=O)-R4e、 -NR4cR4dFrom 0 to 4R4cSubstituted C3-10Carbocyclic or substituted by 0 to 4R4cSubstituted by3 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from N, O or S;
Z is selected from-NH-or-N (C)1-6Alkyl) -;
R4ais selected from C3-15A carbocycle or 3-to 15-membered heterocycle containing 1 to 4 heteroatoms selected from N, O or S, said carbocycle or heterocycle optionally further substituted with 0 to 4 heteroatoms selected from F, Cl, Br, I, amino, hydroxy, C1-6Alkoxy radical, C1-6Alkyl or by 1 to 2C1-6Substituted with a substituent of an alkyl-substituted amino group;
R4bis selected from-C (═ O) C1-6Alkyl, -O-C (═ O) C1-6Alkyl radical, C1-10Alkoxy radical, C3-15A carbocycle or a 3-to 15-membered heterocycle, said alkyl, alkoxy, carbocycle or heterocycle optionally being further substituted with 0 to 4 substituents selected from F, Cl, Br, I, amino, -NR4cR4dHydroxy, C1-6Alkyl radical, C1-6Alkoxy or halogen substituted C1-6Alkyl, said heterocycle containing 1 to 4 heteroatoms selected from N, O or S;
R4cand R4dSelected from H, C1-10Alkyl, -C (═ O) C1-6Alkyl or-C (═ O) C1-6An alkoxy group;
R4eselected from amino, hydroxy, C1-10Alkyl radical, C3-15A carbocycle or a 3-to 15-membered heterocycle, said amino, alkyl, carbocycle or heterocycle being optionally further substituted with 0 to 4 substituents selected from F, Cl, Br, I, amino, hydroxy, C1-6Alkyl radical, C1-6Alkoxy, -C (═ O) C1-6Alkyl, -C (═ O) -NH2、-O-C(=O)C1-6Alkyl or halogen substituted C1-6Alkyl, said heterocycle containing 1 to 4 heteroatoms selected from N, O or S;
R5Selected from H, F, Cl, Br, I or a 5 to 15 membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S, said heterocyclic ring optionally further substituted by 0 to 4 heteroatoms selected from F, Cl, Br, I, ═ O, -C (═ O) C1-6Alkyl radical, C1-6Alkyl or C1-6Substituent of alkoxyGeneration;
f is selected from 0, 1, 2, 3, 4, 5 or 6;
n is selected from 0, 1, 2 or 3;
in each scheme of the invention, when-B- (R)1)fIs selected from And R is2Selected from H, F, Cl, methyl or cyano, R3Selected from H, methoxy or methyl, f is 1, R5When is H, R4Is not H,
In a preferred embodiment of the present invention, the compound represented by the general formula (I) and an optical isomer, a pharmaceutically acceptable salt or a co-crystal thereof, wherein:
b is selected from 6 to 15 membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S;
R1each independently selected from F, Cl, Br, I, hydroxy, cyano, C1-4Alkyl radical, C1-4Alkoxy, -NR1aR1b、 -C(=O)C1-4Alkyl, -S (═ O)2-C1-4Alkyl, -C (═ O) -3 to 7 membered heterocycle, -C (═ O) -C3-7Carbocyclic ring, - (CH)2)n-C3-6Carbocyclic ring or 3 to 7 membered heterocyclic ring, said CH2Alkyl, alkoxy, carbocycle or heterocycle is optionally further substituted by 0 to 4 groups selected from F, Cl, Br, I, ═ O, hydroxy, C1-4Alkyl radical, C1-4Alkoxy, -C (═ O) C1-4Alkoxy, - (CH) 2)n-OH、 -(CH2)n-F、-C(=O)C3-6Carbocyclic ring, -C (═ O) C1-4Alkyl, - (CH)2)n-C3-6Carbocyclic ring or- (CH)2)n-3 to 6 membered heteroA ring substituent, said heterocycle containing 1 to 4 heteroatoms selected from N, O or S;
R1aand R1bSelected from H or C1-4An alkyl group;
R2selected from H, F, Cl, Br, I, cyano, C1-4Alkyl or C1-4Alkoxy, said alkyl or alkoxy being optionally further substituted by 0 to 4 substituents selected from F, Cl, Br, I, C1-4Alkyl or C1-4Substituted by a substituent of alkoxy;
R3selected from H, C2-6Alkenyl radical, C3-6Cycloalkyl radical, C1-4Alkyl or C1-4Alkoxy, said alkenyl, cycloalkyl, alkyl or alkoxy being optionally further selected from 0 to 4 from F, Cl, Br, I, C1-4Alkyl or C1-4Substituted by a substituent of alkoxy;
R4selected from H, F, Cl, Br, I, 5-to 15-membered spirocyclic ring, 4-to 15-membered fused ring, 3-to 10-membered heterocyclic ring, -Z- (CH)2)nR4a、 -O-(CH2)nR4b、-Z-(CH2)nNR4cR4dor-O- (CH)2)nNR4cR4dSaid heterocycle containing 1 to 4 heteroatoms selected from N, O or S, said CH2Spiro, fused or heterocyclic ring optionally further substituted by 0 to 4 groups selected from F, Cl, Br, I, amino, hydroxy, C1-4Alkyl, -NR4cR4d、-C(=O)-R4eOr C1-4Substituted by a substituent of alkoxy;
z is selected from-NH-or-N (C)1-4Alkyl) -;
R4ais selected from C3-6A carbocyclic ring or a 3 to 7 membered heterocyclic ring, said heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S, said carbocyclic or heterocyclic ring optionally further substituted by 0 to 4 heteroatoms selected from F, Cl, Br, I, amino, hydroxy, C 1-4Alkyl radical, by 1 to 2C1-4Substituted with a substituent of an alkyl-substituted amino group;
R4bis selected from C3-6A carbocyclic ring or a 3 to 7 membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O, S, the carbocyclic or heterocyclic ringThe ring is optionally further substituted by 0 to 4 substituents selected from F, Cl, Br, I, amino, hydroxy, -NR4cR4d、 C1-4Alkyl or C substituted by 1 to 2 halogens1-4Alkyl is substituted by a substituent;
R4cand R4dIs selected from H or C1-4An alkyl group;
R4eselected from amino, hydroxy, C1-4Alkyl radical, C3-6A carbocycle or a 3-to 7-membered heterocycle, said amino, alkyl, carbocycle or heterocycle being optionally further substituted with 0 to 4 substituents selected from F, Cl, Br, I, amino, hydroxy, C1-4Alkyl radical, C1-4Alkoxy or halogen substituted C1-4Alkyl, said heterocycle containing 1 to 4 heteroatoms selected from N, O or S;
R5selected from H, F, Cl, Br, I or a 5 to 6 membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O, S, said heterocyclic ring optionally further substituted with 0 to 4 heteroatoms selected from H, F, Cl, Br, I, ═ O, -C (═ O) C1-4Alkyl radical, C1-4Alkyl or C1-4Substituted by a substituent of alkoxy;
f is selected from 0, 1, 2, 3 or 4;
each n is independently selected from 0, 1, 2 or 3.
In a preferred embodiment of the present invention, the compound represented by the general formula (I) and an optical isomer, a pharmaceutically acceptable salt or a co-crystal thereof, wherein:
B is selected from an 8 to 13 membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S;
R1each independently selected from F, Cl, Br, I, hydroxy, cyano, -S (═ O)2-C1-4Alkyl, -C (═ O) -C3-6Carbon ring, C1-4Alkyl, - (CH)2)n-C3-6Carbocyclic ring or- (CH)2)n-5 to 6 membered heterocycle, preferably H, F, Cl, -S (═ O)2-C1-4Alkyl radical, C1-4Alkyl, -C (═ O) -C3-6Carbocyclic ring, - (CH)2)n-C3-6Carbocyclic ring or- (CH)2)n-a 5 to 6 membered heterocyclic ring; the CH2Alkyl, carbocyclic or heterocyclic ringIs further substituted by 0 to 4 substituents selected from F, Cl, Br, I, ═ O, hydroxy, C1-4Alkyl radical, C1-4Alkoxy, -CH2-cyclopropyl, -tert-butoxycarbonyl, - (CH)2)n-OH、-(CH2)n-F、-C(=O)C1-4Alkyl, - (CH)2)n-C3-6Carbocyclic ring or- (CH)2)n-3 to 6 membered heterocycle, preferably further substituted with 0 to 4 substituents selected from F, hydroxy, C1-4Alkyl or-C (═ O) C1-4Alkyl is substituted by a substituent; said heterocycle containing from 1 to 4 heteroatoms selected from N, O or S;
R2selected from H, F, Cl, C1-4Alkyl or C1-4Alkoxy, preferably H, F, Cl or C1-4An alkoxy group;
R3is H, C2-4Alkenyl radical, C3-4Cycloalkyl radical, C1-4Alkyl or C1-4Alkoxy, preferably H, C1-4Alkyl or C1-4An alkoxy group; said alkoxy is optionally further substituted by 0 to 4 substituents selected from F, Cl or Br;
R4selected from H, F, Cl, 7-to 11-membered spirocyclic ring, 6-to 10-membered fused ring, 3-to 6-membered heterocyclic ring, -Z- (CH) 2)nR4a、 -Z-(CH2)nNR4cR4d、-O-(CH2)nR4bor-O- (CH)2)nNR4cR4dSaid heterocycle containing 1 to 4 heteroatoms selected from N, O or S, said CH2Spiro, fused or heterocyclic ring optionally further substituted by 0 to 4 groups selected from F, Cl, Br, I, amino, -NH (CH)3)、-N(CH3)2Methyl or ethyl;
z is selected from-NH-or-N (C)1-4Alkyl) -;
R4ais selected from C3-4A carbocycle or 5-membered heterocycle containing 1 to 4 heteroatoms selected from N, O, S, said carbocycle or heterocycle optionally further substituted with 0 to 4 heteroatoms selected from F, Cl, Br, I, amino, hydroxy, -NHCH3、 -N(CH3)2Methyl or ethyl;
R4bis selected from C3-4A carbocycle or a 4-to 6-membered heterocycle containing 1 to 4 heteroatoms selected from N, O, S, said carbocycle or heterocycle optionally further substituted with 0 to 4 heteroatoms selected from F, Cl, Br, I, amino, hydroxy, -NH (CH)3)、 -N(CH3)2、-CH2CH2F. Methyl or ethyl;
R4cand R4dSelected from H, methyl or ethyl;
R5selected from H, F, Cl or a 5 to 6 membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O, S, said heterocyclic ring optionally further substituted by 0 to 4 heteroatoms selected from F, Cl, Br, I, ═ O, -C (═ O) C1-4Alkyl radical, C1-4Alkyl or C1-4Substituted by a substituent of alkoxy;
n is selected from 0, 1, 2 or 3.
In a preferred embodiment of the present invention, the compound represented by the general formula (I) and an optical isomer, a pharmaceutically acceptable salt or a co-crystal thereof, wherein:
R1Each independently selected from F, Cl, Br, I, -S (═ O)2CH3-C (═ O) -cyclopropyl, hydroxy, cyano, methyl, ethyl, isopropyl, cyclopropyl, -CH2-cyclopropyl, -CH (CH)3) -cyclopropyl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl, preferably H, F, Cl, -S (═ O)2CH3Methyl, ethyl, isopropyl, cyclopropyl, -CH2-cyclopropyl, -CH2(CH3) -cyclopropyl, -C (═ O) -cyclopropyl, morpholinyl, or piperazinyl; said methyl, ethyl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl group being optionally further substituted by 0 to 4 substituents selected from F, Cl, Br, I, ═ O, hydroxy, methyl, ethyl, methoxy, isopropyl, cyclopropyl, -CH2-cyclopropyl, hydroxyethyl, 2-fluoroethyl, tert-butoxycarbonyl, oxetanyl, -C (═ O) CH3or-C (═ O) CH2CH3Is preferably optionally further substituted with 0 to 4 substituents selected from F, hydroxy, methyl, -CH2-cyclopropyl, hydroxyethyl, 2-fluoroethyl, tert-butoxycarbonyl or-C (═ O) CH3Substituted with the substituent(s);
R2selected from H, F, Cl, methyl or methoxy, preferably H, F, Cl or methoxy;
R3selected from H, methyl, ethyl, vinyl, cyclopropyl, methoxy, fluoromethoxy, difluoromethoxy or trifluoromethoxy, preferably H, ethyl, methoxy or difluoromethoxy;
R4Selected from H, F, Cl, 7-to 11-membered spirocyclic ring, 3-to 6-membered heterocyclic ring, -Z- (CH)2)nR4a、-O-(CH2)nR4b、 -Z-(CH2)nNR4cR4dor-O- (CH)2)nNR4cR4dPreferably F, 7-to 11-membered spirocyclic ring, 3-to 6-membered heterocyclic ring, -Z- (CH)2)nR4a、-O-(CH2)nR4b、-Z-(CH2)nNR4cR4dor-O- (CH)2)nNR4cR4d(ii) a Said heterocycle containing 1 to 4 hetero atoms selected from N, O or SA, the CH2Spiro or heterocycle optionally further substituted by 0 to 4 substituents selected from F, Cl, Br, I, methyl, ethyl or-N (CH)3)2Is preferably optionally further substituted with 0 to 2 substituents selected from F or methyl;
z is selected from-NH-or-N (CH)3)-;
R4aSelected from substituted or unsubstituted cyclopropyl or tetrahydropyrrolyl, when substituted, optionally further substituted by 1 to 4 substituents selected from F, Cl, Br, I, amino, hydroxy, -NHCH3、-N(CH3)2Methyl or ethyl;
R4bselected from substituted or unsubstituted cyclopropyl,Tetrahydropyrrolyl, piperazinyl, piperidinyl or morpholinyl; when substituted, is optionally further substituted with 1 to 4 substituents selected from F, Cl, Br, I, amino, hydroxy, -NHCH3、 -N(CH3)2、-CH2CH2F. Methyl or ethyl, preferably by 1 to 4 substituents selected from amino or-CH2CH2Substituted with a substituent of F;
R4cand R4dSelected from H, methyl or ethyl, preferably H or methyl;
R5selected from H, F, Cl or morpholinyl, preferably H, F or morpholinyl;
n is selected from 0, 1, 2 or 3.
In a preferred embodiment of the present invention, the compound represented by the general formula (I) and an optical isomer, a pharmaceutically acceptable salt or a co-crystal thereof, wherein:
R1Each independently selected from F, Cl, -S (═ O)2CH3Hydroxy, cyano, methyl, difluoromethyl, ethyl, -CH2CH2OH, isopropyl, cyclopropyl, -CH2-cyclopropyl group, Morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl, preferably H, F, methyl, morpholinyl, piperazinyl,OrFurther preferably H, F, methyl or morpholinyl;
R2selected from H, F, Cl, methyl or methoxy, preferably H, F, Cl or methoxy;
R3selected from H, ethyl, methoxy or difluoromethoxy, preferably H or methoxy;
R4selected from H, F, Cl,
R5Selected from H, F, Cl or morpholinyl, preferably H, F or morpholinyl;
f is selected from 0, 1, 2 or 3, preferably 0, 1 or 2.
Preferred embodiment of the present invention, -B- (R)1)fSelected from, but not limited to, one of the following structures:
the invention relates to a compound shown in a general formula (II) and an optical isomer, pharmaceutically acceptable salt or eutectic thereof, wherein:
b is selected from 6-membered heterocycle, 7-membered heterocycle, 8-membered heterocycle, 9-membered heterocycle or 10-membered heterocycle, optionally further substituted with 0, 1, 2, 3 or 4R 1(ii) substituted, said heterocycle containing 1, 2, 3, or 4 heteroatoms selected from N, O, S;
R1each independently selected from H, F, Cl, Br, I, S (═ O)2-C1-4Alkyl radical, C1-4Alkyl, NR1aR1b、-C(=O)C1-4Alkyl, -C (═ O) -3 membered heterocycle, -C (═ O) -4 membered heterocycle, -C (═ O) -5 membered heterocycle, -C (═ O) -6 membered heterocycle, -C (═ O) -7 membered heterocycle, C1-4Alkoxy radical, C3Carbocyclic ring, C4Carbocyclic ring, C5Carbocyclic ring, C6Carbocycle or 3-membered heterocycle, 4-membered heterocycle, 5-membered heterocycle, 6-membered heterocycle or 7-membered heterocycle, said alkyl, alkoxy, carbocycle or heterocycle being optionally further substituted with 0, 1, 2, 3 or 4 substituents selected from H, F, Cl, Br, I, (═ O), C1-4Alkyl radical, C1-4Alkoxy, -C (═ O) C1-4Alkyl radical, C3Carbocyclic ring, C4Carbocyclic ring, C5Carbocyclic ring, C6Carbocyclic or 3-membered heterocyclic, 4-membered heterocyclic, 5-membered heterocyclic, or 6-membered heterocyclic substituent, said heterocyclic containing 1, 2, 3, or 4 heteroatoms selected from N, O, S;
R1aand R1bSelected from H or C1-4An alkyl group;
R2selected from H, F, Cl, Br, I, C1-4Alkyl or C1-4Alkoxy, said alkyl or alkoxy being optionally further substituted by 0, 1, 2, 3 or 4 substituents selected from H, F, Cl, Br, I, C1-4Alkyl or C1-4Substituted by a substituent of alkoxy;
R3is H, C2-6Alkenyl radical, C3Cycloalkyl radical, C4Cycloalkyl radical, C5Cycloalkyl radical, C 6Cycloalkyl radical, C1-4Alkyl or C1-4Alkoxy, said alkenyl, cycloalkyl, alkyl or alkoxy being optionally further 0, 1, 2, 3 or 4 selected from H, F, Cl, Br, I, C1-4Alkyl or C1-4Substituted by a substituent of alkoxy;
R4selected from H, F, Cl, Br, I, 9-membered spiro ring, Z- (CH)2)nR4a、O-(CH2)nR4bOr O- (CH)2)nNR4cR4dSaid spiro ring containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, said spiro ring optionally further substituted with 0, 1, 2, 3 or 4 heteroatoms selected from H, F, Cl, Br, I, C1-4Alkyl or C1-4Substituted by a substituent of alkoxy;
alternatively, when R4Is selected from Z- (CH)2)n-6-membered heterocycle, 3-membered heterocycle, 4-membered heterocycle, 5-membered heterocycle, 6-membered heterocycle or N (CH)3)-(CH2)nNR4cR4dWhen said heterocycle contains from 1 to 4 heteroatoms selected from N, O, S, said heterocycle is optionally further substituted with from 0 to 4H, F, Cl, Br, I, amino, C1-4Alkyl or by 1 to 2C1-4Substituted by substituents of alkyl-substituted amino groups, other radicals being defined optionally byOne of the following conditions:
1):R3selected from ethyl or C substituted by 1, 2 or 3F, Cl, Br or I1-4An alkyl group, a carboxyl group,
2):R2is selected from C1-4Alkoxy or C substituted by 1, 2 or 3F, Cl, Br or I1-4An alkoxy group,
3): b is selected from 6-membered heterocycle, 7-membered heterocycle, 8-membered heterocycle, 9-membered heterocycle, or 10-membered heterocycle, said heterocycle containing 1, 2, 3, or 4 heteroatoms selected from N, O, S, said heterocycle optionally further substituted with 1, 2, 3, or 4 heteroatoms selected from H, F, Cl, Br, I, S (═ O) 2-C1-4Alkyl radical, C1-4Alkyl radical, C1-4Alkoxy radical, C3Carbocyclic ring, C4Carbocyclic ring, C5Carbocyclic ring, C6Carbocyclic, 3-membered heterocyclic, 4-membered heterocyclic, 5-membered heterocyclic, or 6-membered heterocyclic;
z is selected from NH or N-C1-4An alkyl group;
R4ais selected from C3Carbocyclic ring, C4Carbocyclic ring, C5Carbocyclic ring, C6A carbocycle, a 3-membered heterocycle, a 4-membered heterocycle or a 5-membered heterocycle, said heterocycle containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, said carbocycle or heterocycle optionally further substituted with 0, 1, 2, 3 or 4 heteroatoms selected from H, F, Cl, Br, I, amino, C1-4Alkyl or by 1 to 2C1-4Substituted with a substituent of an alkyl-substituted amino group;
R4bis selected from C3Carbocyclic ring, C4Carbocyclic ring, C5Carbocyclic ring, C6A carbocycle, a 3-membered heterocycle, a 4-membered heterocycle, a 5-membered heterocycle or a 6-membered heterocycle, said heterocycle containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, said carbocycle or heterocycle optionally further substituted with 0, 1, 2, 3 or 4 heteroatoms selected from H, F, Cl, Br, I, amino, C1-4Alkyl or by 1 to 2C1-4Substituted with a substituent of an alkyl-substituted amino group;
R4cand R4dIs selected from H or C1-4An alkyl group;
R5selected from H, F, Cl, Br, I, -O-5 membered heterocycle, -O-6 membered heterocycle, -O-7 membered heterocycle, 5 membered heterocycle, 6 membered heterocycle or 7 membered heterocycle,said heterocycle containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, said heterocycle being optionally further substituted with 0, 1, 2, 3 or 4 heteroatoms selected from H, F, Cl, Br, I, (═ O), -C (═ O) C 1-4Alkyl radical, C1-4Alkyl or C1-4Substituted by a substituent of alkoxy;
alternatively, when R3And R4Each independently is H, R5Selected from a 5-membered heterocycle or a 6-membered heterocycle, said heterocycle containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, said heterocycle optionally further substituted with 0, 1, 2, 3 or 4 heteroatoms selected from H, F, Cl, Br, I, (═ O), -C (═ O) C1-4Alkyl radical, C1-4Alkyl or C1-4Substituted by a substituent of alkoxy;
n is selected from 0, 1 or 2.
In a preferred embodiment of the present invention, a compound represented by general formula (II) and an optical isomer, a pharmaceutically acceptable salt or a co-crystal thereof, wherein:
b is selected from 8-, 9-or 10-membered heterocycle, preferably 9-membered heterocycle, further preferably pyridopyrazinyl or benzopyrolyl, said heterocycle optionally further substituted with 0, 1, 2, 3 or 4R1(ii) substituted, said heterocycle containing 1, 2, 3, or 4 heteroatoms selected from N, O, S;
R1each independently selected from H, F, Cl, Br, I, S (═ O)2-C1-4Alkyl radical, C1-4Alkyl, NR1aR1b、 C1-4Alkoxy radical, C3Carbocyclic ring, C4Carbocyclic ring, C5Carbocyclic ring, C6Carbocycle, 3-membered heterocycle, 4-membered heterocycle, 5-membered heterocycle or 6-membered heterocycle, preferably H, F, Cl, Br, I, S (═ O)2-C1-4Alkyl radical, C1-4Alkyl radical, C5Carbocyclic ring, C6Carbocycle, 5-membered heterocycle or 6-membered heterocycle, and further preferably H, F, Cl, Br, I, S (═ O) 2-C1-4Alkyl radical, C1-4Alkyl, 5-or 6-membered heterocycle, more preferably H, F, Cl, Br, I, S (═ O)2CH3Methyl, isopropyl, cyclopropyl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl,
R1aand R1bSelected from H or C1-4An alkyl group;
said alkyl, alkoxy, carbocycle, heterocycle, methyl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl, optionally further substituted with 0, 1, 2, 3 or 4 substituents selected from H, F, Cl, Br, I, (═ O), C1-4Alkyl radical, C1-4Alkoxy, -C (═ O) C1-4Alkyl radical, C3Carbocyclic ring, C4Carbocyclic ring, C5Carbocyclic ring, C6Carbocyclic or 3-, 4-, 5-or 6-membered heterocyclic substituents, preferably 0, 1, 2, 3 or 4 substituents selected from H, F, Cl, Br, I, (═ O), C1-4Alkyl radical, C1-4Alkoxy, -C (═ O) C1-4Alkyl radical, C3Carbocyclic ring, C4Carbocyclic ring, C5Carbocyclic ring, C6Carbocycle, 3-membered heterocycle, 4-membered heterocycle, 5-membered heterocycle or 6-membered heterocycle, and further preferably substituted with 0, 1, 2, 3 or 4 substituents selected from H, F, Cl, Br, I, (═ O), methyl, methoxy, isopropyl, cyclopropyl, -C (═ O) CH3or-C (═ O) CH2CH3Said heterocycle containing 1, 2, 3, or 4 heteroatoms selected from N, O, S.
In a preferred embodiment of the present invention, a compound represented by general formula (II) and an optical isomer, a pharmaceutically acceptable salt or a co-crystal thereof, wherein:
R4Selected from H, F, Cl, 9-membered spiro ring, Z- (CH)2)nR4a、O-(CH2)nR4bOr O- (CH)2)nNR4cR4d(ii) said spirocyclic ring containing 1, 2, 3, or 4 heteroatoms selected from N, O, S, said spirocyclic ring optionally further substituted with 0, 1, 2, 3, or 4 substituents selected from H, F, Cl, Br, I, methyl, or ethyl;
alternatively, when R4Is selected from Z- (CH)2)n-6-membered, 3-membered, 4-membered, 5-membered or 6-membered heterocycle or N (CH)3)-(CH2)nNR4cR4dWhen said heterocycle contains from 1 to 4 heteroatoms selected from N, O, S, said carbocycle or heterocycle is optionally further substituted with from 0 to 4 heteroatomsFrom H, F, Cl, Br, I, amino, NHCH3、N(CH3)2Methyl or ethyl, the other groups defining optionally one of the following conditions:
1):R3selected from ethyl or C substituted by 1, 2 or 3F, Cl, Br or I1-4Alkyl, preferably methyl substituted by 1, 2 or 3F,
2):R2is selected from C1-4Alkoxy or C substituted by 1, 2 or 3F, Cl, Br or I1-4Alkoxy, preferably methoxy, fluoromethoxy, difluoromethoxy or trifluoromethoxy,
3): b is selected from a 9 membered heterocyclic ring containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, said heterocyclic ring optionally further substituted with 1, 2, 3 or 4 heteroatoms selected from H, F, Cl, Br, I, SO2CH3Methyl, isopropyl or cyclopropyl;
Z is selected from NH or NC1-4An alkyl group;
R4ais selected from C3Carbocyclic ring, C4A carbocyclic ring or a 5 membered heterocyclic ring, preferably cyclopropyl or tetrahydropyrrolyl, said heterocyclic ring containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, said carbocyclic or heterocyclic ring optionally further substituted with 0, 1, 2, 3 or 4 heteroatoms selected from H, F, Cl, Br, I, amino, NHCH3、N(CH3)2Methyl or ethyl;
R4bis selected from C3Carbocyclic ring, C4A carbocycle, a 5-membered heterocycle or a 6-membered heterocycle, preferably cyclopropyl, tetrahydropyrrolyl or piperazinyl, said heterocycle containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, said carbocycle or heterocycle optionally further substituted with 0, 1, 2, 3 or 4 heteroatoms selected from H, F, Cl, Br, I, amino, NHCH3、N(CH3)2Methyl or ethyl;
R4cand R4dSelected from H, methyl or ethyl.
In a preferred embodiment of the present invention, a compound represented by general formula (II) and an optical isomer, a pharmaceutically acceptable salt or a co-crystal thereof, wherein:
b is selected from 8-membered heterocycle, 9-membered heterocycle or 10-membered heterocycle, said heterocycle optionally further substituted with 0, 1, 2, 3 or 4R1(ii) substituted, said heterocycle containing 1, 2, 3, or 4 heteroatoms selected from N, O, S;
R1each independently selected from H, F, Cl, Br, I, C1-4Alkyl, S (═ O)2-C1-4Alkyl radical, C 3-6Carbocyclic, 5-or 6-membered heterocyclic ring, NR1aR1b、-C(=O)C1-4Alkyl, -C (═ O) -3 membered heterocycle, -C (═ O) -4 membered heterocycle, -C (═ O) -5 membered heterocycle, -C (═ O) -6 membered heterocycle or-C (═ O) -7 membered heterocycle, preferably H, F, Cl, Br, I, S (═ O)2-C1-4Alkyl radical, C1-4Alkyl or a 5-or 6-membered heterocycle; said alkyl or heterocycle is optionally further substituted by 0, 1, 2, 3 or 4 substituents selected from H, F, Cl, Br, I, (═ O), C1-4Alkyl radical, C1-4Alkoxy, -C (═ O) C1-4Alkyl, C3 carbocycle, C4 carbocycle, C5 carbocycle, C6 carbocycle, 3-membered heterocycle, 4-membered heterocycle, 5-membered heterocycle, or 6-membered heterocycle, said heterocycle containing 1, 2, 3, or 4 heteroatoms selected from N, O, S;
R1aand R1bSelected from H or C1-4An alkyl group;
R2selected from H, F, Cl, C1-4Alkyl or C1-4An alkoxy group;
R3is H, C2-4Alkenyl radical, C3-4Cycloalkyl radical, C1-4Alkyl or C1-4Alkoxy, optionally further substituted with 0, 1, 2, 3 or 4 substituents selected from H, F, Cl or Br;
R4selected from H, F, Cl, 9-membered spiro ring, Z- (CH)2)nR4a、O-(CH2)nR4bOr O- (CH)2)nNR4cR4d(ii) said spirocyclic ring containing 1, 2, 3, or 4 heteroatoms selected from N, O, S, said spirocyclic ring optionally further substituted with 0, 1, 2, 3, or 4 substituents selected from H, F, Cl, Br, I, methyl, or ethyl;
Alternatively, when R4Is selected from Z- (CH)2)n-6-membered, 3-membered, 4-membered, 5-membered or 6-membered heterocycle or N (CH)3)-(CH2)nNR4cR4dWhen said heterocycle contains 1 to 4 heteroatoms selected from N, O, S, said carbocycle or heterocycle is optionally further substituted with 0 to 4 heteroatoms selected from H, F, Cl, Br, I, amino, NHCH3、N(CH3)2Methyl or ethyl, the other groups defining optionally one of the following conditions:
1):R3selected from ethyl or C substituted by 1, 2 or 3F, Cl, Br or I1-4An alkyl group, a carboxyl group,
2):R2is selected from C1-4Alkoxy or C substituted by 1, 2 or 3F, Cl, Br or I1-4An alkoxy group,
3): b is selected from a 9 membered heterocyclic ring containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, said heterocyclic ring optionally further substituted with 1, 2, 3 or 4 heteroatoms selected from H, F, Cl, Br, I, SO2CH3Methyl, isopropyl or cyclopropyl;
z is selected from NH or NC1-4An alkyl group;
R4ais selected from C3Carbocyclic ring, C4A carbocycle or 5-membered heterocycle containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, said carbocycle or heterocycle optionally further substituted with 0, 1, 2, 3 or 4 heteroatoms selected from H, F, Cl, Br, I, amino, NHCH3、N(CH3)2Methyl or ethyl;
R4bis selected from C3Carbocyclic ring, C4A carbocycle, a 5-membered heterocycle or a 6-membered heterocycle, said heterocycle containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, said carbocycle or heterocycle optionally further substituted with 0, 1, 2, 3 or 4 heteroatoms selected from H, F, Cl, Br, I, amino, NHCH 3、N(CH3)2Methyl or ethyl;
R4cand R4dSelected from H, methyl or ethyl;
R5selected from H, F, Cl, a 5-membered heterocycle, a 6-membered heterocycle, an-O-5-membered heterocycle, an-O-6-membered heterocycle or-O-7 membered heterocycle containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, said heterocycle being optionally further substituted with 0, 1, 2, 3 or 4 heteroatoms selected from H, F, Cl, Br, I, (═ O), -C (═ O) C1-4Alkyl radical, C1-4Alkyl or C1-4Substituted by a substituent of alkoxy;
alternatively, when R3And R4Each independently is H, R5Is a 5 to 6 membered heterocyclic ring containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, said heterocyclic ring optionally further substituted with 0, 1, 2, 3 or 4 heteroatoms selected from H, F, Cl, Br, I, (═ O), -C (═ O) C1-4Alkyl radical, C1-4Alkyl or C1-4Substituted by a substituent of alkoxy.
In a preferred embodiment of the present invention, a compound represented by general formula (II) and an optical isomer, a pharmaceutically acceptable salt or a co-crystal thereof, wherein:
b is selected from a 9-membered heterocyclic ring, preferably pyridopyrazolyl or benzopyrolyl, said heterocyclic ring optionally further substituted with 0, 1, 2, 3 or 4R1(ii) substituted, said heterocycle containing 1, 2, 3, or 4 heteroatoms selected from N, O, S;
R1each independently selected from H, F, Cl, Br, I, methyl, S (═ O) 2CH3Isopropyl, cyclopropyl, NHCH3、 N(CH3)2、N(CH3)(C2H5)、-C(=O)C1-4Alkyl, -C (═ O) -cyclopropoxy, -C (═ O) -cyclobutoxy, -C (═ O) -tetrahydropyrrolyl, -C (═ O) -morpholinyl, -C (═ O) -piperazinyl, -C (═ O) -piperidinyl, -C (═ O) -7 membered heterocycle, morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl, preferably H, F, Cl, Br, I, S (═ O)2CH3Methyl, isopropyl, cyclopropyl, morpholinyl, piperazinyl, piperidinyl, or tetrahydropyrrole; said methyl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl group being optionally further substituted by 0, 1, 2, 3 or 4 substituents selected from H, F, Cl, Br, I, (═ O), methyl, methoxy, isopropyl, cyclopropyl, -C (═ O) CH3or-C (═ O) CH2CH3Substituted with the substituent(s);
R2selected from H, F, Cl, methyl or methoxy;
R3selected from H, methyl, ethyl, vinyl, cyclopropyl, methoxy, fluoromethoxy, difluoromethoxy or trifluoromethoxy, preferably H, methoxy, cyclopropyl or difluoromethoxy;
R4selected from H, F, Cl, 9-membered spiro ring, Z- (CH)2)nR4a、O-(CH2)nR4bOr O- (CH)2)nNR4cR4d(ii) said spirocyclic ring containing 1, 2, 3, or 4 heteroatoms selected from N, O, S, said spirocyclic ring optionally further substituted with 0, 1, 2, 3, or 4 substituents selected from H, F, Cl, Br, I, methyl, or ethyl;
Alternatively, when R4Is selected from Z- (CH)2)n-6-membered, 3-membered, 4-membered, 5-membered or 6-membered heterocycle or N (CH)3)-(CH2)nNR4cR4dWhen said heterocycle contains 1 to 4 heteroatoms selected from N, O, S, said carbocycle or heterocycle is optionally further substituted with 0 to 4 heteroatoms selected from H, F, Cl, Br, I, amino, NHCH3、N(CH3)2Methyl or ethyl, the other groups defining optionally one of the following conditions:
1):R3selected from ethyl or methyl substituted by 1, 2 or 3F, preferably difluoromethoxy,
2):R2is methoxy, fluoromethoxy, difluoromethoxy or trifluoromethoxy, preferably methoxy,
3): b is selected from a 9-membered heterocyclic ring, preferably pyridopyrazolyl or benzopyrolyl, said heterocyclic ring containing 1, 2, 3 or 4 heteroatoms selected from N, O, S, said heterocyclic ring, pyridopyrazolyl or benzopyrolyl being optionally further substituted by 1, 2, 3 or 4 heteroatoms selected from H, F, Cl, Br, I, SO2CH3Methyl, isopropyl or cyclopropyl;
z is selected from NH or NCH3;
R4aSelected from substituted or unsubstituted cyclopropyl or tetrahydropyrrolyl, when takenOptionally substituted by 0, 1, 2, 3 or 4 substituents selected from H, F, Cl, Br, I, amino, NHCH3、N(CH3)2Methyl or ethyl;
R4bSelected from substituted or unsubstituted cyclopropyl, tetrahydropyrrolyl or piperazinyl, when substituted, optionally further substituted with 0, 1, 2, 3 or 4 substituents selected from H, F, Cl, Br, I, amino, NHCH3、N(CH3)2Methyl or ethyl;
R4cand R4dSelected from H, methyl or ethyl;
R5selected from H, F, Cl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl, -O-piperazinyl, -O-piperidinyl, -O-morpholinyl or-O-7 membered heterocyclic ring, preferably morpholinyl or piperazinyl, said morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl group being optionally further substituted by 0 to 4 substituents selected from H, F, Cl, Br, I, (═ O), -C (═ O) CH3、-C(=O)CH2CH3Methyl, ethyl, methoxy;
alternatively, when R3And R4Each independently is H, R5Is morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl, preferably morpholinyl or piperazinyl, said morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl being optionally further substituted by 0 to 4 substituents selected from H, F, Cl, Br, I, (═ O), -C (═ O) CH3、-C(=O)CH2CH3Methyl, ethyl, methoxy.
The invention preferably relates to a compound shown in a general formula (II) and an optical isomer, pharmaceutically acceptable salt or eutectic crystal thereof, wherein
B is selected from one of the following substituted or unsubstituted structures:when substituted, is optionally substituted with 1R1Substitution;
R1each independently selected from H, F, Cl, S (═ O)2CH3Isopropyl, cyclopropyl, morpholinyl, piperazinyl, piperidinyl, or tetrahydropyrrole;
R2selected from H, F, Cl, methyl or methoxy;
R3selected from H, methoxy or difluoromethoxy;
R4selected from H, F, Cl or one of the following structures:
alternatively, when R4Is selected fromOptionally, the other groups define one of the following conditions:
1):R3selected from ethyl or methyl substituted by 1, 2 or 3F,
2):R2is a methoxyl group, and the compound is a methoxyl group,
R5selected from H, F, Cl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl;
alternatively, when R3And R4Each independently is H, R5Is morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl.
In a preferred embodiment of the present invention, the compound of formula (I) or formula (II) is selected from, but not limited to, one of the following structures:
the invention relates to a compound shown in a general formula (I) or a general formula (II) and an optical isomer, a pharmaceutically acceptable salt or a eutectic crystal thereof, wherein the salt is selected from hydrochloride, sulfate, phosphate, acetate, trifluoroacetate, fumarate, benzoate, benzenesulfonate, methanesulfonate, trifluoromethanesulfonate or a combination thereof.
The invention relates to a pharmaceutical composition, which contains a therapeutically effective dose of a compound shown in any one of the compounds, an optical isomer, a pharmaceutically acceptable salt or a eutectic crystal thereof, and a pharmaceutically acceptable carrier or excipient.
The invention further relates to an application of the compound, an optical isomer, pharmaceutically acceptable salt or eutectic crystal thereof, or the pharmaceutical composition in preparation of drugs for treating cancers.
In a preferred embodiment of the present invention, the cancer comprises head and neck cancer, ovarian cancer, bladder cancer, cervical cancer, esophageal cancer, gastric cancer, breast cancer, intimal cancer, colon cancer, lung cancer, brain tumor, non-small cell lung cancer, pancreatic cancer, solid tumor, colorectal tumor or glioblastoma.
The present invention further relates to a method of treating cancer, which comprises administering a compound of the invention as set forth above or an optical isomer, a pharmaceutically acceptable salt or a co-crystal thereof, or a pharmaceutical composition of the invention.
In a preferred embodiment of the present invention, the cancer comprises head and neck cancer, ovarian cancer, bladder cancer, cervical cancer, esophageal cancer, gastric cancer, breast cancer, intimal cancer, colon cancer, lung cancer, brain tumor, non-small cell lung cancer, pancreatic cancer, solid tumor, colorectal tumor or glioblastoma.
Synthesis method
R6Selected from H, F, Cl, Br, I or OH,
B、f、R1、R2、R3、R4or R5Is in accordance with the definition given for the compounds of the general formula (I);
if R is4Is H, F, Cl, Br or I, then R6And R4In the same way, the nitro group of the compound of the general formula (I-A) is reduced to obtain the compound of the general formula (I-B), and the reducing agent is selected from H2、Pt、Fe、Zn、LiAlH4Or NaBH4;
If R is4Is nitro, then: in the compound of the general formula (I-A)6Is H and reacts with a nitrating reagent (such as nitric acid and the like) to obtain a compound with a general formula (I-B '), and the nitro group of the compound with the general formula (I-B') is reduced to obtain a compound with a general formula (I-B);
if R is4Is alkyl, then R in the compound of the formula (I-A)6H, reacting with a format reagent or an alkyl lithium reagent and the like to obtain a compound with a general formula (I-B '), and reducing the nitro of the compound with the general formula (I-B') to obtain a compound with the general formula (I-B);
otherwise: compounds of the general formula (I-A) and H-R4Reacting in the presence of a base to obtain a compound with a general formula (I-B '), wherein the nitro group of the compound with the general formula (I-B') is reduced to obtain the compound with the general formula (I-B), the base is selected from diisopropylethylamine, diisopropylamine, triethylamine, potassium carbonate, sodium bicarbonate, sodium carbonate, sodium tert-butoxide, potassium acetate, sodium hydride or cesium carbonate, and the reducing agent is selected from H 2、Pt、Fe、Zn、LiAlH4Or NaBH4;
Reacting the compound of the general formula (I-B) with an acryloyl halide (e.g., acryloyl chloride) or acrylic acid in the presence of a base selected from diisopropylethylamine, diisopropylamine, triethylamine, potassium carbonate, sodium bicarbonate, sodium carbonate, sodium tert-butoxide, potassium acetate, sodium hydride, cesium carbonate, or the like to obtain a compound of the general formula (I);
the compound of the general formula (I-A) is prepared by purchasing or referring to literature methods such as WO 2013014448.
Alternatively, the first and second electrodes may be,
R6selected from H, F, Cl, Br, I or OH,
B、R1、R2、R3、R4or R5Is in accordance with the definition given for the compound of the general formula (II);
if R is4Is H, F, Cl, Br or I, then R6And R4In the same way, the nitro group of the compound of the general formula (I-A-1) is reduced to obtain the compound of the general formula (I-B-1), and the reducing agent is selected from H2、Pt、Fe、Zn、LiAlH4Or NaBH4;
If R is4Is nitro, then R in the compound of the general formula (I-A-1)6Is H and reacts with a nitrating reagent (such as nitric acid and the like) to obtain a compound with a general formula (I-B' -1); the nitro group of the compound of the general formula (I-B' -1) is reduced to obtain a compound of the general formula (I-B-1);
if R is4Is alkyl, then R in the compound of the formula (I-A-1)6H, reacting with a format reagent or an alkyl lithium reagent and the like to obtain a compound of a general formula (I-B '-1), and reducing the nitro of the compound of the general formula (I-B' -1) to obtain a compound of the general formula (I-B-1);
Otherwise: compounds of the general formula (I-A-1) and H-R4Reacting in the presence of a base to obtain a compound with a general formula (I-B '-1), wherein the nitro group of the compound with the general formula (I-B' -1) is reduced to obtain the compound with the general formula (I-B-1), the base is selected from diisopropylethylamine, diisopropylamine, triethylamine, potassium carbonate, sodium bicarbonate, sodium carbonate, sodium tert-butoxide, potassium acetate, sodium hydride or cesium carbonate, and the reducing agent is selected from H2、Pt、Fe、Zn、LiAlH4Or NaBH4;
Reacting the compound of the general formula (I-B-1) with an acryloyl halide (e.g., acryloyl chloride) or acrylic acid in the presence of a base selected from diisopropylethylamine, diisopropylamine, triethylamine, potassium carbonate, sodium bicarbonate, sodium carbonate, sodium tert-butoxide, potassium acetate, sodium hydride, cesium carbonate, or the like, to obtain a compound of the general formula (II);
the compound of the general formula (I-A-1) is obtained by purchasing or referring to a literature method such as WO 2013014448.
Unless stated to the contrary, the terms used in the specification and claims have the following meanings.
The carbon, hydrogen, oxygen, sulfur, nitrogen or halogen referred to in the groups and compounds of the invention all include their isotopes, and the carbon, hydrogen, oxygen, sulfur, nitrogen or halogen referred to in the groups and compounds of the invention are optionally further replaced by one or more of their corresponding isotopes, wherein the carbon isotopes include carbon isotopes 12C、13C and14c, isotopes of hydrogen including protium (H), deuterium (D, also known as deuterium), tritium (T, also known as deuterium), and isotopes of oxygen including16O、17O and18isotopes of O, sulfur including32S、33S、34S and36isotopes of S, nitrogen include14N and15isotopes of N, F19Isotopes of F, chlorine including35Cl and37cl, isotopes of bromine including79Br and81Br。
"alkyl" means a straight and branched chain saturated aliphatic hydrocarbon group having a main chain comprising 1 to 20 carbon atoms, preferably 1 to 12 carbon atoms, more preferably 1 to 8 carbon atoms, still more preferably 1 to 6 carbon atoms, still more preferably 1 to 4 carbon atoms, and most preferably 1 to 2 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, n-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2, 3-dimethyl-2-butyl3, 3-dimethyl-2-butyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2-dimethylpentyl, 2, 3-dimethylpentyl, 2, 4-dimethylpentyl, 3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2-dimethylhexyl, 2, 3-dimethylhexyl, 2, 4-dimethylhexyl, 2, 5-dimethylhexyl, 3-dimethylhexyl, 4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylhexyl, 2-ethylhexyl-pentyl, 2-ethylhexyl, 5-pentyl, 2-pentyl, 3-ethylhexyl, N-nonyl, 2-methyl-2-ethylhexyl, n-decyl and the like. Alkyl groups may be substituted or unsubstituted, and when substituted, substituents may be substituted at any available point of attachment, and are preferably selected from F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged ring, spiro, fused ring, hydroxyalkyl, ═ O, carbonyl, aldehyde, carboxylic acid ester, - (CH) O, carbonyl, aldehyde, carboxylic acid ester, and the like 2)r-C(=O)-Ra、 -O-(CH2)r-C(=O)-Ra、-(CH2)r-C(=O)-NRbRc、-(CH2)rS(=O)qRa、-(CH2)r-alkenyl-Ra、ORdOr- (CH)2)r-alkynyl-Ra(wherein r, q are 0, 1 or 2), arylthio, thiocarbonyl, silyl or-NRbRcWherein R isbAnd RcIndependently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, and trifluoromethanesulfonyl, and optionally, RbAnd RcFive or six membered cycloalkyl or heterocycloalkyl groups may be formed. RaAnd RdEach independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, carbonyl, ester, bridged, spiro, or fused ring.
"alkylene" refers to straight or branched chain alkanes derived from the above alkyl group by removal of two hydrogen atoms, and includes- (CH)2)v- (v being an integer from 1 to 18), alkylene radicalsExamples include, but are not limited to, methylene, ethylene, and propylene, among others. The alkylene group may be substituted or unsubstituted, and when substituted, the substituent is preferably selected from F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged ring, spiro ring, fused ring, hydroxyalkyl, ═ O, carbonyl, aldehyde, carboxylic acid ester, - (CH) 2)r-C(=O)-Ra、-O-(CH2)r-C(=O)-Ra、-(CH2)r-C(=O)-NRbRc、-(CH2)rS(=O)qRa、 -(CH2)r-alkenyl-Ra、ORdOr- (CH)2)r-alkynyl-Ra(wherein r, q are 0, 1 or 2), arylthio, thiocarbonyl, silyl or-NRbRcWherein R isbAnd RcIndependently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, RbAnd RcFive or six membered cycloalkyl or heterocyclyl groups may be formed. RaAnd RdEach independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged, spiro, or fused ring.
"alkoxy" means an-O-alkyl group, wherein alkyl is as defined herein above. Alkoxy groups may be substituted or unsubstituted, and examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and the like. When substituted, the substituents are preferably 1 to 5 substituents selected from F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged ring, spiro, fused ring, hydroxyalkyl, ═ O, carbonyl, aldehyde, carboxylic acid, carboxylic ester- (CH), aryl ester, heteroaryl 2)r-C(=O)-Ra、-O-(CH2)r-C(=O)-Ra、 -(CH2)r-C(=O)-NRbRc、-(CH2)rS(=O)qRa、-(CH2)r-alkenyl-Ra、ORdOr- (CH)2)r-alkynyl-Ra(wherein r, q are 0, 1 or 2), arylthio, thiocarbonyl, silyl or-NRbRcWherein R isbAnd RcIndependently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, and trifluoromethanesulfonyl, and optionally, RbAnd RcMay form a five-or six-membered cycloalkyl or heterocyclyl radical, RaAnd RdEach independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged ring, spiro ring, or fused ring.
"alkenyl" means an alkyl group as defined herein above consisting of at least one carbon-carbon double bond, preferably containing 2 to 20 carbon atoms, more preferably 2 to 12 carbon atoms, and more preferably 2 to 8 carbon atoms in the main chain, and the alkenyl group may be substituted or unsubstituted. Non-limiting examples include vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-3-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 1-octenyl, 2-pentenyl, and the like, 3-octenyl, 1-nonenyl, 3-nonenyl, 1-decenyl, 4-decenyl, 1, 3-butadiene, 1, 3-pentadiene, 1, 4-hexadiene, 3-undecenyl, 4-dodecenyl, and 4,8, 12-tetradecatrienyl, and the like. When substituted, the substituents are 1 to 5 substituents selected from F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged ring, spiro, fused, hydroxyalkyl, ═ O, carbonyl, aldehyde, carboxylic acid, carboxylate ester, - (CH, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged ring, spiro, fused, hydroxyalkyl, (-) O, carbonyl, aldehyde, carboxylic acid, carboxylate 2)r-C(=O)-Ra、-O-(CH2)r-C(=O)-Ra、-(CH2)r-C(=O)-NRbRc、-(CH2)rS(=O)qRa、 -(CH2)r-alkenyl-Ra、ORdOr- (CH)2)r-alkynyl-Ra(wherein r, q are 0, 1 or 2), arylthio, thiocarbonyl, silyl or-NRbRcWherein R isbAnd RcIndependently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, RbAnd RcFive or six membered cycloalkyl or heterocyclyl groups may be formed. RaAnd RdEach independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged, spiro, or fused ring.
"alkynyl" means an alkyl group as defined herein above consisting of at least one carbon-carbon triple bond, preferably containing from 2 to 20 carbon atoms, further preferably from 2 to 8 carbon atoms, more preferably from 2 to 4 carbon atoms in the backbone. Alkynyl groups may be substituted or unsubstituted. Non-limiting examples include ethynyl, 1-propynyl, 2-propynyl, butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 4-pentynyl, 3-pentynyl, 1-methyl-2-butynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, 4-decynyl, 3-undecylynyl, 4-dodecaynyl and the like; when substituted, the substituents are preferably one or more groups independently selected from F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged ring, spiro ring, fused ring, hydroxyalkyl, ═ O, carbonyl, aldehyde, carboxylic acid ester, - (CH) 2)r-C(=O)-Ra、-O-(CH2)r-C(=O)-Ra、 -(CH2)r-C(=O)-NRbRc、-(CH2)rS(=O)qRa、-(CH2)r-alkenyl-Ra、ORdOr- (CH)2)r-alkynyl-Ra(wherein r, q are 0, 1 or 2), arylthio, thiocarbonyl, silyl or-NRbRcWherein R isbAnd RcIndependently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, and trifluoromethanesulfonyl, and optionally, RbAnd RcFive or six membered cycloalkyl or heterocyclyl groups may be formed. RaAnd RdEach independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged ring, spiro ring, or fused ring.
"alkylthio" refers to-S-alkyl or-S- (unsubstituted cycloalkyl), non-limiting examples include methylthio, ethylthio, propylthio, butylthio, and the like.
"amino" means-NH2。
"acyl" or "carbonyl" refers to-C (═ O) -RaGroup, wherein RaAs defined above.
"aldehyde" refers to-C (═ O) -H.
"thio" means ═ S.
"halogen" means fluorine, chlorine, bromine, iodine.
"hydroxy" means-OH.
"cyano" means-C.ident.N.
"isocyano" means-N.ident.C.
"nitro" means-NO2。
"carboxylic acid" refers to-C (═ O) -OH.
"Carboxylic acid ester" means-C (═ O) -O-Rd,RdSelected from alkyl, cycloalkyl or heterocyclyl.
"mercapto" means-SH.
"mercaptan" refers to a hydrocarbon in which one or more hydrogen atoms in the alkyl group are replaced with a mercapto group, non-limiting examples include methyl mercaptan, ethyl mercaptan, 1, 2-dithiol.
"carbocyclic" means a substituted or unsubstituted saturated or unsaturated aromatic or non-aromatic ring which may be a monocyclic, bicyclic, tricyclic or polycyclic ring system, non-limiting examples of which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclopentene, cyclohexadiene, cycloheptatriene, phenyl, naphthyl, benzocyclopentyl, bicyclo [3.2.1 ] bicyclo]Octyl, bicyclo [5.2.0 ]]Nonanyl, tricyclo [5.3.1.1]Dodecyl, adamantyl or spiro [3.3 ]]Heptalkyl, and the like. When substituted, the substituents are independently selected from F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged ring, spiro, fused ring, hydroxyalkyl, ═ O, carbonyl, aldehyde, carboxylic acid ester, - (CH), aryl, heteroaryl, heterocyclic, and heterocyclic2)r-C(=O)-Ra、-O-(CH2)r-C(=O)-Ra、-(CH2)r-C(=O)-NRbRc、-(CH2)rS(=O)qRa、-(CH2)r-alkenyl-Ra、ORdOr- (CH)2)r-alkynyl-Ra(wherein r, q are 0, 1 or 2), arylthio, thiocarbonyl, silyl or-NR bRcWherein R isbAnd RcIndependently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, RbAnd RcFive or six membered cycloalkyl or heterocyclyl groups may be formed. RaAnd RdEach independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged ring, spiro ring, or fused ring.
"heterocycle" means a substituted or unsubstituted saturated or unsaturated aromatic, non-aromatic ring and contains at least one heteroatom selected from N, O, P or S, and optionally substituted N, S, P in the heterocyclic ring can be oxidized to various oxidation states. The aromatic and non-aromatic rings may be monocyclic, bicyclic, tricyclic or polycyclic ring systems, without limitationIllustrative examples include ethylene oxide, aziridine, oxetane, azetidine, 1, 3-dioxolane, 1, 4-dioxolane, 1, 3-dioxane, azepinyl, pyridyl, furyl, thienyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, piperidinyl, perinyl, morpholinyl, thiomorpholinyl, 1, 3-dithiane, dihydrofuran, dihydropyran, dithiane, tetrahydrofuran, tetrahydropyrrole, tetrahydroimidazol, thiazolidine, pyrrolopyridine, chroman, azabicyclo [ 3.2.1.1 ] azabicyclo [3.2.1 ]Octyl, azabicyclo [5.2.0 ] groups]Nonoalkyl oxatricyclo [5.3.1.1 ]]Dodecyl, azaadamantyl, oxaspiro [3.3 ]]A heptylalkyl group,Etc.; when substituted, the substituents are preferably 1 to 5, independently selected from F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged, spiro, fused, hydroxyalkyl, ═ O, carbonyl, aldehyde, carboxylic acid ester, - (CH2)r-C(=O)-Ra、-O-(CH2)r-C(=O)-Ra、-(CH2)r-C(=O)-NRbRc、-(CH2)rS(=O)qRa、 -(CH2)r-alkenyl-Ra、ORdOr- (CH2)r-alkynyl-Ra(wherein r, q are 0, 1 or 2), arylthio, thiocarbonyl, silyl or-NRbRcWherein R isbAnd RcIndependently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, RbAnd RcFive or six membered cycloalkyl or heterocyclyl groups may be formed. RaAnd RdEach independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged, spiro, or fused ring.
"cycloalkyl" means a saturated or unsaturated monocyclic cycloalkyl group, which may be substituted or unsubstituted, and the ring carbon atoms include 3 to 20 carbon atoms, preferably 3 to 10 carbon atoms, further preferably 3 to 8 carbon atoms, and non-limiting examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1, 5-cyclooctadienyl, 1, 4-cyclohexadienyl, cycloheptatrienyl, and the like. When substituted, the substituents are 1 to 5 substituents selected from F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged ring, spiro, fused, hydroxyalkyl, ═ O, carbonyl, aldehyde, carboxylic acid ester, - (CH, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged ring, spiro, fused, hydroxyalkyl, (-) O, carbonyl, aldehyde, carboxylic acid 2)r-C(=O)-Ra、 -O-(CH2)r-C(=O)-Ra、-(CH2)r-C(=O)-NRbRc、-(CH2)rS(=O)qRa、-(CH2)r-alkenyl-Ra、ORdOr- (CH)2)r-alkynyl-Ra(wherein r, q are 0, 1 or 2), arylthio, thiocarbonyl, silyl or-NRbRcWherein R isbAnd RcIndependently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, RbAnd RcFive or six membered cycloalkyl or heterocyclyl groups may be formed. RaAnd RdEach independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged ring, spiro ring, or fused ring.
"spiro" refers to a 5-to 20-membered polycyclic group sharing one carbon atom (referred to as spiro atom) between substituted or unsubstituted monocyclic rings, which may contain 0 to 5 double bonds, and may contain 0 to 5 substituents selected from N, O, P or S (═ O)nAnd (n is 0, 1 or 2). Preferably 6 to 14, more preferably 6 to 12, and even more preferably 6 to 10, non-limiting examples of which include
When substituted, the substituents are 1 to 5 substituents selected from F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged ring, spiro ring, fused ring, hydroxyalkyl, ═ O, carbonyl, aldehyde, carboxylic acid ester, - (CH, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged ring, spiro ring, fused ring, hydroxyalkyl, (-) O, carbonyl, aldehyde 2)r-C(=O)-Ra、 -O-(CH2)r-C(=O)-Ra、-(CH2)r-C(=O)-NRbRc、-(CH2)rS(=O)qRa、-(CH2)r-alkenyl-Ra、ORdOr- (CH)2)r-alkynyl-Ra(wherein r, q are 0, 1 or 2), arylthio, thiocarbonyl, silyl or-NRbRcWherein R isbAnd RcIndependently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, RbAnd RcFive or six membered cycloalkyl or heterocyclyl groups may be formed. RaAnd RdEach independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged ring, spiro ring, or fused ring.
"fused ring" means a polycyclic group in which each ring in the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more of the rings may contain 0 or more double bonds, and may be substituted or unsubstituted, and each ring in the fused ring system may contain 0 to 5 rings selected from N, S (═ O)nOr a heteroatom of O. Preferably 5 to 20, more preferably 5 to 14, more preferably 5 to 12, and even more preferably 5 to 10 yuan. Non-limiting examples include When substituted, the substituents are 1 to 5 substituents selected from F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged ring, spiro, fused ring, hydroxyalkyl, ═ O, carbonyl, aldehyde, carboxylic acid ester, - (CH, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged ring, spiro, fused ring, hydroxyalkyl, (-) O, carbonyl, aldehyde, carboxylic 2)r-C(=O)-Ra、-O-(CH2)r-C(=O)-Ra、-(CH2)r-C(=O)-NRbRc、-(CH2)rS(=O)qRa、-(CH2)r-alkenyl-Ra、ORdOr- (CH)2)r-alkynyl-Ra(wherein r, q are 0, 1 or 2), arylthio, thiocarbonyl, silyl or-NRbRcWherein R isbAnd RcIndependently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, RbAnd RcFive or six membered cycloalkyl or heterocyclyl groups may be formed. RaAnd RdEach independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged ring, spiro ring, or fused ring.
"bridged ring" means any two polycyclic group of carbon atoms not directly attached, which may contain 0 or more double bonds, and which may be substituted or unsubstituted, and any ring in the fused ring system may contain 0 to 5 rings selected from N, S (═ O)nOr an O heteroatom or group (where n is 1, 2). The ring atoms contain 5 to 20 atoms, preferably 5 to 14 atoms, further preferably 5 to 12, and further preferably 5 to 10. Non-limiting examples includeAnd adamantane. When substituted, the substituents are 1 to 5 substituents selected from F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto Group, amino group, cyano group, isocyano group, aryl group, heteroaryl group, heterocyclic group, bridged ring group, spiro ring group, fused ring group, hydroxyalkyl group, (═ O, carbonyl group, aldehyde, carboxylic acid ester, - (CH)2)r-C(=O)-Ra、-O-(CH2)r-C(=O)-Ra、-(CH2)r-C(=O)-NRbRc、-(CH2)rS(=O)qRa、-(CH2)r-alkenyl-Ra、ORdOr- (CH)2)r-alkynyl-Ra(wherein r, q are 0, 1 or 2), arylthio, thiocarbonyl, silyl or-NRbRcWherein R isbAnd RcIndependently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, RbAnd RcFive or six membered cycloalkyl or heterocyclyl groups may be formed. RaAnd RdEach independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged ring, spiro ring, or fused ring.
"benzyl" means-CH2-phenyl, said phenyl being substituted or unsubstituted, non-limiting examples of which include-CH2-phenyl, -CH2P-methylphenyl, and the like.
"aryl" refers to substituted or unsubstituted 6 to 14 membered cyclic aromatic groups, including monocyclic aromatic groups and fused ring aromatic groups. Preferably 6 to 14-membered aromatic ring, further preferably 6 to 10-membered aromatic ring, non-limiting examples of which include phenyl, naphthyl, anthryl, phenanthryl and the like. The aryl ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring attached to the parent structure is an aryl ring, non-limiting examples of which include:
When substituted, the substituents are 1 to 5 substituents selected from F, Cl, Br, I, alkyl, cycloalkyl, alkoxy,Haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged cyclic, spiro cyclic, fused cyclic, hydroxyalkyl, ═ O, carbonyl, aldehyde, carboxylic acid ester, - (CH)2)r-C(=O)-Ra、 -O-(CH2)r-C(=O)-Ra、-(CH2)r-C(=O)-NRbRc、-(CH2)rS(=O)qRa、-(CH2)r-alkenyl-Ra、ORdOr- (CH)2)r-alkynyl-Ra(wherein r, q are 0, 1 or 2), arylthio, thiocarbonyl, silyl or-NRbRcWherein R isbAnd RcIndependently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, RbAnd RcFive or six membered cycloalkyl or heterocyclyl groups may be formed. RaAnd RdEach independently selected from the group consisting of aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged ring, spiro ring, and fused ring.
"heteroaryl" refers to a substituted or unsubstituted 5 to 14 membered aromatic ring and contains 1 to 5 substituents selected from N, O or S (═ O)nA hetero atom or group, preferably a 5-to 10-membered heteroaromatic ring, further preferably 5-to 6-membered. Non-limiting examples of heteroaryl groups include, but are not limited to, pyridyl, furyl, thienyl, pyridyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, piperidinyl, morpholine, thiomorpholine, 1, 3-dithiane, benzimidazole, perindopyl, benzimidazole, benzopyridine, pyrrolopyridine, and the like. The heteroaryl ring may be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring attached to the parent structure is a heteroaryl ring, non-limiting examples of which include
When substituted, 1 to 5 substituents are selected from F, Cl, Br, I, alkylA group, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclyl, bridged ring, spiro, fused ring, hydroxyalkyl, (-) O, carbonyl, aldehyde, carboxylic acid ester, - (CH)2)r-C(=O)-Ra、 -O-(CH2)r-C(=O)-Ra、-(CH2)r-C(=O)-NRbRc、-(CH2)rS(=O)qRa、-(CH2)r-alkenyl-Ra、ORdOr- (CH)2)r-alkynyl-Ra(wherein r, q are 0, 1 or 2), arylthio, thiocarbonyl, silyl or-NRbRcWherein R isbAnd RcIndependently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, RbAnd RcFive or six membered cycloalkyl or heterocyclyl groups may be formed. RaAnd RdEach independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged ring, spiro ring, or fused ring.
"Arylthio" means-S-aryl or-S-heteroaryl as defined herein. Examples of arylthio include, but are not limited to, phenylthio, pyridylthio, furylthio, thienylthio, pyrimidylthio and the like.
"silyl" refers to a group formed by substituting one or more hydrogen atoms in silane with an alkyl group, and examples include, but are not limited to, trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, and the like.
"optional" or "optionally" means that the subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs or does not. Such as: "alkyl optionally substituted with F" means that the alkyl group may, but need not, be substituted with F, and the description includes the case where the alkyl group is substituted with F and the case where the alkyl group is not substituted with F.
"pharmaceutically acceptable salt" or "pharmaceutically acceptable salt thereof" means that the biological effectiveness and properties of the free acid or free base are maintained and the free acid is obtained by reaction with a non-toxic inorganic or organic base or salts of the free acid obtained by reaction with a non-toxic inorganic or organic acid, including alkali metal salts such as sodium, potassium, lithium, and the like; alkaline earth metal salts such as calcium salts, magnesium salts, and the like; other metal salts such as iron salts, copper salts, cobalt salts, etc.; organic base salts such as ammonium salts, triethylamine salts, pyridine salts, picoline salts, 2, 6-lutidine salts, ethanolamine salts, diethanolamine salts, triethanolamine salts, cyclohexylamine salts, ethylenediamine salts, guanidine salts, isopropylamine salts, trimethylamine salts, tripropylamine salts, triethanolamine salts, diethanolamine salts, ethanolamine salts, dimethylethanolamine salts, dicyclohexylamine salts, caffeine salts, procaine salts, choline salts, betaine salts, benzamidine penicillin salts, glucamine salts, N-methylglucamine salts, theobromine salts, tromethamine salts, purine salts, piperazine salts, morpholine salts, piperidine salts, N-ethylpiperidine salts, tetramethylamine salts, dibenzylamine salts, phenylglycine alkyl ester salts and the like; hydrohalic acid salts such as hydrofluoride, hydrochloride, hydroiodide, hydrobromide and the like; inorganic acid salts such as hydrochloride, nitrate, sulfate, perchlorate, phosphate and the like; lower alkanesulfonates such as methanesulfonate, trifluoromethanesulfonate, ethanesulfonate and the like; arylsulfonates such as benzenesulfonate, p-toluenesulfonate and the like; organic acid salts such as acetate, benzoate, fumarate, formate, trifluoroacetate, furoate, gluconate, glutamate, glycolate, isethionate, lactate, maleate, malate, mandelate, mucate, pamoate, pantothenate, stearate, succinate, sulfa, tartrate, malonate, 2-hydroxypropionate, citrate, salicylate, oxalate, glycolate, glucuronate, galacturonate, citrate, lysine, arginine, aspartate, cinnamate and the like.
"pharmaceutical composition" means a mixture of one or more compounds described herein or a physiologically/pharmaceutically acceptable salt thereof with other ingredients, wherein the other ingredients comprise physiologically/pharmaceutically acceptable carriers and excipients.
"carrier" refers to a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
"excipient" refers to an inert substance added to a pharmaceutical composition to further depend on the administration of the compound. Examples of excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives (including microcrystalline cellulose), gelatin, vegetable oils, polyethylene glycols, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like.
"prodrug" refers to a compound that can be converted under physiological conditions or by solvolysis to a compound of the invention that is biologically active. Prodrugs of the invention are prepared by modifying the phenolic groups in the compounds, which modifications may be removed in vivo or by conventional procedures, to provide the parent compounds. When a prodrug of the present invention is administered to a mammalian subject, the prodrug is cleaved to form free hydroxyl groups, respectively. Examples of prodrugs include, but are not limited to, phenolic hydroxy and phosphoric acid sodium salt derivatives of the compounds of the present invention.
"cocrystal" or "cocrystal" refers to a crystal of an Active Pharmaceutical Ingredient (API) and a cocrystal former (CCF) combined by hydrogen bonding or other non-covalent bonds, wherein the API and CCF are both solid in pure form at room temperature and a fixed stoichiometric ratio exists between the components. A co-crystal is a multi-component crystal that contains both a binary co-crystal formed between two neutral solids and a multicomponent co-crystal formed between a neutral solid and a salt or solvate. The "co-crystal former" includes, but is not limited to, various pharmaceutically acceptable acids, bases, non-ionic compounds, water, amino acids, alcohols or other solvents, non-limiting examples of which include alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile), proline (Pro), phenylalanine (Phe), tryptophan (Trp), methionine (Met), glycine (Gly), serine (Ser), threonine (Thr), cysteine (Cys), tyrosine (Tyr), asparagine (Asn), glutamine (gin), lysine (Lys), arginine (Arg), histidine (His), aspartic acid (Asp), glutamic acid (Glu), pyroglutamic acid, sulfuric acid, phosphoric acid, nitric acid, hydrobromic acid, hydrochloric acid, formic acid, acetic acid, propionic acid, benzenesulfonic acid, benzoic acid, phenylacetic acid, salicylic acid, alginic acid, Anthranilic acid, camphoric acid, citric acid, vinylsulfonic acid, formic acid, fumaric acid, furoic acid, gluconic acid, glucuronic acid, glutamic acid, glycolic acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, mucic acid, pamoic acid, pantothenic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, p-toluenesulfonic acid, malonic acid, 2-hydroxypropionic acid, oxalic acid, glycolic acid, glucuronic acid, galacturonic acid, citric acid, lysine, arginine, aspartic acid, cinnamic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid or trifluoromethanesulfonic acid, ammonia, isopropylamine, trimethylamine, diethylamine, triethylammonium, tripropylammonium, diethanolamine, ethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, caffeine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, and mixtures thereof, Procaine, choline, betaine, phentermine, ethylenediamine, glucosamine, methylglucamine, theobromine, tromethamine, purine, piperazine, piperidine, N-ethylpiperidine, methanol, ethanol, butynediol, 1, 2-propanediol, (R)1, 2-propanediol, (S)1, 2-propanediol or 1-methyl-1, 2-ethanediol.
An "effective dose" refers to an amount of a compound that causes physiological or medical translation in a tissue, system, or subject that is sought, including an amount of the compound that is sufficient to prevent, or alleviate to some extent, one or more symptoms of the condition or disorder being treated when administered to a subject.
"solvates" refers to compounds of the invention or salts thereof, which also include stoichiometric or non-stoichiometric amounts of solvents bound by intermolecular non-covalent forces. When the solvent is water, it is a hydrate.
The technical solutions of the present invention are described in detail below with reference to examples, but the scope of the present invention includes, but is not limited to, these examples.
Detailed Description
The technical solutions of the present invention are described in detail below with reference to the drawings and the embodiments, but the scope of the present invention includes but is not limited thereto.
The structure of the compounds is determined by Nuclear Magnetic Resonance (NMR) or (and) Mass Spectrometry (MS). NMR shift (. delta.) by 10-6The units in (ppm) are given. NMR was measured using (Bruker Avance III 400 and Bruker Avance 300) nuclear magnetic spectrometers in deuterated dimethyl sulfoxide (DMSO-d)6) Deuterated chloroform (CDCl)3) Deuterated methanol (CD)3OD), internal standard Tetramethylsilane (TMS).
MS was measured by Agilent 6120B (ESI) and Agilent 6120B (APCI).
HPLC was carried out using an Agilent 1260DAD high pressure liquid chromatograph (Zorbax SB-C18100X 4.6 mm).
The thin layer chromatography silica gel plate adopts HSGF254 of tobacco yellow sea or GF254 of Qingdao, the specification of the silica gel plate used by Thin Layer Chromatography (TLC) is 0.15 mm-0.20 mm, and the specification of the thin layer chromatography separation and purification product is 0.4 mm-0.5 mm.
The column chromatography generally uses 200-300 mesh silica gel of the Tibet Huanghai silica gel as a carrier.
Known starting materials of the present invention can be synthesized by or according to methods known in the art, or can be purchased from companies such as Tatan technology, Anniji chemistry, Shanghai Demer, Chengdong chemical, Shaoshanghi chemical technology, and Bailingwei technology.
The nitrogen atmosphere means that the reaction flask is connected with a nitrogen balloon with a volume of about 1L.
The hydrogen atmosphere refers to a reaction flask connected with a hydrogen balloon with a volume of about 1L.
The hydrogenation reaction was usually evacuated and charged with hydrogen and repeated 3 times.
In the examples, the reaction was carried out under a nitrogen atmosphere without specific mention.
In the examples, the solution means an aqueous solution unless otherwise specified.
In the examples, the reaction temperature is room temperature, unless otherwise specified.
The room temperature is the most suitable reaction temperature and is 20-30 ℃.
Boc is tert-butyloxycarbonyl;
n-Bu is n-butyl;
t-Bu is tert-butyl;
TBS is tert-butyl dimethyl silicon base;
TIPS is triisopropylsilyl.
Intermediate 1
5- (difluoromethoxy) -N1- (2- (dimethylamino) ethyl) -N1-methyl-2-nitrophenyl-1, 4-diamine (intermediate 1)
5-(difluoromethoxy)-N1-(2-(dimethylamino)ethyl)-N1-methyl-2-nitrobenzene-1,4-dia mine
The first step is as follows: (4-fluoro-2-hydroxyphenyl) carbamic acid tert-butyl ester (1b)
tert-butyl(4-fluoro-2-hydroxyphenyl)carbamate
2-amino-5-fluorophenol 1a (5g, 39.4mmol) and tetrahydrofuran (100mL) were added to a reaction flask, and after dissolving with stirring, di-tert-butyl dicarbonate (17.2g, 78.7mmol) was added, and the reaction was stirred at room temperature for two days. Concentrated to dryness under reduced pressure, water (150mL), ethyl acetate (200mL) were added to the residue, liquid separation was performed with stirring, the aqueous layer was extracted with ethyl acetate (150mL × 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 20:1) to give tert-butyl (4-fluoro-2-hydroxyphenyl) carbamate (1b) as an off-white solid (6g, yield 67%).
1H NMR(400MHz,CDCl3)δ8.55(s,1H),6.95(dd,1H),6.69(dd,1H),6.56(ddd, 2H),1.52(s,9H)。
The second step is that: (2- (Difluoromethoxy) -4-fluorophenyl) carbamic acid tert-butyl ester (1c)
tert-butyl(2-(difluoromethoxy)-4-fluorophenyl)carbamate
Tert-butyl (4-fluoro-2-hydroxyphenyl) carbamate (1b) (4g, 17.6mmol) and acetonitrile (40mL) were added to a reaction flask, cooled in an ice bath, added with a solution of potassium hydroxide (19.7g, 352mmol) in water (40mL), cooled to-78 deg.C, and added dropwise with diethyl bromofluoromethylphosphate (11.8g, 44.1mmol) and allowed to warm to room temperature for 30 minutes. To the reaction solution was added ethyl acetate (100mL), followed by liquid separation with stirring, extraction of the aqueous layer with ethyl acetate (50mL × 2), combination of organic phases, drying of the organic phase with anhydrous sodium sulfate, filtration, concentration of the filtrate under reduced pressure, and separation and purification of the residue by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 20:1) to give tert-butyl (2- (difluoromethoxy) -4-fluorophenyl) carbamate (1c) as a yellow liquid (3g, 61% yield).
1H NMR(400MHz,CDCl3)δ8.09(t,1H),6.95-6.83(m,2H),6.72(s,1H),6.52(t, 1H),1.52(s,9H)。
The third step: 2- (Difluoromethoxy) -4-fluoro-5-nitroaniline (1d)
2-(difluoromethoxy)-4-fluoro-5-nitroaniline
Concentrated sulfuric acid (10mL) and water (0.7mL) were added to the reaction flask, cooled in an ice bath, tert-butyl (2- (difluoromethoxy) -4-fluorophenyl) carbamate (1c) (2.7g, 9.8mmol) was added, stirring was completed for 10 minutes, potassium nitrate (0.98g, 9.8mmol) was slowly added, and the reaction was completed in an ice bath for 1 hour. The reaction solution was poured into ice water (50mL), cooled in an ice bath, the pH of the system was adjusted to 9 with aqueous ammonia, extracted with ethyl acetate (50mL × 3), the organic phases were combined, the organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 20:1-10:1) to give 2- (difluoromethoxy) -4-fluoro-5-nitroaniline (1d) as a brown solid (370mg, yield 17%).
1H NMR(400MHz,DMSO-d6)δ7.50(d,1H),7.32(s,1H),7.29(t,1H),6.52(t,1H), 5.59(s,2H)。
The fourth step: 5- (difluoromethoxy) -N1- (2- (dimethylamino) ethyl) -N1-methyl-2-nitrophenyl-1, 4-diamine (intermediate 1)
5-(difluoromethoxy)-N1-(2-(dimethylamino)ethyl)-N1-methyl-2-nitrobenzene-1,4-dia mine
To a reaction flask were added 2- (difluoromethoxy) -4-fluoro-5-nitroaniline (1d) (250mg, 1.15mmol), N, N, N '-trimethylethylenediamine (18A) (118mg, 1.15mmol), diisopropylethylamine (375mg, 2.9mmol) and N, N' -dimethylacetamide (5mL), and reacted at 140 ℃ for 1 hour under microwave. The reaction mixture was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 50:1) to give 5- (difluoromethoxy) -N as a brown oil 1- (2- (dimethylamino) ethyl) -N1Methyl-2-nitrophenyl-1, 4-diamine (intermediate 1) (120mg, 34% yield).
MS m/z(ESI):305.3[M+1]+。
1H NMR(400MHz,DMSO-d6)δ7.25(t,1H),7.13(d,2H),5.40(s,2H),3.08(t,2H), 2.67(t,2H),2.63(s,3H),2.39(s,6H)。
Intermediate 2
3- (2-Chloropyrimidin-4-yl) -1-methyl-1H-indole (intermediate 2)
3-(2-chloropyrimidin-4-yl)-1-methyl-1H-indole
The first step is as follows: 3- (2-Chloropyrimidin-4-yl) -1H-indole (2b)
3-(2-chloropyrimidin-4-yl)-1H-indole
Indole (4g, 34.1mmol) and 1, 2-dichloroethane (114mL) were added to the reaction flask, and after stirring and dissolution, the mixture was cooled in an ice bath, and a 3mol/L methylmagnesium bromide tetrahydrofuran solution (11.4mL, 34.1mmol) was added dropwise. After the incubation was completed for 15 minutes, 2, 4-dichloropyrimidine (2a) (5.6g, 37.6mmol) was added, and the mixture was allowed to slowly warm to room temperature for reaction for 3 hours. The reaction solution was cooled in an ice bath, methanol (10mL) was added dropwise, the mixture was stirred for 15 minutes, the mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 4:1-2:1) to give 3- (2-chloropyrimidin-4-yl) -1H-indole (2b) as a yellow solid (2.9g, yield 37%).
MS m/z(ESI):230.1[M+1]+。
1H NMR(400MHz,DMSO-d6)δ12.07(s,1H),8.58–8.47(m,2H),8.47–8.36(m, 1H),7.91(d,1H),7.51(dd,1H),7.31–7.15(m,2H)。
The second step is that: 3- (2-Chloropyrimidin-4-yl) -1-methyl-1H-indole (intermediate 2)
3-(2-chloropyrimidin-4-yl)-1-methyl-1H-indole
3- (2-Chloropyrimidin-4-yl) -1H-indole (2b) (2.5g, 10.9mmol) and tetrahydrofuran (77mL) were added to a reaction flask, and after stirring and dissolving, the mixture was cooled in an ice bath, sodium hydride (0.48g, 12mmol) was added in portions, the reaction was allowed to proceed for 30 minutes after completion of the incubation, methyl iodide (0.75mL, 12mmol) was added dropwise, and the reaction was allowed to proceed for 2 hours after completion of the incubation. To the reaction solution were added saturated aqueous sodium bicarbonate (100mL), ethyl acetate (200mL), and the mixture was stirred, separated, and the organic layer was washed with saturated aqueous sodium bicarbonate (50mL × 1) and saturated brine (50mL × 1) in this order, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was slurried with dichloromethane (10mL × 1) to give 3- (2-chloropyrimidin-4-yl) -1-methyl-1H-indole (intermediate 2) (2.3g, yield 85%) as a pale yellow solid.
MS m/z(ESI):244.1[M+1]+。
1H NMR(400MHz,CDCl3)δ8.45(d,1H),8.32(dd,1H),7.98(s,1H),7.51(d,1H), 7.45–7.30(m,3H),3.90(s,3H)。
Intermediate 3
5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 3)
5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-fluoro-1-nitrobenzene
Reference is made to the synthesis of intermediate 129 of WO 2013014448.
Intermediate 4
5-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (intermediate 4)
5-chloro-N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin -2-amine
The first step is as follows: 3- (2, 5-dichloropyrimidin-4-yl) -1H-indole (4b)
3-(2,5-dichloropyrimidin-4-yl)-1H-indole
Indole 4a (12.78g, 109mmol) was dissolved in tetrahydrofuran (60mL), cooled to 0 ℃ under nitrogen, methyl magnesium bromide (36.4mL, 109mmol) was added dropwise, stirring was continued for 0.5 h, trichloropyrimidine (10g, 54.5 mmol) was added, the reaction was carried out at room temperature for 1h, and the reaction was carried out at 60 ℃ for 1.5 h. The reaction mixture was cooled to room temperature, acetic acid (6.34 mL) was added dropwise, the mixture was stirred for 10 minutes, water (100mL) and tetrahydrofuran (30mL) were added, the mixture was stirred at 60 ℃ for 30 minutes, the mixture was separated, n-heptane (100mL) was added to the organic phase to precipitate a yellow solid, the yellow solid was filtered, the filter cake was washed with n-heptane (100mL), and the filter cake was dried to give 3- (2, 5-dichloropyrimidin-4-yl) -1H-indole (4b) (13g, yield 91%).
MS m/z:264.0[M+1]+。
1H NMR(400MHz,DMSO-d6)δ12.26(s,1H),8.73(s,2H),8.53(s,1H),7.57(s, 1H),7.28(s,2H)。
The second step is that: 3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1H-indole (4c)
3-(2,5-dichloropyrimidin-4-yl)-1-methyl-1H-indole
3- (2, 5-dichloropyrimidin-4-yl) -1H-indole (4b) (6g, 22.8mmol) was dissolved in tetrahydrofuran (100mL), cooled to 0 deg.C, sodium hydride (1.1g, 27.4mmol) was added, the reaction was continued for 30 minutes, methyl iodide (4.26 mL, 68.4mmol) was added, and the mixture was allowed to warm to room temperature for 2 hours. The reaction was concentrated and the residue was washed with water (50mL) and tetrahydrofuran (50mL), filtered, and the filter cake was dried to give the compound 3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1H-indole (4c) as a yellow solid (4.7g, 75% yield).
MS m/z:278.0[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.75(d,2H),8.55(d,1H),7.61(d,1H),7.43–7.22 (m,2H),3.96(s,3H)。
The third step: 4-fluoro-2-methoxy-5-nitroaniline (4e)
4-fluoro-2-methoxy-5-nitroaniline
4-fluoro-2-methoxyaniline (4d) (17.1g, 0.1mmol) was dissolved in concentrated sulfuric acid (100mL) under ice bath, and potassium nitrate (10.1g, 0.1mmol) was slowly added thereto to react at 10 ℃ for 2 hours. The reaction solution was poured into crushed ice, aqueous ammonia was added to adjust the pH to 8, ethyl acetate (400 mL. times.2) was added for extraction, the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to give 4-fluoro-2-methoxy-5-nitroaniline (4e) as a yellow solid (18.6g, crude product).
1H NMR(400MHz,DMSO-d6)δ7.34(d,1H),7.03(d,1H),5.22(s,2H),3.90(s, 3H)。
The fourth step: 5-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (intermediate 4)
5-chloro-N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin -2-amine
3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1H-indole (4c) (1g, 3.6mmol) was dissolved in 2-pentanol (100mL), and 4-fluoro-2-methoxy-5-nitroaniline (4e) (672mg, 3.6mmol) and p-toluenesulfonic acid (822mg, 4.32mmol) were added, and the reaction was heated to 120 ℃ and refluxed for 2 days. The reaction was cooled to room temperature, acetonitrile (50mL) was added, filtered, the filter cake was washed with acetonitrile (50mL) and water (50mL) in sequence, and the filter cake was dried to give 5-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (intermediate 4) as a pale green solid (1.48g, 97%).
MS m/z:428.0[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.74(s,1H),8.66(d,1H),8.58(s,1H),8.47(s,1H), 8.33(d,1H),7.53(d,1H),7.38(t,1H),7.27(t,1H),7.06(t,1H),3.97(s,3H),3.92(s, 3H)。
Intermediate 5
5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 5)
5-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-fluor o-1-nitrobenzene
The first step is as follows: (E) -4- (2-butoxyvinyl) -2, 5-dichloropyrimidine (5b)
(E)-4-(2-butoxyvinyl)-2,5-dichloropyrimidine
2,4, 5-trichloropyrimidine (5a) (5g,27.3mmol), 1-butoxyethylene (2.85g,28.5mmol), triethylamine (2.88g,28.5mmol) and palladium acetate (0.21g,0.95mmol) were added to polyethylene glycol (30mL) and reacted at 50 ℃ for 5 hours under nitrogen. The reaction solution was cooled to room temperature, water (50mL) was added, extraction was performed with ethyl acetate (50mL × 3), the organic phases were combined, the organic phase was dried over anhydrous sodium sulfate, concentrated, and the residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate (v/v) ═ 50:1) to give the title compound (E) -4- (2-butoxyvinyl) -2, 5-dichloropyrimidine (5b) as a yellow solid (0.6g, yield 9%).
1H NMR(400MHz,CDCl3)δ8.32(s,1H),8.07(d,1H),6.09(d,1H),4.03(t,2H), 1.76–1.70(m,2H),1.48–1.43(m,2H),0.97(t,3H)。
The second step is that: 3- (2, 5-dichloropyrimidin-4-yl) pyrazolo [1,5-a ] pyridine (5c)
3-(2,5-dichloropyrimidin-4-yl)pyrazolo[1,5-a]pyridine
(E) -4- (2-butoxyvinyl) -2, 5-dichloropyrimidine (5b) (0.6g,2.4mmol), 1-amino-pyridin-1-ium (0.6g,2.4mmol) and potassium carbonate (0.84g,6.0mmol) were added to N, N-dimethylformamide (30mL) and reacted at room temperature to 110 ℃ for 5 hours. After cooling to room temperature, water (20mL) was added to the reaction solution, extraction was performed with ethyl acetate (50mL × 3), the organic phases were combined, the organic phase was washed with water (50mL × 2), dried over anhydrous sodium sulfate, concentrated, and the residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate (v/v) ═ 10:1) to give the title compound 3- (2, 5-dichloropyrimidin-4-yl) pyrazolo [1,5-a ] pyridine (5c) as a yellow solid (0.1g, yield 16%).
1H NMR(400MHz,DMSO-d6)δ9.08(s,1H),8.96(d,1H),8.80(s,1H),8.57(d, 1H),7.75–7.71(m,1H),7.27(td,1H)。
MS m/z:265.1[M+1]+。
The third step: 5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrophenyl (intermediate 5)
5-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-fluor o-1-nitrobenzene
3- (2, 5-dichloropyrimidin-4-yl) pyrazolo [1,5-a ] pyridine (5c) (1g,3.7mmol), 4-fluoro-2-methoxy-5-nitroaniline (0.84g,4.5mmol) and p-toluenesulfonic acid (1.08g,5.6mmol) were added to 2-pentanol (30mL), and the mixture was heated to 120 ℃ for 12 hours. Cooled to room temperature, methanol (50mL) was added to the reaction solution, filtered, the filter cake was washed with diethyl ether (30mL), and the filter cake was dried to give the title compound 5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 5) as a yellow solid (1g, 64% yield).
MS m/z:415.1[M+1]+。
Intermediate 6
5- ((4- (indol-3-yl) -5-chloropyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 6)
5-((4-(indol-3-yl)-5-chloropyrimidin-2-yl)amino)-4-methoxy-2-fluoro-1-nitrobenzene
Reference is made to the synthesis of intermediate 68 of WO 2013014448.
Intermediate 7
5-chloro-4- (4-fluoro-1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (intermediate 7)
5-chloro-4-(4-fluoro-1H-indol-3-yl)-N-(4-fluoro-2-methoxy-5-nitrophenyl)pyrimidin- 2-amine
The first step is as follows: 3- (2, 5-dichloropyrimidin-4-yl) -4-fluoro-1H-indole (7b)
3-(2,5-dichloropyrimidin-4-yl)-4-fluoro-1H-indole
4-fluoro-1H-indole (7a) (15g, 0.11mol) and tetrahydrofuran (90mL) are added into a reaction bottle, the mixture is cooled by an ice salt bath, 3mol/L methyl magnesium bromide tetrahydrofuran solution (37mL) is dripped, the internal temperature is kept lower than-5 ℃, the reaction is kept for 30 minutes after the dripping, 2,4, 5-trichloropyrimidine (10.2g,0.06mol) is added, and the temperature is raised to 60 ℃ after the addition for 1 hour. The reaction solution was cooled to room temperature, acetic acid (10mL), water (90mL), tetrahydrofuran (50mL) were added, the reaction was warmed to 60 ℃ for 1 hour, cooled to room temperature, the organic layer was separated, dried over anhydrous sodium sulfate, concentrated to dryness under reduced pressure, and purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 8:1-6:1) to give tert-butyl 3- (2, 5-dichloropyrimidin-4-yl) -4-fluoro-1H-indole (7b) as a yellow solid (3.7g, 24% yield).
MS m/z(ESI):280.1[M-1]-。
1H NMR(400MHz,DMSO-d6)δ12.26(s,1H),8.87(s,1H),8.14(d,1H),7.37(d, 1H),7.23(td,1H),6.93(dd,1H)。
The second step is that: 5-chloro-4- (4-fluoro-1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (intermediate 7)
5-chloro-4-(4-fluoro-1H-indol-3-yl)-N-(4-fluoro-2-methoxy-5-nitrophenyl)pyrimidin- 2-amine
To a reaction flask were added 3- (2, 5-dichloropyrimidin-4-yl) -4-fluoro-1H-indole (7b) (2.6g, 9.1mmol), 4-fluoro-2-methoxy-5-nitroaniline (4e) (1.3g, 9.1mmol), p-toluenesulfonic acid (1.2g, 11.1mmol) and 2-pentanol (55mL), and the mixture was heated to 120 ℃ for reaction for 9 hours. The reaction solution was cooled to room temperature, filtered, and the filter cake was washed with acetonitrile (5mL × 1) and dichloromethane (5mL × 1), respectively, the filter cake was collected, petroleum ether (30mL) was added to the filtrate, stirred, and filtered, and the solid was collected with acetonitrile (5mL × 1) and dichloromethane (15mL × 1) of the filter cake, twice to give 5-chloro-4- (4-fluoro-1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (intermediate 7) (2.2g, 55% yield) as a yellow-brown solid.
MS m/z(ESI):430.1[M-1]-。
Intermediate 8
4- (7-fluoro-1-methyl-1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (intermediate 8)
4-(7-fluoro-1-methyl-1H-indol-3-yl)-N-(4-fluoro-2-methoxy-5-nitrophenyl)pyrimidin -2-amine
The first step is as follows: 3- (2-Chloropyrimidin-4-yl) -7-fluoro-1H-indole (8b)
3-(2-chloropyrimidin-4-yl)-7-fluoro-1H-indole
7-fluoroindole (10g, 74mmol) and 1, 2-dichloroethane (270mL) are added into a reaction flask, after stirring and dissolution, the mixture is cooled in an ice bath, 3mol/L methyl magnesium bromide tetrahydrofuran solution (24.7mL, 74mmol) is added dropwise, the reaction is kept for 15 minutes after the dropwise addition, 2, 4-dichloropyrimidine (2a) (16g, 110mmol) is added, and the temperature is slowly raised to 45 ℃ for reaction for 24 hours. The reaction solution was cooled in an ice bath, methanol (100mL) was added dropwise, and the mixture was stirred for 15 minutes, concentrated under reduced pressure, and purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 5:1-1:1) to give 3- (2-chloropyrimidin-4-yl) -7-fluoro-1H-indole (8b) (8.4g, yield 46.6%) as a yellow solid.
MS m/z(ESI):246.1[M-1]-。
1H NMR(400MHz,DMSO-d6)δ12.59(s,1H),8.61–8.54(m,2H),8.25(d,1H), 7.97(d,1H),7.21(td,1H),7.09(dd,1H)。
The second step is that: 3- (2-Chloropyrimidin-4-yl) -7-fluoro-1-methyl-1H-indole (8c)
3-(2-chloropyrimidin-4-yl)-7-fluoro-1-methyl-1H-indole
3- (2-Chloropyrimidin-4-yl) -7-fluoro-1H-indole (8b) (280mg, 1.13mmol) and tetrahydrofuran (14mL) were added to a reaction flask, stirred to dissolve, cooled in an ice bath, added sodium hydride (58mg, 2.4mmol) in portions, incubated for 30 minutes after completion of the incubation, added iodomethane (0.15mL, 2.4mmol) dropwise, incubated for 30 minutes after completion of the incubation, and heated to 40 ℃ for 3 hours. The reaction mixture was cooled in an ice bath, water (10mL) was added, extraction was performed with ethyl acetate (20mL × 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 3:1) to give 3- (2-chloropyrimidin-4-yl) -7-fluoro-1-methyl-1H-indole (8c) as a yellow solid (260mg, 88% yield).
MS m/z(ESI):262.2[M+1]+。
1H NMR(400MHz,CDCl3)δ8.43(d,1H),8.08(d,1H),7.80(s,1H),7.42(d,1H), 7.17(td,1H),6.97(dd,1H),4.05(d,3H)。
The third step: 4- (7-fluoro-1-methyl-1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (intermediate 8)
4-(7-fluoro-1-methyl-1H-indol-3-yl)-N-(4-fluoro-2-methoxy-5-nitrophenyl)pyrimidin -2-amine
To a reaction flask was added 3- (2-chloropyrimidin-4-yl) -7-fluoro-1-methyl-1H-indole (8c) (260mg,1mmol), 4-fluoro-2-methoxy-5-nitroaniline (186mg, 1mmol), p-toluenesulfonic acid (132mg, 1.2mmol) and 2-pentanol (5mL), and heated to 105 ℃ for 3 hours. The reaction solution was cooled to room temperature, filtered, and the filter cake was washed with acetonitrile (10mL × 1) to collect the filter cake, yielding 4- (7-fluoro-1-methyl-1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (intermediate 8) (280mg, 68% yield) as a pale yellow solid.
MS m/z(ESI):410.2[M-1]-。
Intermediate 9
N- (4-fluoro-2-methoxy-5-nitro-phenyl) -5-methoxy-4-pyrazolo [1,5-a ] pyridin-3-yl-pyrimidin-2-amine (intermediate 9)
N-(4-fluoro-2-methoxy-5-nitro-phenyl)-5-methoxy-4-pyrazolo[1,5-a]pyridin-3-yl-pyri midin-2-amine
The first step is as follows: (trans) -4- (2-n-butoxyvinyl) -2-chloro-5-methoxypyrimidine (9b)
(E)-4-(2-butoxyvinyl)-2-chloro-5-methoxypyrimidine
2, 4-dichloro-5-methoxypyrimidine (9a) (10.74g,60mmol) was weighed out and placed in a 500mL round-bottomed flask, and polyethylene glycol 400(150mL), triethylamine (12.5mL,90.00mmol), vinyl-n-butyl ether (11.6mL,90.00mmol) and palladium acetate (0.67g,3mmol) were added to the flask in this order, and the mixture was heated to 80 ℃ and stirred for 16 hours. The reaction solution was cooled to room temperature, water (200mL) was added, extraction was performed with ethyl acetate (250mL × 2), the organic phases were combined, the organic phase was washed with saturated brine (150mL), dried over anhydrous sodium sulfate, and concentrated and purified by column chromatography (petroleum ether/ethyl acetate (v/v) ═ 5:1) to give (trans) -4- (2-n-butoxyvinyl) -2-chloro-5-methoxypyrimidine (9b) as a yellow liquid (6.64g, yield 46%).
1H NMR(400MHz,CDCl3)δ7.98-7.94(m,2H),6.04-6.01(d,1H),3.98-3.95(m, 2H),3.90(s,3H),1.75-1.68(m,2H),1.45-1.41(m,2H),0.97-0.93(m,3H)。
The second step is that: 3- (2-chloro-5-methoxy-pyrimidin-4-yl) pyrazolo [1,5-a ] pyridine (9c)
3-(2-chloro-5-methoxy-pyrimidin-4-yl)pyrazolo[1,5-a]pyridine
(trans) -4- (2-N-butoxyvinyl) -2-chloro-5-methoxypyrimidine (9b) (9.0g,37.3mmol) was weighed out and placed in a 250mL round-bottomed flask, N-dimethylacetamide (100mL), 1-aminopyridine iodide (8.2g,37.3mmol) and potassium carbonate (12.9g,92.5mmol) were added in this order to a reaction flask, and the mixture was stirred at 110 ℃ for 24 hours. The reaction solution was cooled to room temperature, water (100mL) was added, extraction was performed with ethyl acetate (150mL × 2), the organic phases were combined, the organic phase was washed with saturated brine (50mL × 2), dried over anhydrous sodium sulfate, and concentrated and purified by column chromatography (petroleum ether/ethyl acetate (v/v) ═ 3:1) to give 3- (2-chloro-5-methoxy-pyrimidin-4-yl) pyrazolo [1,5-a ] pyridine (9c) as a yellow solid (3.9g, yield 40%).
1H NMR(400MHz,CDCl3)δ8.81-8.78(m,2H),8.57-8.56(d,1H),8.15(s,1H), 7.46-7.44(m,1H),7.02-6.99(m,1H),4.08(s,3H)。
The third step: n- (4-fluoro-2-methoxy-5-nitro-phenyl) -5-methoxy-4-pyrazolo [1,5-a ] pyridin-3-yl-pyrimidin-2-amine (intermediate 9)
N-(4-fluoro-2-methoxy-5-nitro-phenyl)-5-methoxy-4-pyrazolo[1,5-a]pyridin-3-yl- pyrimidin-2-amine
3- (2-chloro-5-methoxy-pyrimidin-4-yl) pyrazolo [1,5-a ] pyridine (9c) (1.04g,4mmol) was weighed into a 50mL round-bottomed flask and 2-pentanol (15mL), 4-fluoro-2-methoxy-5-nitroaniline (0.74 g,4mmol), p-toluenesulfonic acid (0.84g,4.4mmol) were added to the reaction flask in that order. The reaction system was warmed to 120 ℃ and stirred for 48 hours and then cooled to room temperature. Acetonitrile (20mL), aqueous ammonia (20mL) was added to the reaction flask. Filtration, washing of the filter cake with acetonitrile (10mL × 2), washing with water (10mL × 2), collecting the filter cake, and drying to give N- (4-fluoro-2-methoxy-5-nitro-phenyl) -5-methoxy-4-pyrazolo [1,5-a ] pyridin-3-yl-pyrimidin-2-amine (intermediate 9) (0.6g, 37% yield) as a yellow solid.
Intermediate 10
N- (3, 4-difluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (intermediate 10)
N-(3,4-difluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-a mine
The first step is as follows: n- (3, 4-difluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (intermediate 10)
N-(3,4-difluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-a mine
3- (2-Chloropyrimidin-4-yl) -1-methyl-1H-indole (intermediate 2) (3g,12mmol), 3, 4-difluoro-2-methoxy-5-nitroaniline (10a) (3g,14mmol) and p-toluenesulfonic acid (3.5g,18mmol) were added to 2-pentanol (30mL) and reacted at 120 ℃ for 12 hours. The reaction was cooled to room temperature, methanol (50mL) was added, filtered, the filter cake was washed with ethyl ether (30mL), and the filter cake was dried to give the title compound N- (3, 4-difluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (intermediate 10) as a yellow solid (3g, 62.5% yield).
MS m/z:494.3[M+1]+。
Example 1
N- (5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) phenyl) acrylamide (compound 1)
N-(5-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2 -(1-methyl-1,7-diazaspiro[4.4]nonan-7-yl)phenyl)acrylamide
The first step is as follows: 5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) -1-nitrobenzene (1B)
5-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(1- methyl-1,7-diazaspiro[4.4]nonan-7-yl)-1-nitrobenzene
5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 5) (0.3g,0.72mmol), 1-methyl-1, 7-diazaspiro [4.4] nonane (1A) (0.15g,10.8mmol) and N, N-diisopropylethylamine (i.e., DIPEA) (0.28g,2.17mmol) were added to N, N-dimethylformamide (3 mL) and reacted with microwaves at 140 ℃ for 1.5 hours. Cooled to room temperature, water (20mL) was added to the reaction solution, extracted with ethyl acetate (50mL × 3), the organic phases were combined, the organic phase was washed with water (50mL × 2), dried over anhydrous sodium sulfate, and concentrated to give the title compound 5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) -1-nitrobenzene (1B) as a red solid (0.3g, yield 79%).
1H NMR(400MHz,DMSO-d6)δ8.94(s,1H),8.84(d,1H),8.68(s,1H),8.41(s,2H), 8.06(s,1H),7.32(m,1H),7.13(m,1H),6.56(s,1H),3.90(s,3H),3.43–3.41(m,2H), 3.26-3.24(m,1H),2.77–2.64(m,3H),2.31(s,3H),2.12-2.09(m,1H),1.79–1.66(m, 5H)。
MS m/z:535.3[M+1]+。
The second step is that: 5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) aniline (1C)
5-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(1- methyl-1,7-diazaspiro[4.4]nonan-7-yl)aniline
5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) -1-nitrobenzene (1B) (0.6g,1.12mmol), iron powder (0.378g,6.7mmol) and ammonium chloride were added to a mixed solution of ethanol (20mL) and water (5mL) and reacted at 90 ℃ for 4 hours. Cooled to room temperature, water (20mL) was added to the reaction solution, extracted with dichloromethane (50mL × 3), the organic phases were combined, washed with water (50mL × 2), dried over anhydrous sodium sulfate, and concentrated to give the title compound 5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) aniline (1C), a red solid (0.56g, crude product).
1H NMR(400MHz,DMSO-d6)δ8.94(s,1H),8.82(d,1H),8.44–8.36(m,3H), 7.32(m,1H),7.12(m,1H),6.94(s,1H),6.69(s,1H),4.26(s,2H),3.66(s,3H),3.21(d, 1H),3.13(s,1H),3.07–3.01(m,1H),2.70–2.64(m,3H),2.34(s,3H),2.10–2.03(m,1H), 1.93–1.83(m,2H),1.80–1.61(m,3H)。
MS m/z;505.3[M+1]+。
The third step: n- (5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) phenyl) acrylamide (compound 1)
N-(5-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2 -(1-methyl-1,7-diazaspiro[4.4]nonan-7-yl)phenyl)acrylamide
5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) aniline (1C) (0.6g,1.1mmol), N-ethyldiisopropylamine (0.3g,2.2mmol) were added to tetrahydrofuran (20mL) and a solution of acryloyl chloride (0.1g,1.1mmol) in tetrahydrofuran (5mL) was added dropwise at-40 ℃ and allowed to react at this temperature for half an hour. Water (10mL) was added to the reaction solution, extraction was performed with ethyl acetate (50mL × 3), the organic phases were combined, the organic phase was washed with water (50mL × 2), dried over anhydrous sodium sulfate, concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 50:1) to give the title compound N- (5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) phenyl) acrylamide (compound 1) as a yellow solid (0.18g, yield 27%).
1H NMR(400MHz,CDCl3)δ9.10(s,1H),8.93(s,1H),8.54–8.51(m,2H),8.41(s, 1H),8.18(s,1H),7.40(s,1H),7.31(m,1H),6.90(t,1H),6.71(s,1H),6.35–6.31(m,2H), 5.72–5.69(m,1H),3.89(s,3H),3.25(s,2H),3.06(d,1H),2.78(s,3H),2.50(s,3H),2.22 (s,1H),2.00(s,2H),1.87(s,3H)。
MS m/z:559.4[M+1]+。
Example 2
(S) -N- (5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) phenyl) acrylamide (Compound 2)
(S)-N-(5-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methoxy -2-(1-methyl-1,7-diazaspiro[4.4]nonan-7-yl)phenyl)acrylamide
Example 3
(R) -N- (5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) phenyl) acrylamide (Compound 3)
(R)-N-(5-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methoxy -2-(1-methyl-1,7-diazaspiro[4.4]nonan-7-yl)phenyl)acrylamide
The resolution method of example 2 and example 3 is as follows:
n- (5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) phenyl) acrylamide (compound 1) (100mg) was taken for resolution under the conditions: instrument GX-281C0630, (0.1% diethylamine + n-hexane)/isopropanol 70/30, 10.0mL/min, 254nm, column temperature 40 ℃ (AD-H20 × 250mm 5um H-37); two optical isomers were obtained: isomer 1 (peak 1, 50mg, yellow solid, ee% ═ 100%, t ═ 33.97min), isomer 2 (peak 2, 50mg, yellow solid, ee% ═ 100%, t ═ 40.78 min).
Isomer 1
1H NMR(400MHz,CDCl3)δ9.11(s,1H),8.93(s,1H),8.53(d,2H),8.42(s,1H), 8.16(s,1H),7.40(s,1H),7.30(d,1H),6.90(t,1H),6.72(s,1H),6.40–6.16(m,2H),5.71 (d,1H),3.89(s,3H),3.24(d,2H),3.07(d,1H),2.77(s,3H),2.48(s,3H),2.21(s,1H),2.05 –1.78(m,5H)。
MS m/z:559.3[M+1]+。
Isomer 2
1H NMR(400MHz,CDCl3)δ9.11(s,1H),8.93(s,1H),8.53(d,2H),8.42(s,1H), 8.16(s,1H),7.40(s,1H),7.30(d,1H),6.90(t,1H),6.72(s,1H),6.35–6.25(m,2H),5.71 (d,1H),3.89(s,3H),3.34–3.13(m,2H),3.08–3.06(m,1H),2.95–2.64(m,3H),2.48 (s,3H),2.21(s,1H),2.09–1.78(m,5H)。
MS m/z:559.3[M+1]+。
Example 4
N- (5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) phenyl) acrylamide trifluoroacetate (Compound 4)
N-(5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(1-methyl-1,7 -diazaspiro[4.4]nonan-7-yl)phenyl)acrylamide triflouro
The first step is as follows: 5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) -1-nitrobenzene (4B)
5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(1-methyl-1,7-diazasp iro[4.4]nonan-7-yl)-1-nitrobenzene
5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 3) (1.0g,2.5mmol) and N, N-diisopropylethylamine (0.65g,5.0mmol) were added to N, N-dimethylformamide (3mL) and reacted with microwaves at 140 ℃ for 1.5 hours. After cooling to room temperature, water (20mL) was added to the reaction solution, extraction was performed with dichloromethane (50mL × 3), the organic phases were combined, the organic phase was washed with water (50mL × 2), dried over anhydrous sodium sulfate, concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 50:1) to give the title compound 5- ((5-chloro-4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) -1-nitrobenzene (4B) as a yellow solid (0.5g, yield 38.4%).
1H NMR(400MHz,DMSO-d6)δ8.54(s,1H),8.36(d,1H),8.34–8.25(m,2H), 8.04(s,1H),7.51(d,1H),7.24(t,1H),7.18(d,1H),7.10(t,1H),6.57(s,1H),3.96(s,3H), 3.87(s,3H),3.42(d,2H),3.25(d,1H),2.78–2.68(m,3H),2.31(s,3H),2.11–2.09(m, 1H),1.83–1.65(m,5H)。
MS m/z:514.3[M+1]+。
The second step is that: 5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) aniline (4C)
5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(1-methyl-1,7-diazasp iro[4.4]nonan-7-yl)aniline
5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) -1-nitrobenzene (4B) (0.5g,0.97mmol), iron powder (0.32g,5.8mmol) and ammonium chloride (0.52g,9.7 mmol) were added to a mixed solution of ethanol (5 mL)/water (2mL) and reacted at 90 ℃ for 4 hours. Cooled to room temperature, water (20mL) was added to the reaction solution, extracted with dichloromethane (50mL × 3), the organic phases were combined, washed with water (50mL × 2), dried over anhydrous sodium sulfate, and concentrated to give the title compound 5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) aniline (4C) as a yellow solid (0.4g, 85% yield).
MS m/z:484.4[M+1]+。
The third step: n- (5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) phenyl) acrylamide (4D)
N-(5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(1-methyl-1,7-diaz aspiro[4.4]nonan-7-yl)phenyl)acrylamide
5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) aniline (4C) (0.5g,1mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) (0.149g,2.0mmol) and acrylic acid (0.79g,4mmol) were added to pyridine (5mL) and reacted at room temperature for 2 hours. Water (10mL) was added to the reaction solution, extraction was performed with dichloromethane (50mL × 3), the organic phases were combined, the organic phase was washed with water (50mL × 2), dried over anhydrous sodium sulfate, concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 50:1) to give the title compound N- (5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) phenyl) acrylamide (4D) as a yellow solid (0.2g, yield 36%).
1H NMR(400MHz,DMSO-d6)δ9.29(s,1H),8.40(s,1H),8.33(d,1H),8.27(d,1H), 8.15(s,1H),7.78(s,1H),7.51(d,1H),7.27–7.11(m,3H),6.59(s,1H),6.56–6.49(m, 1H),6.21(dd,1H),5.75–5.69(m,1H),3.89–3.86(m,6H),3.37(d,1H),3.25–3.22(m, 2H),2.77–2.59(m,3H),2.31(s,3H),2.05–2.02(m,1H),1.81–1.58(m,5H)。
MS m/z:538.1[M+1]+。
The fourth step: n- (5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) phenyl) acrylamide trifluoroacetate (Compound 4)
N-(5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(1-methyl-1,7 -diazaspiro[4.4]nonan-7-yl)phenyl)acrylamide triflouroacetate
N- (5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) phenyl) acrylamide (4D) (50mg,0.09mmol) was dissolved in dichloromethane (10mL), trifluoroacetic acid (15mg) was added, and stirring was carried out at room temperature for 30 minutes, followed by concentration to give N- (5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (1-methyl-1, 7-diazaspiro [4.4] nonan-7-yl) phenyl) acrylamide trifluoroacetate (Compound 4), yellow solid (57 mg).
1H NMR(400MHz,DMSO-d6)δ10.14(s,1H),9.31(d,1H),8.54(d,1H),8.31– 8.27(m,3H),7.54(d,1H),7.25–7.18(m,3H),6.77(d,1H),6.66–6.45(m,1H),6.23(d, 1H),5.74(d,1H),3.91(s,3H),3.88(s,3H),3.75–3.51(m,3H),3.18–3.13(m,3H),2.88 (s,3H),2.38–1.90(m,6H)。
MS m/z:538.2[M+1]+。
Example 5
N- (2- ((1-Aminocyclopropyl) methoxy) -5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide trifluoroacetate (Compound 5)
N-(2-((1-aminocyclopropyl)methoxy)-5-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl )pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide trifluoroacetate
The first step is as follows: (1- ((4- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -5-methoxy-2-nitrophenoxy) methyl) cyclopropyl) carbamic acid tert-butyl ester (5B)
tert-butyl(1-((4-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)-5- methoxy-2-nitrophenoxy)methyl)cyclopropyl)carbamate
5-chloro-N- (4-fluoro-2-methoxy-5-nitro-phenyl) -4-pyrazolo [1,5-a ] pyridin-3-yl-pyrimidin-2-amine (intermediate 5) (0.41g,1.00mmol) was placed in a round-bottom flask, tetrahydrofuran (20mL) was added to the reaction flask, cooled to 0 ℃, sodium hydride (0.08g,1.1mmol, wt% ═ 60%) was added to the reaction flask, stirred for 5 minutes, and (1-hydroxymethylcyclopropyl) -tert-butoxycarbonylamino (5A) (0.21g,1.1mmol) was added. The reaction was terminated after 4 hours when the temperature was raised to room temperature. Water (20mL) was added to the reaction flask, the aqueous phase was extracted with ethyl acetate (50mL × 2), the combined organic phases were washed with saturated brine (30mL), dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (petroleum ether/ethyl acetate (v/v) ═ 1:1) to give tert-butyl (1- ((4- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -5-methoxy-2-nitrophenoxy) methyl) cyclopropyl) carbamate (5B) (0.56g, 97% yield) as a yellow solid.
1H NMR(400MHz,CDCl3)δ8.60(s,1H),8.58(s,1H),8.46-8.42(m,1H),8.40-8.35 (m,1H),8.32(s,1H),8.25(br,1H),7.43-7.39(m,1H),7.05-7.02(m,1H),5.25(br,1H), 4.19(s,2H),4.01(s,3H),1.42(s,9H),097(s,4H)。
The second step is that: (1- ((2-amino-4- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenoxy) methyl) cyclopropyl) carbamic acid tert-butyl ester (5C)
tert-butyl(1-((2-amino-4-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)a mino)-5-methoxyphenoxy)methyl)cyclopropyl)carbamate
Tert-butyl (1- ((4- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -5-methoxy-2-nitrophenyloxy) methyl) cyclopropyl) carbamate (5B) (0.58g,1.0mmol) was weighed out and placed in a 100mL round-bottomed flask, ethanol (21mL), water (7mL), reduced iron powder (0.34g,6.0mmol) and ammonium chloride (0.037g,0.7mmol) were added in this order to a reaction flask, and the reaction was refluxed at elevated temperature and worked up after 6 hours. The reaction was filtered, the filter cake was washed with dichloromethane (10mL × 2) and methanol (10mL × 2) in that order, the filtrates were combined, concentrated, and the residue was purified by column chromatography (petroleum ether/ethyl acetate (v/v) ═ 1:1) to give tert-butyl (1- ((2-amino-4- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenoxy) methyl) cyclopropyl) carbamate (5C) (0.37g, 67% yield) as a gray solid.
The third step: (1- ((2-Acrylamido-4- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenoxy) methyl) cyclopropyl) carbamic acid tert-butyl ester (5D)
tert-butyl(1-((2-acrylamido-4-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2- yl)amino)-5-methoxyphenoxy)methyl)cyclopropyl)carbamate
Tert-butyl (1- ((2-amino-4- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenoxy) methyl) cyclopropyl) carbamate (5C) (0.37g,0.67mmol) was weighed, placed in a 100mL round-bottom flask, tetrahydrofuran (15mL) and diisopropylethylamine (0.12mL,0.74 mmol) were sequentially added to the reaction flask, cooled to 0 ℃, acryloyl chloride (0.055mL,0.70mmol) was added dropwise, and after the addition was completed, the temperature was raised for reaction for 1 hour. The reaction solution was concentrated under reduced pressure, methylene chloride (50mL) and a saturated aqueous solution of sodium hydrogencarbonate (30mL) were added to the residue, the aqueous phase was separated, the aqueous phase was extracted with methylene chloride (50mL), the organic phases were combined, the organic phase was washed with saturated brine (30mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (methylene chloride/methanol (v/v) ═ 10:1) to give tert-butyl (1- ((2-acrylamido-4- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenoxy) methyl) cyclopropyl) carbamate (5D) as a yellow solid (0.20g, yield 49%).
The fourth step: n- (2- ((1-Aminocyclopropyl) methoxy) -5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide trifluoroacetate (Compound 5)
N-(2-((1-aminocyclopropyl)methoxy)-5-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3- yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide 2,2,2-trifluoroacetate
Tert-butyl (1- ((2-acrylamido-4- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenoxy) methyl) cyclopropyl) carbamate (5D) (0.2g,0.33mmol) was weighed and placed in a 100mL round-bottomed flask, and dichloromethane (15mL) and trifluoroacetic acid (5mL) were sequentially added to the reaction flask and reacted at room temperature for 1 hour. Concentration under reduced pressure gave N- (2- ((1-aminocyclopropyl) methoxy) -5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide trifluoroacetate (compound 5) as a yellow solid (0.03g, 15% yield).
MS m/z(ESI):506.3[(M-MTFA)+1]+。
1H NMR(400MHz,DMSO-d6)δ9.23(s,1H),8.84(s,1H),8.78-8.76(d,1H),8.69(s, 1H),8.48(br,3H),8.38(m,2H),8.22(s,1H),7.33-7.31(m,1H),7.11-7.08(m,1H),6.88 (s,1H),6.57-6.55(m,1H),6.23-6.20(d,1H),5.78-5.75(d,1H),4.24(s,2H),3.77(s,3H), 1.12-1.09(m,2H),1.03-1.00(m,2H)。
Example 6
N- (2- (((1-aminocyclopropyl) methyl) (methyl) amino) -5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide trifluoroacetate (Compound 6)
N-(2-(((1-aminocyclopropyl)methyl)(methyl)amino)-5-((5-chloro-4-(1H-indol-3-yl) pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide trifluoroacetate
The first step is as follows: (1- (((4- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxy-2-nitrophenyl) (methyl) amino) methyl) cyclopropyl) carbamic acid tert-butyl ester (6B)
tert-butyl-(1-(((4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-5-methoxy-2 -nitrophenyl)(methyl)amino)methyl)cyclopropyl)carbamate
5- ((4- (indol-3-yl) -5-chloropyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 6) (1.0 g,2.4mmol), (1- ((methylamino) methyl) cyclopropyl) carbamic acid tert-butyl ester (6A) (0.96g,4.8mmol) and N, N-diisopropylethylamine (0.62g,4.8mmol) were added to trifluoroethanol (3mL) and reacted with microwaves at 140 ℃ for 1.5 hours. The reaction solution was cooled to room temperature, water (20mL) was added, extraction was performed with dichloromethane (50mL × 3), the organic phases were combined, the organic phase was washed with water (50mL × 2), dried over anhydrous sodium sulfate, concentrated, and the residue was chromatographed on a silica gel column (dichloromethane: methanol (v/v) ═ 50:1) to give the title compound (tert-butyl 1- (((4- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxy-2-nitrophenyl) (methyl) amino) methyl) cyclopropyl) carbamate (6B), red solid (0.5g, yield 34.97%).
MS m/z:594.3[M+1]+。
The second step is that: (1- (((4- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxy-2-aminophenyl) (methyl) amino) methyl) cyclopropyl) carbamic acid tert-butyl ester (6C)
tert-butyl-(1-(((4-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-5-methoxy-2 -aminophenyl)(methyl)amino)methyl)cyclopropyl)carbamate
Tert-butyl (1- (((4- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxy-2-nitrophenyl) (methyl) amino) methyl) cyclopropyl) carbamate (6B) (0.27g,0.45mmol), iron powder (0.15g,2.7mmol) and amine chloride (0.24g,4.5mmol) were added to ethanol (5mL) and water (2mL) and reacted at 90 ℃ for 4 hours. After cooling to room temperature, water (20mL) was added to the reaction solution, extraction was performed with dichloromethane (50 mL. times.3), the organic phases were combined, washed with water (50 mL. times.2), dried over anhydrous sodium sulfate, and concentrated to give the title compound (tert-butyl 1- (((4- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxy-2-aminophenyl) (methyl) amino) methyl) cyclopropyl) carbamate (6C) as a yellow solid (0.18g, yield 70.3%).
MS m/z:564.2[M+1]+。
The third step: n- (2- (((1- (tert-butoxycarbonyl) aminocyclopropyl) methyl) (methyl) amino) -5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (6D)
N-(2-(((1-(tert-butoxycarbonyl)aminocyclopropyl)methyl)(methyl)amino)-5-((5-chloro- 4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide
Tert-butyl (1- (((4- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxy-2-aminophenyl) (methyl) amino) methyl) cyclopropyl) carbamate (6C) (0.16g,0.28mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.21g,1.1mmol) and acrylic acid (40.9mg,0.56mmol) were added to pyridine (5mL) and reacted at room temperature for 2 hours. Water (10mL) was added to the reaction solution, and extracted with dichloromethane (50mL × 3), the organic phases were combined, the organic phase was washed with water (50mL × 2), dried over anhydrous sodium sulfate, concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 50:1) to give the title compound N- (2- (((1- (tert-butoxycarbonyl) aminocyclopropyl) methyl) (methyl) amino) -5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (6D) as a yellow solid (0.15g, yield 88%).
MS m/z:618.2[M+1]+。
The fourth step: n- (2- (((1-aminocyclopropyl) methyl) (methyl) amino) -5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide trifluoroacetate (Compound 6)
N-(2-(((1-aminocyclopropyl)methyl)(methyl)amino)-5-((5-chloro-4-(1H-indol-3-yl) pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide trifluoroacetate
N- (2- (((1- (tert-butoxycarbonyl) aminocyclopropyl) methyl) (methyl) amino) -5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (6D) (0.15g,0.24mmol) was added to dichloromethane (2mL) and trifluoroacetic acid (1mL) and reacted at room temperature for 2 hours. The reaction was concentrated to give the title compound N- (2- (((1-aminocyclopropyl) methyl) (methyl) amino) -5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide trifluoroacetate (compound 6) as a yellow solid (0.1g, 88% yield).
1H NMR(400MHz,DMSO-d6)δ11.85(s,1H),9.21(s,1H),8.50–8.49(m,2H), 8.43(s,1H),8.36(s,1H),8.35–8.22(m,4H),7.45(m,1H),7.15(m,1H),7.00(m,1H), 6.95(s,1H),6.71–6.64(m,1H),6.23(d,1H),5.76(d,1H),3.77(s,3H),3.16(s,1H),2.65 (s,3H),1.04(s,2H),0.85(s,2H)。
MS m/z:518.1[M+1]+。
Example 7
N- (2- ((1-Aminocyclopropyl) methoxy) -5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 7)
N-(2-((1-aminocyclopropyl)methoxy)-5-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)a mino)-4-methoxyphenyl)acrylamide
The first step is as follows: (1- ((2-Nitro-4- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenoxy) methyl) cyclopropyl) carbamic acid tert-butyl ester (7B)
tert-butyl(1-((4-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-metho xy-2-nitrophenoxy)methyl)cyclopropyl)carbamate
5-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (intermediate 4) (650mg, 1.52mmol) was dissolved in tetrahydrofuran (50mL), and sodium hydride (121.6mg, 3.04 mmol, wt% ═ 60%) was added under ice-cooling, followed by stirring for 30 minutes, dropwise addition of tert-butyl (1- (hydroxymethyl) cyclopropyl) carbamate (313.1mg, 1.67mmol), and reaction at room temperature overnight. To the reaction mixture were added water (100mL) and ethyl acetate (150mL), the mixture was partitioned, the aqueous phase was extracted with ethyl acetate (100mL), the organic phases were combined, the organic phase was dried over anhydrous sodium sulfate, and concentrated to give compound (tert-butyl 1- ((2-nitro-4- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenoxy) methyl) cyclopropyl) carbamate (7B) as a yellow solid (903 mg).
MS m/z:595.1[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.58(d,2H),8.40(s,1H),8.39–8.22(m,2H), 7.51(d,1H),7.25(dd,9.8Hz,2H),7.01(s,2H),4.29(s,2H),3.94(s,3H),3.91(s,3H), 1.99(s,1H),1.37(s,9H),0.87(s,2H),0.77(s,2H)。
The second step is that: (1- ((2-amino-4- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenoxy) methyl) cyclopropyl) carbamic acid tert-butyl ester (7C)
tert-butyl(1-((2-amino-4-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino) -5-methoxyphenoxy)methyl)cyclopropyl)carbamate
Tert-butyl (1- ((2-nitro-4- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenoxy) methyl) cyclopropyl) carbamate (7B) (900mg, 1.52mmol) was dissolved in ethanol (30mL), water (10mL), iron powder (509mg, 9.12mmol) and ammonium chloride (57mg, 10.6mmol) were added, the temperature was raised to 90 ℃ and the reaction was refluxed for 4 hours. The reaction was cooled to room temperature, filtered and concentrated. Separation and purification by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 20:1) gave compound (tert-butyl 1- ((2-amino-4- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenoxy) methyl) cyclopropyl) carbamate (7C) as a yellow-green solid (800mg, yield 93%).
MS m/z:565.2[M+1]+。
The third step: n- (2- ((1- (tert-butoxycarbonyl) aminocyclopropyl) methoxy) -5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (7D)
N-(2-((1-(tert-butoxycarbonyl)aminocyclopropyl)methoxy)-5-((5-chloro-4-(1H-indol- 3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide
Tert-butyl (1- ((2-amino-4- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenoxy) methyl) cyclopropyl) carbamate (7C) (800mg, 1.4mmol) was dissolved in tetrahydrofuran (30mL), N-diisopropylethylamine (0.278mg, 1.68mmol) was added, the reaction was cooled to 0 ℃, a solution of acryloyl chloride (0.17mL, 2.1mmol) in tetrahydrofuran (5mL) was added dropwise, and the mixture was warmed to room temperature for 4 hours. To the reaction solution were added a saturated aqueous sodium bicarbonate solution (100mL) and dichloromethane (100mL), and the organic phase was separated, concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 25:1) to give the compound N- (2- ((1- (tert-butoxycarbonyl) aminocyclopropyl) methoxy) -5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (7D) as a red solid (450mg, yield 52%).
MS m/z:619.2[M+1]+。
The fourth step: n- (2- ((1-Aminocyclopropyl) methoxy) -5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 7)
N-(2-((1-aminocyclopropyl)methoxy)-5-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)a mino)-4-methoxyphenyl)acrylamide
N- (2- ((1- (tert-butoxycarbonyl) aminocyclopropyl) methoxy) -5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (7D) (450mg, 0.73mmol) was dissolved in dichloromethane (12mL), and trifluoroacetic acid (3mL) was added to react at room temperature for 2 hours. To the reaction solution was added water (50mL), the pH was adjusted to 8 with a saturated aqueous solution of sodium hydrogen carbonate, ethyl acetate (100mL) was added, the layers were separated, the organic phase was concentrated, and the residue was purified to give N- (2- ((1-aminocyclopropyl) methoxy) -5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 7) as a pale yellow solid (70mg, yield 19%).
MS m/z:519.1[M+1]+。
1H NMR(400MHz,CDCl3)δ9.32(s,1H),8.41(d,2H),8.33(d,2H),7.41(s,1H), 7.36(d,1H),7.29(d,1H),7.21(t,1H),6.57(s,1H),6.38(dd,1H),6.34–6.25(m,1H), 5.70(d,1H),3.90(s,5H),3.87(s,3H),1.25(s,1H),0.75(t,2H),0.67(t,2H)。
Example 8
N- (5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (methyl (2- (tetrahydropyrrole-1-yl) ethyl) amino) phenyl) acrylamide (compound 8)
N-(5-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(2-(pyr rolidin-1-yl)ethyl)amino)phenyl)acrylamide
The first step is as follows: 5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (methyl (2- (tetrahydropyrrole-1-yl) ethyl) amino) -1-nitrobenzene (8B)
5-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(2-(pyrroli din-1-yl)ethyl)amino)-nitrobenzene
5- ((4- (indol-3-yl) -5-chloropyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 6) (1.0 g,2.4mmol), N-methyl-2- (tetrahydropyrrol-1-yl) ethylamine (8A) (0.60g,4.8mmol) and N, N-diisopropylethylamine (0.6g,4.8mmol) were added to N, N-dimethylacetamide (3mL) and microwaved at 140 ℃ for 1.5 hours. The reaction solution was cooled to room temperature, water (20mL) was added, extraction was performed with dichloromethane (50mL × 3), the organic phases were combined, the organic phase was washed with water (50mL × 2), dried over anhydrous sodium sulfate, concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 50:1) to give the title compound 5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (methyl (2- (tetrahydropyrrole-1-yl) ethyl) amino) -1-nitrobenzene (8B) as a red solid (0.5g, yield 40%).
1H NMR(400MHz,CDCl3)δ9.17(s,1H),9.04(s,1H),8.45(m,1H),8.39(s,1H), 8.29(s,1H),7.51(s,1H),7.41(m,1H),7.34–7.19(m,2H),6.65(s,1H),3.93(s,3H), 3.36–3.25(m,2H),2.86(s,3H),2.81–2.72(m,2H),2.58(s,4H),1.77(s,4H)。
5-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(2-(pyrroli din-1-yl)ethyl)amino)aniline
5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (methyl (2- (tetrahydropyrrol-1-yl) ethyl) amino) -1-nitrobenzene (8B) (0.5g,0.95mmol), iron powder (0.32g,5.7mmol) and amine chloride (0.51 g,9.5mmol) were added to ethanol (5mL) and water (2mL) and reacted at 90 ℃ for 4 hours. The reaction was cooled to room temperature, water (20mL) was added to the reaction, extraction was performed with dichloromethane (50mL × 3), the organic phases were combined, washed with water (50mL × 2), dried over anhydrous sodium sulfate, and concentrated to give the title compound 5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (methyl (2- (tetrahydropyrrolyl-1-yl) ethyl) amino) aniline (8C) as a red solid (0.4g, yield 85%).
MS m/z:492.4[M+1]+。
The third step: n- (5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (methyl (2- (tetrahydropyrrole-1-yl) ethyl) amino) phenyl) acrylamide (compound 8)
N-(5-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(2-(pyr rolidin-1-yl)ethyl)amino)phenyl)acrylamide
5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (methyl (2- (tetrahydropyrrol-1-yl) ethyl) amino) aniline (8C) (0.4g,0.8mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.31g,1.6mmol) and acrylic acid (0.12g,1.6mmol) were added to pyridine (5mL) and reacted at room temperature for 2 hours. Water (10mL) was added to the reaction solution, and extraction was performed with dichloromethane (50mL × 3), the organic phases were combined, the organic phase was washed with water (50mL × 2), dried over anhydrous sodium sulfate, and concentrated, and the residue was separated and purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 50:1) to give the title compound N- (5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (methyl (2- (tetrahydropyrrol-1-yl) ethyl) amino) phenyl) acrylamide (compound 8) as a yellow solid (0.12g, yield 27%).
1H NMR(400MHz,CDCl3)δ9.85(s,1H),9.44(s,1H),9.32(s,1H),8.51–8.48(m, 1H),8.28–8.25(m,2H),7.55(s,1H),7.35–7.32(m,1H),7.22–7.17(m,2H),6.79(s, 1H),6.42–6.39(m,2H),5.72–5.69(m,1H),3.88(s,3H),2.99(s,2H),2.71(s,3H),257 –2.40(m,6H),1.85(s,4H)。
MS m/z:546.3[M+1]+。
Example 9
N- (4-methoxy-2- (methyl (2- (pyrrolidin-1-yl) ethyl) amino) -5- ((4- (1-methyl-1H-indol-3-yl) pyridin-2-yl) amino) phenyl) acrylamide (Compound 9)
N-(4-methoxy-2-(methyl(2-(pyrrolidin-1-yl)ethyl)amino)-5-((4-(1-methyl-1H-indol-3 -yl)pyrimidin-2-yl)amino)phenyl)acrylamide
The first step is as follows: 2-methoxy-N4-methyl-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-nitro-N4- (2- (pyrrolidin-1-yl) ethyl) phenyl-1, 4-diamine (9B)
2-methoxy-N4-methyl-N1-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-5-nitro-N4-(2-( pyrrolidin-1-yl)ethyl)benzene-1,4-diamine
5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 3) (1.0g,2.5mmol), N-methyl-2- (pyrrolidin-1-yl) ethylamine (9A) (650mg,5.1mmol), N-diisopropylethylamine (660mg,5.1mmol) and N, N-dimethylaniline (5mL) were placed in a 25mL microwave reaction tube and microwave reacted at 140 ℃ for 1.5 hours. The reaction mixture was added with water (50mL) and dichloromethane (50mL), separated, the organic phase was washed with water (50mL × 2) and saturated brine (50mL × 1) in turn, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent was petroleum ether: ethyl acetate (v/v) ═ 1:1 to 0:1, and dichloromethane: methanol (v/v) ═ 32:1 to 9:1) to give the title compound 2-methoxy-N4-methyl-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-nitro-N4- (2- (pyrrolidin-1-yl) ethyl) phenyl-1, 4-diamine (9B) as a yellow solid (820mg, 66% yield).
1H NMR(400MHz,CDCl3)δ9.56(s,1H),8.39(d,1H),8.26(s,1H),8.17(m,1H), 7.54(s,1H),7.43–7.37(m,1H),7.35–7.27(m,2H),7.19(d,1H),6.70(s,1H),3.99(s, 3H),3.94(s,3H),3.41–3.34(m,2H),2.91(s,3H),2.88–2.78(m,2H),2.64(br,4H), 1.81(br,4H)。
MS m/z:502.2[M+1]+。
The second step is that: 5-methoxy-N1-methyl-N4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (pyrrolidin-1-yl) ethyl) benzene-1, 2, 4-triamine (9C)
5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-N1-(2-(pyrrolid in-1-yl)ethyl)benzene-1,2,4-triamine
2-methoxy-N4-methyl-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-nitro-N4- (2- (pyrrolidin-1-yl) ethyl) phenyl-1, 4-diamine (9B) (820mg,1.63mmol) was dissolved in ethanol (30mL) and water (10mL), and iron powder (546mg,9.78mmol) and ammonium chloride (872mg,16.3mmol) were added to conduct a reaction at 95 ℃ under reflux for 3 hours. The reaction mixture was added with water (50mL) and dichloromethane (50mL), separated, the organic phase was washed with water (30mL × 2) and saturated brine (30mL × 1) in turn, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent was petroleum ether: ethyl acetate (v/v) ═ 1:1 to 0:1, and then dichloromethane: methanol (v/v) ═ 32:1 to 9:1, respectively) to obtain the title compound 5-methoxy-N1-methyl-N4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (pyrrolidin-1-yl) ethyl) benzene-1, 2, 4-triamine (9C), brown solid (410mg, 53% yield).
1H NMR(400MHz,CDCl3)δ8.48(dd,1H),8.33(d,1H),8.16(s,1H),7.80(s,1H), 7.60(s,1H),7.41–7.35(m,1H),7.35–7.27(m,2H),7.03(d,1H),6.69(s,1H),3.88(s, 3H),3.85(s,3H),3.23(t,2H),2.95(m,6H),2.70(s,3H),1.98(br,4H)。
MS m/z:472.3[M+1]+。
The third step: n- (4-methoxy-2- (methyl (2- (pyrrolidin-1-yl) ethyl) amino) -5- ((4- (1-methyl-1H-indol-3-yl) pyridin-2-yl) amino) phenyl) acrylamide (Compound 9)
N-(4-methoxy-2-(methyl(2-(pyrrolidin-1-yl)ethyl)amino)-5-((4-(1-methyl-1H-indol-3 -yl)pyrimidin-2-yl)amino)phenyl)acrylamide
Reacting 5-methoxy-N1-methyl-N4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (pyrrolidin-1-yl) ethyl) benzene-1, 2, 4-triamine (9C) (410mg,0.87mmol) was dissolved in 15mL of pyridine, and acrylic acid (313mg, 4.35mmol) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (834mg,4.35mmol) were added and reacted at room temperature for 4 hours. Water (50mL) and dichloromethane (50mL) were added to the reaction mixture, followed by liquid separation, and the organic phase was washed with a 10% sodium hydroxide solution (50mL × 2), water (50mL × 2) and a saturated saline solution (50mL × 1) in this order, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent was petroleum ether: ethyl acetate (v/v) ═ 1:1 to 0:1, and dichloromethane: methanol (v/v) ═ 32:1 to 19:1) to give the title compound N- (4-methoxy-2- (methyl (2- (pyrrolidin-1-yl) ethyl) amino) -5- ((4- (1-methyl-1H-indol-3-yl) pyridin-2-yl) amino) phenyl) acrylamide (compound 9), yellow solid (190mg, 42% yield).
1H NMR(400MHz,DMSO-d6)δ9.84(s,1H),9.08(s,1H),8.65(s,1H),8.33(d,1H), 8.25(d,1H),7.89(s,1H),7.52(d,1H),7.24(t,2H),7.15(t,1H),7.03(s,1H),6.50(s,1H), 6.26(dd,1H),5.77(d,1H),3.91(s,3H),3.87(s,3H),2.98(s,2H),2.71(s,3H),2.55– 2.45(m,6H),1.75(br,4H)。
MS m/z:526.2[M+1]+。
Example 10
N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl) acrylamide (compound 10)
N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(2-(4 -methylpiperazin-1-yl)ethoxy)phenyl)acrylamide
The first step is as follows: 5-chloro-N- (2-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (10B)
5-chloro-N-(2-methoxy-4-(2-(4-methylpiperazin-1-yl)ethoxy)-5-nitrophenyl)-4-(1- methyl-1H-indol-3-yl)pyrimidin-2-amine
5-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (intermediate 4) (854.1mg, 2mmol) was dissolved in tetrahydrofuran (50mL), sodium hydride (80mg, 2.2mmol, wt% ═ 60%) was added under ice-cooling, stirred for 30 minutes, and 2- (4-methylpiperazin-1-yl) ethanol (576.5mg, 4mmol) was added dropwise and reacted at room temperature overnight. After the reaction was completed, 100mL of water and 100mL of ethyl acetate were added, the mixture was separated, the organic phase was dried over anhydrous sodium sulfate, and concentrated to give the compound 5-chloro-N- (2-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (10B) as a yellow solid (800mg, yield 80%).
MS m/z:552.2[M+1]+。
1H NMR(400MHz,CDCl3)δ9.20(s,1H),8.46(d,1H),8.38(s,1H),8.21(s,1H), 7.50(s,1H),7.38(d,1H),7.36–7.30(m,1H),7.29–7.23(m,1H),6.61(s,1H),4.24(t, 2H),3.99(s,3H),3.90(d,3H),2.89(t,2H),2.77–2.64(m,4H),2.50(s,4H),2.31(s, 3H)。
The second step is that: n is a radical of1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl-1, 3-diamine (10C)
N1-(5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-4-(2-(dimethylamino)ethoxy )-6-methoxybenzene-1,3-diamine
Mixing 5-chloro-N- (2-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) -5-nitrophenyl) -4- (1-methyl-1H-indolidin-3-yl) pyrimidin-2-amine (10B) (800mg, 1.4)5mmol) was dissolved in ethanol (15mL), water (5mL), iron powder (486.3mg, 8.7mmol) and ammonium chloride (54mg, 1mmol) were added, the temperature was raised to 90 ℃ and the reaction was refluxed for 4 hours. The reaction was cooled to room temperature, filtered and concentrated. Separating and purifying the extract by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain a compound N 1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl-1, 3-diamine (10C), yellow solid (200mg, 26.5% yield).
MS m/z:522.2[M+1]+。
1H NMR(400MHz,CDCl3)δ8.63(d,1H),8.31(s,1H),8.22(s,1H),8.06(s,1H), 7.51(s,1H),7.40(d,1H),7.34(dd,1H),7.28(dd,4.0Hz,1H),6.57(s,1H),4.11(t,2H), 3.90(s,3H),3.84(s,3H),2.79(t,2H),2.66(s,4H),2.60–2.44(m,4H),2.32(d,3H)。
The third step: n- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl) acrylamide (compound 10)
N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(2-(4 -methylpiperazin-1-yl)ethoxy)phenyl)acrylamide
Will N1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl-1, 3-diamine (10C) (150mg, 0.288mmol) was dissolved in tetrahydrofuran (10mL), N-diisopropylethylamine (0.057mL, 0.345mmol) was added, cooled to 0 ℃ and a solution of acryloyl chloride (0.028mL, 0.345mmol) in tetrahydrofuran (5mL) was added dropwise and allowed to warm to room temperature for reaction for 1 hour. To the reaction solution were added a saturated aqueous sodium bicarbonate solution (50mL) and ethyl acetate (50mL), followed by liquid separation and concentration to give compound N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl) acrylamide (compound 10) as a pale yellow solid (40mg, yield 24.1%).
MS m/z:576.2[M+1]+。
1H NMR(400MHz,CDCl3)δ9.32(s,1H),8.41(s,1H),8.40(s,1H),8.31(s,1H),7.41 (s,1H),7.36(d,1H),7.29(d,1H),7.21(t,1H),6.61(s,1H),6.41–6.35(m,2H),5.71(dd, 1H),4.18(t,2H),3.90(s,3H),3.87(s,3H),2.72(t,2H),2.62(s,4H),2.53(s,4H),2.33(s, 3H)。
Example 11
N- (4-methoxy-2- (methyl (1-methyltetrahydropyrrol-3-yl) amino) -5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 11)
N-(5-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(methyl(1- methylpyrrolidin-3-yl)amino)phenyl)acrylamide
The first step is as follows: n is a radical of1- (5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) -2-methoxy-N4-methyl-N4- (1-Methyltetrahydropyrrole-3-yl) -5-nitrobenzene-1, 4-diamine (11B)
N1-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)-2-methoxy-N4-methyl-N4-(1- methylpyrrolidin-3-yl)-5-nitrobenzene-1,4-diamine
5- ((4- (indol-3-yl) -5-chloropyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 6) (1.0g,2.4mmol), N, 1-dimethyltetrahydropyrrole-3-amine (11A) (0.55g,4.8mmol) and N, N-Diisopropylethylamine (DIPEA) (0.6g,4.8mmol) were added to N, N-dimethylacetamide (3mL) and microwaved at 140 ℃ for 1.5 hours. After cooling to room temperature, water (20mL) was added to the reaction mixture, extraction was performed with dichloromethane (50mL × 3), the organic phases were combined, the organic phase was washed with water (50mL × 2), dried over anhydrous sodium sulfate, concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 50:1) to give the title compound N1- (5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) -2-methoxy-N4-methyl-N4- (1-methyltetrahydropyrrole-3-yl) -5-nitrobenzene-1, 4-diamine (11B), red solid (0.5g, 42% yield).
MS m/z:508.3[M+1]+。
The second step is that: n is a radical of4- (5-chloro-4- (1H-indole-3-)Yl) pyrimidin-2-yl) -5-methoxy-N1-methyl-N1- (1-Methyltetrahydropyrrole-3-yl) benzene-1, 2, 4-triamine (11C)
N4-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)-5-methoxy-N1-methyl-N1-(1- methylpyrrolidin-3-yl)benzene-1,2,4-triamine
Will N1- (5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) -2-methoxy-N 4-methyl-N4- (1-Methyltetrahydropyrroln-3-yl) -5-nitrobenzene-1, 4-diamine (11B) (0.5g,0.98mmol), iron powder (0.33g,5.9mmol) and ammonium chloride (0.52g,9.8mmol) were added to ethanol (5mL) and water (2mL) and reacted at 90 ℃ for 4 hours. The reaction solution was cooled to room temperature, water (20mL) was added, extraction was performed with methylene chloride (50 mL. times.3), the organic phases were combined, the organic phase was washed with water (50 mL. times.2), dried over anhydrous sodium sulfate, and concentrated to obtain the title compound N4- (5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methyl-N1- (1-Methyltetrahydropyrrole-3-yl) benzene-1, 2, 4-triamine (11C), red solid (0.3g, yield 64%).
MS m/z:478.3[M+1]+。
The third step: n- (4-methoxy-2- (methyl (1-methyltetrahydropyrrol-3-yl) amino) -5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 11)
N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-( methyl(1-methylpyrrolidin-3-yl)amino)phenyl)acrylamide
Will N4- (5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methyl-N1- (1-Methyltetrahydropyrroln-3-yl) benzene-1, 2, 4-triamine (11C) (0.3g,0.62mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) (0.48g,2.5mmol) and acrylic acid (0.09g,1.2mmol) were added to pyridine (5mL) and reacted at room temperature for 2 hours. Water (10mL) was added to the reaction mixture, and extraction was performed with dichloromethane (50mL × 3), the organic phases were combined, the organic phase was washed with water (50mL × 2), dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 50:1) to give the title compound N- (4-methoxy-2- (methyl: (1): N-methyl ether) 1-Methyltetrahydropyrroln-3-yl) amino) -5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (Compound 11) as a yellow solid (0.07g, 21% yield).
1H NMR(400MHz,CDCl3)δ9.50(s,1H),9.22(d,2H),8.49–8.47(m,1H),8.29– 8.28(m,2H),7.56(s,1H),7.35–7.33(m,1H),7.21–7.18(m,2H),6.74(s,1H), 6.40-6.38(m,2H),5.73(d,1H),3.88(s,3H),3.59(s,1H),2.79(s,1H),2.60(br,6H),2.32 (s,3H),2.07–1.98(m,1H),1.82(s,1H)。
MS m/z:546.2[M+1]+。
Example 12
N- (4-methoxy-2- (methyl (1-methyltetrahydropyrrol-3-yl) amino) -5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 12)
N-(4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)-5-((4-(1-methyl-1H-indol-3 -yl)pyrimidin-2-yl)amino)phenyl)acrylamide
The first step is as follows: n is a radical of1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -2-methoxy-N4-methyl-N4- (1-methyltetrahydropyrrole-3-yl) -5-nitrobenzene-1, 4-diamine (12B)
N1-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-2-methoxy-N4-methyl-N4-(1-methyl pyrrolidin-3-yl)-5-nitrobenzene-1,4-diamine
5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 3) (1.0g,2.5mmol), N, 1-dimethylpyrrolidin-3-amine (11A) (580mg,5.1mmol), N-diisopropylethylamine (660mg,5.1mmol), and trifluoroethanol (5mL) were placed in a 25mL microwave reaction tube and reacted with microwaves at 140 ℃ for 1.5 hours. To the reaction mixture were added water (50mL) and dichloromethane (50mL), and the mixture was separated, and the organic phase was washed with water (50mL × 2), washed with saturated brine (50mL × 1), dried over anhydrous sodium sulfate, concentrated, and separated and purified by silica gel column chromatography (petroleum ether: ethyl acetate (v/v) ═ 1:1-0: 1; dichloromethane: methanol (v/v) ═ 32:1 to 9:1) to give the title compound N 1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -2-methoxy-N4-methyl-N4- (1-Methyltetrahydropyrrole-3-yl) -5-nitrobenzene-1, 4-diamine (12B) as a yellow solid (370mg, 31% yield).
1H NMR(400MHz,CDCl3)δ9.52(s,1H),8.39(d,1H),8.22(s,1H),8.18(dd,1H), 7.57(s,1H),7.44–7.36(m,1H),7.35–7.28(m,2H),7.19(d,1H),6.66(s,1H),4.03(dd, 1H),3.98(s,3H),3.93(s,3H),2.95–2.85(m,1H),2.84(d,3H),2.79–2.62(m,3H),2.45 (s,3H),2.18(m,1H),2.07–1.93(m,1H)。
MS m/z:488.4[M+1]+。
The second step is that: n is a radical of4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methyl-N1- (1-MethylTetrahydropyrrol-3-yl) benzene-1, 2, 4-triamine (12C)
N4-(5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-5-methoxy-N1-methyl-N1 -(1-methylpyrrolidin-3-yl)benzene-1,2,4-triamine
Will N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -2-methoxy-N4-methyl-N4- (1-Methyltetrahydropyrroln-3-yl) -5-nitrobenzene-1, 4-diamine (12B) (0.37g,0.75mmol), iron powder (0.25g,4.5mmol) and ammonium chloride (0.4g,7.59mmol) were added to a mixed solution of ethanol (5mL) and water (2mL) and reacted at 90 ℃ for 4 hours. The reaction was cooled to room temperature, water (20mL) was added, extraction was performed with dichloromethane (50 mL. times.3), the organic phases were combined, washed with water (50 mL. times.2), dried over anhydrous sodium sulfate, and concentrated to give the title compound N4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methyl-N1- (1-Methyltetrahydropyrrole-3-yl) benzene-1, 2, 4-triamine (12C), black solid (0.3g, 88% yield).
MS m/z:458.4[M+1]+。
The third step: n- (4-methoxy-2- (methyl (1-methyltetrahydropyrrol-3-yl) amino) -5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 12)
N-(4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)-5-((4-(1-methyl-1H-indol-3 -yl)pyrimidin-2-yl)amino)phenyl)acrylamide
Will N4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methyl-N1- (1-Methyltetrahydropyrroln-3-yl) benzene-1, 2, 4-triamine (12C) (0.4g,88mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) (0.67,3.5mmol) and acrylic acid (0.127g,1.7mmol) were added to pyridine (5mL) and reacted at room temperature for 2 hours. Water (10mL) was added to the reaction solution, and extraction was performed with dichloromethane (50mL × 3), the organic phases were combined, the organic phase was washed with water (50mL × 2), dried over anhydrous sodium sulfate, concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 50:1) to give the title compound N- (4-methoxy-2- (methyl (1-methyltetrahydropyrrol-3-yl) amino) -5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 12) as a yellow solid (0.012g, 83% yield).
1H NMR(400MHz,DMSO-d6)δ9.39(s,1H),9.07(s,1H),8.65(s,1H),8.33(d,1H), 8.24(d,1H),7.89(s,1H),7.52(d,1H),7.26–7.22(m,2H),7.15(t,1H),7.00(s,1H), 6.65-5.59(m,1H),6.26(d,1H),5.76(d,1H),3.91(s,3H),3.86(s,3H),3.60(s,1H),2.59 (s,5H),2.42(s,2H),2.23(s,3H),1.92(s,1H),1.74(s,1H)。
MS m/z:512.2[M+1]+。
Example 13
(R) -N- (5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- ((1-methyltetrahydropyrrole-3-yl) oxy) phenyl) acrylamide (Compound 13)
(R)-N-(5-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methoxy -2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide
The first step is as follows: (R) -5-chloro-N- (2-methoxy-4- ((1-methyltetrahydropyrrole-3-yl) oxy) -5-nitrophenyl) -4- (pyrido [1,5-a ] pyridin-3-yl) pyrimidine-2-diamine (13B)
(R)-5-chloro-N-(2-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)-5-nitrophenyl)-4-(pyraz olo[1,5-a]pyridin-3-yl)pyrimidin-2-amine
Sodium hydride (0.09g, 2.25mmol) was added to the reaction flask, cooled to 0 deg.C, tetrahydrofuran (5mL) and 5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 5) (0.413g, 2.25mmol) were added, and a solution of (R) - (-) -1-methyl-3-hydroxypyrrolidine (0.118g, 1.17mmol) in tetrahydrofuran (5mL) was added dropwise and allowed to react overnight at room temperature. The reaction solution was cooled to 0 ℃, a saturated ammonium chloride solution (10mL) was added, the reaction was quenched, water (10mL) was added, the reaction solution was separated, the aqueous phase was extracted with ethyl acetate (50mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate (v/v) ═ 2:1, methanol: dichloromethane (v/v) ═ 1:2) to give the title compound (R) -5-chloro-N- (2-methoxy-4- ((1-methyltetrahydropyrrole-3-yl) oxy) -5-nitrophenyl) -4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidine-2-diamine (13B), a yellow solid (0.22g, yield 44%).
1H NMR(400MHz,DMSO-d6)δ8.95(s,1H),8.86-8.84(d,1H),8.81(s,1H),8.46(s, 1H),8.30(s,1H),7.38-7.34(dt,1H),7.17-7.13(dt,1H),6.87(s,1H),5.25(s,1H),3.95(s, 3H)。
MS m/z:496.2[M+1]+。
The second step is that: (R) -N1- (5-chloro-4- (pyrazolo [1, 5-a)]Pyridin-3-yl) pyrimidin-2-yl) -6-methoxy-4- ((1-methyltetrahydropyrrole-3-yl) oxy) phenyl-1, 3-diamine (13C)
(R)-N1-(5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)-6-methoxy-4-((1-me thylpyrrolidin-3-yl)oxy)benzene-1,3-diamine
Mixing (R) -5-chloro-N- (2-methoxy-4- ((1-methyltetrahydropyrrole-3-yl) oxy) -5-nitrophenyl) -4- (pyrazolo [1, 5-a) ]Pyridin-3-yl) pyrimidine-2-diamine (13B) (0.20g,0.40mmol), iron powder (0.145g,2.60mmol) and ammonium chloride (0.04g,0.75mmol) were dissolved in a mixed solvent of absolute ethanol (9mL) and water (3mL), and the temperature was raised to 90 ℃ to react for 4.5 hours.The reaction mixture was cooled to room temperature, filtered with suction, the filtrate was concentrated, and the residue was purified by silica gel column chromatography (methanol: dichloromethane (v/v) ═ 1:2) to give the title compound (R) -N1- (5-chloro-4- (pyrazolo [1, 5-a)]Pyridin-3-yl) pyrimidin-2-yl) -6-methoxy-4- ((1-methylpyrrolidin-3-yl) oxy) phenyl-1, 3-diamine (13C), yellow-green solid (0.07g, 38% yield).
1H NMR(400MHz,CDCl3)δ8.93(s,1H),8.62-8.55(m,2H),8.35(s,1H),7.90(s, 1H),7.44(s,1H),7.38-7.36(dt,1H),6.98-6.94(dt,1H),6.49(s,1H),4.93(s,1H),3.84(s, 3H),3.49(s,1H),3.20-3.06(m,4H),2.66(s,3H),2.43-2.35(m,2H)。
MS m/z:466.3[M+1]+。
The third step: (R) -N- (5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- ((1-methyltetrahydropyrrole-3-yl) oxy) phenyl) acrylamide (Compound 13)
(R)-N-(5-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methoxy -2-((1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide
Reacting (R) -N1- (5-chloro-4- (pyrazolo [1, 5-a)]Pyridin-3-yl) pyrimidin-2-yl) -6-methoxy-4- ((1-methyltetrahydropyrrol-3-yl) oxy) phenyl-1, 3-diamine (13C) (0.07g,0.15mmol) was dissolved in freshly distilled tetrahydrofuran (3mL), the reaction solution was cooled to 0 ℃ and a solution of diisopropylethylamine (0.3mL) in freshly distilled tetrahydrofuran (9.7mL) and acryloyl chloride (0.13mL) in freshly distilled tetrahydrofuran (0.87mL) was added dropwise and reacted at room temperature for 1.5 hours. To the reaction solution was added a saturated sodium bicarbonate solution (50mL), the reaction was quenched, the aqueous phase was extracted with ethyl acetate (50mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by silica gel column chromatography (methanol: dichloromethane (v/v) ═ 1:2 to 1:1), and the title compound (R) -N- (5- ((5-chloro-4- (pyrazolo [1, 5-a): the title compound ]Pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- ((1-methylpyrrolidin-3-yl) oxy) phenyl) acrylamide (compound 13) as a yellow solid (0.03g, 41% yield).
1H NMR(400MHz,DMSO-d6)δ9.27(s,1H),8.93(s,1H),8.82-8.81(d,1H),8.65(s, 1H),8.37(s,1H),8.14(s,1H),7.30-7.28(dt,1H),7.11-7.08(dt,1H),6.79(s,1H),6.61-6.50 (m,1H),6.19-6.14(dd,1H),5.70-5.67(dd,1H),4.98(s,1H),3.82(s,1H),3.76(s,3H), 2.84-2.66(m,4H),2.39-2.36(m,2H),2.30(s,3H)。
MS m/z:520.3[M+1]+。
Example 14
N- (5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -2- (2- (dimethylamino) ethoxy) -4-methoxyphenyl) acrylamide (compound 14)
N-(5-((5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)-2-( 2-(dimethylamino)ethoxy)-4-methoxyphenyl)acrylamide
The first step is as follows: 5-chloro-N- (4- (2-dimethylamino) ethoxy) -2-methoxy-5-nitrophenyl) -4-pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-amine (14B)
5-chloro-N-(4-(2-(dimethylamino)ethoxy)-2-methoxy-5-nitrophenyl)-4-(pyrazolo[1,5- a]pyridin-3-yl)pyrimidin-2-amine
5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 5) (0.41g,1.00mmol) was dissolved in tetrahydrofuran (20mL), the reaction solution was cooled to 0 ℃, sodium hydride (0.08g,1.1mmol,% by weight ═ 60%) was added, and after stirring for 5 minutes, N-dimethylethanolamine (14A) (0.11 mL,1.1mmol) was added, and the reaction was warmed to room temperature and reacted for 4 hours. Water (20mL) was added to the reaction flask, the aqueous phase was extracted with ethyl acetate (50mL × 2), the organic phases were combined, the organic phase was washed with saturated brine (30mL), dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (dichloromethane/methanol (v/v) ═ 15:1) to give 5-chloro-N- (4- (2-dimethylamino) ethoxy) -2-methoxy-5-nitrophenyl) -4-pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-amine (14B) as a yellow solid (0.36g, 75% yield).
1H NMR(400MHz,CDCl3)δ9.06(s,1H),8.93(s,1H),8.55-8.47(m,2H),8.41(s, 1H),7.48(s,1H),7.37-7.35(m,1H),6.96-6.94(m,1H),6.67(s,1H),4.27-4.24(m,2H), 4.01(s,3H),2.91-2.88(m,2H),2.42(s,6H)。
The second step is that: n is a radical of1- (5-chloro-4-pyrazolo [1, 5-a)]Pyridin-3-yl-pyrimidin-2-yl) -4- (2-dimethylaminoethoxy) -6-methoxy-phenyl-1, 3-diamine (14C)
N1-(5-chloro-4-pyrazolo[1,5-a]pyridin-3-yl-pyrimidin-2-yl)-4-(2-dimethylaminoethyl oxy)-6-methoxy-benzene-1,3-diamine
Weighing 5-chloro-N- (4- (2-dimethylamino) ethoxy) -2-methoxy-5-nitrophenyl) -4-pyrazolo [1,5-a]Pyridin-3-yl) pyrimidin-2-amine (14B) (0.36g,0.74mmol) was placed in a 100mL round-bottomed flask, ethanol (21mL), water (7mL), reduced iron powder (0.25g,4.44mmol), and ammonium chloride (0.028g,0.52 mmol) were added in this order to a reaction flask, and the reaction was refluxed at elevated temperature for 6 hours. The reaction mixture was filtered, the filter cake was washed with dichloromethane (10mL × 2) and methanol (10mL × 2) in this order, the filtrates were combined, concentrated, and the residue was purified by column chromatography (dichloromethane/methanol (v/v) ═ 15:1) to give N as a gray solid1- (5-chloro-4-pyrazolo [1, 5-a)]Pyridin-3-yl-pyrimidin-2-yl) -4- (2-dimethylaminoethoxy) -6-methoxy-phenyl-1, 3-diamine (14C) (0.30g, 88% yield).
1H NMR(400MHz,CDCl3)δ8.94(s,1H),8.60-8.55(m,2H),8.35(s,1H),7.87(s, 1H),7.42-7.37(m,2H),6.96-6.93(m,1H),6.59(s,1H),4.19-4.17(m,2H),3.85(s,3H), 2.91-2.88(m,2H),2.42(s,6H)。
The third step: n- (5- ((5-chloro-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) -2- (2- (dimethylamino) ethoxy) -4-methoxyphenyl) acrylamide (compound 14)
N-[5-[(5-chloro-4-pyrazolo[1,5-a]pyridin-3-yl-pyrimidin-2-yl)amino]-2-(2-dimethyla minoethyloxy)-4-methoxy-phenyl]prop-2-enamide
Weighing N1- (5-chloro-4-pyrazolo [1, 5-a)]Pyridin-3-yl-pyrimidin-2-yl) -4- (2-dimethylaminoethoxy) -6-methoxy-phenyl-1, 3-diamine (14C) (0.2g,0.43mmol) was placed in a 100mL round bottom flask, and tetrahydrofuran (15mL) and diisopropylethylamine (0.09mL, 0.56mmol), cooled to 0 ℃, acryloyl chloride (0.04mL,0.52mmol) was added dropwise, and after the addition was complete, the reaction was allowed to warm for 1 hour. The reaction mixture was concentrated under reduced pressure, methylene chloride (50mL), a saturated aqueous sodium bicarbonate solution (30mL) were added to the residue, the mixture was separated, the aqueous phase was extracted with dichloromethane (50mL), the organic phases were combined, the organic phase was washed with a saturated saline solution (30mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography (methylene chloride/methanol (v/v) ═ 15:1) to give N- (5- ((5-chloro-4- (pyrazolo [1, 5-a) as a yellow solid]Pyridin-3-yl) pyrimidin-2-yl) amino) -2- (2- (dimethylamino) ethoxy) -4-methoxyphenyl) acrylamide (compound 14) (0.08g, 48% yield).
MS m/z(ESI):517.2[M+1]+。
1H NMR(400MHz,CDCl3)δ10.02(s,1H),9.53(s,1H),8.82(s,1H),8.76-8.74(d, 1H),8.53-8.51(d,1H),8.25(s,1H),7.36(s,1H),7.28-7.26(m,1H),6.91-6.89(m,1H), 6.77(s,1H),6.38-6.36(m,2H),5.68-5.65(m,1H),3.98(s,3H),3.87(s,3H),2.82-2.80(m, 2H),2.72(s,3H),2.34-2.30(m,8H)。
Example 15
N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((dimethylamino) ethoxy) -4-methoxyphenyl) acrylamide (compound 15)
N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(2-(dimethylamino) ethoxy)-4-methoxyphenyl)acrylamide
The first step is as follows: 5-chloro-N- (4- (2- (dimethylamino) ethoxy) -2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (15B)
5-chloro-N-(4-(2-(dimethylamino)ethoxy)-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H -indol-3-yl)pyrimidin-2-amine
5-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (intermediate 4) (500mg, 1.17mmol) was dissolved in tetrahydrofuran (50mL), sodium hydride (51.5mg, 1.28mmol) was added under ice-bath, stirred for 30 min, dimethylethanolamine (14A) (0.24mL, 2.34mmol) was added dropwise, and reacted at room temperature for 4 hours. To the reaction mixture were added water (100mL) and ethyl acetate (150mL), the layers were separated, the organic layer was dried over anhydrous sodium sulfate, and the concentrate was concentrated to give the compound 5-chloro-N- (4- (2- (dimethylamino) ethoxy) -2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (15B) as a yellow solid (500mg, 86.2% yield).
MS m/z:497.1[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.58(d,2H),8.40(s,1H),8.33(s,1H),8.27(d, 1H),7.51(d,1H),7.25(t,1H),7.09–6.97(m,2H),4.34(t,2H),3.96(d,3H),3.91(d,3H), 2.72(t,2H),2.25(d,6H)。
The second step is that: n is a radical of1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (2- (dimethylamino) ethoxy) -6-methoxyphenyl-1, 3-diamine (15C)
N1-(5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-4-(2-(dimethylamino)ethoxy )-6-methoxybenzene-1,3-diamine
5-chloro-N- (4- (2- (dimethylamino) ethoxy) -2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (15B) (500mg, 1mmol) was dissolved in a mixed solution of ethanol (15mL) and water (5mL), iron powder (335mg, 6mmol) and ammonium chloride (37.4mg, 0.7mmol) were added, the temperature was raised to 90 ℃ and the reaction was refluxed for 4 hours. Cooling the reaction solution to room temperature, filtering, concentrating, and separating and purifying the residue by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-50: 1) to obtain compound N1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (2- (dimethylamino) ethoxy) -6-methoxyphenyl-1, 3-diamine (15C) as a yellow solid (350mg, 75.1% yield).
MS m/z:467.2[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.53(s,1H),8.36(d,1H),8.30(s,1H),8.25(s,1H), 7.50(d,1H),7.24(t,1H),7.07(t,1H),6.98(s,1H),6.74(s,1H),5.75(s,1H),4.23(s,2H), 3.90(s,3H),3.68(s,3H),3.05(d,3H),2.67(s,6H)。
The third step: n- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((dimethylamino) ethoxy) -4-methoxyphenyl) acrylamide (compound 15)
N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(2-(dimethylamino) ethoxy)-4-methoxyphenyl)acrylamide
Will N1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (2- (dimethylamino) ethoxy) -6-methoxyphenyl-1, 3-diamine (15C) (350mg, 0.75mmol) was dissolved in tetrahydrofuran (28mL), N-diisopropylethylamine (i.e., DIPEA) (0.15mL, 0.9mmol) was added, cooled to 0 deg.C, a solution of acryloyl chloride (0.073mL, 0.9mmol) in tetrahydrofuran (5mL) was added dropwise, and the mixture was allowed to warm to room temperature for reaction for 3 hours. To the reaction mixture were added saturated aqueous sodium bicarbonate (100mL) and dichloromethane (100mL), and the organic phase was separated and concentrated to give N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((dimethylamino) ethoxy) -4-methoxyphenyl) acrylamide (compound 15) as a white solid (40mg, 10.3%).
MS m/z:521.2[M+1]+。
1H NMR(400MHz,CDCl3)δ9.65(s,1H),9.38(s,1H),8.39(d,2H),8.33(s,1H), 7.45(s,1H),7.35(d,1H),7.29(d,1H),7.22(dd,1H),6.63(s,1H),6.44–6.26(m,2H), 5.68(d,1H),4.17–4.10(m,2H),3.90(s,3H),3.87(s,3H),2.63(s,2H),2.39(s,6H)。
Example 16
N- (5- ((5-chloro-4- (1-methyl-6-morpholinyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2-fluoro-4-methoxyphenyl) acrylamide (compound 16)
N-(5-((5-chloro-4-(1-methyl-6-morpholino-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-fl uoro-4-methoxyphenyl)acrylamide
The first step is as follows: 1- (6-Nitro-1H-indol-1-yl) ethanone (16B)
1-(6-nitro-1H-indol-1-yl)ethanone
6-Nitroindole (16A) (16.2g, 0.1mol) was dissolved in pyridine (40mL), acetic anhydride (40.8g, 0.4mol) was added, and the reaction was allowed to proceed overnight at room temperature. The reaction mixture was concentrated, and to the residue were added saturated brine (200mL) and ethyl acetate (200mL), followed by separation, drying of the organic phase over anhydrous sodium sulfate, and concentration to give the objective compound 1- (6-nitro-1H-indol-1-yl) ethanone (16B) as a yellow solid (6g, yield 30%).
MS m/z:205.1[M+1]+。
The second step is that: 1- (6-amino-1H-indol-1-yl) ethanone (16C)
1-(6-amino-1H-indol-1-yl)ethanone
1- (6-Nitro-1H-indol-1-yl) ethanone (16B) (20g, 0.1mol) was dissolved in methanol (50mL) and tetrahydrofuran (50mL), palladium on carbon (2g, 10%) and ammonium formate (40.3g, 6.4mol) were added, and the mixture was reacted at 60 ℃ for 2 hours. After the reaction, filtration was performed, the filter cake was washed with ethyl acetate (100mL), the filtrates were combined, concentrated, ethyl acetate (150mL) and saturated brine (150mL) were added to the residue, followed by liquid separation, the aqueous phase was washed with ethyl acetate (150mL), the organic phases were combined, the organic phase was dried over anhydrous sodium sulfate, and concentrated to give 1- (6-amino-1H-indol-1-yl) ethanone (16C) as a yellow solid (9.3g, 53.4% yield).
The third step: 4- (1H-indol-6-yl) morpholine (16D)
4-(1H-indol-6-yl)morpholine
1- (6-amino-1H-indol-1-yl) ethanone (16C) (8g, 60.1mmol) and 2,2' -dibromodiethyl ether (9mL, 72mmol) were dissolved in N, N-dimethylformamide (100mL), and N, N-diisopropylethylamine (i.e., ethyl DIP acetate) (29.7mL, 180mmol) was added and reacted at 90 ℃ overnight. The reaction was cooled to room temperature, ethyl acetate (200mL) and saturated brine (200mL) were added, the layers were separated, the aqueous layer was washed with ethyl acetate (200mL), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give 4- (1H-indol-6-yl) morpholine (16D) as a yellow solid (9.2g, 76% yield).
MS m/z:203.1[M+1]+。
1H NMR(400MHz,CDCl3)δ8.04(s,1H),7.53(d,1H),7.09(dd,1H),6.98–6.80 (m,2H),6.46(ddd,1H),4.00–3.83(m,4H),3.25–3.08(m,4H)。
The fourth step: 4- (3- (2, 5-dichloropyrimidin-4-yl) -1H-indol-6-yl) morpholine (16E)
4-(3-(2,5-dichloropyrimidin-4-yl)-1H-indol-6-yl)morpholine
4- (1H-indol-6-yl) morpholine (16D) (4.5g, 22.3mmol) was dissolved in tetrahydrofuran (100mL), cooled to 0 ℃ under nitrogen, methyl magnesium bromide (7.5mL, 22.3mmol) was added dropwise, stirring was continued for 0.5H, trichloropyrimidine (2.05g, 22.3mmol) was added, the reaction was allowed to react at room temperature for 1H, and the temperature was raised to 60 ℃ for 1H. The reaction mixture was cooled to room temperature, acetic acid (6.34mL) was added dropwise, the mixture was stirred for 10 minutes, water (100mL) was added, the mixture was stirred at 60 ℃ for 30 minutes, the mixture was separated, the organic phase was added with n-heptane (100mL), the mixture was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 50:1) to give compound 4- (3- (2, 5-dichloropyrimidin-4-yl) -1H-indol-6-yl) morpholine (16E) as a yellowish green solid (3g, yield 39%).
MS m/z:349.0[M+1]+。
The fifth step: 4- (3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1H-indol-6-yl) morpholine (16F)
4-(3-(2,5-dichloropyrimidin-4-yl)-1-methyl-1H-indol-6-yl)morpholine
4- (3- (2, 5-dichloropyrimidin-4-yl) -1H-indol-6-yl) morpholine (16E) (3g, 8.6mmol) was dissolved in tetrahydrofuran (50mL), cooled to 0 ℃, sodium hydride (460mg, 11.5mmol) was added, the reaction was carried out for 30 minutes, methyl iodide (1.6mL, 25.8mmol) was added, and the mixture was warmed to room temperature and reacted for 3 hours. The reaction was concentrated and the residue was washed with water (50mL) and tetrahydrofuran (20mL), filtered, and the filter cake was dried to give 4- (3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1H-indol-6-yl) morpholine (16F) as a pale yellow solid (1.9g, 61.3% yield).
MS m/z:363.0[M+1]+。
1H NMR(400MHz,CDCl3)δ8.59(d,1H),8.41(s,1H),8.29(s,1H),7.07(d,1H), 6.82(s,1H),3.99–3.89(m,4H),3.85(s,3H),3.30–3.20(m,4H)。
And a sixth step: 5-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-amine (16G)
5-chloro-N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-6-morpholino-1H-indol- 3-yl)pyrimidin-2-amine
4- (3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1H-indol-6-yl) morpholine (16F) (724g, 2mmol) was dissolved in 2-pentanol (20mL), 4-fluoro-2-methoxy-5-nitroaniline (372mg, 2mmol) and p-toluenesulfonic acid (456.5mg, 2.4mmol) were added, and the reaction was heated to 120 ℃ and refluxed for 2 days. The reaction was cooled to room temperature, acetonitrile (50mL) was added, filtered, the filter cake was washed with water (50mL), and dried to give-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-amine (16G) as a grey solid (800mg, 80% yield).
MS m/z:513.1[M+1]+。
1H NMR(400MHz,CDCl3)δ9.35(d,1H),8.39(s,1H),8.34(d,1H),8.14(s,1H),7.56 (s,1H),6.97(d,1H),6.80(s,1H),6.75(d,1H),4.02(s,3H),3.93(s,4H),3.84(s,3H),3.23(s, 4H)。
The seventh step: n is a radical of1- (5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) -4-fluoro-6-methoxybenzene-1, 3-diamine (16H)
N1-(5-chloro-4-(1-methyl-6-morpholino-1H-indol-3-yl)pyrimidin-2-yl)-4-fluoro-6- methoxybenzene-1,3-diamine
-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-amine (16G) (600mg, 1.17mmol) was dissolved in ethanol (30mL) and water (10mL), iron powder (392mg, 7.03mmol) and ammonium chloride (43.8mg, 0.82mmol) were added, the temperature was raised to 90 ℃ and the reaction was refluxed for 4 hours. Cooling the reaction solution to room temperature, filtering, washing a filter cake with methanol (50mL), combining filtrates, concentrating, and purifying the residue by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-50: 1) to obtain N1- (5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) -4-fluoro-6-methoxybenzene-1, 3-diamine (16H), brown solid (150mg, 26.6% yield).
MS m/z:483.1[M+1]+。
Eighth step: n- (5- ((5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) amino) -2-fluoro-4-methoxyphenyl) acrylamide (compound 16)
N-(5-((5-chloro-4-(1-methyl-6-morpholino-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-fl uoro-4-methoxyphenyl)acrylamide
Will N1- (5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) -4-fluoro-6-methoxybenzene-1, 3-diamine (16H) (150mg, 0.31mmol) was dissolved in tetrahydrofuran (10mL), N-diisopropylethylamine (0.06mL, 0.37mmol) was added, cooled to 0 deg.C, a solution of acryloyl chloride (0.03mL, 0.37mmol) in tetrahydrofuran (5mL) was added dropwise, and the mixture was allowed to warm to room temperature for reaction for 1.5 hours. To the reaction mixture were added saturated aqueous sodium bicarbonate (100mL) and dichloromethane (100mL), which were separated and concentrated to give N- (5- ((5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) amino) -2-fluoro-4-methoxyphenyl) acrylamide (compound 16) as a pale yellow solid (20mg, yield 12%).
MS m/z:537.1[M+1]+。
1H NMR(400MHz,CDCl3)δ9.14(s,1H),8.37(s,1H),8.35(s,1H),8.22(s,1H), 7.50(d,1H),7.19(s,1H),6.99(s,1H),6.73(d,1H),6.40(dd,1H),6.26(dd,1H),5.75(d, 1H),3.96(s,4H),3.90(s,3H),3.86(s,3H),3.26(s,4H)。
Example 17
(R) -N- (5- ((5-chloro-4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (3- (dimethylamino) pyrrolidin-1-yl) -4-methoxyphenyl) acrylamide (Compound 17)
(R)-N-(5-((5-chloro-4-(4-fluoro-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(3-(dimethyl amino)pyrrolidin-1-yl)-4-methoxyphenyl)acrylamide
The first step is as follows: (R) -5-chloro-N- (4- (3- (dimethylamino) pyrrolidin-1-yl) -2-methoxy-5-nitrophenyl) -4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-amine (17B)
(R)-5-chloro-N-(4-(3-(dimethylamino)pyrrolidin-1-yl)-2-methoxy-5-nitrophenyl)-4-(4 -fluoro-1H-indol-3-yl)pyrimidin-2-amine
5-chloro-4- (4-fluoro-1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (intermediate 7) (1.1g, 2.5mmol), (R) -N, N-dimethylpyrrol-3-amine (17A) (0.5g, 2.8mmol), diisopropylethylamine (1.5g, 11.5mmol) and N, N' -dimethylacetamide (10mL) were added to a reaction flask and reacted at 140 ℃ for 1 hour under microwave. The reaction solution was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 100:1) to give (R) -5-chloro-N- (4- (3- (dimethylamino) pyrrolidin-1-yl) -2-methoxy-5-nitrophenyl) -4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-amine (17B) as a brown oil (0.5g, 38% yield).
MS m/z(ESI):526.3[M+1]+。
1H NMR(400MHz,DMSO-d6)δ12.00(s,1H),8.48(d,2H),8.26(s,1H),7.85(d, 1H),7.32(d,1H),7.17(m,1H),6.84(dd,1H),6.51(s,1H),3.94(s,3H),3.40(dd,1H), 3.27–3.19(m,1H),3.17(d,1H),3.11(d,2H),2.23(s,6H),2.16–2.12(m,1H),1.80(m, 1H)。
The second step is that: (R) -N1- (5-chloro-4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-yl) -4- (3- (dimethylamino) pyrrolidin-1-yl) -6-methoxybenzene-1, 3-diamine (17C)
(R)-N1-(5-chloro-4-(4-fluoro-1H-indol-3-yl)pyrimidin-2-yl)-4-(3-(dimethylamino) pyrrolidin-1-yl)-6-methoxybenzene-1,3-diamine
To a reaction flask were added (R) -5-chloro-N- (4- (3- (dimethylamino) pyrrolidin-1-yl) -2-methoxy-5-nitrophenyl) -4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-amine (17B) (0.5g, 0.95mmol), iron powder (0.32g, 5.7mmol), ammonium chloride (51mg, 0.95mmol) and ethanol/water (27mL/9.5mL), and the mixture was heated to reflux for 2 hours. The reaction solution was filtered, the filter cake was washed with ethanol (10mL × 3), the filtrates were combined, concentrated, and the residue was purified by silica gel column chromatography (dichloromethane/methanolic ammonia (v/v) ═ 80:1-30:1) to give (R) -N as a yellowish brown solid 1- (5-chloro-4- (4-fluoro-1H-indole-3-yl) pyrimidin-2-yl) -4- (3- (dimethylamino) pyrrolidin-1-yl) -6-methoxybenzene-1, 3-diamine (17C) (0.2g, 42.6% yield).
MS m/z(ESI):496.4[M+1]+。
The third step: (R) -N- (5- ((5-chloro-4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (3- (dimethylamino) pyrrolidin-1-yl) -4-methoxyphenyl) acrylamide (Compound 17)
(R)-N-(5-((5-chloro-4-(4-fluoro-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(3-(dimethyl amino)pyrrolidin-1-yl)-4-methoxyphenyl)acrylamide
Adding (R) -N into a reaction bottle1- (5-chloro-4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-yl) -4- (3- (dimethylamino) tetrahydropyrrole-1-yl) -6-methoxybenzene-1, 3-diamine (17C) (0.18g, 0.36mmol), diisopropylethylamine (52 mg, 0.4mmol) and dichloromethane (4.6mL) were cooled in an ice bath, acryloyl chloride (33mg,0.36mmol) in dichloromethane (1mL) was added dropwise and reacted in an ice bath for 2 hours. To the reaction mixture was added a saturated aqueous sodium chloride solution (10mL), the mixture was stirred, the aqueous layer was extracted with dichloromethane (30mL × 3), the organic phases were combined, the organic phase was dried over anhydrous sodium sulfate, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 50:1-25:1) to give (R) -N- (5- ((5-chloro-4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (3- (dimethylamino) tetrahydropyrrole-1-yl) -4-methoxyphenyl) acrylamide (compound 17) (50mg, yield 25.5%) as a pale yellow solid.
MS m/z(ESI):550.3[M+1]+。
1H NMR(400MHz,DMSO-d6)δ11.95(s,1H),9.28(s,1H),8.42(s,1H),8.11(s, 1H),7.87(s,1H),7.84(s,1H),7.31(d,1H),7.15(m,1H),6.83(dd,1H),6.53(s,2H),6.19 (d,1H),5.68(d,1H),3.83(s,3H),3.23(m,5H),2.32(s,6H),2.11(s,1H),1.82(s,1H)。
Example 18
N- (5- ((5-chloro-4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 18)
N-(5-((5-chloro-4-(4-fluoro-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylami no)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
The first step is as follows: n is a radical of1- (5-chloro-4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenzene-1, 4-diamine (18B)
N1-(5-chloro-4-(4-fluoro-1H-indol-3-yl)pyrimidin-2-yl)-N4-(2-(dimethylamino)ethyl) -2-methoxy-N4-methyl-5-nitrobenzene-1,4-diamine
5-chloro-4- (4-fluoro-1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (intermediate 7) (1g, 2.5mmol), N, N, N '-trimethylethylenediamine (18A) (0.28g, 2.8mmol), diisopropylethylamine (1.3g, 10.4mmol) and N, N' -dimethylacetamide (10mL) were added to a reaction flask and reacted at 140 ℃ for 1 hour under microwave. The reaction mixture was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 50:1) to give a brown oil N1- (5-chloro-4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4Methyl-5-nitrophenyl-1, 4-diamine (18B) (0.55g, 45.8% yield).
MS m/z(ESI):514.3[M+1]+。
The second step is that: n is a radical of4- (5-chloro-4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylphenyl-1, 2, 4-triamine (18C)
N4-(5-chloro-4-(4-fluoro-1H-indol-3-yl)pyrimidin-2-yl)-N1-(2-(dimethylamino)ethyl)- 5-methoxy-N1-methylbenzene-1,2,4-triamine
Adding N into a reaction bottle1- (5-chloro-4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-yl) -N 4- (2- (dimethylamino) ethyl) -2-methoxy-N4Methyl-5-nitrophenyl-1, 4-diamine (18B) (0.52g, 1mmol), iron powder (0.34g, 6.1 mmol), ammonium chloride (54mg, 1mmol) and ethanol/water (28mL/10mL) heated to reflux for 2 hours. The reaction was filtered, the filter cake was washed with ethanol (10 mL. times.3), the filtrates were combined, concentrated, and the residue was washed with silicaSeparating and purifying by gel column chromatography (dichloromethane/ammonia methanol (v/v) ═ 100:1-50:1) to obtain yellow solid N4- (5-chloro-4- (4-fluoro-1H-indole-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylphenyl-1, 2, 4-triamine (18C) (350mg, 71.5% yield).
MS m/z(ESI):484.3[M+1]+。
1H NMR(400MHz,DMSO-d6)δ11.96(s,1H),8.45(s,1H),7.97(s,1H),7.86(s, 1H),7.42(s,1H),7.33(d,1H),7.17(m,1H),6.87(dd,1H),6.72(s,1H),4.50(s,2H),3.73 (s,3H),2.84(t,2H),2.59(s,3H),2.32(t,2H),2.15(s,6H)。
The third step: n- (5- ((5-chloro-4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 18)
N-(5-((5-chloro-4-(4-fluoro-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylami no)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
Adding N into a reaction bottle4- (5-chloro-4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylphenyl-1, 2, 4-triamine (18C) (0.32g, 0.66mmol), diisopropylethylamine (94 mg, 0.73mmol) and dichloromethane (8.6mL), cooled in an ice bath, a solution of acryloyl chloride (60mg,0.66mmol) in dichloromethane (2mL) was added dropwise, and the reaction was carried out for 2 hours in an ice bath. To the reaction solution was added an aqueous sodium bicarbonate solution (10mL), followed by stirring, liquid separation, extraction of the aqueous layer with dichloromethane (30mL × 3), combination of organic phases, washing of the organic phase with saturated brine (20mL), drying over anhydrous sodium sulfate, filtration, concentration, and column chromatography of the residue on silica gel (dichloromethane/methanol (v/v) ═ 50:1-30:1) to give N- (5- ((5-chloro-4- (4-fluoro-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 18) (140m g, yield 39.4%) as a pale yellow solid.
MS m/z(ESI):538.3[M+1]+。
1H NMR(400MHz,DMSO-d6)δ11.98(s,1H),10.03(s,1H),8.81(s,1H),8.46(s, 1H),8.22(s,1H),7.93(d,1H),7.31(d,1H),7.15(m,1H),6.98(s,1H),6.83(dd,1H), 6.38(dd,1H),6.26(dd,1H),5.74(d,1H),3.82(s,3H),2.96–2.78(m,2H),2.68(s,3H), 2.31(m,2H),2.20(s,6H)。
Example 19
N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (7-fluoro-1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (Compound 19)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(7-fluoro-1-methyl-1H-indol-3- yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide
The first step is as follows: n is a radical of1- (2- (dimethylamino) ethyl) -N4- (4- (7-fluoro-1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methyl-2-nitrobenzene-1, 4-diamine (19B)
N1-(2-(dimethylamino)ethyl)-N4-(4-(7-fluoro-1-methyl-1H-indol-3-yl)pyrimidin-2-yl )-5-methoxy-N1-methyl-2-nitrobenzene-1,4-diamine
To a reaction flask were added 4- (7-fluoro-1-methyl-1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (intermediate 8) (280mg, 0.68mmol), N, N, N '-trimethylethylenediamine (18A) (69mg, 0.68mmol), diisopropylethylamine (219mg, 1.7mmol) and N, N' -dimethylacetamide (4.5mL) and reacted at 140 ℃ for 1.5 hours under microwave. Cooling the reaction solution to room temperature, adding water (10mL), extracting with ethyl acetate (20mL × 2), combining the organic phases, drying the organic phases with anhydrous sodium sulfate, filtering, concentrating, and purifying the residue by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 100:1-20:1) to obtain a brown solid N1- (2- (dimethylamino) ethyl) -N4- (4- (7-fluoro-1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1Methyl-2-nitrophenyl-1, 4-diamine (19B) (120mg, 36% yield).
1H NMR(400MHz,DMSO-d6)δ8.58(s,1H),8.33(d,1H),8.30(s,1H),8.18(t,1H) 8.13(s,1H),7.20(d,1H),7.03(m,2H),6.84(s,1H),4.03(d,3H),3.95(s,3H),3.27(t, 2H),2.86(s,3H),2.49(t,2H),2.16(s,6H)。
The second step is that: n is a radical of1- (2- (dimethylamino) ethyl) -N 4- (4- (7-fluoro-1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (19C)
N1-(2-(dimethylamino)ethyl)-N4-(4-(7-fluoro-1-methyl-1H-indol-3-yl)pyrimidin-2-yl )-5-methoxy-N1-methylbenzene-1,2,4-triamine
MS m/z(ESI):464.6[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.29(m,2H),8.25(d,1H),7.83(s,1H),7.41(s, 1H),7.13(d,1H),7.09-6.99(m,2H),6.76(s,1H),4.04(d,2H),3.73(s,3H),2.89(t,3H), 2.63(s,3H),2.37(t,2H),2.18(s,6H)。
The third step: n- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (7-fluoro-1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (Compound 19)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(7-fluoro-1-methyl-1H-indol-3- yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide
Adding N into a reaction bottle1- (2- (dimethylamino) ethyl) -N4- (4- (7-fluoro-1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (19C) (0.36g, 0.78mmol), diisopropylethylamine (111 mg, 0.86mmol) and dichloromethane (10mL), cooled in an ice bath, and a solution of acryloyl chloride (70mg,0.78mmol) in dichloromethane (2mL) was added dropwise over 2 hours of the ice bath reaction. To the reaction solution was added an aqueous sodium bicarbonate solution (10mL), followed by partition with stirring, extraction of the aqueous layer with dichloromethane (20mL × 2), combination of the organic phases, drying over anhydrous sodium sulfate, filtration, concentration of the filtrate under reduced pressure, and separation and purification of the residue by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 30:1-20:1) to give N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (7-fluoro-1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 19) as a brown oil (360mg, 90% yield).
MS m/z(ESI):518.3[M+1]+。
1H NMR(400MHz,DMSO-d6)δ10.13(s,1H),9.07(s,1H),8.63(s,1H),8.35(d, 1H),8.07(d,1H),7.96(s,1H),7.22(d,1H),7.14–6.96(m,3H),6.49(dd,1H),6.27(dd, 1H),5.77(d,1H),4.08(m,3H),3.86(s,3H),2.94(br,2H),2.71(s,3H),2.40(br,2H), 2.27(s,6H)。
Example 20
N- (2- ((2-dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((5-methoxy-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 20)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((5-methoxy-4-(pyrazol o[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
The first step is as follows: n is a radical of4- (2-dimethylaminoethyl) -2-methoxy-N1- (5-methoxy-4-pyrazolo [1, 5-a)]Pyridin-3-yl-pyrimidin-2-yl) -N4-methyl-5-nitro-phenyl-1, 4-diamine (20B)
N4-(2-dimethylaminoethyl)-2-methoxy-N1-(5-methoxy-4-pyrazolo[1,5-a]pyridin-3-yl -pyrimidin-2-yl)-N4-methyl-5-nitro-benzene-1,4-diamine
Weighing N- (4-fluoro-2-methoxy-5-nitro-phenyl) -5-methoxy-4-pyrazolo [1,5-a]Pyridin-3-yl-pyrimidin-2-amine (intermediate 9) (0.41g,1mmol) was placed in a 10mL microwave reaction tube, N, N-dimethylacetamide (2mL), N, N, N' -trimethylethylenediamine (18A) (0.16mL,1.2mmol) and diisopropylethylamine (0.2mL,1.2mmol) were added sequentially to the reaction tube, and the reaction was heated to 140 ℃ for 1 hour under microwave. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane/methanol (v/v) ═ 15:1) to give N as a red solid4- (2-dimethylaminoethyl) -2-methoxy-N1- (5-methoxy-4-pyrazolo [1, 5-a)]Pyridin-3-yl-pyrimidin-2-yl) -N4-methyl-5-nitro-phenyl-1, 4-diamine (20B) (0.22g, 45% yield).
1H NMR(400MHz,CDCl3)δ9.00(s,1H),8.82(s,1H),8.68-8.66(d,1H),8.54-8.53 (d,1H),8.17(s,1H),7.41-7.34(m,2H),6.94-6.91(m,1H),6.75(s,1H),4.01(s,3H),4.00 (s,3H),3.33-3.30(m,2H),2.88(s,3H),2.66-2.63(m,2H),2.37(s,6H)。
The second step is that: n is a radical of1- (2-dimethylaminoethyl) -5-methoxy-N4- (5-methoxy-4-pyrazolo [1, 5-a) ]Pyridin-3-yl-pyrimidin-2-yl) -N1-methyl-phenyl-1, 2, 4-triamine (20C)
N1-(2-dimethylaminoethyl)-5-methoxy-N4-(5-methoxy-4-pyrazolo[1,5-a]pyridin-3-yl- pyrimidin-2-yl)-N1-methyl-benzene-1,2,4-triamine
Weighing N4- (2-dimethylaminoethyl) -2-methoxy-N1- (5-methoxy-4-pyrazolo [1, 5-a)]Pyridin-3-yl-pyrimidin-2-yl) -N4Methyl-5-nitro-phenyl-1, 4-diamine (20B) (0.22g,0.45mmol) was placed in a 100mL round-bottomed flask, ethanol (21mL), water (7mL), reduced iron powder (0.15g,2.70mmol) and ammonium chloride (0.017g,0.32mmol) were added to the flask in this order, and the reaction was refluxed at elevated temperature for 6 hours. The reaction mixture was filtered, the filter cake was washed with dichloromethane (10mL × 2) and methanol (10mL × 2) in this order, the filtrates were combined, concentrated, and the residue was purified by column chromatography (dichloromethane/methanol (v/v) ═ 15:1) to give N as a gray solid1- (2-dimethylaminoethyl) -5-methoxy-N4- (5-methoxy-4-pyrazolo [1, 5-a)]Pyridin-3-yl-pyrimidin-2-yl) -N1Methyl-phenyl-1, 2, 4-triamine (20C) (0.20g, 98% yield).
1H NMR(400MHz,CDCl3)δ8.82-8.80(m,2H),8.55-8.53(d,2H),8.11(s,1H), 7.94(s,1H),7.37-7.36(m,2H),6.92-6.90(m,2H),6.71(s,1H),4.96(br,1H),3.95(s,3H), 3.85(s,3H),3.02-3.00(m,2H),2.67(s,3H),2.50-2.46(m,2H),2.42(s,6H)。
The third step: n- (2- ((2-dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((5-methoxy-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 20)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((5-methoxy-4-(pyrazol o[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
Weighing N1- (2-dimethylaminoethyl) -5-methoxy-N4- (5-methoxy-4-pyrazolo [1, 5-a)]Pyridin-3-yl-pyrimidin-2-yl) -N 1-methyl-phenyl-1, 2, 4-triamine (20C) (0.2g,0.43mmol), placed in a 100mL round bottom flask, tetrahydrofuran (15mL) and diisopropylethylamine (0.09mL,0.56mmol) were added sequentially, cooled to 0 deg.C, acryloyl chloride (0.04mL,0.52mmol) was added dropwise, and allowed to warm to room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and methylene chloride (50mL), a saturated aqueous sodium bicarbonate solution (30mL) and added to the residue, followed by liquid separation, extraction of the aqueous phase with methylene chloride (50mL), combination of the organic phases, washing of the organic phase with a saturated saline solution (30mL), drying over anhydrous sodium sulfate, concentration under reduced pressure, and column chromatography purification (methylene chloride/methanol (v/v) ═ 15:1) gave N- (2- ((2-dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((5-methoxy-4- (pyrazolo [1, 5-a): 5) as a yellow solid]Pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 20) (0.08g, 48% yield).
MS m/z(ESI):517.2[M+1]+。
1H NMR(400MHz,CDCl3)δ10.02(s,1H),9.53(s,1H),8.82(s,1H),8.76-8.74(d, 1H),8.53-8.51(d,1H),8.25(s,1H),7.36(s,1H),7.28-7.26(m,1H),6.91-6.89(m,1H), 6.77(s,1H),6.38-6.36(m,2H),5.68-5.65(m,1H),3.98(s,3H),3.87(s,3H),2.82-2.80(m, 2H),2.72(s,3H),2.34-2.30(m,8H)。
Example 21
N- (2- ((2-dimethylamino) ethyl) (methyl) amino) -5- ((5-methoxy-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 21)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((5-methoxy-4-(pyrazolo[1,5-a]pyri din-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
The first step is as follows: n- (4-fluoro-3-nitro-phenyl) -5-methoxy-4-pyrazolo [1,5-a ] pyridin-3-yl-pyrimidin-2-amine (21B)
N-(4-fluoro-3-nitro-phenyl)-5-methoxy-4-pyrazolo[1,5-a]pyridin-3-yl-pyrimidin-2-a mine
3- (2-chloro-5-methoxy-pyrimidin-4-yl) pyrazolo [1,5-a ] pyridine (9c) (0.52g,2mmol) was weighed and placed in a 50mL round-bottomed flask, 2-pentanol (15mL), 4-fluoro-3-nitroaniline (0.31g,2mmol) and p-toluenesulfonic acid (0.46g,2.4mmol) were added sequentially to a reaction flask, and the mixture was heated to 120 ℃ for 48 hours. The reaction solution was cooled to room temperature, acetonitrile (20mL) and aqueous ammonia (20mL) were added, filtered, the filter cake was washed with acetonitrile (10mL × 2) and water (10mL × 2), the filter cake was collected and dried to give N- (4-fluoro-3-nitro-phenyl) -5-methoxy-4-pyrazolo [1,5-a ] pyridin-3-yl-pyrimidin-2-amine (21B) as a yellow solid (0.68g, 89% yield).
1H NMR(400MHz,DMSO-d6)δ9.82(s,1H),8.88-8.75(m,4H),8.37(s,1H), 8.03-8.01(m,1H),7.51-7.47(m,2H),7.18-7.16(m,1H),4.02(s,3H)。
The second step is that: n is a radical of1- (2-dimethylaminoethyl) -N4- (5-methoxy-4-pyrazolo [1, 5-a)]Pyridin-3-yl-pyrimidin-2-yl) -N1-methyl-2-nitro-phenyl-1, 4-diamine (21C)
N1-(2-dimethylaminoethyl)-N4-(5-methoxy-4-pyrazolo[1,5-a]pyridin-3-yl-pyrimidin- 2-yl)-N1-methyl-2-nitro-benzene-1,4-diamine
Weighing N- (4-fluoro-3-nitro-phenyl) -5-methoxy-4-pyrazolo [1,5-a]Pyridin-3-yl-pyrimidin-2-amine (21B) (0.38g,1mmol) was placed in a 10mL microwave reaction tube and N, N-dimethylacetamide (2mL), N, N, N' -trimethylethylenediamine (18A) (0.16mL,1.2mmol) and diisopropylethylamine (0.2mL, 1.2mmol) were added to the reaction tube in that order,the temperature is raised to 140 ℃ and the reaction is carried out for 1 hour under microwave. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane/methanol (v/v) ═ 15:1) to give N as a red solid1- (2-dimethylaminoethyl) -N4- (5-methoxy-4-pyrazolo [1, 5-a)]Pyridin-3-yl-pyrimidin-2-yl) -N1-methyl-2-nitro-phenyl-1, 4-diamine (21C) (0.46 g).
1H NMR(400MHz,CDCl3)δ8.82(s,1H),8.64-8.62(m,1H),8.57-8.53(m,1H), 8.30(s,1H),8.14(s,1H),7.51-7.49(m,1H),7.40-7.38(m,1H),7.24-7.22(d,1H),7.04(s, 1H),6.97-6.93(m,1H),4.01(s,3H),3.33-3.30(m,2H),2.84-2.79(m,5H),2.55(s,6H)。
The third step: n is a radical of1- (2-dimethylaminoethyl) -N4- (5-methoxy-4-pyrazolo [1, 5-a)]Pyridin-3-yl-pyrimidin-2-yl) -N1-methyl-phenyl-1, 2, 4-triamine (21D)
N1-(2-dimethylaminoethyl)-N4-(5-methoxy-4-pyrazolo[1,5-a]pyridin-3-yl-pyrimidin- 2-yl)-N1-methyl-benzene-1,2,4-triamine
Weighing N1- (2-dimethylaminoethyl) -N4- (5-methoxy-4-pyrazolo [1, 5-a)]Pyridin-3-yl-pyrimidin-2-yl) -N1Methyl-2-nitro-phenyl-1, 4-diamine (21C) (0.8g,1.73mmol) was placed in a 100mL round-bottomed flask, ethanol (30mL), water (10mL), reduced iron powder (0.58g,10.4mmol) and ammonium chloride (0.065g,1.21mmol) were added to the reaction flask in this order, and the reaction was refluxed at elevated temperature for 6 hours. The reaction mixture was filtered, the filter cake was washed with dichloromethane (10mL × 2) and methanol (10mL × 2), the filtrates were combined, concentrated, and the residue was purified by column chromatography (dichloromethane/methanol (v/v) ═ 15:1) to give N as a gray solid 1- (2-dimethylaminoethyl) -N4- (5-methoxy-4-pyrazolo [1, 5-a)]Pyridin-3-yl-pyrimidin-2-yl) -N1-methyl-phenyl-1, 2, 4-triamine (21D) (0.63g, 84% yield).
1H NMR(400MHz,CDCl3)δ8.81(s,1H),8.78-8.75(d,1H),8.55-8.53(d,1H),8.11 (s,1H),7.79-7.77(d,2H),7.28(s,1H),7.20-7.17(m,3H),3.98(s,3H),3.18-3.15(m,2H), 2.90-2.87(m,2H),2.64(s,6H)。
The fourth step: n- (2- ((2-dimethylamino) ethyl) (methyl) amino) -5- ((5-methoxy-4- (pyrazolo [1,5-a ] pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 21)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((5-methoxy-4-(pyrazolo[1,5-a]pyri din-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
Weighing N1- (2-dimethylaminoethyl) -N4- (5-methoxy-4-pyrazolo [1, 5-a)]Pyridin-3-yl-pyrimidin-2-yl) -N1Methyl-phenyl-1, 2, 4-triamine (21D) (0.63g,1.46mmol) was placed in a 100mL round bottom flask, tetrahydrofuran (15mL) and diisopropylethylamine (0.29mL,1.75mmol) were sequentially added to the reaction flask, the reaction solution was cooled to 0 ℃, acryloyl chloride (0.14mL,1.75mmol) was added dropwise, and after completion of the addition, the temperature was raised for reaction for 1 hour. The reaction mixture was concentrated under reduced pressure, methylene chloride (50mL), a saturated aqueous sodium bicarbonate solution (30mL) were added to the residue, the mixture was separated, the aqueous phase was extracted with methylene chloride (50mL), the organic phases were combined, the organic phase was washed with a saturated saline solution (30mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (methylene chloride/methanol (v/v) ═ 15:1) to give N- (2- ((2-dimethylamino) ethyl) (methyl) amino) -5- ((5-methoxy-4- (pyrazolo [1, 5-a) as a yellow solid ]Pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 21) (0.15g, 48% yield).
MS m/z(ESI):487.3[M+1]+。
1H NMR(400MHz,CDCl3)δ8.82(s,1H),8.77-8.73(m,1H),8.56-8.53(m,2H), 8.21(s,1H),8.02(s,1H),7.78-7.76(d,1H),7.72-7.70(m,1H),7.30-7.28(m, 1H),7.23-7.21(m,2H),7.01(s,1H),6.45-6.41(m,1H),5.73-5.70(m,1H),3.99(s,3H), 2.82-2.80(m,2H),2.72(s,3H),2.34-2.30(m,8H)。
Example 22
N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -3-fluoro-4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) phenyl) acrylamide (compound 22)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-3-fluoro-4-methoxy-5-((4-(1-methyl- 1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
The first step is as follows: n is a radical of4- (2- (dimethylamino) ethyl) -3-fluoro-2-methoxy-N4-methyl-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-nitrophenyl-1, 4-diamine (22B)
N4-(2-(dimethylamino)ethyl)-3-fluoro-2-methoxy-N4-methyl-N1-(4-(1-methyl-1H- indol-3-yl)pyrimidin-2-yl)-5-nitrobenzene-1,4-diamine
N- (3, 4-difluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (intermediate 10) (1.4g,3.4mmol), N, N, N' -trimethylethylenediamine (18A) (0.69g,6.8mmol) and N, N-diisopropylethylamine (0.87g,6.8mmol) were added to N, N-dimethylformamide (3mL) and reacted with microwave at 140 ℃ for 1.5 hours. The reaction solution was cooled to room temperature, water (20mL) was added to the reaction solution, extraction was performed with dichloromethane (50mL × 3), the organic phases were combined, the organic phase was washed with water (50mL × 2), dried over anhydrous sodium sulfate, concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 50:1) to give the title compound N4- (2- (dimethylamino) ethyl) -3-fluoro-2-methoxy-N4-methyl-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-nitrobenzene-1, 4-diamine (22B) as a red solid (0.25g, 15% yield).
1H NMR(400MHz,DMSO-d6)δ8.62(s,1H),8.56(s,1H),8.42–8.38(m,2H),8.35 (s,1H),7.54(d,1H),7.32(d,1H),7.30–7.22(m,2H),7.16(t,1H),4.02(s,3H),3.88(s, 3H),3.20(t,2H),2.82(s,3H),2.65(s,2H),2.35(s,6H)。
MS m/z:494.3[M+1]+。
The second step is that: n is a radical of1- (2- (dimethylamino) ethyl) -6-fluoro-5-methoxy-N1-methyl-N4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) benzene-1, 2, 4-triamine (22C)
N1-(2-(dimethylamino)ethyl)-6-fluoro-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H- indol-3-yl)pyrimidin-2-yl)benzene-1,2,4-triamine
Will N4- (2- (dimethylamino) ethyl) -3-fluoro-2-methoxy-N4-methyl-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-nitrobenzene-1, 4-diamine (22B) (0.25g,5mmol), iron powder (0.17g,30mmol) and ammonium chloride (0.27g,50mmol) were added to a mixed solution of ethanol (5mL) and water (2mL), and the temperature was raised to 90 ℃ for 4 hours. The reaction mixture was cooled to room temperature, water (20mL) was added, extraction was performed with dichloromethane (50 mL. times.3), the organic phases were combined, the organic phase was washed with water (50 mL. times.2), dried over anhydrous sodium sulfate, and concentrated to give the title compound N1- (2- (dimethylamino) ethyl) -6-fluoro-5-methoxy-N1-methyl-N4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) benzene-1, 2, 4-triamine (22C), red solid (0.22g, 96% yield).
MS m/z:464.4[M+1]+。
The third step: n- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -3-fluoro-4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) phenyl) acrylamide (compound 22)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-3-fluoro-4-methoxy-5-((4-(1-methyl- 1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
Will N1- (2- (dimethylamino) ethyl) -6-fluoro-5-methoxy-N1-methyl-N4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) phenyl-1, 2, 4-triamine (22C) (0.27g,0.55mmol), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) (0.42g,2.19mmol) and acrylic acid (0.078g,1.09mmol) were added to pyridine (5mL) and reacted at room temperature for 2 hours. Water (10mL) was added to the reaction solution, and extraction was performed with dichloromethane (50mL × 3), the organic phases were combined, the organic phase was washed with water (50mL × 2), dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 50:1) to give the title compound N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -3-fluoro-4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) phenyl) acrylamide (compound 22) as a yellow solid (40mg, yield 14%).
1H NMR(400MHz,DMSO-d6)δ10.58(s,1H),9.04(s,1H),8.68(s,1H),8.37(d, 1H),8.24(d,1H),8.20(s,1H),7.53(d,1H),7.29(d,1H),7.25(m,1H),7.14(m,1H),6.41 –6.25(m,2H),5.83(m,1H),3.92(s,3H),3.86(s,3H),3.06(s,2H),2.81(s,3H),2.28(s, 2H),2.22(s,6H)。
MS m/z:518.4[M+1]+。
Example 23
N- (4- (difluoromethoxy) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 23)
N-(4-(difluoromethoxy)-2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl- 1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
The first step is as follows: 2- (difluoromethoxy) -N4- (2- (dimethylamino) ethyl) -N4-methyl-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-nitrophenyl-1, 4-diamine (23B)
2-(difluoromethoxy)-N4-(2-(dimethylamino)ethyl)-N4-methyl-N1-(4-(1-methyl-1H-i ndol-3-yl)pyrimidin-2-yl)-5-nitrobenzene-1,4-diamine
To a reaction flask was added 5- (difluoromethoxy) -N- (2- (dimethylamino) ethyl) -N-methyl-2-nitrobenzene-1, 4-diamine (intermediate 1) (120mg, 0.39mmol), 3- (2-chloropyrimidin-4-yl) -1-methyl-1H-indole (intermediate 2) (115 mg, 0.47mmol), p-toluenesulfonic acid (94mg, 0.86mmol) and 2-pentanol (2mL), and heated to 110 ℃ for 3 hours. The reaction mixture was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography (dichloromethane/aminomethanol (v/v) ═ 50:1) to give 2- (difluoromethoxy) -N as a brown oil4- (2- (dimethylamino) ethyl) -N4-methyl-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-nitrophenyl-1, 4-diamine (23B) (150mg, 75% yield).
MS m/z(ESI):512.3[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.56(d,2H),8.37–8.29(m,3H),7.50(dd,1H), 7.39(t,1H),7.30–7.22(m,2H),7.20(s,1H),7.17–7.07(m,1H),3.88(s,3H),3.41(t, 2H),2.98(s,2H),2.83(s,3H),2.56(s,6H)。
The second step is that: 5- (difluoromethoxy) -N1- (2- (dimethylamino) ethyl) -N1-methyl-N4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) benzene-1, 2, 4-triamine (23C)
5-(difluoromethoxy)-N1-(2-(dimethylamino)ethyl)-N1-methyl-N4-(4-(1-methyl-1H-in dol-3-yl)pyrimidin-2-yl)benzene-1,2,4-triamine
Adding 2- (difluoromethoxy) -N into a reaction bottle4- (2- (dimethylamino) ethyl) -N4-methyl-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-nitrobenzene-1, 4-diamine (23B) (150mg, 0.29mmol), iron powder (99 mg, 1.76mmol), ammonium chloride (11mg, 0.2mmol) and ethanol/water (5mL/1.5mL) were heated to reflux for 2 hours. The reaction mixture was concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography (dichloromethane/aminomethanol (v/v) ═ 50:1) to give 5- (difluoromethoxy) -N as a brown solid1- (2- (dimethylamino) ethyl) -N1-methyl-N4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) benzene-1, 2, 4-triamine (23C) (100mg, 72% yield).
MS m/z(ESI):482.4[M+1]+。
The third step: n- (4- (difluoromethoxy) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 23)
N-(4-(difluoromethoxy)-2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl- 1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
Adding 5- (difluoromethoxy) -N into a reaction bottle1- (2- (dimethylamino) ethyl) -N1-methyl-N4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) benzene-1, 2, 4-triamine (23C) (110mg, 0)23mmol), diisopropylethylamine (39mg, 0.3mmol) and dichloromethane (3mL) were cooled in an ice bath, acryloyl chloride (23mg,0.25mmol) was added dropwise, and the reaction was carried out in an ice bath for 1 hour after the addition. Dichloromethane (20mL) and saturated brine (20mL) were added to the reaction solution, and the mixture was separated, and the aqueous layer was extracted with dichloromethane (10mL × 4), the organic phases were combined, the organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 30:1) to give N- (4- (difluoromethoxy) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 23) (45m g, yield 37%) as a pale yellow oil.
MS m/z(ESI):536.3[M+1]+。
1H NMR(400MHz,DMSO-d6)δ10.21(s,1H),8.94(s,1H),8.50(s,1H),8.35–8.28(m, 2H),8.24(d,1H),7.51(d,1H),7.28–7.15(m,3H),7.10(d,1H),7.07(t,1H),6.55–6.38(m, 1H),6.27(d,1H),5.80(d,1H),3.89(s,3H),2.90(s,2H),2.71(s,3H),2.40(m,2H),2.26(s, 6H)。
Example 24
N- (3- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -5-morpholinylbenzene) acrylamide (compound 24)
N-(3-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-morpholinophenyl)acryla mide
The first step is as follows: 4- (3-iodo-5-nitrophenyl) morpholine (24B)
4-(3-iodo-5-nitrophenyl)morpholine
1-fluoro-3-iodo-5-nitrobenzene (24A) (5.0g, 18.7mmol) and morpholine (3.4g,39.3mmol) were dissolved in dimethyl sulfoxide (15mL) and reacted at 90 ℃ for 17 hours to complete the reaction, 30mL of water was added, extraction was performed with dichloromethane (30 mL. times.2), 30mL of water was washed, 30mL of saturated brine was washed, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 4- (3-iodo-5-nitrophenyl) morpholine (24B) as a yellow solid (6.0g, 96.8% yield).
1H NMR(400MHz,CDCl3)δ7.99–7.95(m,1H),7.64(t,1H),7.45(dd,1H),3.86 (dd,4H),3.24(dd,4H)。
LC-MS(m/z):335.1[M+1]+。
The second step is that: 3-morpholinyl-5-nitroaniline (24C)
3-morpholino-5-nitroaniline
4- (3-iodo-5-nitrophenyl) morpholine (24B) (1.0g, 3.0mmol) was dissolved in N, N-dimethylformamide (2mL), and ammonia (51mg, 30mmol) and copper powder (190mg, 3.0mmol) were added to react overnight in a closed system at 100 ℃. After completion of the reaction, 60mL of water was added, followed by extraction with dichloromethane (60mL × 2), washing with water (60mL), washing with saturated brine (60mL), drying over anhydrous sodium sulfate, concentration under reduced pressure, and silica gel column chromatography (ethyl acetate/petroleum ether: 1:10 to 1:1) to give 3-morpholinyl-5-nitroaniline (24C) (0.35g, yield 52.23%) as a red solid.
1H NMR(400MHz,CDCl3)δ7.14(t,1H),7.01(t,1H),6.42(t,1H),3.87–3.83(m, 4H),3.22–3.16(m,4H)。
The third step: 4- (1-methyl-1H-indol-3-yl) -N- (3-morpholinyl-5-nitrophenyl) pyrimidin-2-amine (24D)
4-(1-methyl-1H-indol-3-yl)-N-(3-morpholino-5-nitrophenyl)pyrimidin-2-amine
3- (2-Chloropyrimidin-4-yl) -1-methyl-1H-indole (intermediate 2) (0.4g, 1.6mmol), 3-morpholino-5-nitroaniline (0.37g, 1.6mmol), p-toluenesulfonic acid (0.31g, 1.6mmol) was added to 40mL of 2-pentanol and reacted at 120 ℃ overnight. After the reaction, the reaction mixture was cooled to precipitate a solid, which was then filtered and the cake was dried to give 4- (1-methyl-1H-indol-3-yl) -N- (3-morpholinyl-5-nitrophenyl) pyrimidin-2-amine (24D) as a yellow solid (0.3g, 53.5% yield).
LC-MS(m/z):431.1[M+1]+。
The fourth step: n is a radical of1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-morpholinylbenzene-1, 3-diamine (24E)
N1-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-5-morpholinobenzene-1,3-diamine
4- (1-methyl-1H-indol-3-yl) -N- (3-morpholin-5-nitrophenyl) pyrimidin-2-amine (24D) (0.4g, 0.93mmol) was dissolved in a mixed solvent of ethanol (20ml) and water (10ml), and iron powder (311mg, 5.6mmol) and ammonium chloride (497.5mg, 9.3mmol) were added. The reaction was carried out at 90 ℃ for 2 hours. Water (30mL) was added to the reaction mixture, followed by extraction with methylene chloride (30 mL. times.2), and the organic phases were combined, washed successively with water (30mL) and saturated brine (30mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the title compound N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-morpholinylbenzene-1, 3-diamine (24E) as a brown solid (250mg, 68% yield).
1H NMR(400MHz,CDCl3)δ8.45(dd,1H),8.28(d,1H),7.82(s,1H),7.44–7.35 (m,2H),7.35–7.27(m,2H),7.02(d,1H),6.77(m,1H),6.71(m,1H),5.99(m,1H),3.87 (s,3H),3.83–3.79(m,4H),3.17–3.12(m,4H)。
MS m/z(ESI):401.1[M+1]+。
The fifth step: n- (3- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -5-morpholinylbenzene) acrylamide (compound 24)
N-(3-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-morpholinophenyl)acryla mide
Will N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -5-morpholinylbenzene-1, 3-diamine (24E) (250mg, 0.625mmol) was dissolved in 5mL of pyridine, acrylic acid (90mg, 1.25mmol) was added, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (2.5mmol, 478mg) was added, and the reaction was carried out at room temperature for 2 hours. 60mL of methylene chloride was added, and the mixture was washed with water (60 mL. times.2), saturated sodium bicarbonate (60 mL. times.2), and saturated brine (30mL) in this order, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (methylene chloride/methanol (v/v) ═ 100/1-100/3) to give N- (3- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -5-morpholinylbenzene) acrylamide (compound 24) (150mg, yield 52.8%) as a pale red solid.
1H NMR(400MHz,CDCl3)δ8.36(d,1H),8.27(d,1H),7.96(s,1H),7.62(s,1H), 7.50(d,2H),7.37(d,1H),7.31(m,1H),7.23(d,1H),7.17(s,1H),7.03(d,1H),6.87(s, 1H),6.41(d,1H),6.23(dd,1H),5.73(d,1H),3.85(s,3H),3.83–3.76(m,4H),3.20– 3.12(m,4H)。
MS m/z(ESI):455.2[M+1]+。
Example 25
N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-ethylphenyl) acrylamide (compound 25)
N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylam ino)ethyl)(methyl)amino)-4-ethylphenyl)acrylamide
The first step is as follows: 2-Ethyl-4-fluoro-5-nitroaniline (25B)
2-ethyl-4-fluoro-5-nitroaniline
To a reaction flask was added 25mL of concentrated sulfuric acid, 2-ethyl-4-fluoroaniline (25A) (3.88g, 27.9mmol) was added dropwise at 0 ℃, potassium nitrate ((2.82g, 27.9mmol) was added, and the reaction was carried out at 0 ℃ for 1 hour, ice cubes (100mL) were added to a saturated sodium bicarbonate solution (300mL), the reaction system was slowly poured into the above solution, sodium bicarbonate solid was added until no more bubbles were generated, liquid separation was carried out, the aqueous phase was extracted with ethyl acetate (150mL × 4), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was separated and purified by silica gel column chromatography (petroleum ether: ethyl acetate (v/v) ═ 10:1 to 2:1) to give the title compound 2-ethyl-4-fluoro-5-nitroaniline (25B) (3.33g, yield 55%) as an orange solid.
MS m/z:185.1[M+1]+。
The second step is that: 5-chloro-N- (2-ethyl-4-fluoro-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (25C)
5-chloro-N-(2-ethyl-4-fluoro-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-a mine
2-Ethyl-4-fluoro-5-nitroaniline (25B) (1.31g,7.1mmol) and 3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1H-indole (4c) (1.97g,7.1mmol) were dissolved in 1, 4-dioxane (70mL), 4.5-bis-diphenylphosphine-9.9-dimethylxanthene (0.46g,0.79mmol), cesium carbonate (4.85g,14.9mmol) and palladium acetate (0.10g,0.47 mmol) were added, the mixture was cooled with liquid nitrogen, replaced with nitrogen for 0.5 hour, and the mixture was allowed to warm to room temperature and reacted at 120 ℃ overnight. Cooled to room temperature, the solid was filtered off with suction, concentrated, and the residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate (v/v) ═ 10:1 to 3:1) to give the title compound 5-chloro-N- (2-ethyl-4-fluoro-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (25C) as a yellow-green solid (0.59g, 20% yield).
MS m/z:426.1[M+1]+。
The third step: n is a radical of1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-ethyl-N4-methyl-5-nitrophenyl-1, 4-diamine (25D)
N1-(5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-N4-(2-(dimethylamino)ethyl) -2-ethyl-N4-methyl-5-nitrobenzene-1,4-diamine
5-chloro-N- (2-ethyl-4-fluoro-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (25C) (0.56g,1.32mmol) was added to a microwave reaction tube, N, N-dimethylacetamide (8mL) was added thereto and dissolved, and diisopropylethylamine (0.26mL,1.59mmol), N, N, N' -trimethylethylenediamine (18A) (0.21mL,1.59mmol) and microwave-reacted at 140 ℃ for 1 hour. The reaction system was cooled to room temperature, concentrated, and the residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate (v/v) ═ 4:1 to 2:1 to dichloromethane: methanol (v/v) ═ 15:1 to 5:1) to give the title compound as an orange solid N 1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-ethyl-N4Methyl-5-nitrophenyl-1, 4-diamine (25D) (0.49g, 73% yield).
MS m/z=509.2[M+1]+。
The fourth step: n is a radical of4- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-ethyl-N1-methylphenyl-1, 2, 4-triamine (25E)
N4-(5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-N1-(2-(dimethylamino)ethyl) -5-ethyl-N1-methylbenzene-1,2,4-triamine
Will N1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-ethyl-N4-methyl-5-nitrobenzene-1, 4-diamine (25D) (0.46g,0.91mmol), iron powder (0.30g,5.43mmol) and ammonium chloride (0.04g,0.75mmol) were added to a mixed solvent of absolute ethanol (12mL) and water (4mL), heated to 90 ℃ for reaction overnight, supplemented with iron powder (0.15g,2.72mmol) and ammonium chloride (0.02g,0.37mmol), and reacted at 90 ℃ for 2 hours. Cooling to room temperature, suction-filtering to remove the solid, concentrating, and separating and purifying the residue by silica gel column chromatography (petroleum ether: ethyl acetate (v/v) ═ 1: 1-ethyl acetate: methanol (v/v) ═ 10: 1-3: 1) to obtain the title compound as an orange solid N4- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-ethyl-N1-methylphenyl-1, 2, 4-triamine (25E) (0.43g, 92% yield).
MS m/z:479.2[M+1]+。
The fifth step: n- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-ethylphenyl) acrylamide (compound 25)
N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylam ino)ethyl)(methyl)amino)-4-ethylphenyl)acrylamide
Diisopropylethylamine (1.7mL) was added to freshly distilled tetrahydrofuran (8.3mL) to give solution 1; acryloyl chloride (0.75mL) was added to freshly distilled tetrahydrofuran (9.25mL) to give solution 2. Will N4- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-ethyl-N1-methylphenyl-1, 2, 4-triamine (25E) (0.40g,0.84mmol) was dissolved in freshly distilled tetrahydrofuran (10mL), and solution 1(1mL) and solution 2(1 mL) were added dropwise at 0 ℃ and reacted at room temperature for 1.5 hours. The reaction mixture was quenched by adding water (80mL), the aqueous phase was extracted with ethyl acetate (70mL × 5), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and the residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate (v/v) ═ 1: 1-acetic acid)Ethyl ester methanol (v/v) ═ 10:1 to 1:1) to give the title compound N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyridin-2-yl) N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-ethylphenyl) acrylamide (compound 25) (0.07g, 16% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ10.12(s,1H),8.88(s,1H),8.53(s,2H),7.46-7.44 (m,1H),7.23(s,1H),7.18-7.15(m,1H),6.89-6.86(m,1H),6.43-6.36(m,1H),6.21-6.16 (m,1H),5.74-5.72(m,1H),5.33-5.31(m,1H),3.87(s,3H),3.17-3.16(m,2H),2.75(s, 3H),2.58-2.52(m,2H),2.37-2.34(m,2H),2.21(s,6H),1.09-1.05(t,3H)。
MS m/z:533.2[M+1]+。
Example 26
4- (3- (2- ((5-acrylamido-2-methoxyphenyl) amino) -5-chloropyrimidin-4-yl) -1-methyl-1H-indol-6-yl) piperazine-1-carboxylic acid tert-butyl ester (Compound 26)
tert-butyl 4-(3-(2-((5-acrylamido-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)- 1-methyl-1H-indol-6-yl)piperazine-1-carboxylate
The first step is as follows: 6-bromo-1- (triisopropylsilyl) -1-hydro-indole (26B)
6-bromo-1-(triisopropylsilyl)-1H-indole
Tetrahydrofuran (250mL) was added to a 2L round bottom flask, and sodium hydride (24.5 g,0.612mol, 60% w/w) was added to the flask at 0 deg.C, and a solution of 6-bromoindole (100.0g,0.510mol) in tetrahydrofuran (500mL) was added dropwise. After completion of the addition, the mixture was stirred at 0 ℃ for 30 minutes, and a solution of triisopropylchlorosilane (100g,0.518mol) in tetrahydrofuran (250mL) was added dropwise. After the addition was complete, the reaction was stirred for a further 30 minutes at 0 ℃. The reaction solvent was removed under reduced pressure, the residue was poured into ethyl acetate (3000mL), the organic phase was washed successively with water (1000mL), saturated brine (500mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure and subjected to column chromatography (petroleum ether/ethyl acetate (v/v) ═ 15:1) to give 6-bromo-1- (triisopropylsilyl) -1-hydro-indole (26B) as a white solid (160g, 93% yield).
1H NMR(400MHz,CDCl3)δ7.63(s,1H),7.49-7.47(d,1H),7.20-7.18(m,2H), 6.59-6.58(d,1H),1.71-1.64(m,3H),1.16-1.14(m,18H)。
The second step is that: 4- (1H-indol-6-yl) piperidine-1-carboxylic acid tert-butyl ester (26C)
tert-butyl 4-(1H-indol-6-yl)piperazine-1-carboxylate
6-bromo-1- (triisopropylsilyl) -1-hydro-indole (26B) (1.2g, 3.6mmol) was charged in a 100mL round-bottom flask, and o-xylene (40mL), 1-tert-butoxycarbonylpiperazine (1.0g, 5.4mmol), sodium tert-butoxide (0.51g, 5.4mmol), tri-tert-butylphosphine (0.11g, 0.54mmol), and palladium acetate (0.04g, 0.18mmol) were added sequentially to the reaction flask, and replaced with a nitrogen balloon several times, stirred at room temperature for 30 minutes, and the reaction was continued for 2 hours while the temperature was raised to 120 ℃. The reaction mixture was filtered, the filter cake was washed with ethyl acetate (50 mL. times.2), the filtrate was washed with saturated brine (20mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product. The crude product was dissolved in 100mL of tetrahydrofuran, and tetrabutylammonium fluoride (1.9g,7.2mmol) was added thereto and reacted at room temperature for 1 hour. The reaction solvent was removed under reduced pressure, and column chromatography separation (petroleum ether/ethyl acetate (v/v) ═ 2:1) gave tert-butyl 4- (1 h-indol-6-yl) piperidine-1-carboxylate (26C) as a white solid (0.65g, yield: 60%).
1H NMR(400MHz,CDCl3)δ8.09(br,1H),7.55-7.53(d,1H),6.96(s,1H), 6.95-6.89(m,2H),6.47(s,1H),3.65(s,4H),3.13(s,4H),1.50(s,9H)。
The third step: 4- (3- (2, 5-dichloropyrimidin-4-yl) -1H-indol-6-yl) piperidine-1-carboxylic acid tert-butyl ester (26D)
tert-butyl 4-(3-(2,5-dichloropyrimidin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate
Tert-butyl 4- (1-hydro-indol-6-yl) piperidine-1-carboxylate (26C) (0.3g, 1mmol) was added to a 50mL round-bottom flask, and tetrahydrofuran (5mL) was added to the reaction flask. An ether solution of methyl magnesium bromide (0.5mL, 1.5mmol,3mol/L) was added dropwise at 0 deg.C, after which the reaction was allowed to warm to room temperature and stirred for 1 hour. 2,4, 5-trichloropyrimidine (0.2g,1.1mmol) was added to the reaction flask at 0 ℃. The reaction was heated to reflux for 2 hours. The reaction solution was cooled to room temperature, water (20mL) was added to quench the reaction, the residue was extracted with ethyl acetate (50mL × 2), the organic phases were combined, washed with saturated brine (30mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure and subjected to column chromatography (petroleum ether/ethyl acetate (v/v) ═ 2:1) to separate 4- (3- (2, 5-dichloropyrimidin-4-yl) -1 h-indol-6-yl) piperidine-1-carboxylic acid tert-butyl ester (26D) as a yellow solid (0.1g, 20% yield).
1H NMR(400MHz,CDCl3)δ9.15(s,1H),8.58-8.57(d,1H),8.56-8.41(m,2H), 7.08-7.06(d,1H),6.96(s,1H),3.67-3.65(m,4H),3.17(s,4H),1.51(s,9H)。
MS m/z:448.0[M+1]+。
The fourth step: 4- (3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1H-indol-6-yl) piperidine-1-carboxylic acid tert-butyl ester (26E)
tert-butyl 4-(3-(2,5-dichloropyrimidin-4-yl)-1-methyl-1H-indol-6-yl)piperazine-1-car boxylate
Tert-butyl 4- (3- (2, 5-dichloropyrimidin-4-yl) -1 h-indol-6-yl) piperidine-1-carboxylate (26D) (1.1g, 2.4mmol) was added to a 100mL round-bottom flask and N, N-dimethylformamide (20mL) was added to the reaction flask. Sodium hydride (0.14g,5.9mol, 60%) was added to the reaction flask at 0 ℃ and the reaction was continued at 0 ℃ for 30 minutes. Methyl iodide (1.0g,7.1mmol) was added to the reaction solution, and the reaction was warmed to room temperature and stirred for 2 hours. The reaction mixture was poured into water (100mL), a large amount of solid precipitated, and the precipitate was filtered, washed with petroleum ether (20mL × 2) and water (20mL × 2) in this order, and naturally dried to give tert-butyl 4- (3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1 h-indol-6-yl) piperidine-1-carboxylate (26E) (1.1g, yield 99%) as a yellow solid.
The fifth step: 4- (3- (5-chloro-2- ((2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1-methyl-1 h-indol-6-yl) piperidine-1-carboxylic acid tert-butyl ester (26F)
tert-butyl 4-(3-(5-chloro-2-((2-methoxy-5-nitrophenyl)amino)pyrimidin-4-yl)-1-meth yl-1H-indol-6-yl)piperazine-1-carboxylate
Tert-butyl 4- (3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1 h-indol-6-yl) piperidine-1-carboxylate (26E) (0.46g, 1.0mmol) was charged to a 100mL round-bottomed flask, and to the reaction flask were added 1, 4-dioxane (20mL), 2-amino-4-nitrobenzyl ether (0.2g, 1.2mmol), and sodium tert-butoxide (0.24g, 2.5mmol) in that order. The reaction system was purged with nitrogen for 10 minutes, and 4, 5-bis-diphenylphosphine-9, 9-dimethylxanthene (0.063g, 0.11mmol) and palladium acetate (0.022g, 0.1mmol) were added to replace the reaction system with nitrogen again. The temperature is increased to reflux reaction and stirring is carried out for 6 hours. After the reaction was cooled to room temperature, the reaction was quenched by adding water (20mL), the residue was extracted with ethyl acetate (50mL × 2), the organic phases were combined, washed with saturated brine (20mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure and separated by column chromatography (petroleum ether/ethyl acetate (v/v) ═ 2:1) to give 4- (3- (5-chloro-2- ((2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1-methyl-1 h-indol-6-yl) piperidine-1-carboxylic acid tert-butyl ester (26F) (0.25g, 42% yield) as a yellow solid.
1H NMR(400MHz,CDCl3)δ9.49(s,1H),8.43-8.39(m,2H),8.17(s,1H),7.92-7.90 (d,1H),7.77(s,1H),7.02-6.94(m,3H),4.05(s,3H),3.86(s,3H),3.68(s,4H),3.21(s, 4H),1.50(s,9H)。
And a sixth step: 4- (3- (2- ((5-amino-2-methoxyphenyl) amino) -5-chloro-pyrimidin-4-yl) -1-methyl-1 h-indol-6-yl) piperidine-1-carboxylic acid tert-butyl ester (26G)
tert-butyl 4-(3-(2-((5-amino-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)-1-met hyl-1H-indol-6-yl)piperazine-1-carboxylate
Tert-butyl 4- (3- (5-chloro-2- ((2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1-methyl-1 h-indol-6-yl) piperidine-1-carbonate (26F) (0.12g,0.2mmol) was charged to a 100mL round-bottomed flask, ethanol (15mL), water (5mL), reduced iron powder (0.067g,1.2mmol), and ammonium chloride (0.007g,0.14mmol) were added in that order, and the temperature was raised to reflux for 4 hours. The reaction mixture was cooled to room temperature, filtered, and the filter cake was washed with dichloromethane (10 mL. times.2) and methanol (10 mL. times.2). The filtrate was concentrated and purified by column chromatography (petroleum ether/ethyl acetate (v/v) ═ 1:1) to give tert-butyl 4- (3- (2- ((5-amino-2-methoxyphenyl) amino) -5-chloro-pyrimidin-4-yl) -1-methyl-1 h-indolin-6-yl) piperidine-1-carboxylate (26G) as a yellow solid (0.06G, 55% yield).
1H NMR(400MHz,CDCl3)δ8.56-8.54(d,1H),8.31(s,1H),8.14-8.11(m,1H), 7.74(s,1H),7.04-7.02(d,1H),6.79(s,1H),6.75-6.72(d,1H),6.32-6.29(m,1H),3.84(s, 3H),3.81(s,3H),3.65-3.63(m,4H),3.19-3.16(m,4H),1.50(s,9H)。
The seventh step: 4- (3- (2- ((5-acrylamido-2-methoxyphenyl) amino) -5-chloropyrimidin-4-yl) -1-methyl-1H-indol-6-yl) piperazine-1-carboxylic acid tert-butyl ester (Compound 26)
tert-butyl 4-(3-(2-((5-acrylamido-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)- 1-methyl-1H-indol-6-yl)piperazine-1-carboxylate
Tert-butyl 4- (3- (2- ((5-amino-2-methoxyphenyl) amino) -5-chloro-pyrimidin-4-yl) -1-methyl-1 h-indol-6-yl) piperidine-1-carboxylate (26G) (0.65G,1.2mmol) was added to a 50mL round-bottom flask. To the reaction flask were added pyridine (10mL), acrylic acid (0.17g,2.4mmol) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.88g,4.8mmol) in that order. The reaction was stirred at room temperature for 6 hours. The reaction solvent was removed under reduced pressure, a saturated aqueous sodium bicarbonate solution (40mL) was added, the residue was extracted with ethyl acetate (50mL × 2), the organic phases were combined, washed with saturated brine (40mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure and subjected to column chromatography (ethyl acetate) to isolate tert-butyl 4- (3- (2- ((5-acrylamido-2-methoxyphenyl) amino) -5-chloropyrimidin-4-yl) -1-methyl-1H-indol-6-yl) piperazine-1-carboxylate (compound 26) as a yellow solid (0.50g, yield 70%).
1H NMR(400MHz,CDCl3)δ8.51-8.49(m,2H),8.31(s,1H),8.35(s,1H),8.17(s, 1H),7.79-7.77(m,2H),7.15(s,1H),7.02-7.00(m,1H),6.90-6.88(d,1H),6.39-6.35(d, 1H),6.08-6.06(m,1H),5.69-5.66(m,1H),3.93(s,3H),3.86(s,3H),3.69(s,4H),3.22(s, 4H),1.50(s,9H)。
MS m/z:618.1[M+1]+。
Example 27
N- (3- ((5-chloro-4- (1-methyl-6- (4-methylpiperazin-1-yl) indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 27)
N-(3-((5-chloro-4-(1-methyl-6-(4-methylpiperazin-1-yl)-1H-indol-3-yl)pyrimidin-2-yl )amino)-4-methoxyphenyl)acrylamide
The first step is as follows: n- (3- ((5-chloro-4- (1-methyl-6- (4-methylpiperazin-1-yl) indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 27)
N-(3-((5-chloro-4-(1-methyl-6-(4-methylpiperazin-1-yl)-1H-indol-3-yl)pyrimidin-2-yl )amino)-4-methoxyphenyl)acrylamide
Tert-butyl 4- [3- [ 5-chloro-2- [ 2-methoxy-5- (acrylamido) anilino ] pyrimidin-4-yl ] -1-methyl-indol-6-yl ] piperidine-1-carboxylate (compound 26) (0.40g,0.65mmol) was added to a 50mL round-bottom flask. At 0 ℃, dichloromethane (10mL) and trifluoroacetic acid (5mL) were added in this order, and the reaction was stirred at room temperature for 2 hours. Dichloromethane (50mL) and saturated aqueous sodium bicarbonate (20mL) were added to the reaction mixture, the layers were separated, the aqueous phase was extracted with dichloromethane (50mL), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product. Methylene chloride (10mL), acetic acid (2mL) and an aqueous formaldehyde solution (1mL) were added to the crude product in this order at 0 ℃ and stirred for 30 minutes. Sodium triacetoxyborohydride (0.29g,1.3mmol) was added to the reaction solution, and the reaction was warmed to room temperature and stirred for 3 hours. The reaction was quenched by dropwise addition of saturated aqueous sodium bicarbonate (30mL), extracted with dichloromethane (50mL × 2), the organic phases were combined, washed with saturated brine (40mL), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and column chromatographed (dichloromethane/methanol (v/v) ═ 15:1) to give N- (3- ((5-chloro-4- (1-methyl-6- (4-methylpiperazin-1-yl) indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 27) (0.20g, 56%) as a yellow solid.
1H NMR(400MHz,CDCl3)δ8.54-8.53(m,1H),8.49-8.47(d,1H),8.35(s,1H),8.13(s, 1H),7.83-7.82(m,1H),7.77(s,1H),7.12(s,1H),6.97-6.83(m,3H),6.38-6.34(d,1H), 6.06-6.03(m,1H),5.71-5.68(d,1H),3.93(s,3H),3.86(s,3H),3.37(s,4H),2.79(s,4H), 2.50(s,3H)。
MS m/z:532.1[M]。
Example 28
N- (2- ((1-aminocyclopropyl) methoxy) -4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 28)
N-(2-((1-aminocyclopropyl)methoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyri midin-2-yl)amino)phenyl)acrylamide
The first step is as follows: (1- ((5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2-nitrophenoxy) methyl) cyclopropyl) carbamic acid tert-butyl ester (28A)
tert-butyl(1-((5-methoxy-4-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-nitr ophenoxy)methyl)cyclopropyl)carbamate
5- ((4- (1-Methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 3) (1g, 2.54mmol) was dissolved in tetrahydrofuran (20mL), sodium hydride (203mg, 5.08mmol) was added under ice-cooling, stirred for 30 minutes, added dropwise (1-hydroxymethylcyclopropyl) -tert-butoxycarbonylamino (951mg, 5.08mmol), and reacted at room temperature for 8 hours. After completion of the reaction, 150mL of water and 150mL of ethyl acetate were added and the mixture was separated. The aqueous phase was extracted with 100mL ethyl acetate, the organic phases combined, dried over anhydrous sodium sulfate and concentrated to give the compound tert-butyl 1- ((5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2-nitrophenoxy) methyl) cyclopropyl) carbamate (28A) as a yellow solid (1g, 71.4% yield).
MS m/z:561.1[M+1]+。
The second step is that: (1- ((2-amino-5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenoxy) methyl) cyclopropyl) carbamic acid tert-butyl ester (28B)
tert-butyl(1-((2-amino-5-methoxy-4-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amin o)phenoxy)methyl)cyclopropyl)carbamate
Tert-butyl (1- ((5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2-nitrophenoxy) methyl) cyclopropyl) carbamate (28A) (1.1g, 2.1mmol) was dissolved in 20mL of ethanol, 7mL of water, iron powder (356mg, 6.4mmol) and ammonium chloride (78.6mg, 1.5mmol) were added in this order, and the mixture was heated to 90 ℃ for reflux reaction for 6 hours. The reaction was cooled to room temperature, filtered and concentrated. Purification by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) gave tert-butyl (1- ((2-amino-5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenoxy) methyl) cyclopropyl) carbamate (28B) as a brown solid (750mg, 68.2% yield).
MS m/z:531.1[M+1]+。
The third step: (1- ((2-Acrylamido-5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenoxy) methyl) cyclopropyl) carbamic acid tert-butyl ester (28C)
tert-butyl(1-((2-acrylamido-5-methoxy-4-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl) amino)phenoxy)methyl)cyclopropyl)carbamate
Tert-butyl (1- ((2-amino-5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenoxy) methyl) cyclopropyl) carbamate (28B) (750mg, 1.4mmol) was dissolved in 20mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (1.2g, 6.3mmol) and acrylic acid (0.15mL, 2.1mmol) were added in that order and reacted at room temperature for 4 hours. Pyridine was removed by spin-drying, and 100mL of water and 100mL of methylene chloride were added to separate the layers. The organic phase was washed with 4mol/L aqueous sodium hydroxide (100 mL). The organic phase was dried over anhydrous sodium sulfate. Silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) gave tert-butyl (1- ((2-acrylamido-5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenoxy) methyl) cyclopropyl) carbamate (28C) as a white solid (730mg, 89.4% yield).
MS m/z:585.2[M+1]+。
The fourth step: n- (2- ((1-aminocyclopropyl) methoxy) -4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 28)
N-(2-((1-aminocyclopropyl)methoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyri midin-2-yl)amino)phenyl)acrylamide
Tert-butyl (1- ((2-acrylamido-5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenoxy) methyl) cyclopropyl) carbamate (28C) (730mg, 1.25mmol) was dissolved in 20mL of dichloromethane, 10mL of trifluoroacetic acid was added, and the reaction was carried out at room temperature for 2 hours. After the reaction, the solvent was removed by spin-drying, and the pH of the solution was adjusted to 8 with a saturated aqueous solution of sodium hydrogen carbonate. 100mL of methylene chloride was added, the layers were separated, and the organic layer was dried over anhydrous sodium sulfate. The resulting product was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give N- (2- ((1-aminocyclopropyl) methoxy) -4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 28) (130mg, 21.5%) as a white solid.
MS m/z:485.1[M+1]+。
Example 29
N- (4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (2-morpholinoethoxy) phenyl) acrylamide (compound 29)
N-(4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(2-morpholino ethoxy)phenyl)acrylamide
The first step is as follows: n- (2-methoxy-4- (2-morpholinoethoxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (29A)
N-(2-methoxy-4-(2-morpholinoethoxy)-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyr imidin-2-amine
5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 3) (1.2 g, 3.05mmol) was dissolved in 30mL of tetrahydrofuran, and sodium hydride (244.2mg, 6.1mmol) was added under ice-cooling, followed by stirring for 30 minutes, dropwise addition of 2-morpholinoethanol (800.8mg, 6.1mmol), and reaction at room temperature for 6 hours. After completion of the reaction, 150mL of water and 150mL of ethyl acetate were added and the mixture was separated. The aqueous phase was extracted with 100mL ethyl acetate and the organic phase was dried over anhydrous sodium sulfate and concentrated to give the compound N- (2-methoxy-4- (2-morpholinoethoxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (29A) as a yellow solid (1g, 66.7% yield).
The second step is that: 6-methoxy-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (2-morpholinoethoxy) benzene-1, 3-diamine (29B)
6-methoxy-N1-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-4-(2-morpholinoethoxy)b enzene-1,3-diamine
N- (2-methoxy-4- (2-morpholinoethoxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (29A) (1g, 2mmol) was dissolved in 30mL of ethanol, 10mL of water, iron powder (672mg, 12mmol) and ammonium chloride (74.2mg, 1.4mmol) were added in this order, and the mixture was heated to 90 ℃ for reflux reaction for 8 hours. The reaction was cooled to room temperature, filtered and concentrated. Separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain brown solid compound 6-methoxy-N 1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (2-morpholinoethoxy) benzene-1, 3-diamine (29B) (600mg, 63.3% yield).
The third step: n- (4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (2-morpholinoethoxy) phenyl) acrylamide (compound 29)
N-(4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(2-morpholino ethoxy)phenyl)acrylamide
Reacting 6-methoxy-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (2-morpholinoethoxy) benzene-1, 3Diamine (29B) (600mg, 1.26mmol) was dissolved in 10mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (722mg, 3.78mmol) and acrylic acid (0.13mL, 1.89mmol) were added in this order to react at room temperature for 4 hours. Pyridine was removed by spin-drying, and 100mL of water and 100mL of methylene chloride were added to separate the layers. The organic phase was washed with 4mol/L aqueous sodium hydroxide (100 mL). The organic phase was dried over anhydrous sodium sulfate. The compound N- (4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (2-morpholinoethoxy) phenyl) acrylamide (compound 29) was obtained as a white solid by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) (65mg, yield 7.8%).
MS m/z:529.1[M+1]+。
Example 30
N- (5- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 30)
N-(5-((4-(1-(difluoromethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylam ino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
The first step is as follows: 3- (2-Chloropyrimidin-4-yl) -1- (difluoromethyl) -1H-indole (30A)
3-(2-chloropyrimidin-4-yl)-1-(difluoromethyl)-1H-indole
3- (2-Chloropyrimidin-4-yl) -1H-indole (2b) (1g, 4.35mmol) was dissolved in 15mL acetonitrile, potassium hydroxide (4.88g, 87mmol) and 10mL water were added, the temperature was reduced to 0 deg.C, diethyl bromofluoromethylphosphonate (2.32g, 8.7mmol) was added dropwise, and the reaction was allowed to warm to room temperature for 2 hours. The reaction solution was poured into 50mL of water, extracted with ethyl acetate (50mL), and the organic phase was washed with water (50mL), dried over anhydrous sodium sulfate, and concentrated to give 3- (2-chloropyrimidin-4-yl) -1- (difluoromethyl) -1H-indole (30A) (1.2g, crude) as a brown solid.
MS m/z=280.0[M+1]+。
The second step is that: 4- (1- (difluoromethyl) -1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (30B)
4-(1-(difluoromethyl)-1H-indol-3-yl)-N-(4-fluoro-2-methoxy-5-nitrophenyl)pyrimidin -2-amine
3- (2-Chloropyrimidin-4-yl) -1- (difluoromethyl) -1H-indole (30A) (0.1g, 0.36mmol) was dissolved in 2-pentanol (10mL), 4-fluoro-2-methoxy-5-nitroaniline (4e) (67mg, 0.36mmol) and p-toluenesulfonic acid (83 mg, 0.43mmol) were added, and the reaction was heated to 120 ℃ for 1 day under reflux. The reaction was cooled to room temperature, filtered, and the filter cake was washed with water (50mL) and dried to give 4- (1- (difluoromethyl) -1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (30B) as a yellow solid (0.1g, 66.7% yield).
MS m/z=430.0[M+1]+。
The third step: n is a radical of1- (4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenzene-1, 4-diamine (30C)
N1-(4-(1-(difluoromethyl)-1H-indol-3-yl)pyrimidin-2-yl)-N4-(2-(dimethylamino)ethyl )-2-methoxy-N4-methyl-5-nitrobenzene-1,4-diamine
4- (1- (difluoromethyl) -1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (30B) (0.6g, 1.4mmol) was dissolved in N, N-dimethylacetamide (5mL), N, N-diisopropylethylamine (220mg, 1.7mmol) and N, N, N' -trimethylethylenediamine (18A) (172mg, 1.7mmol) were added, and the mixture was reacted at 140 ℃ for 1 hour under microwave. After completion of the reaction, 150mL of water and 150mL of ethyl acetate were added and the mixture was separated. The organic phase was dried over anhydrous sodium sulfate and concentrated to give a brown oily compound N1- (4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4Methyl-5-nitrophenyl-1, 4-diamine (30C) (0.7g, 97.9% yield).
MS m/z=512.1[M+1]+。
The fourth step: n is a radical of4- (4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (30D)
N4-(4-(1-(difluoromethyl)-1H-indol-3-yl)pyrimidin-2-yl)-N1-(2-(dimethylamino)ethyl )-5-methoxy-N1-methylbenzene-1,2,4-triamine
Will N1- (4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenzene-1, 4-diamine (30C) (0.9g, 1.76mmol) was dissolved in 30mL ethanol, 10mL water, iron powder (295mg, 5.28mmol) and ammonium chloride (66mg, 1.23mmol) were added sequentially, the reaction was refluxed for 4 hours at 90 ℃ and concentrated. Separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain brown solid compound N 4- (4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (30D) (350mg, 41.3% yield).
MS m/z=482.1[M+1]+。
The fifth step: n- (5- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 30)
N-(5-((4-(1-(difluoromethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylam ino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
Will N4- (4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (30D) (350mg, 0.73mmol) was dissolved in 10mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (416mg, 2.18mmol) and acrylic acid (0.075mL, 1.09mmol) were added in this order to react at room temperature for 4 hours. The pyridine was spin-dried, 150mL of water and 150mL of dichloromethane were added, and the layers were separated. The organic phase was washed with 100mL of 4mol/L aqueous sodium hydroxide solution. The organic phase was dried over anhydrous sodium sulfate. Separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain white solid N- (5- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidine-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (meth) amino) -4-methoxyphenyl) acrylamide (compound 30) (170mg, yield 43.6%).
MS m/z:536.1[M+1]+。
1H NMR(400MHz,CDCl3)δ9.76(s,1H),9.43(s,1H),8.46(d,1H),8.04(dd,1H), 7.79(dd,2H),7.38–7.32(m,2H),6.75(s,1H),6.40(d,1H),5.77(d,1H),3.90(s,3H), 2.74(s,3H),1.55(s,6H)。
Example 31
N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (1-isopropyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 31)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-isopropyl-1H-indol-3-yl)pyri midin-2-yl)amino)-4-methoxyphenyl)acrylamide
The first step is as follows: 3- (2-Chloropyrimidin-4-yl) -1-isopropyl-1H-indole (31A)
3-(2-chloropyrimidin-4-yl)-1-isopropyl-1H-indole
3- (2-Chloropyrimidin-4-yl) -1H-indole (2b) (2g, 8.7mmol) was dissolved in 30mL of tetrahydrofuran, and sodium hydride (836mg, 10.4mmol) was added at 0 ℃ to react for 30 minutes, and isopropyl iodide (5.24mL, 26.3mmol) was added and warmed to room temperature to react for 32 hours. After completion of the reaction, 150mL of methylene chloride and 100mL of water were added to separate the reaction solution. The aqueous phase was extracted with 100mL of dichloromethane and the organic phase was dried over anhydrous sodium sulfate. Purification by silica gel column chromatography (petroleum ether: ethyl acetate (v/v) ═ 1:0 to 2:1) gave 3- (2-chloropyrimidin-4-yl) -1-isopropyl-1H-indole (31A) as a brown solid (0.75g, 32.6% yield).
MS m/z=272.1[M+1]+。
1H NMR(400MHz,CDCl3)δ8.44–8.39(m,1H),8.36(d,1H),8.02(s,1H),7.38 (dd,1H),7.27(dt,2H),7.22(d,1H),4.64(dt,1H),1.59–1.45(m,6H)。
The second step is that: n- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-isopropyl-1H-indol-3-yl) pyrimidin-2-amine (31B)
N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-isopropyl-1H-indol-3-yl)pyrimidin-2-ami ne
3- (2-Chloropyrimidin-4-yl) -1-isopropyl-1H-indole (31A) (0.75g, 2.77mmol) was dissolved in 2-pentanol (40 mL), 4-fluoro-2-methoxy-5-nitroaniline (4e) (515mg, 2.77mmol) and p-toluenesulfonic acid (632 mg, 3.33mmol) were added, and the reaction was heated to 120 ℃ for 3 days under reflux. The reaction was cooled to room temperature, a solid precipitated, and the filter cake was washed with 20mL of acetonitrile and 100mL of water in this order. The filter cake was dried to give N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-isopropyl-1H-indol-3-yl) pyrimidin-2-amine (31B) as a yellow solid (0.6g, 51.3% yield).
1H NMR(400MHz,CDCl3)δ9.15(d,1H),8.51(s,1H),8.46–8.26(m,3H),7.63(d, 1H),7.39(dd,2H),7.25(t,1H),7.14(t,1H),4.98–4.78(m,1H),4.02(s,3H),1.54(d, 6H)。
The third step: n is a radical of1- (2- (dimethylamino) ethyl) -N4- (4- (1-isopropyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methyl-2-nitrobenzene-1, 4-diamine (31C)
N1-(2-(dimethylamino)ethyl)-N4-(4-(1-isopropyl-1H-indol-3-yl)pyrimidin-2-yl)-5-met hoxy-N1-methyl-2-nitrobenzene-1,4-diamine
N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-isopropyl-1H-indol-3-yl) pyrimidin-2-amine (31B) (0.6g, 1.4mmol) was dissolved in N, N-dimethylacetamide (10mL), followed by the addition of N, N-diisopropylethylamine (221mg, 1.71mmol) and N, N, N' -trimethylethylenediamine (18A) (175mg, 1.71mmol), and reacted at 140 ℃ for 1 hour under microwave. After the reaction, the mixture was concentrated. Separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-30: 1) to obtain red solid compound N1- (2- (dimethylamino) ethyl) -N4- (4- (1-isopropyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1Methyl-2-nitrophenyl-1, 4-diamine (31C) (0.6g, 85.2% yield).
MS m/z:504.3[M+1]+。
The fourth step: n is a radical of1- (2- (dimethylamino) ethyl) -N4- (4- (1-isopropyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (31D)
N1-(2-(dimethylamino)ethyl)-N4-(4-(1-isopropyl-1H-indol-3-yl)pyrimidin-2-yl)-5-me thoxy-N1-methylbenzene-1,2,4-triamine
Will N1- (2- (dimethylamino) ethyl) -N4- (4- (1-isopropyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methyl-2-nitrophenyl-1, 4-diamine (31C) (0.6g, 1.2mmol) was dissolved in 15mL of ethanol, and 5mL of water, iron powder (201mg, 3.6mmol) and ammonium chloride (45mg, 0.84mmol) were added in this order, and the mixture was heated to 90 ℃ for 4 hours under reflux. The reaction was cooled to room temperature, filtered and concentrated. Separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-30: 1) to obtain brown solid compound N 1- (2- (dimethylamino) ethyl) -N4- (4- (1-isopropyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (31D) (550mg, 96.8% yield).
MS m/z:474.3[M+1]+。
The fifth step: n- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (1-isopropyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 31)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-isopropyl-1H-indol-3-yl)pyri midin-2-yl)amino)-4-methoxyphenyl)acrylamide
Will N1- (2- (dimethylamino) ethyl) -N4- (4- (1-isopropyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (31D) (550mg, 1.16mmol) was dissolved in 10mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (997mg, 5.22mmol) and acrylic acid (0.12mL, 1.74mmol) were added to react at room temperature for 4 hours. Pyridine was dried by spinning, and an aqueous solution of sodium hydroxide (100mL, 4mol/L) and 100mL of ethyl acetate were added to separate the layers. The organic phase was washed with 100mL of saturated brine and dried over anhydrous sodium sulfate. Separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain a white solid compound N- (2- ((2- (bis)Methylamino) ethyl) (methyl) amino) -5- ((4- (1-isopropyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 31) (400mg, 65.5% yield).
MS m/z:528.2[M+1]+。
Example 32
N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (1-ethyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 32)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-ethyl-1H-indol-3-yl)pyrimidi n-2-yl)amino)-4-methoxyphenyl)acrylamide
The first step is as follows: 3- (2-Chloropyrimidin-4-yl) -1-ethyl-1H-indole (32A)
3-(2-chloropyrimidin-4-yl)-1-ethyl-1H-indole
3- (2-Chloropyrimidin-4-yl) -1H-indole (2b) (2g, 8.7mmol) was dissolved in 30mL of tetrahydrofuran, cooled to 0 ℃ and reacted at 0 ℃ for 30 minutes with sodium hydride (0.836g, 10.4 mmol). Iodothane (4.1g, 26.3mmol) was added, the reaction was allowed to warm to room temperature and continued for 4 hours, after which the reaction was terminated and the solvent was spin-dried. The solid was washed with 100mL of water and 20mL of tetrahydrofuran. The solid was dried to give 3- (2-chloropyrimidin-4-yl) -1-ethyl-1H-indole (32A) (2.1g, 95.5% yield) as a yellow solid.
MS m/z:258.0[M+1]+。
The second step is that: 4- (1-ethyl-1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (32B)
4-(1-ethyl-1H-indol-3-yl)-N-(4-fluoro-2-methoxy-5-nitrophenyl)pyrimidin-2-amine
3- (2-Chloropyrimidin-4-yl) -1-ethyl-1H-indole (32A) (0.257g, 1mmol) was dissolved in 2-pentanol (10mL), 4-fluoro-2-methoxy-5-nitroaniline (4e) (186mg, 1mmol) and p-toluenesulfonic acid (228mg, 1.2 mmol) were added, and the reaction was heated to 120 ℃ for 1 day under reflux. The reaction was cooled to room temperature, filtered, and the filter cake was washed with 50mL of water and dried to give 4- (1-ethyl-1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (32B) as a yellow solid (0.3g, 73.7% yield).
MS m/z:408.0[M+1]+。
1H NMR(400MHz,DMSO-d6)δ9.15(d,1H),8.48–8.35(m,3H),8.27(s,1H), 7.59(d,1H),7.39–7.33(m,2H),7.26(t,1H),7.15(t,1H),4.30(q,2H),4.03(s,3H),1.46 (t,3H)。
The third step: n is a radical of1- (2- (dimethylamino) ethyl) -N4- (4- (1-ethyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methyl-2-nitrobenzene-1, 4-diamine (32C)
N1-(2-(dimethylamino)ethyl)-N4-(4-(1-ethyl-1H-indol-3-yl)pyrimidin-2-yl)-5-methox y-N1-methyl-2-nitrobenzene-1,4-diamine
4- (1-Ethyl-1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (32B) (1g, 2.46mmol) was dissolved in 12mL of N, N-dimethylacetamide, and N, N-diisopropylethylamine (387.8mg, 3mmol), and N, N, N' -trimethylethylenediamine (18A) (300mg, 3mmol) were added and reacted at 140 ℃ for 1 hour under microwave. After completion of the reaction, 150mL of water and 150mL of methylene chloride were added and the mixture was separated. Drying the organic phase with anhydrous sodium sulfate, and concentrating to obtain red solid compound N1- (2- (dimethylamino) ethyl) -N4- (4- (1-ethyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1Methyl-2-nitrophenyl-1, 4-diamine (32C) (1g, 83.3% yield).
MS m/z:490.1[M+1]+。
The fourth step: n is a radical of1- (2- (dimethylamino) ethyl) -N4- (4- (1-ethyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (32D)
N1-(2-(dimethylamino)ethyl)-N4-(4-(1-ethyl-1H-indol-3-yl)pyrimidin-2-yl)-5-methox y-N1-methylbenzene-1,2,4-triamine
Will N1- (2- (dimethylamino) ethyl) -N4- (4- (1-ethyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methyl-2-nitrophenyl-1, 4-diamine (32C) (1g, 2 mmol)) Dissolved in 15mL of ethanol, 5mL of water, iron powder (335mg, 6mmol) and ammonium chloride (75mg, 1.4mmol) were added in this order, and the mixture was heated to 90 ℃ for reflux reaction for 6 hours. Concentrating the reaction solution, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain brown solid compound N 1- (2- (dimethylamino) ethyl) -N4- (4- (1-ethyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (32D) (800mg, 87.1% yield).
MS m/z:460.1[M+1]+。
The fifth step: n- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (1-ethyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 32)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-ethyl-1H-indol-3-yl)pyrimidi n-2-yl)amino)-4-methoxyphenyl)acrylamide
Will N1- (2- (dimethylamino) ethyl) -N4- (4- (1-ethyl-1H-indol-3-yl) pyrimidin-2-yl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (32D) (800mg, 1.74mmol) was dissolved in 15mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (999mg, 5.2mmol) and acrylic acid (0.18mL, 2.61mmol) were added in this order to react at room temperature for 4 hours. The pyridine was spin-dried, 100mL of water and 100mL of dichloromethane were added, and the layers were separated. The organic phase was washed with aqueous sodium hydroxide (100mL, 4 mol/L). The organic phase was dried over anhydrous sodium sulfate. The resulting product was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (1-ethyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 32) as a white solid (110mg, yield 12.3%).
MS m/z:514.2[M+1]+。
Example 33
N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (1- (2-hydroxyethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 33)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-(2-hydroxyethyl)-1H-indol-3 -yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide
The second step is that: 1- (2- ((tert-butyldimethylsilyl) oxy) ethyl) -3- (2-chloropyrimidin-4-yl) -1H-indole (33A)
1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-(2-chloropyrimidin-4-yl)-1H-indole
3- (2-Chloropyrimidin-4-yl) -1H-indole (2b) (1g, 4.35mmol) was dissolved in 25mL tetrahydrofuran, cooled to 0 deg.C, and reacted at 0 deg.C for 30 min with sodium hydride (125.3mg, 5.22 mmol). (2-Bromoethoxy) -tert-butyldimethylsilane (2.5g, 8.7mmol) was added, and the reaction was allowed to warm to room temperature for 1 day. At the end of the reaction, the solvent was spun off, the solid was washed with 100mL water and the solid was dried to give the compound 1- (2- ((tert-butyldimethylsilyl) oxy) ethyl) -3- (2-chloropyrimidin-4-yl) -1H-indole (33A) as a yellow solid (1.3g, 77.4% yield).
1H NMR(400MHz,CDCl3)δ8.79(d,1H),8.76–8.72(m,1H),8.38(s,1H),7.81(d, 1H),7.79–7.74(m,1H),7.70–7.65(m,2H),4.65(t,2H),4.32(t,2H),1.20–1.17(m, 9H),0.23–0.21(m,6H)。
The second step is that: 2- (3- (2- ((4-fluoro-2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1H-indol-1-yl) ethanol (33B)
2-(3-(2-((4-fluoro-2-methoxy-5-nitrophenyl)amino)pyrimidin-4-yl)-1H-indol-1-yl)eth anol
1- (2- ((tert-butyldimethylsilyl) oxy) ethyl) -3- (2-chloropyrimidin-4-yl) -1H-indole (33A) (1.3g, 3.36mmol) was dissolved in 2-pentanol (50mL), and 4-fluoro-2-methoxy-5-nitroaniline (4e) (625mg, 3.36mmol) and p-toluenesulfonic acid (774mg, 4.03mmol) were added in this order, and the mixture was heated to 120 ℃ for reflux for 2 days. The reaction solution was cooled to room temperature, filtered, and the filter cake was washed with 100mL of water and dried to give 2- (3- (2- ((4-fluoro-2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1H-indol-1-yl) ethanol (33B) (1.1g, 78.6% yield) as a yellow solid.
MS m/z:424.0[M+1]+。
The third step: 2- (3- (2- ((4- ((2- (dimethylamino) ethyl) (methyl) amino) -2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1H-indol-1-yl) ethanol (33C)
2-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5-nitrophenyl)amin o)pyrimidin-4-yl)-1H-indol-1-yl)ethanol
2- (3- (2- ((4-fluoro-2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1H-indol-1-yl) ethanol (33B) (1g, 2.4mmol) was dissolved in 10mL of N, N-dimethylacetamide, and N, N-diisopropylethylamine (366mg, 2.8mmol) and N, N, N' -trimethylethylenediamine (18A) (290mg, 2.8mmol) were added in this order, and the reaction was carried out by microwave at 140 ℃ for 1 hour. After completion of the reaction, 150mL of water and 150mL of ethyl acetate were added and the mixture was separated. The organic phase was washed with 100mL of water, dried over anhydrous sodium sulfate, filtered and concentrated to give the compound 2- (3- (2- ((4- ((2- (dimethylamino) ethyl) (methyl) amino) -2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1H-indol-1-yl) ethanol (33C) as a red oil (1g, 83.3% yield).
The fourth step: n is a radical of1- (4- (1- (2- ((tert-butyldimethylsilyl) oxy) ethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenzene-1, 4-diamine (33D)
N1-(4-(1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-indol-3-yl)pyrimidin-2-yl)-N4-(2- (dimethylamino)ethyl)-2-methoxy-N4-methyl-5-nitrobenzene-1,4-diamine
2- (3- (2- ((4- ((2- (dimethylamino) ethyl) (methyl) amino) -2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1H-indol-1-yl) ethanol (33C) (1g, 1.98mmol) was dissolved in 20mL of dichloromethane, triethylamine (600mg, 5.94mmol) was added, tert-butyldimethylchlorosilane (448mg, 2.97mmol) was added dropwise, and the reaction was carried out at room temperature for 4 hours. After the reaction, 10mL of water was added and the mixture was stirred for 30 minutes. 100mL of water and 100mL of methylene chloride were added to the reaction mixture, and the mixture was separated. The aqueous phase is extracted with 100mL of dichloromethane and washed with 150mL of saturated sodium chloride. Concentrating to obtain red oily N 1- (4- (1- (2- ((tert-butyldimethylsilyl) silicon)Yl) oxy) ethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4Methyl-5-nitrophenyl-1, 4-diamine (33D) (1g, 83.3% yield).
MS m/z:620.0[M+1]+。
The fifth step: n is a radical of4- (4- (1- (2- ((tert-butyldimethylsilyl) oxy) ethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (33E)
N1-(2-(dimethylamino)ethyl)-N4-(4-(1-ethyl-1H-indol-3-yl)pyrimidin-2-yl)-5-methox y-N1-methylbenzene-1,2,4-triamine
Will N1- (4- (1- (2- ((tert-butyldimethylsilyl) oxy) ethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenzene-1, 4-diamine (33D) (1g, 1.6mmol) was dissolved in 30mL of ethanol, 10mL of water, iron powder (270mg, 4.8mmol) and ammonium chloride (60mg, 1.1mmol) were added in this order, and the mixture was heated to 90 ℃ for reflux reaction for 6 hours. Concentrating the reaction solution, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain brown solid compound N4- (4- (1- (2- ((tert-butyldimethylsilyl) oxy) ethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (33E) (1.1g, crude).
And a sixth step: n- (5- ((4- (1- (2- ((tert-butyldimethylsilyl) oxy) ethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (33F)
N-(5-((4-(1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-indol-3-yl)pyrimidin-2-yl)ami no)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
Will N4- (4- (1- (2- ((tert-butyldimethylsilyl) oxy) ethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (33E) (943mg, 1.6mmol) was dissolved in 15mL pyridine, and the solution was added sequentially1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (917mg, 4.8mmol), acrylic acid (0.17mL, 2.4mmol) were added and reacted at room temperature for 4 hours. The reaction solution was spin-dried to remove pyridine, and 150mL of water and 150mL of ethyl acetate were added to separate the solution. The organic phase was washed with aqueous sodium hydroxide (100mL, 4mol/L), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give N- (5- ((4- (1- (2- ((tert-butyldimethylsilyl) oxy) ethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (33F) as a brown solid (360mg, yield 35%).
MS m/z:644.2[M+1]+。
The seventh step: n- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (1- (2-hydroxyethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 33)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-(2-hydroxyethyl)-1H-indol-3 -yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide
N- (5- ((4- (1- (2- ((tert-butyldimethylsilyl) oxy) ethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (33F) (0.36g, 0.52 mmol) was dissolved in 10mL of dichloromethane, and tetrabutylammonium fluoride (293mg, 1.12mmol) was added and reacted at room temperature for 6 hours. After completion of the reaction, 100mL of water and 100mL of methylene chloride were added and the mixture was separated. The aqueous phase was extracted with 100mL of dichloromethane, the organic phases were combined and the organic phase was washed with 150mL of saturated sodium chloride. The organic phase was concentrated and purified by column chromatography on silica gel (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (1- (2-hydroxyethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 33) as a brown solid (0.25g, 84.6% yield).
MS m/z:530.1[M+1]+。
1H NMR(400MHz,CDCl3)δ9.69(s,1H),9.08(s,1H),8.38(d,1H),8.08–8.00(m, 1H),7.72(s,1H),7.46–7.40(m,1H),7.27(d,1H),7.23(t,1H),6.75(s,1H),6.38(d,1H), 5.76(d,1H),4.45(t,2H),4.06(t,2H),3.89(s,3H),3.06(d,2H),2.70(s,3H),2.43(s,2H), 1.60(s,6H)。
Example 34
N- (5- ((4- (1- (cyclopropylmethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 34)
N-(5-((4-(1-(cyclopropylmethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimeth ylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
The first step is as follows: n- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1H-indol-3-yl) pyrimidin-2-amine (34A)
N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1H-indol-3-yl)pyrimidin-2-amine
3- (2-Chloropyrimidin-4-yl) -1H-indole (2b) (3g, 13.1mmol) was dissolved in 2-pentanol (10mL), 4-fluoro-2-methoxy-5-nitroaniline (4e) (2.44g, 13.1mmol) and p-toluenesulfonic acid (3.02g, 15.7mmol) were added, and the reaction was heated to 120 ℃ for 3 days under reflux. The reaction solution was cooled to room temperature, 200mL of aqueous ammonia was added to precipitate a solid, which was filtered, and the filter cake was washed with 250mL of water and 100mL of petroleum ether and dried to obtain a pale green solid, N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1H-indol-3-yl) pyrimidin-2-amine (34A) (4g, yield 80.5%).
MS m/z=380.1[M+1]+。
The second step is that: n is a radical of1- (4- (1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenzene-1, 4-diamine (34B)
N1-(4-(1H-indol-3-yl)pyrimidin-2-yl)-N4-(2-(dimethylamino)ethyl)-2-methoxy-N4-me thyl-5-nitrobenzene-1,4-diamine
Reacting N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1H-indol-3-yl) pyrimidin-2-amine (II)34A) (2g, 5.3mmol) was dissolved in 15mL of N, N-dimethylacetamide, and N, N-diisopropylethylamine (1.02g, 7.9mmol) and N, N, N' -trimethylethylenediamine (18A) (809mg, 7.9mmol) were added and reacted at 120 ℃ for 1.5 hours under microwave. After completion of the reaction, the reaction mixture was cooled to room temperature, and 200mL of water and 200mL of ethyl acetate were added to separate the reaction mixture. The organic phase was washed with 100mL of saturated brine, dried over anhydrous sodium sulfate, and concentrated to give Compound N as a reddish brown solid 1- (4- (1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4Methyl-5-nitrophenyl-1, 4-diamine (34B) (1.8g, 75% yield).
The third step: n is a radical of1- (4- (1- (cyclopropylmethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenzene-1, 4-diamine (34C)
N1-(4-(1-(cyclopropylmethyl)-1H-indol-3-yl)pyrimidin-2-yl)-N4-(2-(dimethylamino)e thyl)-2-methoxy-N4-methyl-5-nitrobenzene-1,4-diamine
Will N1- (4- (1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenzene-1, 4-diamine (34B) (2g, 4.3mmol) was dissolved in 20mL dimethylformamide, cooled to 0 deg.C, sodium hydride (0.26g, 6.5mmol) was added and reacted at 0 deg.C for 30 minutes. Bromomethylcyclopropane (0.585g, 4.3mmol) was added, and the reaction was allowed to warm to room temperature for 6 hours. After completion of the reaction, 100mL of water and 100mL of ethyl acetate were added and the mixture was separated. The aqueous phase was extracted with 100mL of ethyl acetate. Combining the organic phases, drying the organic phase with anhydrous sodium sulfate, and concentrating to obtain brown solid compound N1- (4- (1- (cyclopropylmethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4Methyl-5-nitrophenyl-1, 4-diamine (34C) (2g, 90.9% yield).
MS m/z:516.1[M+1]+。
The fourth step: n is a radical of4- (4- (1- (cyclopropylmethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N 1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (34D)
N4-(4-(1-(cyclopropylmethyl)-1H-indol-3-yl)pyrimidin-2-yl)-N1-(2-(dimethylamino)e thyl)-5-methoxy-N1-methylbenzene-1,2,4-triamine
Will N1- (4- (1- (cyclopropylmethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenzene-1, 4-diamine (34C) (2g, 3.88mmol) was dissolved in 24mL ethanol, 8mL water, iron powder (1.3g, 23.3mmol) and ammonium chloride (145mg, 2.7mmol) were added in that order, and the reaction was refluxed at 92 ℃ for 5 hours. Concentrating the reaction solution, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain brown solid compound N4- (4- (1- (cyclopropylmethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (34D) (1.1g, 58.5% yield).
MS m/z:486.1[M+1]+。
The fifth step: n- (5- ((4- (1- (cyclopropylmethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 34)
N-(5-((4-(1-(cyclopropylmethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimeth ylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
Will N4- (4- (1- (cyclopropylmethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (34D) (1g, 2.06mmol) was dissolved in 25mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (1.18g, 6.2mmol) and acrylic acid (0.213mL, 3.1 mmol) were added in this order to react at room temperature for 4 hours. Removing pyridine from the reaction liquid by rotary drying, adding 150mL of ethyl acetate and sodium hydroxide aqueous solution (100mL, 4mol/L), separating, extracting the aqueous phase with 100mL of ethyl acetate, combining the organic phases, washing with 150mL of saturated sodium chloride, drying with anhydrous sodium sulfate, filtering, rotary drying, separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain a white solid compound N- (5- ((4- (1- (cyclopropylmethyl) -1H-indole) compound -3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 34) (250mg, 22.7% yield).
MS m/z=540.4[M+1]+。
1H NMR(400MHz,CDCl3)δ10.09(s,1H),9.83(s,1H),9.07(s,1H),8.38(d,1H), 8.08(dd,1H),7.71(s,1H),7.51–7.42(m,1H),7.28–7.24(m,3H),7.22(d,1H),6.79(s, 1H),6.40(s,2H),5.74–5.67(m,1H),4.21(d,2H),3.88(s,3H),3.48(s,1H),2.89(dd, 2H),2.70(s,3H),2.28(s,8H),1.44(dtd,1H),0.61–0.52(m,2H),0.50–0.42(m,2H)。
Example 35
N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((5-methoxy-4- (1-methyl-1H-indole-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (Compound 35)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((5-methoxy-4-(1-meth yl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
The first step is as follows: 3- (2-chloro-5-methoxypyrimidin-4-yl) -1H-indole (35A)
3-(2-chloro-5-methoxypyrimidin-4-yl)-1H-indole
Indole (4a) (2.34g, 20mmol) was dissolved in 40mL tetrahydrofuran, cooled to 0 ℃ under nitrogen, and methyl magnesium bromide (6.7mL, 20mmol) was added dropwise with stirring for an additional 0.5 h. 2, 4-dichloro-5-methoxypyrimidine (3.58g, 20mmol) was added thereto, and the mixture was reacted at room temperature for 1 hour and at elevated temperature to 65 ℃ for 4 hours. 150mL of water and 150mL of methylene chloride were added to the reaction mixture, and the mixture was separated. The organic phase was dried over anhydrous sodium sulfate, filtered, spun-dried, and purified by silica gel column chromatography (petroleum ether: ethyl acetate (v/v) ═ 10:1 to 2:1) to give 3- (2-chloro-5-methoxypyrimidin-4-yl) -1H-indole (35A) (2.81g, 55.1% yield) as a yellow solid.
MS m/z=260.0[M+1]+。
The second step is that: 3- (2-chloro-5-methoxypyrimidin-4-yl) -1-methyl-1H-indole (35B)
3-(2-chloro-5-methoxypyrimidin-4-yl)-1-methyl-1H-indole
3- (2-chloro-5-methoxypyrimidin-4-yl) -1H-indole (35A) (1.4g, 5.4mmol) was dissolved in 25mL of tetrahydrofuran, and the solution was cooled to 0 ℃ and reacted with sodium hydride (0.261g, 10.9mmol) at 0 ℃ for 30 minutes. Methyl iodide (2.3g, 16.2mmol) was added, the reaction was continued at room temperature for 4 hours, and after completion of the reaction, 10mL of water was added to quench the reaction, and the solvent was dried by spinning. Separation and purification by silica gel column chromatography (petroleum ether: ethyl acetate (v/v) ═ 1:0 to 2:1) gave 3- (2-chloro-5-methoxypyrimidin-4-yl) -1-methyl-1H-indole (35B) (0.3g, yield 20.4%) as a yellow solid.
MS m/z=274.0[M+1]+。
The third step: n- (4-fluoro-2-methoxy-5-nitrophenyl) -5-methoxy-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (35C)
N-(4-fluoro-2-methoxy-5-nitrophenyl)-5-methoxy-4-(1-methyl-1H-indol-3-yl)pyrimid in-2-amine
3- (2-chloro-5-methoxypyrimidin-4-yl) -1-methyl-1H-indole (35B) (0.3g, 1.1mmol) was dissolved in 2-pentanol (20mL), 4-fluoro-2-methoxy-5-nitroaniline (4e) (204mg, 1.1mmol) and p-toluenesulfonic acid (253 mg, 1.32mmol) were added, and the reaction was heated to 120 ℃ for 18 hours under reflux. The reaction mixture was cooled to room temperature, and 150mL of water and 150mL of ethyl acetate were added to separate the reaction mixture. The organic phase was dried over anhydrous sodium sulfate, and separated and purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give N- (4-fluoro-2-methoxy-5-nitrophenyl) -5-methoxy-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (35C) (0.55g, yield 45.8%) as a red solid.
The fourth step: n is a radical of1- (2- (dimethylamino) ethyl) -5-methoxy-N4- (5-methoxy-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N1-methyl-2-nitrobenzene-1, 4-diamine (35D)
N1-(2-(dimethylamino)ethyl)-5-methoxy-N4-(5-methoxy-4-(1-methyl-1H-indol-3-yl)p yrimidin-2-yl)-N1-methyl-2-nitrobenzene-1,4-diamine
N- (4-fluoro-2-methoxy-5-nitrophenyl) -5-methoxy-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (35C) (1g, 2.36mmol) was dissolved in 10mL of N, N-dimethylacetamide, and N, N-diisopropylethylamine (367mg, 2.84mmol) and N, N, N' -trimethylethylenediamine (18A) (290mg, 2.84mmol) were added and reacted at 125 ℃ for 1 hour under microwave. After the reaction, N-dimethylacetamide was removed by rotation, 150mL of water and 150mL of dichloromethane were added, and the mixture was separated. The aqueous phase was extracted with 100mL of dichloromethane and the organic phases were combined. Drying the organic phase with anhydrous sodium sulfate, filtering, and concentrating to obtain red solid compound N 1- (2- (dimethylamino) ethyl) -5-methoxy-N4- (5-methoxy-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N1Methyl-2-nitrophenyl-1, 4-diamine (35D) (1g, 83.3% yield).
MS m/z:490.1[M+1]+。
The fifth step: n is a radical of1- (2- (dimethylamino) ethyl) -5-methoxy-N4- (5-methoxy-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N1-methylbenzene-1, 2, 4-triamine (35E)
N1-(2-(dimethylamino)ethyl)-5-methoxy-N4-(5-methoxy-4-(1-methyl-1H-indol-3-yl)p yrimidin-2-yl)-N1-methylbenzene-1,2,4-triamine
Will N1- (2- (dimethylamino) ethyl) -5-methoxy-N4- (5-methoxy-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N1-methyl-2-nitrobenzene-1, 4-diamine (35D) (3.5g, 6.93mmol) was dissolved in 30mL of ethanol, 10mL of water, iron powder (2.32g, 41.6mmol) and ammonium chloride (260mg, 4.85mmol) were added in this order, and the mixture was heated to 90 ℃ for reflux reaction for 6 hours. Concentrating the reaction solution, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain brown solid compound N1- (2- (dimethylamino) ethyl) -5-methoxy-N4- (5-methoxy-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N1-methylbenzene-1, 2, 4-triamine (35E) (2g, 60.6% yield).
MS m/z:476.1[M+1]+。
And a sixth step: n- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((5-methoxy-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 35)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((5-methoxy-4-(1-meth yl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
Will N1- (2- (dimethylamino) ethyl) -5-methoxy-N4- (5-methoxy-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N1-methylbenzene-1, 2, 4-triamine (35E) (350mg, 1.05mmol) was dissolved in 10mL of pyridine, EDCI (600mg, 3.14mmol) and acrylic acid (0.11mL, 1.57mmol) were added, and the reaction was carried out at room temperature for 4 hours. The reaction mixture was spin-dried to remove pyridine, and 100mL of water and 100mL of dichloromethane were added to separate the reaction mixture. The organic phase was washed with aqueous sodium hydroxide (100mL, 4mol/L) and dried over anhydrous sodium sulfate. The brown solid compound N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((5-methoxy-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 35) was obtained by separation and purification by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) (210mg, yield 37.8%).
MS m/z:530.1[M+1]+。
Example 36
N- (4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (3-morpholinopropoxy) phenyl) acrylamide (compound 36)
N-(4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(3-morpholino propoxy)phenyl)acrylamide
The first step is as follows: n- (2-methoxy-4- (3-morpholinopropoxy) -5-nitrobenzene) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (36A)
N-(2-methoxy-4-(3-morpholinopropoxy)-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)p yrimidin-2-amine
5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 3) (1g, 2.54mmol) was dissolved in 50mL tetrahydrofuran, and sodium hydride (122mg, 3.1mmol) was added under ice bath and stirred for 30 min. 3-Morpholinopropyl-1-ol (552mg, 3.8mmol) was added dropwise and reacted at room temperature overnight. After the reaction was completed, 100mL of water and 150mL of ethyl acetate were added, the mixture was separated, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give N- (2-methoxy-4- (3-morpholinopropoxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (36A) (1g, yield 71.4%) as a yellow solid.
MS m/z:519.2[M+1]+。
1H NMR(400MHz,CDCl3)δ9.66(d,1H),8.39(dd,1H),8.24(d,1H),8.15(dd,1H), 7.51(s,1H),7.43–7.37(m,1H),7.35–7.28(m,2H),7.19(d,1H),6.56(s,1H),4.18(t, 2H),4.01(s,1H),4.00(s,3H),3.93(d,3H),3.83–3.78(m,1H),3.75–3.68(m,4H),3.48 (s,1H),2.67–2.59(m,3H),2.56–2.45(m,4H),2.11–1.98(m,2H),1.73(dt,1H)。
The second step is that: 6-methoxy-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (3-morpholinepropoxy) benzene-1, 3-diamine (36B)
6-methoxy-N1-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-4-(3-morpholinopropoxy) benzene-1,3-diamine
N- (2-methoxy-4- (3-morpholinopropoxy) -5-nitrobenzene) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (36A) (1g, 1.93mmol) was dissolved in 30mL of ethanol, and 10L of water, iron powder (646.5g, 11.58mol) and ammonium chloride (72.3g, 1.35mol) were sequentially added, and the mixture was heated to 90 ℃ for reflux reaction for 4 hours. Cooling the reaction solution to room temperature, filtering, concentrating, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain a brown solid compound 6-methoxy-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (3-morpholinopropoxy) benzene-1, 3-diamine (36B) (600mg, 63.7% yield).
MS m/z:489.2[M+1]+。
The third step: n- (4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (3-morpholinopropoxy) phenyl) acrylamide (compound 36)
N-(4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(3-morpholino propoxy)phenyl)acrylamide
Reacting 6-methoxy-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (3-morpholinopropoxy) benzene-1, 3-diamine (36B) (600mg, 1.23mmol) was dissolved in 10mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (703mg, 3.68mmol) and acrylic acid (0.127mL, 1.84mmol) were added in this order to react at room temperature for 3 hours. The reaction mixture was spin-dried to remove pyridine, and 150mL of a 4mol/L aqueous sodium hydroxide solution and 150mL of dichloromethane were added to separate the reaction mixtures. The organic phase was washed with 100mL of saturated brine and dried over anhydrous sodium sulfate. The resulting product was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give N- (4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (3-morpholinopropoxy) phenyl) acrylamide (compound 36) as a pale yellow solid (120mg, yield 18%).
MS m/z=543.2[M+1]+。
1H NMR(400MHz,CDCl3)δ9.68(s,1H),8.87(s,1H),8.34(d,1H),8.09(d,1H), 7.97(s,1H),7.65(s,1H),7.39(d,1H),7.32–7.22(m,1H),7.17(d,1H),6.55(s,1H), 6.44(d,1H),5.76(d,1H),4.13(t,2H),3.96(s,3H),3.90(s,5H),2.75(s,4H),2.20(s,2H), 1.62(s,4H)。
Example 37
N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (3-morpholinopropoxy) phenyl) acrylamide (compound 37)
N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(3-m orpholinopropoxy)phenyl)acrylamide
The first step is as follows: 5-chloro-N- (2-methoxy-4- (3-morpholinopropoxy) -5-nitrobenzene) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (37A)
5-chloro-N-(2-methoxy-4-(3-morpholinopropoxy)-5-nitrophenyl)-4-(1-methyl-1H-ind ol-3-yl)pyrimidin-2-amine
5-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (intermediate 4) (1g, 2.34mmol) was dissolved in 50mL of tetrahydrofuran, and sodium hydride (103mg, 2.57mmol) was added under ice-bath and stirred for 30 min. 3-Morpholpropyl-1-ol (680mg, 4.68mmol) was added dropwise and reacted at room temperature overnight. After the reaction was completed, 100mL of water and 100mL of ethyl acetate were added, the mixture was separated, the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give the compound 5-chloro-N- (2-methoxy-4- (3-morpholinopropoxy) -5-nitrobenzene) -4- (1-methyl-1H-indolin-3-yl) pyrimidin-2-amine (37A) (1.2g, yield 85.7%) as a yellow oil.
1H NMR(400MHz,DMSO-d6)δ8.60(s,1H),8.55(s,1H),8.40(s,1H),8.32(s,1H), 8.25(d,1H),7.51(d,1H),7.28–7.21(m,1H),7.01(t,1H),6.97(s,1H),4.46(s,1H), 4.30(t,2H),3.94(s,3H),3.89(d,3H),3.43(t,4H),2.39(d,4H),2.29(s,1H),2.00–1.91 (m,2H),1.61–1.51(m,4H)。
The second step is that: n is a radical of1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- (3-morpholinepropoxy) benzene-1, 3-diamine (37B)
N1-(5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-6-methoxy-4-(3-morpholino propoxy)benzene-1,3-diamine
5-chloro-N- (2-methoxy-4- (3-morpholinopropoxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (37A) (1g, 1.8mmol) was dissolved in 30mL of ethanol, 10mL of water, iron powder (606.7mg, 10.06 mmol) and ammonium chloride (67.8mg, 1.27mmol) were added in this order, and the mixture was heated to 90 ℃ for 4 hours under reflux. Cooling the reaction solution to room temperature, filtering, concentrating, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain black solid compound N 1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- (3-morpholinopropoxy) benzene-1, 3-diamine (37B) (900mg, 95.3% yield).
MS m/z:523.2[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.52(s,1H),8.34(d,1H),8.29(s,1H),8.24(s,1H), 7.49(d,1H),7.23(t,1H),7.05(t,1H),6.96(s,1H),6.68(s,1H),4.05(t,2H),3.90(s,3H), 3.66(s,4H),3.65(s,4H),3.44(t,2H),2.65(d,6H),2.04–1.92(m,2H)。
The third step: n- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (3-morpholinopropoxy) phenyl) acrylamide (compound 37)
N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(3-m orpholinopropoxy)phenyl)acrylamide
Will N1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- (3-morpholinopropoxy) benzene-1, 3-diamine (37B) (900mg, 1.72mmol) was dissolved in 30mL of tetrahydrofuran, N-diisopropylethylamine (0.34mL, 2.06mmol) was added, and a solution of acryloyl chloride (0.17mL, 2.06mmol) in tetrahydrofuran was added dropwise at 0 ℃ to 5mL, and the mixture was allowed to warm to room temperature for reaction for 4 hours. 100mL of a saturated aqueous sodium bicarbonate solution and 100mL of ethyl acetate were added to separate the layers. The resulting product was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (3-morpholinopropoxy) phenyl) acrylamide (compound 37) as a yellow solid (330mg, yield 41.4%).
MS m/z:577.2[M+1]+。
1H NMR(400MHz,CDCl3)δ9.27(s,1H),8.41(d,1H),8.38(s,1H),8.29(s,1H), 7.65(s,1H),7.35(d,2H),7.29(d,1H),7.20(t,1H),6.57(s,1H),6.36(dd,1H),6.26(dd, 1H),5.71(d,1H),4.11(t,2H),3.89(s,3H),3.88(s,3H),3.77–3.71(m,4H),2.56(d,2H), 2.49(s,4H),2.04(dd,2H)。
Example 38
N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (3-morpholinopropoxy) phenyl) acrylamide mesylate (Compound 38)
N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(3-m orpholinopropoxy)phenyl)acrylamide methanesulfonate
The first step is as follows: n- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (3-morpholinopropoxy) phenyl) acrylamide mesylate (Compound 38)
N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(3-m orpholinopropoxy)phenyl)acrylamide methanesulfonate
N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (3-morpholinopropoxy) phenyl) acrylamide (compound 37) (120mg, 0.208mmol) was dissolved in 20mL of ethanol, 10mL of ethyl acetate was added, and a solution of methanesulfonic acid (0.0135mL, 0.208mmol) in ethyl acetate (5mL) was added dropwise at 70 ℃ and reacted for 2 hours. The reaction mixture was spin-dried to give a yellow solid compound, N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (3-morpholinopropoxy) phenyl) acrylamide methanesulfonate (compound 38) (140 mg).
MS m/z:577.2[M+1]+。
Example 39
N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((4- (1-methyl-1H-pyrrolo [2,3-b ] pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 39)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-pyrro lo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
The first step is as follows: 3- (2-Chloropyrimidin-4-yl) -1H-pyrrolo [2,3-B ] pyridine (39B)
3-(2-chloropyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridine
1H-pyrrolo [2,3-b ] pyridine (39A) (10g, 85.2mmol) was dissolved in 1, 2-dichloroethane (50mL), cooled to 0 ℃ under nitrogen, methylmagnesium bromide (28.6mL, 85.2mmol) was added dropwise, and stirring was continued for 0.5H. 2, 4-dichloropyrimidine (15.26g, 102.4mmol) was added, and the mixture was reacted at room temperature for 4 hours. To the reaction solution, 50mL of methanol was added, the solvent was dried by spinning, and the mixture was purified by silica gel column chromatography (petroleum ether: ethyl acetate (v/v) ═ 1:0 to 2:1) to give 3- (2-chloropyrimidin-4-yl) -1H-pyrrolo [2,3-B ] pyridine (39B) as a yellow solid (10g, yield 51.3%).
MS m/z=230.1[M+1]+。
1H NMR(400MHz,DMSO-d6)δ12.07(s,1H),8.52(dd,2H),8.47–8.37(m,1H), 7.91(d,1H),7.51(dd,1H),7.29–7.19(m,2H)。
The second step is that: 3- (2-Chloropyrimidin-4-yl) -1-methyl-1H-pyrrolo [2,3-b ] pyridine (39C)
3-(2-chloropyrimidin-4-yl)-1-methyl-1H-indole
3- (2-Chloropyrimidin-4-yl) -1H-pyrrolo [2,3-B ] pyridine (39B) (2g, 8.7mmol) was dissolved in 10mL of tetrahydrofuran, and sodium hydride (418mg, 10.4mmol) was added at 0 ℃ to continue the reaction for 30 minutes, and iodomethane (1.63mL, 26.2mmol) was added thereto and allowed to warm to room temperature for 4 hours. The solvent was dried by evaporation to give a solid, which was washed with 50mL of water and 50mL of tetrahydrofuran, filtered, and dried to give the compound 3- (2-chloropyrimidin-4-yl) -1-methyl-1H-pyrrolo [2,3-b ] pyridine (39C) as a yellow solid (2.1 g).
MS m/z:244.1[M+1]+。
The third step: n- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-pyrrolo [2,3-b ] pyridin-3-yl) pyrimidin-2-amine (39D)
N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine
3- (2-Chloropyrimidin-4-yl) -1-methyl-1H-pyrrolo [2,3-b ] pyridine (39C) (1g, 4.1mmol) was dissolved in 2-pentanol (20mL), 4-fluoro-2-methoxy-5-nitroaniline (4e) (765mg, 4.1mmol) and p-toluenesulfonic acid (939mg, 4.9mmol) were added, and the mixture was heated to 120 ℃ for 2 days under reflux. The reaction was cooled to room temperature, 30mL acetonitrile was added, filtered, and the filter cake was washed once with 50mL water and dried to give N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-pyrrolo [2,3-b ] pyridin-3-yl) pyrimidin-2-amine (39D) as a yellow solid (1.2g, 75% yield).
The fourth step: n is a radical of1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (1-methyl-1H-pyrrolo [2, 3-b)]Pyridin-3-yl) pyrimidin-2-yl) -2-nitrophenyl-1, 4-diamine (39E)
N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-pyrrolo[2,3- b]pyridin-3-yl)pyrimidin-2-yl)-2-nitrobenzene-1,4-diamine
Reacting N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-pyrrolo [2,3-b ]]Pyridin-3-yl) pyrimidin-2-amine (39D) (1g, 2.54mmol) was dissolved in 20mL of tetrahydrofuran, sodium hydride (203mg, 5.08mmol) was added under ice-cooling, stirred for 30 minutes, N, N, N' -trimethylethylenediamine (18A) (733mg, 5.08mmol) was added dropwise, and the reaction was allowed to proceed at room temperature for 8 hours. After completion of the reaction, 150mL of water and 150mL of ethyl acetate were added and the mixture was separated. The aqueous phase was extracted once with 100mL ethyl acetate and the organic phases were combined. Drying the organic phase with anhydrous sodium sulfate, filtering, and concentrating to obtain compound N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (1-methyl-1H-pyrrolo [2, 3-b)]Pyridin-3-yl) pyrimidin-2-yl) -2-nitrophenyl-1, 4-diamine (39E) as a yellow solid (1.1g, 84.6% yield).
MS m/z:518.1[M+1]+。
The fifth step: n is a radical of1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (1-methyl-1H-pyrrolo [2, 3-b)]Pyridin-3-yl) pyrimidin-2-yl) benzene-1, 2, 4-triamine (39F)
N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-pyrrolo[2,3- b]pyridin-3-yl)pyrimidin-2-yl)benzene-1,2,4-triamine
Will N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (1-methyl-1H-pyrrolo [2, 3-b) ]Pyridin-3-yl) pyrimidin-2-yl) -2-nitrophenyl-1, 4-diamine (39E) (1.1g, 2.18mmol) in water5mL of water, iron powder (356mg, 6.4mmol) and ammonium chloride (78.7mg, 1.55mmol) were added in this order to 15mL of ethanol, and the mixture was heated to 90 ℃ and reacted under reflux for 4 hours. The reaction was cooled to room temperature, filtered and concentrated. Separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain a compound N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (1-methyl-1H-pyrrolo [2, 3-b)]Pyridin-3-yl) pyrimidin-2-yl) benzene-1, 2, 4-triamine (39F) as a brown solid (550mg, 51.9% yield).
And a sixth step: n- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((4- (1-methyl-1H-pyrrolo [2,3-b ] pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 39)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-pyrro lo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
Will N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (1-methyl-1H-pyrrolo [2, 3-b)]Pyridin-3-yl) pyrimidin-2-yl) benzene-1, 2, 4-triamine (39F) and a brown solid (550mg, 1mmol) were dissolved in 15mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) (573mg, 3mmol) and acrylic acid (0.103mL, 1.5mmol) were added in that order and reacted at room temperature for 4 hours. The reaction mixture was spin-dried to remove pyridine, and 100mL of water and 100mL of dichloromethane were added to separate the reaction mixture. The organic phase was washed once with aqueous sodium hydroxide (100mL, 4 mol/L). The organic phase was dried over anhydrous sodium sulfate. Separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyl-5- ((4- (1-methyl-1H-pyrrolo [2,3-b ] pyrrole [2 ]Pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 39) as a white solid (65mg, 12% yield).
MS m/z:542.1[M+1]+。
Example 40
N- (5- ((5-chloro-4- (1-methyl-6-morpholinyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2-fluoro-4-methoxyphenyl) acrylamide (compound 40)
N-(5-((5-chloro-4-(1-methyl-6-morpholino-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-fl uoro-4-methoxyphenyl)acrylamide
The first step is as follows: 1- (6-nitro-1H-indol-1-yl) ethanone (40B)
1-(6-nitro-1H-indol-1-yl)ethanone
6-Nitro-1H-indole (40A) (16.2g, 0.1mol) was dissolved in 40mL of pyridine, and acetic anhydride (40.8g, 0.4mol) was added to the solution to conduct reaction at room temperature overnight. After the reaction, the mixture was spin-dried, 200mL of saturated brine and 200mL of ethyl acetate were added, followed by liquid separation, and the organic phase was dried over anhydrous sodium sulfate, filtered, and spin-dried to give 1- (6-nitro-1H-indol-1-yl) ethanone (40B) as a yellow solid (6g, yield 30%).
MS m/z:205.1[M+1]+。
The second step is that: 1- (6-amino-1H-indol-1-yl) ethanone (40C)
1-(6-amino-1H-indol-1-yl)ethanone
1- (6-Nitro-1H-indol-1-yl) ethanone (40B) (20g, 0.1mol) was dissolved in 50mL of methanol and 50mL of tetrahydrofuran, and palladium on carbon (2g, 10%) and ammonium formate (40.3g, 6.4mol) were added and reacted at 60 ℃ for 2 hours. After completion of the reaction, the reaction mixture was filtered, washed with 100mL of ethyl acetate, and the filtrate was spin-dried, followed by addition of 150mL of ethyl acetate and 150mL of saturated saline and separation. The aqueous phase was washed once with 150mL ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate to give 1- (6-amino-1H-indol-1-yl) ethanone (40C) as a yellow solid (9.3g, 53.4% yield).
The third step: 4- (1H-indol-6-yl) morpholine (40D)
4-(1H-indol-6-yl)morpholine
1- (6-amino-1H-indol-1-yl) ethanone (40C) (8g, 60.1mmol) and 2,2' -dibromodiethyl ether (9mL, 72mmol) were dissolved in 100mL of N, N-dimethylformamide, and N, N-Diisopropylethylamine (DIPEA) (29.7mL, 180mmol) was added and reacted at 90 ℃ overnight. After completion of the reaction, the mixture was cooled to room temperature, and 200mL of ethyl acetate and 200mL of saturated saline were added thereto and the mixture was separated. The aqueous phase was washed once with 200mL ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate and concentrated to give compound 4- (1H-indol-6-yl) morpholine (40D) as a yellow solid (9.2g, 76% yield).
MS m/z:203.1[M+1]+。
1H NMR(400MHz,CDCl3)δ8.04(s,1H),7.53(d,1H),7.09(dd,1H),6.98–6.80 (m,2H),6.46(ddd,1H),4.00–3.83(m,4H),3.25–3.08(m,4H)。
The fourth step: 4- (3- (2, 5-dichloropyrimidin-4-yl) -1H-indol-6-yl) morpholine (40E)
4-(3-(2,5-dichloropyrimidin-4-yl)-1H-indol-6-yl)morpholine
4- (1H-indol-6-yl) morpholine (40D) (4.5g, 22.3mmol) was dissolved in 100mL tetrahydrofuran, cooled to 0 ℃ under nitrogen, methyl magnesium bromide (7.5mL, 22.3mmol) was added dropwise and stirring continued for 0.5H. Trichloropyrimidine (2.05g, 22.3mmol) was added and the reaction was allowed to proceed at room temperature for 1 hour, then the reaction was allowed to warm to 60 ℃ and continued for 1 hour. The reaction solution was cooled to room temperature, and 6.34mL of acetic acid was added dropwise and stirred for 10 minutes. 100mL of water was added, the mixture was stirred at 60 ℃ for 30 minutes, the organic phase was separated, 100mL of n-heptane was added, the mixture was spin-dried, and the resulting mixture was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 50:1) to give 4- (3- (2, 5-dichloropyrimidin-4-yl) -1H-indol-6-yl) morpholine (40E) as a yellow-green solid (3g, 39% yield).
MS m/z:349.0[M+1]+。
The fifth step: 4- (3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1H-indol-6-yl) morpholine (40F)
4-(3-(2,5-dichloropyrimidin-4-yl)-1-methyl-1H-indol-6-yl)morpholine
4- (3- (2, 5-dichloropyrimidin-4-yl) -1H-indol-6-yl) morpholine (40E) (3g, 8.6mmol) was dissolved in 50mL of tetrahydrofuran, and sodium hydride (460mg, 11.5mmol) was added thereto at 0 ℃ to react for 30 minutes. Methyl iodide (1.6mL, 25.8mmol) was added and the reaction was allowed to warm to room temperature for 3 hours. Spin-dry, wash with 50mL water and 20mL tetrahydrofuran, filter, dry and concentrate to give 4- (3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1H-indol-6-yl) morpholine (40F) as a light yellow solid (1.9g, 61.3% yield).
MS m/z:363.0[M+1]+。
1H NMR(400MHz,CDCl3)δ8.59(d,1H),8.41(s,1H),8.29(s,1H),7.07(d,1H), 6.82(s,1H),3.99–3.89(m,4H),3.85(s,3H),3.30–3.20(m,4H)。
And a sixth step: 5-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-amine (40G)
5-chloro-N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-6-morpholino-1H-indol- 3-yl)pyrimidin-2-amine
4- (3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1H-indol-6-yl) morpholine (40F) (724g, 2mmol) was dissolved in 2-pentanol (20mL), 4-fluoro-2-methoxy-5-nitroaniline (372mg, 2mmol) and p-toluenesulfonic acid (456.5mg, 2.4mmol) were added, and the reaction was heated to 120 ℃ for 2 days under reflux. The reaction was cooled to room temperature, 50mL acetonitrile was added, filtered, the filter cake washed with 50mL water and dried to give 5-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-amine (40G) as a grey solid (800mg, 80% yield).
MS m/z:513.1[M+1]+。
1H NMR(400MHz,CDCl3)δ9.35(d,1H),8.39(s,1H),8.34(d,1H),8.14(s,1H),7.56 (s,1H),6.97(d,1H),6.80(s,1H),6.75(d,1H),4.02(s,3H),3.93(s,4H),3.84(s,3H),3.23(s, 4H)。
The seventh step: n is a radical of1- (5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) -4-fluoro-6-methoxyphenyl-1, 3-diamine (40H)
N1-(5-chloro-4-(1-methyl-6-morpholino-1H-indol-3-yl)pyrimidin-2-yl)-4-fluoro-6-me thoxybenzene-1,3-diamine
5-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-amine (40G) (600mg, 1.17mmol) was dissolved in 30mL of ethanol, 10mL of water was added, and iron powder (392mg, 7.03mmol) and ammonium chloride (43.8mg, 0.82mmol) were added in this order, and the mixture was heated to 90 ℃ and refluxed for 4 hours. The reaction was cooled to room temperature, filtered, washed once with 50mL of methanol, and concentrated. Separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v): 1: 0-50: 1) to obtain N1- (5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) -4-fluoro-6-methoxyphenyl-1, 3-diamine (40H), brown solid (150mg, 26.6% yield).
MS m/z:483.1[M+1]+。
Eighth step: n- (5- ((5-chloro-4- (1-methyl-6-morpholinyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2-fluoro-4-methoxyphenyl) acrylamide (compound 40)
N-(5-((5-chloro-4-(1-methyl-6-morpholino-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-fl uoro-4-methoxyphenyl)acrylamide
Will N1- (5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) -4-fluoro-6-methoxyphenyl-1, 3-diamine (40H) (150mg, 0.31mmol) was dissolved in 10mL of tetrahydrofuran, N-diisopropylethylamine (0.06mL, 0.37mmol) was added, and a solution of acryloyl chloride (0.03mL, 0.37mmol) in tetrahydrofuran (5mL) was added dropwise at 0 ℃ and the mixture was allowed to warm to room temperature for reaction for 1.5 hours. To the reaction mixture were added 100mL of a saturated aqueous sodium bicarbonate solution and 100mL of dichloromethane, and the mixture was separated. Purification by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) gave N- (5- ((5-chloro-4- (1-methyl-6-morpholinyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2-fluoro-4-methoxyphenyl) acrylamide (compound 40) as a pale yellow solid (20mg, yield 12%).
MS m/z=537.1[M+1]+。
1H NMR(400MHz,CDCl3)δ9.14(s,1H),8.37(s,1H),8.35(s,1H),8.22(s,1H), 7.50(d,1H),7.19(s,1H),6.99(s,1H),6.73(d,1H),6.40(dd,1H),6.26(dd,1H),5.75(d, 1H),3.96(s,4H),3.90(s,3H),3.86(s,3H),3.26(s,4H)。
EXAMPLE 41
N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl) acrylamide (compound 41)
N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(2-(4 -methylpiperazin-1-yl)ethoxy)phenyl)acrylamide
The first step is as follows: 5-chloro-N- (2-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (41A)
5-chloro-N-(2-methoxy-4-(2-(4-methylpiperazin-1-yl)ethoxy)-5-nitrophenyl)-4-(1-me thyl-1H-indol-3-yl)pyrimidin-2-amine
5-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (intermediate 4) (854.1mg, 2mmol) was dissolved in 50mL of tetrahydrofuran, sodium hydride (80mg, 2.2mmol) was added under ice-bath, stirred for 30 minutes, 2- (4-methylpiperazin-1-yl) ethanol (576.5mg, 4mmol) was added dropwise, and the reaction was allowed to proceed at room temperature overnight. After the reaction was completed, 100mL of water and 100mL of ethyl acetate were added, the mixture was separated, and the organic phase was dried over anhydrous sodium sulfate, and then concentrated to give compound 5-chloro-N- (2-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (41A) as a yellow solid (800mg, yield 80%).
MS m/z:552.2[M+1]+。
1H NMR(400MHz,CDCl3)δ9.20(s,1H),8.46(d,1H),8.38(s,1H),8.21(s,1H), 7.50(s,1H),7.38(d,1H),7.36–7.30(m,1H),7.29–7.23(m,1H),6.61(s,1H),4.24(t, 2H),3.99(s,3H),3.90(d,3H),2.89(t,2H),2.77–2.64(m,4H),2.50(s,4H),2.31(s, 3H)。
The second step is that: n is a radical of1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) benzene-1, 3-diamine (41B)
N1-(5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-4-(2-(dimethylamino)ethoxy )-6-methoxybenzene-1,3-diamine
Reacting 5-chloro-N- (2-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) -5-nitrophenyl) -4- (1-methyl-1H-indolidin-3-yl) ) Pyrimidin-2-amine (41A) (800mg, 1.45mmol) was dissolved in 15mL of ethanol, and 5mL of water, iron powder (486.3mg, 8.7mmol) and ammonium chloride (54mg, 1mmol) were added in this order, and the reaction was refluxed at 90 ℃ for 4 hours. Cooling the reaction solution to room temperature, filtering, concentrating, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain compound N1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) benzene-1, 3-diamine (41B), yellow solid (200mg, 26.5% yield).
MS m/z:522.2[M+1]+。
1H NMR(400MHz,CDCl3)δ8.63(d,1H),8.31(s,1H),8.22(s,1H),8.06(s,1H), 7.51(s,1H),7.40(d,1H),7.34(dd,1H),7.28(dd,1H),6.57(s,1H),4.11(t,2H),3.90(s, 3H),3.84(s,3H),2.79(t,2H),2.66(s,4H),2.60–2.44(m,4H),2.32(d,3H)。
The third step: n- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl) acrylamide (Compound 41)
N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(2-(dimethylami no)ethoxy)-4-methoxyphenyl)acrylamide
Will N1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) benzene-1, 3-diamine (41B) (150mg, 0.288mmol) was dissolved in 10mL of tetrahydrofuran, DIPEA (0.057mL, 0.345mmol) was added, a solution of acryloyl chloride (0.028mL, 0.345mmol) in tetrahydrofuran was added dropwise at 0 ℃ to 5mL, and the mixture was warmed to room temperature to react for 1 hour. 50mL of a saturated aqueous sodium bicarbonate solution and 50mL of ethyl acetate were added to separate the layers. The compound N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl) acrylamide (compound 41) was obtained by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1), and was a pale yellow solid (40mg, yield 24.1%).
MS m/z=576.2[M+1]+。
1H NMR(400MHz,CDCl3)δ9.32(s,1H),8.41(s,1H),8.40(s,1H),8.31(s,1H),7.41 (s,1H),7.36(d,1H),7.29(d,1H),7.21(t,1H),6.61(s,1H),6.41–6.35(m,2H),5.71(dd, 1H),4.18(t,2H),3.90(s,3H),3.87(s,3H),2.72(t,2H),2.62(s,4H),2.53(s,4H),2.33(s, 3H)。
Example 42
N- (3- ((5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 42)
N-(3-((5-chloro-4-(1-methyl-6-morpholino-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-m ethoxyphenyl)acrylamide
The first step is as follows: 5-chloro-N- (2-methoxy-5-nitrophenyl) -4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-amine (42A)
5-chloro-N-(2-methoxy-5-nitrophenyl)-4-(1-methyl-6-morpholino-1H-indol-3-yl)pyri midin-2-amine
4- (3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1H-indol-6-yl) morpholine (40F) (724g, 2mmol) was dissolved in 2-pentanol (20mL), 2-methoxy-5-nitroaniline (336.3mg, 2mmol) and p-toluenesulfonic acid (456.5mg, 2.4mmol) were added, and the reaction was heated to 120 ℃ for 3 days under reflux. The reaction was cooled to room temperature, 50mL acetonitrile was added, filtered, the filter cake washed with 50mL water and dried to give 5-chloro-N- (2-methoxy-5-nitrophenyl) -4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-amine (42A) as a pale green solid (990 mg).
MS m/z:495.1[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.87(s,1H),8.70(s,1H),8.56(s,1H),8.51(s,1H), 8.33(d,1H),8.07(d,1H),7.48(d,2H),7.36(s,1H),7.32(d,1H),7.11(d,2H),7.02(d, 1H),3.99(s,3H),3.90(s,8H),3.73(s,19H),2.29(s,3H)。
The second step is that: n is a radical of1- (5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxybenzene-1, 3-diamine (42B)
N1-(5-chloro-4-(1-methyl-6-morpholino-1H-indol-3-yl)pyrimidin-2-yl)-6-methoxybenz ene-1,3-diamine
5-chloro-N- (2-methoxy-5-nitrophenyl) -4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-amine (42A) (990mg, 2mmol) was dissolved in 30mL of ethanol, 10mL of water, iron powder (670mg, 12mmol) and ammonium chloride (75mg, 1.4mmol) were added in this order, and the mixture was heated to 90 ℃ for reflux reaction overnight. Cooling the reaction solution to room temperature, filtering, washing with 50mL of methanol once, concentrating, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain compound N 1- (5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxybenzene-1, 3-diamine (42B), brown solid (340mg, 36.6% yield).
MS m/z:465.1[M+1]+。
1H NMR(400MHz,CDCl3)δ8.56(d,1H),8.33(s,1H),8.16(d,1H),8.13(s,1H), 7.75(s,1H),7.03(dd,1H),6.82(d,1H),6.74(d,1H),6.31(dd,1H),3.97–3.91(m,4H), 3.85(s,3H),3.85(s,3H),3.26–3.19(m,4H)。
The third step: n- (3- ((5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 42)
N-(3-((5-chloro-4-(1-methyl-6-morpholino-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-m ethoxyphenyl)acrylamide
Will N1- (5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxybenzene-1, 3-diamine (42B) (280mg, 0.6mmol) was dissolved in 30mL of tetrahydrofuran, N-Diisopropylethylamine (DIPEA) (0.12mL, 0.72mmol) was added, 5mL of a solution of acryloyl chloride (0.059mL, 0.72mmol) in tetrahydrofuran was added dropwise at 0 ℃, and the mixture was allowed to warm to room temperature for reaction for 4 hours. 100mL of a saturated aqueous sodium bicarbonate solution and 100mL of ethyl acetate were added to separate the layers. Purification by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) gave compound N- (3- ((5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 42) as a pale yellow solid (120mg, yield 38.7%).
MS m/z:519.1[M+1]+。
1H NMR(400MHz,CDCl3)δ8.52(dd,2H),8.35(s,1H),8.15(s,1H),7.83(d,1H), 7.78(s,1H),7.12(s,1H),6.98(d,1H),6.89(d,1H),6.37(d,1H),6.09(dd,10.2Hz,1H), 5.69(d,1H),3.93(s,7H),3.87(s,3H),3.25(s,4H)。
Example 43
N- (5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (2- (dimethylamino) ethoxy) -4-methoxyphenyl) acrylamide (compound 43)
N-(5-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy )-4-methoxyphenyl)acrylamide
The first step is as follows: 5-chloro-N- (4- (2- (dimethylamino) ethoxy) -2-methoxy-5-nitrophenyl) -4- (1H-indol-3-yl) pyrimidin-2-amine (43A)
5-chloro-N-(4-(2-(dimethylamino)ethoxy)-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H -indol-3-yl)pyrimidin-2-amine
5-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (intermediate 4) (620mg, 1.5mmol) was dissolved in 30mL of tetrahydrofuran, and sodium hydride (66mg, 1.65mmol) was added under ice-cooling, followed by stirring for 30 minutes, dimethyl ethanolamine (0.3mL, 3mmol) was added dropwise, and the reaction was carried out at room temperature for 4 hours. After the reaction was completed, 100mL of water and 100mL of ethyl acetate were added, the mixture was separated, the organic phase was dried over anhydrous sodium sulfate, and concentrated to give compound 5-chloro-N- (4- (2- (dimethylamino) ethoxy) -2-methoxy-5-nitrophenyl) -4- (1H-indol-3-yl) pyrimidin-2-amine (43A) as a brown solid (660mg, yield 91.3%).
The second step is that: n is a radical of1- (5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) -4- (2- (dimethylamino) ethoxy) -6-methoxy-1, 3-diamine (43B)
N1-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)-4-(2-(dimethylamino)ethoxy)-6-metho xybenzene-1,3-diamine
5-chloro-N- (4- (2- (dimethylamino) ethoxy) -2-methoxy-5-nitrophenyl) -4- (1H-indol-3-yl) pyrimidin-2-amine (43A) (650mg, 1.35mmol) was dissolved in 30mL of ethanol, 10mL of water, iron powder (452mg, 8.1mmol) and ammonium chloride (50.5mg, 0.95mmol) were added in this order, the temperature was raised to 90 ℃ and the reaction was refluxed overnight. Cooling the reaction solution to room temperature, filtering, concentrating, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-20: 1) to obtain compound N 1- (5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) -4- (2- (dimethylamino) ethoxy) -6-methoxy-1, 3-diamine (43B) as a yellow solid (200mg, 32.8% yield).
MS m/z=453.1[M+1]+。
The third step: n- (5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (2- (dimethylamino) ethoxy) -4-methoxyphenyl) acrylamide (compound 43)
N-(5-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethoxy )-4-methoxyphenyl)acrylamide
Will N1- (5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) -4- (2- (dimethylamino) ethoxy) -6-methoxy-1, 3-diamine (43B) (200mg, 0.44mmol) was dissolved in 15mL of tetrahydrofuran, N-Diisopropylethylamine (DIPEA) (0.088mL, 0.53mmol) was added, and a solution of acryloyl chloride (0.043mL, 0.53mmol) in tetrahydrofuran (5mL) was added dropwise at 0 ℃ and allowed to warm to room temperature for 4 hours. To the reaction mixture were added 100mL of a saturated aqueous sodium bicarbonate solution and 100mL of ethyl acetate, and the mixture was separated. The compound N- (5- ((5-chloro-4- (1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (2- (dimethylamino) ethoxy) -4-methoxyphenyl) acrylamide (compound 43) was obtained by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1), and was a beige solid (20mg, yield 9.0%).
MS m/z=507.1[M+1]+。
1H NMR(400MHz,CDCl3)δ9.83(s,1H),9.33(s,1H),9.18(s,1H),8.48(d,1H), 8.29(d,1H),8.26(s,1H),7.41(s,1H),7.33(d,1H),7.24–7.14(m,2H),6.65(s,1H), 6.41(d,1H),6.27(dd,1H),5.71(d,1H),4.20–4.09(m,2H),3.88(s,3H),2.62–2.52(m, 2H),2.37(s,6H)。
Example 44
(S) -N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- ((1-methylpyrrol-3-yl) oxy) phenyl) acrylamide (compound 44)
(S)-N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-( (1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide
The first step is as follows: (S) -5-chloro-N- (2-methoxy-4- ((1-methylpyrrol-3-yl) oxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (44A)
(S)-5-chloro-N-(2-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)-5-nitrophenyl)-4-(1-met hyl-1H-indol-3-yl)pyrimidin-2-amine
5-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (intermediate 4) (854.1mg, 2mmol) was dissolved in 30mL of tetrahydrofuran, sodium hydride (160mg, 4mmol) was added under ice-cooling, stirred for 30 minutes, and (S) - (+) -1-methyl-3-hydroxypyrrolidine (242.76mg, 2.4mmol) was added dropwise and reacted at room temperature overnight. After the reaction was completed, 150mL of water and 150mL of ethyl acetate were added, the mixture was separated, the organic phase was dried over anhydrous sodium sulfate, and concentrated to give compound (S) -5-chloro-N- (2-methoxy-4- ((1-methylpyrrolidin-3-yl) oxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (44A) as a yellow solid (1g, yield 99%).
MS m/z:509.1[M+1]+。
The second step is that: (S) -N1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- ((1-methylpyroll-3-yl) oxy) benzene-1, 3-diamine (44B)
(S)-N1-(5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-6-methoxy-4-((1-methyl pyrrolidin-3-yl)oxy)benzene-1,3-diamine
Reacting (S) -5-chloro-N- (2-methoxy-4- ((1-methylpyrrol-3-yl) oxy) -5-nitrophenyl) -4- (1-methyl-1H-indole-3-yl) pyrimidin-2-amine (44A) (1g, 2mmol) was dissolved in 30mL of ethanol, 10mL of water, iron powder (659.3mg, 11.8mmol) and ammonium chloride (73.7mg, 1.38mmol) were added in that order, the temperature was raised to 90 ℃ and the reaction was refluxed overnight. Cooling the reaction solution to room temperature, filtering, concentrating, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain the compound (S) -N 1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- ((1-methylpyrrol-3-yl) oxy) benzene-1, 3-diamine (44B), brown solid (410mg, 42.9% yield).
The third step: (S) -N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- ((1-methylpyrrol-3-yl) oxy) phenyl) acrylamide (compound 44)
(S)-N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-( (1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide
Reacting (S) -N1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- ((1-methylpyrrol-3-yl) oxy) benzene-1, 3-diamine (44B) (400mg, 0.84mmol) was dissolved in 30mL of tetrahydrofuran, N-Diisopropylethylamine (DIPEA) (0.165mL, 1mmol) was added, and a tetrahydrofuran solution (5mL) of acryloyl chloride (0.08mL, 1mmol) was added dropwise at 0 ℃ and allowed to warm to room temperature for 4 hours. To the reaction mixture were added 100mL of a saturated aqueous sodium bicarbonate solution and 100mL of ethyl acetate, and the mixture was separated. The compound (S) -N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- ((1-methylpyrrol-3-yl) oxy) phenyl) acrylamide (compound 44) was obtained by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1), and a yellow-green solid (80mg, yield 17.9%).
MS m/z:533.1[M+1]+。
1H NMR(400MHz,CDCl3)δ9.33(s,1H),8.39(d,2H),8.32(s,1H),7.42(s,1H), 7.36(d,1H),7.29(d,1H),7.21(t,1H),6.53(s,1H),6.37(s,2H),5.74–5.65(m,1H), 4.81(s,1H),3.90(s,3H),3.86(s,3H),3.18(d,2H),2.51(s,3H),2.39–2.26(m,2H), 2.20(d,2H)。
Example 45
(R) -N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- ((1-methylpyrrol-3-yl) oxy) phenyl) acrylamide (Compound 45)
(R)-N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-( (1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide
The first step is as follows: (R) -5-chloro-N- (2-methoxy-4- ((1-methylpyrrol-3-yl) oxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (45A)
(R)-5-chloro-N-(2-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)-5-nitrophenyl)-4-(1-met hyl-1H-indol-3-yl)pyrimidin-2-amine
5-chloro-N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (intermediate 4) (1mg, 2.3mmol) was dissolved in 30mL of tetrahydrofuran, and sodium hydride (184mg, 4.6mmol) was added under ice-cooling, stirred for 30 minutes, and (R) - (-) -1-methyl-3-hydroxypyrrolidine (284mg, 2.8mmol) was added dropwise and reacted at room temperature overnight. After the reaction was completed, 150mL of water and 150mL of ethyl acetate were added, the mixture was separated, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give compound (R) -5-chloro-N- (2-methoxy-4- ((1-methylpyrrolidin-3-yl) oxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (45A) as a yellow solid (1.1 g).
MS m/z:509.0[M+1]+。
1H NMR(400MHz,CDCl3)δ9.19(s,1H),8.46(d,1H),8.39(s,1H),8.23(d,1H), 7.49(s,1H),7.38(d,1H),7.34(dd,1H),7.30(dd,1H),6.52(s,1H),4.92(ddd,1H),3.99 (s,3H),3.91(s,1H),3.90(s,3H),3.10(dd,1H),2.83–2.74(m,2H),2.72–2.64(m,1H), 2.44(s,3H),2.32(dt,2H),2.19–2.10(m,1H)。
The second step is that: (R) -N1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- ((1-methylpyroll-3-yl) oxy) benzene-1, 3-diamine (45B)
(R)-N1-(5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-6-methoxy-4-((1-methyl pyrrolidin-3-yl)oxy)benzene-1,3-diamine
(R) -5-chloro-N- (2-methoxy-4- ((1-methylpyrrol-3-yl) oxy) -5-nitrophenyl) -4- (1-methyl-1H-indole-3-yl) pyrimidin-2-amine (45A) (1.1g, 2.16mmol) was dissolved in 30mL of ethanol, 10mL of water, iron powder (725mg, 13mmol) and ammonium chloride (81mg, 1.5mmol) were added in this order, the temperature was raised to 90 ℃ and the reaction was refluxed for 4 hours. The reaction was cooled to room temperature, filtered and concentrated. Separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain the compound (R) -N 1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- ((1-methylpyrrol-3-yl) oxy) benzene-1, 3-diamine (45B), green solid (900mg, 90% yield).
1H NMR(400MHz,CDCl3)δ8.63(d,1H),8.32(s,1H),8.21(s,1H),8.09(s,1H), 7.52(s,1H),7.39(d,1H),7.33(t,1H),7.27(dd,1H),6.48(s,1H),4.88(t,1H),3.90(s, 3H),3.85(d,3H),3.16–2.98(m,6H),2.84(s,1H),2.58(s,3H),2.35(dt,1H),2.20(dd, 1H)。
The third step: (R) -N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- ((1-methylpyrrol-3-yl) oxy) phenyl) acrylamide (Compound 45)
(R)-N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-( (1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide
Reacting (R) -N1- (5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- ((1-methylpyrrol-3-yl) oxy) benzene-1, 3-diamine (45B) (900mg, 1.88mmol) was dissolved in 20mL of tetrahydrofuran, DIPEA (0.23mL, 2.26mmol) was added, a solution of acryloyl chloride (0.183mL, 2.26mmol) in tetrahydrofuran was added dropwise at 0 ℃ to 5mL, and the mixture was allowed to warm to room temperature for reaction for 4 hours. A saturated aqueous solution of sodium hydrogencarbonate was added to the reaction mixture to adjust the mixture to alkaline, and 100 mL of ethyl acetate and 150mL of saturated brine were added to separate the mixture. The organic phase was dried over anhydrous sodium sulfate. Separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain the compound (R) -N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl)) Pyrimidin-2-yl) amino) -4-methoxy-2- ((1-methylpyrrol-3-yl) oxy) phenyl) acrylamide (compound 45) as a pale yellow solid (180mg, 16% yield).
MS m/z=533.2[M+1]+。
1H NMR(400MHz,CDCl3)δ9.38(s,1H),8.90(s,1H),8.39(d,2H),8.32(s,1H), 7.42(s,1H),7.35(d,1H),7.31–7.26(m,1H),7.23–7.18(m,1H),6.55(s,1H),6.35(qd, 2H),5.68(dd,1H),4.76(s,1H),3.90(s,3H),3.86(s,3H),3.16(t,1H),3.00(d,1H),2.43 (s,3H),2.34(dd,2H),2.31–2.25(m,1H),2.13(dd,1H),1.25(s,1H)。
Example 46
N- (3- ((5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide hydrochloride (compound 46)
N-(3-((5-chloro-4-(1-methyl-6-morpholino-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-m ethoxyphenyl)acrylamide hydrochloride
N- (3- ((5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 42) (86mg, 0.166mmol) was dissolved in 1, 4-dioxane (30mL), a solution of hydrochloric acid (0.083mL, 0.332mmol) in 1, 4-dioxane was added dropwise at 0 ℃ and allowed to warm to room temperature for 2 hours. The reaction was spin dried to give N- (3- ((5-chloro-4- (1-methyl-6-morpholin-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide hydrochloride (compound 46) as a yellow solid (90mg, 97.8% yield).
MS m/z:519.1[M+1]+。
Example 47
(S) -N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- ((1-methylpyrrol-3-yl) oxy) phenyl) acrylamide methanesulfonate (Compound 47)
(S)-N-(5-((5-chloro-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-( (1-methylpyrrolidin-3-yl)oxy)phenyl)acrylamide methanesulfonate
(S) -N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- ((1-methylpyrrol-3-yl) oxy) phenyl) acrylamide (compound 44) (40mg, 0.075mmol) was dissolved in 10mL of ethanol, 5mL of ethyl acetate was added, and a solution of methanesulfonic acid (0.048mL, 0.075mmol) in ethyl acetate (3mL) was added dropwise at 70 ℃ and reacted for 2 hours. The reaction was spin-dried to give (S) -N- (5- ((5-chloro-4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- ((1-methylpyrrol-3-yl) oxy) phenyl) acrylamide methanesulfonate (compound 47) as a brown solid (47mg, 99.8% yield).
MS m/z:533.1[M+1]+。
Example 48
N- (2- (2- (dimethylamino) ethoxy) -4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 48)
N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin -2-yl)amino)phenyl)acrylamide
The first step is as follows: n- (4- (2- (dimethylamino) ethoxy) -2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (48A)
N-(4-(2-(dimethylamino)ethoxy)-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3- yl)pyrimidin-2-amine
5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 3) (1g, 2.54mmol) was dissolved in 50mL of tetrahydrofuran, and sodium hydride (103mg, 2.57mmol) was added under ice-cooling, followed by stirring for 30 minutes, dropwise addition of 2- (dimethylamino) ethanol (417.2mg, 4.68mmol), and reaction at room temperature for 4 hours. After completion of the reaction, 200mL of water and 200mL of ethyl acetate were added and the mixture was separated. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to give the compound N- (4- (2- (dimethylamino) ethoxy) -2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indolin-3-yl) pyrimidin-2-amine (48A) as a yellow solid (1.05g, 91.3% yield).
MS m/z:463.2[M+1]+。
1H NMR(400MHz,CDCl3)δ9.67(s,1H),8.38(d,1H),8.26(s,1H),8.15(dd,1H), 7.52(s,1H),7.40(dd,1H),7.34–7.27(m,2H),7.19(d,1H),6.63(s,1H),4.23(t,2H), 3.99(d,3H),3.93(s,3H),3.48(s,3H),2.85(t,2H),2.40(s,6H)。
The second step is that: 4- (2- (dimethylamino) ethoxy) -6-methoxy-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) benzene-1, 3-diamine (48B)
4-(2-(dimethylamino)ethoxy)-6-methoxy-N1-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2- yl)benzene-1,3-diamine
N- (4- (2- (dimethylamino) ethoxy) -2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (48A) (1g, 2.16mmol) was dissolved in 30mL of ethanol, 10mL of water, iron powder (725mg, 13mmol) and ammonium chloride (81mg, 1.5mmol) were added in this order, and the mixture was heated to 90 ℃ and refluxed overnight. The reaction solution was cooled to room temperature, filtered and concentrated. Separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain the compound 4- (2- (dimethylamino) ethoxy) -6-methoxyl-N 1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) benzene-1, 3-diamine (48B), brown solid (930mg, 99.7% yield).
MS m/z:433.2[M+1]+。
1H NMR(400MHz,CDCl3)δ8.52–8.47(m,1H),8.31(d,1H),8.13(s,1H),7.77(s, 1H),7.47(s,1H),7.37(dd,1H),7.30(ddd,2H),6.99(d,1H),6.58(s,1H),4.09(t,2H), 3.86(s,3H),3.84(s,3H),2.72(t,2H),2.35(s,6H)。
The third step: n- (2- (2- (dimethylamino) ethoxy) -4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 48)
N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin -2-yl)amino)phenyl)acrylamide
Reacting 4- (2- (dimethylamino) ethoxy) -6-methoxy-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) benzene-1, 3-diamine (48B) (600mg, 1.38mmol) was dissolved in 10mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (794mg, 4.16mmol) and acrylic acid (0.143mL, 2.08mmol) were added in this order to react at room temperature for 3 hours. The reaction mixture was spin-dried, and an aqueous solution of sodium hydroxide (150mL, 4mol/L) and 150mL of methylene chloride were added to separate the reaction mixture. The organic phase was washed once with 100mL of water. The organic phase was dried over anhydrous sodium sulfate. The resulting product was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give N- (2- (2- (dimethylamino) ethoxy) -4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 48) as a yellow solid (330mg, yield 49.1%).
MS m/z:487.2[M+1]+。
1H NMR(400MHz,CDCl3)δ9.80(d,2H),8.99(s,1H),8.37(d,1H),8.10–8.03(m, 1H),7.63(s,1H),7.39(dd,1H),7.19(d,1H),6.64(s,1H),6.49(d,0H),6.44(d,1H),6.38 (d,1H),5.72(dd,1H),4.17–4.09(m,2H),3.98(d,3H),3.88(s,3H),2.59(d,2H),2.37(s, 6H)。
Example 49
(S) -N- (4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((1-methylpyrrol-3-yl) oxy) phenyl) acrylamide (compound 49)
(S)-N-(4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((1-methyl pyrrolidin-3-yl)oxy)phenyl)acrylamide
The first step is as follows: (S) -N- (2 methoxy-4- ((1-methylpyrrol-3-yl) oxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (49A)
(S)-N-(2-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)-5-nitrophenyl)-4-(1-methyl-1H-i ndol-3-yl)pyrimidin-2-amine
5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 3) (1g, 2.54mmol) was dissolved in 30mL of tetrahydrofuran, and sodium hydride (203mg, 5.08mmol) was added under ice-bath, followed by stirring for 30 minutes, dropwise addition of a solution of (S) -1-methylpyrrol-3-ol (308mg, 3.05mmol) in tetrahydrofuran (5mL), and reaction at room temperature for 4 hours. After the reaction was completed, 100mL of water and 150mL of ethyl acetate were added to the reaction solution, followed by liquid separation, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give (S) -N- (2 methoxy-4- ((1-methylpyrrolidin-3-yl) oxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (49A) as a yellow solid (1g, yield 83.3%).
MS m/z:475.2[M+1]+。
The second step is that: (S) -6-methoxy-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- ((1-methylpyrrol-3-yl) oxy) benzene-1, 3-diamine (49B)
(S)-6-methoxy-N1-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-4-((1-methylpyrrolidin -3-yl)oxy)benzene-1,3-diamine
(S) -N- (2-methoxy-4- ((1-methylpyrrol-3-yl) oxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (49A) (1g, 2.11mmol) was dissolved in 30mL of ethanol, 10mL of water, iron powder (707mg, 12.65mmol) and ammonium chloride (78.6mg, 1.47mmol) were added in this order, the mixture was heated to 90 ℃ and refluxed for 4 hours. The reaction was cooled to room temperature, filtered and concentrated. Separating and purifying the extract by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to obtain the compound (S) -6-methoxy-N 1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- ((1-methylpyrrol-3-yl) oxy) benzene-1, 3-diamine (49B), brown solid (500mg, 53.6% yield).
MS m/z:445.2[M+1]+。
The third step: (S) -N- (4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((1-methylpyrrol-3-yl) oxy) phenyl) acrylamide (compound 49)
(S)-N-(4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((1-methyl pyrrolidin-3-yl)oxy)phenyl)acrylamide
Reacting (S) -6-methoxy-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- ((1-methylpyrrol-3-yl) oxy) benzene-1, 3-diamine (49B) (500mg, 1.13mmol) was dissolved in 15mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (646mg, 3.38mmol) and acrylic acid (0.116mL, 1.69mmol) were added in this order and reacted at room temperature for 4 hours. The reaction solution was spin-dried, 150mL of water and 200mL of methylene chloride were added, and the mixture was separated. The organic phase is washed once with 150mL of 4 mol/L aqueous sodium hydroxide solution. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give (S) -N- (4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((1-methylpyrrol-3-yl) oxy) phenyl) acrylamide (compound 49) as a pale yellow solid (210mg, 37.3% yield).
MS m/z:499.2[M+1]+。
Example 50
N- (4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (2- (piperidin-1-yl) ethoxy) phenyl) acrylamide (compound 50)
N-(4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(2-(piperidin- 1-yl)ethoxy)phenyl)acrylamide
The first step is as follows: n- (2-methoxy-5-nitro-4- (2- (piperidin-1-yl) ethoxy) phenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (50A)
N-(2-methoxy-5-nitro-4-(2-(piperidin-1-yl)ethoxy)phenyl)-4-(1-methyl-1H-indol-3-yl )pyrimidin-2-amine
5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 3) (1g, 2.54mmol) was dissolved in 50mL of tetrahydrofuran, and sodium hydride (122mg, 3.1mmol) was added under ice-cooling, followed by stirring for 30min, dropwise addition of 2- (piperidin-1-yl) ethanol (656mg, 5.08mmol), and reaction at room temperature overnight. After completion of the reaction, 150mL of water and 100mL of ethyl acetate were added and the mixture was separated. The aqueous phase was extracted with 100mL ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the compound N- (2-methoxy-5-nitro-4- (2- (piperidin-1-yl) ethoxy) phenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (50A) as a yellow solid (1.2g, 94.5% yield).
MS m/z:503.1[M+1]+。
The second step is that: 6-methoxy-N1- (4- (1-methyl-l-1H-indol-3-yl) pyrimidin-2-yl) -4- (2- (piperidin-1-yl) ethoxy) benzene-1, 3-diamine (50B)
6-methoxy-N1-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-4-(2-(piperidin-1-yl)ethox y)benzene-1,3-diamine
N- (2-methoxy-5-nitro-4- (2- (piperidin-1-yl) ethoxy) phenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (50A) (1.2g, 2.39mmol) was dissolved in 15mL of ethanol, and 5mL of water, iron powder (400mg, 7.17mmol) and ammonium chloride (89.5mg, 1.67mmol) were sequentially added, and the mixture was heated to 90 ℃ and refluxed for 6 hours. Cooling the reaction solution to room temperature, filtering, concentrating, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain the compound 6-methoxy-N 1- (4- (1-methyl l-1H-indol-3-yl) pyrimidin-2-yl) -4- (2- (piperidin-1-yl) ethoxy) benzene-1, 3-diamine (50B), brown solid (750mg, 68.2% yield).
MS m/z:473.3[M+1]+。
The third step: n- (4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (2- (piperidin-1-yl) ethoxy) phenyl) acrylamide (compound 50)
N-(4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(2-(piperidin- 1-yl)ethoxy)phenyl)acrylamide
Reacting 6-methoxy-N1- (4- (1-methyl l-1H-indol-3-yl) pyrimidin-2-yl) -4- (2- (piperidin-1-yl) ethoxy) benzene-1, 3-diamine (50B) (750mg, 1.59mmol) was dissolved in 10mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (911mg, 4.71mmol) and acrylic acid (0.164mL, 2.38mmol) were added and reacted at room temperature for 4 hours. The reaction mixture was spin-dried, and 100mL of a 4mol/L aqueous sodium hydroxide solution and 100mL of ethyl acetate were added to separate the reaction mixture. The organic phase was washed once with 100mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate. Column chromatography on silica gel (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) gave N- (4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (2- (piperidin-1-yl) ethoxy) phenyl) acrylamide (compound 50) as a white solid (300mg, 35.8% yield).
MS m/z:527.2[M+1]+。
1H NMR(400MHz,CDCl3)δ9.60(s,1H),9.40(s,1H),8.83(s,1H),8.33(d,1H), 8.07(d,1H),7.39(d,1H),7.33–7.23(m,1H),7.17(d,1H),6.51(s,1H),6.45(dd,1H), 5.72(d,1H),4.33(s,2H),3.94(s,2H),3.87(d,2H),3.62(s,2H),3.33(d,2H),2.68(s, 2H),2.33(s,2H),1.84(s,3H),1.55(s,3H)。
Example 51
N- (4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl) acrylamide (compound 51)
N-(4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(2-(4-methylp iperazin-1-yl)ethoxy)phenyl)acrylamide
The first step is as follows: n- (2-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (51A)
N-(2-methoxy-4-(2-(4-methylpiperazin-1-yl)ethoxy)-5-nitrophenyl)-4-(1-methyl-1H-i ndol-3-yl)pyrimidin-2-amine
5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 3) (1g, 2.54mmol) was dissolved in 20mL of tetrahydrofuran, and sodium hydride (203mg, 5.08mmol) was added under ice-bath, followed by stirring for 30 minutes, dropwise addition of 1- (2-hydroxyethyl) -4-methylpiperazine (733mg, 5.08mmol), and reaction at room temperature for 8 hours. After completion of the reaction, 150mL of water and 150mL of ethyl acetate were added to the reaction mixture, and the mixture was separated. The aqueous phase was extracted with 100mL ethyl acetate, the organic phases combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give N- (2-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (51A) as a yellow solid (1.1g, 84.6% yield).
MS m/z:518.1[M+1]+。
The second step is that: 6-methoxy-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (2- (4-methylpiperazin-1-yl) ethoxy) benzene-1, 3-diamine (51B)
6-methoxy-N1-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-4-(2-(4-methylpiperazin-1 -yl)ethoxy)benzene-1,3-diamine
N- (2-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) -5-nitrophenyl) -4- (1-methyl-1H-indol-3-yl) pyrimidin-2-amine (51A) (1.1g, 2.18mmol) was dissolved in 15mL of ethanol, 5mL of water was added in this order, and then iron powder (356mg, 6.4mmol) and ammonium chloride (78.7mg, 1.55mmol) were added, and the mixture was heated to 90 ℃ and refluxed for 4 hours. Cooling the reaction solution to room temperature, filtering, concentrating, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain 6-methoxy-N 1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (2- (4-methylpiperazin-1-yl) ethoxy) benzene-1, 3-diamine (51B), brown solid (550mg, 51.9% yield).
The third step: n- (4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl) acrylamide (compound 51)
N-(4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-(2-(4-methylp iperazin-1-yl)ethoxy)phenyl)acrylamide
Reacting 6-methoxy-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -4- (2- (4-methylpiperazin-1-yl) ethoxy) benzene-1, 3-diamine (51B) (550mg, 1mmol) was dissolved in 15mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (573mg, 3mmol) and acrylic acid (0.103mL, 1.5mmol) were added and reacted at room temperature for 4 hours. The reaction solution was spin-dried, and 100mL of water and 100mL of methylene chloride were added to separate the solution. The organic phase is washed once with 100mL of 4mol/L aqueous sodium hydroxide solution. The organic phase was dried over anhydrous sodium sulfate. The resulting product was purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give N- (4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl) acrylamide (compound 51) as a white solid (65mg, 12%).
MS m/z:542.1[M+1]+。
Example 52
(R) -N- (4 methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((1-methylpyrrol-3-yl) amino) phenyl) acrylamide (Compound 52)
(R)-N-(4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((1-methy lpyrrolidin-3-yl)amino)phenyl)acrylamide
The first step is as follows: (R) -tert-butyl 3- ((tert-butoxycarbonyl) amino) pyrrole-1-carboxylate (52B)
(R)-tert-butyl 3-((tert-butoxycarbonyl)amino)pyrrolidine-1-carboxylate
(R) -tert-butyl 3-aminopyrrole-1-carboxylate (52A) (2g, 10.74mmol) was dissolved in 25mL of dichloromethane, and triethylamine (2.17g, 21.5mmol) and di-tert-butyl dicarbonate (2.46g, 11.28mmol) were added to react at room temperature for 3 hours. 100mL of water and 100mL of methylene chloride were added to the reaction mixture, and the mixture was separated. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to give (R) -tert-butyl 3- ((tert-butoxycarbonyl) amino) pyrrole-1-carboxylate (52B) as a colorless oil (3 g).
The second step is that: (R) -N, 1-dimethylpyrrol-3-amine (52C)
(R)-N,1-dimethylpyrrolidin-3-amine
(R) -tert-butyl 3- ((tert-butoxycarbonyl) amino) pyrrole-1-carboxylate (52B) (3g, 10.74mmol) was dissolved in 50mL of tetrahydrofuran, and lithium aluminum hydride (4g, 107.4mmol) was slowly added under ice-bath to react at room temperature for 1 hour, and the reaction was continued for 3 hours by raising the temperature to 60 ℃. After the reaction, 50mL of acetone was added, and water was added dropwise until no bubbles were formed in the reaction solution. Filtration, washing with 50mL tetrahydrofuran, and concentration gave (R) -N, 1-dimethylpyrrol-3-amine (52C) as a yellow liquid (1.65 g).
MS m/z:115.2[M+1]+。
1H NMR(400MHz,CDCl3)δ3.65(t,1H),3.23–3.15(m,1H),2.68–2.60(m,1H), 2.48–2.39(m,1H),2.37(s,3H),2.33(s,3H),2.14(dd,1H),1.70–1.64(m,1H),1.57(d, 1H)。
The third step: (R) -2-methoxy-N4-methyl-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N4- (1-methylpyrrol-3-yl) -5-nitrobenzene-1, 4-diamine (52D)
(R)-2-methoxy-N4-methyl-N1-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-N4-(1-me thylpyrrolidin-3-yl)-5-nitrobenzene-1,4-diamine
5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 3) (1g, 2.54mmol) was dissolved in 10mL of N, N-dimethylacetamide, and N, N-Diisopropylethylamine (DIPEA) (0.51mL, 3.05mmol) and (R) -N, 1-dimethylpyrrol-3-amine (52C) (348mg, 3.05mmol) were added in that order and reacted at 140 ℃ for 1 hour under microwave. After the reaction is finished, concentrating the reaction solution, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain the compound (R) -2-methoxyl-N4-methyl-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N4- (1-methylpyrrol-3-yl) -5-nitrobenzene-1, 4-diamine (52D), red solid (0.5g, 40.3% yield).
MS m/z:488.1[M+1]+。
The fourth step: (R) -5-methoxy-N1-methyl-N4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N1- (1-methylpyrrol-3-yl) benzene-1, 2, 4-triamine (52E)
(R)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-N1-(1-me thylpyrrolidin-3-yl)benzene-1,2,4-triamine
Reacting (R) -2-methoxy-N4-methyl-N1- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N4- (1-Methylpyrrol-3-yl) -5-nitrobenzene-1, 4-diamine (52D) (1.24g, 2.5mmol) was dissolved in 20mL of ethanol, 7mL of water, iron powder (419mg, 7.5mmol) and ammonium chloride (94mg, 1.75mmol) were added, the temperature was raised to 90 ℃ and the reaction was refluxed for 6 hours. Cooling the reaction solution to room temperature, filtering, concentrating, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain the compound (R) -5-methoxy-N 1-methyl-N4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N1- (1-methylpyrrol-3-yl) benzene-1, 2, 4-triamine (52E), brown solid (350mg, yield 30.7%).
MS m/z:458.1[M+1]+。
The fifth step: (R) -N- (4-methoxy-2- (methyl (1-methylpyrrol-3-yl) amino) -5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (Compound 52)
(R)-N-(4-methoxy-2-(methyl(1-methylpyrrolidin-3-yl)amino)-5-((4-(1-methyl-1H-ind ol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
Reacting (R) -5-methoxy-N1-methyl-N4- (4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -N1- (1-Methylpyrrol-3-yl) benzene-1, 2, 4-triamine (52E) (350mg, 0.76mmol) was dissolved in 10mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) (436mg, 2.28mmol) and acrylic acid (0.08mL, 1.14mmol) were added and reacted at room temperature for 4 hours. The reaction solution was spin-dried, and 100mL of water and 100mL of methylene chloride were added to separate the solution. The organic phase is washed once with 100mL of 4mol/L aqueous sodium hydroxide solution. Drying the organic phase with anhydrous sodium sulfate, filtering, concentrating, separating and purifying by silica gel column chromatography (dichloro-chlorine)Methanol (v/v) ═ 1:0 to 10:1, to give (R) -N- (4-methoxy-2- (methyl (1-methylpyrrol-3-yl) amino) -5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 52) as a brown solid (80mg, 20.6% yield).
MS m/z:512.2[M+1]+。
Example 53
N- (5- ((4- (1- (1-cyclopropylethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 53)
N-(5-((4-(1-(1-cyclopropylethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimeth ylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acryamide
The first step is as follows: n is a radical of1- (4- (1- (1-cyclopropylethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrophenyl-1, 4-diamine (53A)
N1-(4-(1-(1-cyclopropylethyl)-1H-indol-3-yl)pyrimidin-2-yl)-N4-(2-(dimethylamino) ethyl)-2-methoxy-N4-methyl-5-nitrobenzene-1,4-diamine
Will N1- (4- (1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4Dissolving (0.065g, 0.14mmol) of (-methyl) -5-nitrobenzene-1, 4-diamine (34B) in 10mL of dichloromethane, adding triphenylphosphine (0.074g, 0.28mmol) and 1-cyclopropylethanol (0.012g, 0.14mmol), cooling to 0 ℃ under the protection of nitrogen, dropwise adding diisopropyl azodicarboxylate (DIAD) (56.6mg, 0.28mmol), heating to room temperature for 4 hours, reacting, spin-drying the reaction solution, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-20: 1) to obtain a compound N1- (4- (1- (1-cyclopropylethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4Methyl-5-nitrobenzene-1, 4-diamine (53A), brown solid (0.03g,yield 40.5%).
MS m/z:530.1[M+1]+。
The second step is that: n is a radical of4- (4- (1- (1-cyclopropylethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N 1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (53B)
N4-(4-(1-(1-cyclopropylethyl)-1H-indol-3-yl)pyrimidin-2-yl)-N1-(2-(dimethylamino) ethyl)-5-methoxy-N1-methylbenzene-1,2,4-triamine
Will N1- (4- (1- (1-cyclopropylethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrophenyl-1, 4-diamine (53A) (0.85g, 1.6mmol) was dissolved in 30mL of ethanol, 10mL of water, iron powder (0.538g, 9.6mmol) and ammonium chloride (60mg, 1.1mmol) were added in this order, the temperature was raised to 90 ℃ and the reaction was refluxed for 6 hours. Concentrating the reaction solution, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain a compound N4- (4- (1- (1-cyclopropylethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (53B), brown solid (0.3g, 37.5% yield).
MS m/z:500.1[M+1]+。
The third step: n- (5- ((4- (1- (1-cyclopropylethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 53)
N-(5-((4-(1-(1-cyclopropylethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimeth ylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
Will N4- (4- (1- (1-cyclopropylethyl) -1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (53B) (0.3g, 0.6mmol) was dissolved in 10mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.344g, 1.8mmol) and acrylic acid (0.062mL, 0.9mmol) were added and reacted at room temperature for 4 hours. The reaction solution was spin-dried, and 150mL of ethyl acetate and 4mol/L of hydrogen were added to oxidize Aqueous sodium solution 100mL, liquid separation, aqueous phase with water 100mL ethyl acetate extraction, combined organic phase, 150mL saturated sodium chloride washing once. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 20:1) to give compound N- (5- ((4- (1- (1-cyclopropylethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 53) as a yellow solid (170mg, yield 51.2%).
MS m/z:554.2[M+1]+。
Compound 53 is resolved by high performance liquid chromatography to give two optical isomers: compound 53-1 (peak 1, t ═ 4.50min), compound 53-2 (peak 2, t ═ 5.07 min). Splitting conditions are as follows: detection wavelength: 254nM, column temperature: 30 ℃, mobile phase: acetonitrile and water (0.1% ammonia), and acetonitrile/water 81% and 19% in water.
Example 54
N- (2- (((1-aminocyclopropyl) methyl) (methyl) amino) -4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 54)
N-(2-(((1-aminocyclopropyl)methyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-i ndol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
The first step is as follows: (1- ((tert-Butoxycarbonyl) amino) cyclopropyl) methyl methanesulfonate (54B)
(1-((tert-butoxycarbonyl)amino)cyclopropyl)methyl methanesulfonate
Tert-butyl (1- (hydroxymethyl) cyclopropyl) carbamate (54A) (5g, 26.7mmol) was dissolved in 30mL of dichloromethane, triethylamine (5.4g, 53.4mmol) was added under ice bath, methanesulfonyl chloride (3.36g, 29.4mmol) was added dropwise, the reaction was allowed to proceed at room temperature for 2 hours, and the reaction was continued for 6 hours while warming to room temperature. After completion of the reaction, 150mL of water and 150mL of methylene chloride were added to the reaction mixture, and the mixture was separated. The aqueous phase was extracted once with 100mL of dichloromethane, the organic phases were combined, washed once with 150mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give (1- ((tert-butoxycarbonyl) amino) cyclopropyl) methyl methanesulfonate (54B) as a white solid (4g, 89.3% yield).
MS m/z:288.1[M+23]+。
The second step is that: (1- ((methylamino) methyl) cyclopropyl) carbamic acid tert-butyl ester (54C)
tert-butyl(1-((methylamino)methyl)cyclopropyl)carbamate
(1- ((tert-Butoxycarbonyl) amino) cyclopropyl) methyl methanesulfonate (54B) (3.5g, 13.2mmol) was dissolved in 50mL of tetrahydrofuran, methylamine (615mg, 19.8mmol) was added, and the reaction was carried out at 50 ℃ for 6 hours. After the reaction is finished, the solvent is dried by spinning. 150mL of water and 200mL of ethyl acetate were added, and the mixture was separated. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to give compound (tert-butyl 1- ((methylamino) methyl) cyclopropyl) carbamate (54C) as a white solid (1.1g, 42.3% yield).
MS m/z:201.2[M+1]+。
The third step: (1- (((5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2-nitrophenyl) (methyl) amino) methyl) cyclopropyl) carbamic acid tert-butyl ester (54D)
tert-butyl(1-(((5-methoxy-4-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-nit rophenyl)(methyl)amino)methyl)cyclopropyl)carbamate
5- ((4- (1-methylindol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2-fluoro-1-nitrobenzene (intermediate 3) (1g, 2.54mmol) was dissolved in 15mL of N, N-dimethylacetamide, N-diisopropylethylamine (0.63mL, 3.82mmol) and tert-butyl (1- ((methylamino) methyl) cyclopropyl) carbamate (54C) (764mg, 3.82mmol) were added and reacted at 140 ℃ for 1 hour under microwave. After the reaction was completed, 100mL of methylene chloride and 100mL of water were added, the layers were separated, the aqueous phase was extracted once with 100mL of methylene chloride, the organic phases were combined, washed once with 200mL of saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to give a brown solid compound, tert-butyl 1- (((5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2-nitrophenyl) (methyl) amino) methyl) cyclopropyl) carbamate (54D) (1.1g, yield 91.6%).
MS m/z:574.2[M+1]+。
The fourth step: (1- (((2-amino-5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) (methyl) amino) methyl) cyclopropyl) carbamic acid tert-butyl ester (54E)
tert-butyl(1-(((2-amino-5-methoxy-4-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)ami no)phenyl)(methyl)amino)methyl)cyclopropyl)carbamate
Tert-butyl (1- (((5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2-nitrophenyl) (methyl) amino) methyl) cyclopropyl) carbamate (54D) (1.1g, 1.92mmol) was dissolved in 60mL of ethanol, 20mL of water, iron powder (643mg, 11.5mmol) and ammonium chloride (72mg, 1.34mmol) were added in this order, the temperature was raised to 90 ℃ and the reaction was refluxed for 4 hours. The reaction mixture was cooled to room temperature, filtered, concentrated, and purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to obtain tert-butyl 1- (((2-amino-5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) (methyl) amino) methyl) cyclopropyl) carbamate (54E) (900mg, yield 90%) as a brown solid.
MS m/z:544.2[M+1]+。
The fifth step: (1- (((2-acrylamido-5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) (methyl) amino) methyl) cyclopropyl) carbamic acid tert-butyl ester (54F)
tert-butyl(1-(((2-acrylamido-5-methoxy-4-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl )amino)phenyl)(methyl)amino)methyl)cyclopropyl)carbamate
Tert-butyl (1- (((2-amino-5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) (methyl) amino) methyl) cyclopropyl) carbamate (54E) (900mg, 1.66mmol) was dissolved in 15mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) (955mg, 5mmol) and acrylic acid (0.17mL, 2.48mmol) were added and reacted at room temperature for 2 hours. The reaction mixture was spin-dried, and 100mL of water and 100mL of dichloromethane were added to separate the reaction mixture. The organic phase was washed once with 100mL of a 4mol/L aqueous solution of sodium hydroxide and dried over anhydrous sodium sulfate. Concentration gave tert-butyl (1- (((2-acrylamido-5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) (methyl) amino) methyl) cyclopropyl) carbamate (54F) as a yellow oil (600mg, 60.5% yield).
MS m/z:598.2[M+1]+。
And a sixth step: n- (2- (((1-aminocyclopropyl) methyl) (methyl) amino) -4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 54)
N-(2-(((1-aminocyclopropyl)methyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-i ndol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
Tert-butyl (1- (((2-acrylamido-5-methoxy-4- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) (methyl) amino) methyl) cyclopropyl) carbamate (54F) (600mg, 1mmol) was dissolved in 20mL of dichloromethane and 10mL of trifluoroacetic acid was added to react at room temperature for 3 hours. The reaction mixture was spin-dried, 100mL of water was added, the pH of the solution was adjusted to 8 with saturated sodium bicarbonate, 150mL of dichloromethane was added, and the layers were separated. The aqueous phase was extracted once with 100mL of dichloromethane, the organic phases were combined, washed once with 150mL of saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and subjected to silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give N- (2- (((1-aminocyclopropyl) methyl) (methyl) amino) -4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 54) as a brown solid (450mg, yield 90.5%).
MS m/z:498.1[M+1]+。
1H NMR(400MHz,CDCl3)δ9.88(s,1H),9.65(s,1H),9.07(s,1H),8.38(d,1H), 8.07(d,1H),7.68(s,1H),7.39(d,1H),7.20(d,1H),6.72(s,1H),6.48(dd,2H),5.70(d, 1H),3.99(s,3H),3.88(s,3H),2.80(s,3H),2.73(d,2H),1.55(m,4H)。
Example 55
N- (5- ((4- (1- (cyclopropylcarbonyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 55)
N-(5-((4-(1-(cyclopropanecarbonyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dim ethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
The first step is as follows: cyclopropyl (3- (2- ((4- ((2- (dimethylamino) ethyl) (methyl) amino) -2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1H-indol-1-yl) methanone (55A)
cyclopropyl(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5-nitrophe nyl)amino)pyrimidin-4-yl)-1H-indol-1-yl)methanone
Will N1- (4- (1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenzene-1, 4-diamine (34B) (1g, 2.17mmol) was dissolved in 20mL tetrahydrofuran, N-diisopropylethylamine (0.42g, 3.25mmol) was added, cooled to 0 ℃ under nitrogen, cyclopropanecarbonyl chloride (0.3mL, 3.25mmol) was added dropwise, the reaction was allowed to proceed at 0 ℃ for 1 hour, and the reaction was allowed to warm to room temperature for 1 hour. After completion of the reaction, 10mL of water was added to quench the reaction, the reaction mixture was spin-dried, 100mL of water and 100mL of dichloromethane were added, and the mixture was separated. The aqueous phase was extracted once with 100mL of dichloromethane. The organic phases were combined, washed once with 100mL of saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to give the compound cyclopropyl (3- (2- ((4- ((2- (dimethylamino) ethyl) (methyl) amino) -2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1H-indol-1-yl) methanone (55A) as a brown solid (1g, 87% yield).
MS m/z=530.1[M+1]+。
The second step is that: (3- (2- ((5-amino-4- ((2- (dimethylamino) ethyl) (methyl) amino) -2-methoxyphenyl) amino) pyrimidin-4-yl) -1H-indol-1-yl) (cyclopropyl) methanone (55B)
(3-(2-((5-amino-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino )pyrimidin-4-yl)-1H-indol-1-yl)(cyclopropyl)methanone
Cyclopropyl (3- (2- ((4- ((2- (dimethylamino) ethyl) (methyl) amino) -2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1H-indol-1-yl) methanone (55A) (1g, 1.89mmol) was dissolved in 30mL of ethanol, 10mL of water was added, followed by iron powder (0.633g, 11.3mmol) and ammonium chloride (71mg, 1.32mmol), the mixture was heated to 90 ℃ and refluxed for 6 hours. The reaction solution was concentrated, and separated and purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to obtain a compound (3- (2- ((5-amino-4- ((2- (dimethylamino) ethyl) (methyl) amino) -2-methoxyphenyl) amino) pyrimidin-4-yl) -1H-indol-1-yl) (cyclopropyl) methanone (55B) as a brown solid (0.5g, yield 53%).
The third step: n- (5- ((4- (1- (cyclopropylcarbonyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 55)
N-(5-((4-(1-(cyclopropanecarbonyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dim ethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
(3- (2- ((5-amino-4- ((2- (dimethylamino) ethyl) (methyl) amino) -2-methoxyphenyl) amino) pyrimidin-4-yl) -1H-indol-1-yl) (cyclopropyl) methanone (55B) (0.5g, 1mmol) was dissolved in 10mL of pyridine, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.573g, 3mmol) was added, acrylic acid (0.103mL, 1.5mmol) was added, and the reaction was allowed to proceed at room temperature for 3 hours. The reaction mixture was spin-dried, 150mL of ethyl acetate and 100mL of 4mol/L aqueous sodium hydroxide solution were added, the mixture was separated, and the aqueous phase was extracted once with 100mL of ethyl acetate. The organic phases were combined, washed once with 150mL of a saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and purified by column chromatography on silica gel (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give N- (5- ((4- (1- (cyclopropylcarbonyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 55) as a pale yellow solid (60mg, yield 11.3%).
MS m/z:554.4[M+1]+。
Example 56
N- (3- ((5-chloro-4- (6- (4- (2-hydroxyethyl) piperazin-1-yl) -1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 56)
N-(3-((5-chloro-4-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-1-methyl-1H-indol-3-yl)pyri midin-2-yl)amino)-4-methoxyphenyl)acrylamide
The first step is as follows: n- (3- ((5-chloro-4- (1-methyl-6- (piperazin-1-yl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (56A)
N-(3-((5-chloro-4-(1-methyl-6-(piperazin-1-yl)-1H-indol-3-yl)pyrimidin-2-yl)amino)- 4-methoxyphenyl)acrylamide
Tert-butyl 4- (3- (2- ((5-acrylamido-2-methoxyphenyl) amino) -5-chloropyrimidin-4-yl) -1-methyl-1H-indol-6-yl) piperazine-1-carboxylate (compound 26) (0.40g,0.65mmol) was placed in a 50mL round-bottom flask. To the reaction flask were added dichloromethane (10mL) and trifluoroacetic acid (5mL) in this order at 0 ℃. The reaction was warmed to room temperature and stirred for 2 hours. To the residue was added dichloromethane (50mL), saturated aqueous sodium bicarbonate (20mL), the layers were separated, the aqueous phase was extracted with dichloromethane (50mL), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give N- (3- ((5-chloro-4- (1-methyl-6- (piperazin-1-yl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (56A) as a yellow oil (0.335 g).
The second step is that: n- (3- ((5-chloro-4- (6- (4- (2-hydroxyethyl) piperazin-1-yl) -1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 56)
N-(3-((5-chloro-4-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-1-methyl-1H-indol-3-yl)pyri midin-2-yl)amino)-4-methoxyphenyl)acrylamide
N- (3- ((5-chloro-4- (1-methyl-6- (piperazin-1-yl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (56A) (0.16g, 0.31mmol) was dissolved in 40mL of acetonitrile, and potassium carbonate (86mg,0.62 mmol) and bromoethanol (58.1mg, 0.47mmol) were added, followed by reaction at 60 ℃ for 3 hours. After the reaction, the solvent was dried by spinning, 100mL of water and 100mL of dichloromethane were added, the mixture was separated, the aqueous phase was extracted with 100mL of dichloromethane, and the organic phases were combined, washed with 150mL of saturated brine, and dried over anhydrous sodium sulfate. Concentration and purification of the residue by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) gave N- (3- ((5-chloro-4- (6- (4- (2-hydroxyethyl) piperazin-1-yl) -1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 56) as a yellow solid (150mg, yield 86.2%).
LC-MS m/z:562.3[M+1]+。
Example 57
N- (5- ((4- (1H-pyrrolo [2,3-b ] pyridin-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 57)
N-(5-((4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino )ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
The first step is as follows: 3- (2-Chloropyrimidin-4-yl) -1H-pyrrolo [2,3-B ] pyridine (57B)
3-(2-chloropyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridine
7-azaindole (57A) (6g,50.8mmol) was dissolved in 100mL tetrahydrofuran, cooled to 0 ℃ under nitrogen, methylmagnesium bromide (17mL,50.8mmol) was added dropwise, and stirring was continued for 0.5 h. 2, 4-dichloropyrimidine (7.6g, 50.8mmol) was added, the reaction was carried out at room temperature for 1 hour, and the reaction was continued for 2 hours while the temperature was raised to 60 ℃. To the reaction mixture were added 30mL of methanol and 20mL of acetic acid, the solvent was evaporated, the reaction mixture was washed with 200mL of water and 10mL of tetrahydrofuran, and the mixture was dried to give 3- (2-chloropyrimidin-4-yl) -1H-pyrrolo [2,3-B ] pyridine (57B) as a yellow solid (10g, 86.2% yield).
LC-MS(m/z):231.0[M+1]+。
The second step is that: n- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1H-pyrrolo [2,3-b ] pyridin-3-yl) pyrimidin-2-amine (57C)
N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2- amine
3- (2-Chloropyrimidin-4-yl) -1H-pyrrolo [2,3-B ] pyridine (57B) (2g, 8.7mmol) was dissolved in 20mL of 2-pentanol, 4-fluoro-2-methoxy-5-nitroaniline (4e) (1.62g, 8.7mmol) and p-toluenesulfonic acid monohydrate (2g, 10.4mmol) were added, and the reaction was heated to 120 ℃ for 18 hours under reflux. The reaction was cooled to room temperature, 50mL of aqueous ammonia was added, the mixture was filtered, and the filter cake was washed with 100mL of water. Oven dried to give N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1H-pyrrolo [2,3-b ] pyridin-3-yl) pyrimidin-2-amine (57C) as a yellow solid (2.3g, 69.7% yield).
LC-MS(m/z):381.0[M+1]+。
The third step: n is a radical of1- (4- (1H-pyrrolo [2,3-b ]]Pyridin-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenzo-1, 4-diamine (57D)
N1-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)-N4-(2-(dimethylamino)ethyl)-2 -methoxy-N4-methyl-5-nitrobenzene-1,4-diamine
Reacting N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (1H-pyrrolo [2, 3-b)]Pyridin-3-yl) pyrimidin-2-amine (57C) (2.5g, 6.58mmol) was dissolved in 15mL of N, N-dimethylacetamide, and N, N-diisopropylethylamine (1.02g, 7.9mmol) and N, N, N' -trimethylethylenediamine (18A) (807mg, 7.89mmol) were added and reacted at 120 ℃ for 1.5 hours under microwave. After the reaction is finished, the solvent is dried by spinning. Separating and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-10: 1), Obtaining a reddish brown solid N1- (4- (1H-pyrrolo [2,3-b ]]Pyridin-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenzo-1, 4-diamine (57D) (1g, 33.3% yield).
LC-MS(m/z):463.1[M+1]+。
The fourth step: n is a radical of4- (4- (1H-pyrrolo [2,3-b ]]Pyridin-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzo-1, 2, 4-triamine (57E)
N4-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)-N1-(2-(dimethylamino)ethyl)-5 -methoxy-N1-methylbenzene-1,2,4-triamine
Will N1- (4- (1H-pyrrolo [2,3-b ]]Pyridin-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenzo-1, 4-diamine (57D) (1g, 2.11mmol) was dissolved in 30mL of ethanol, 10mL of water, iron powder (362mg, 6.44mmol) and ammonium chloride (81mg, 1.5mmol) were added in this order, and the mixture was heated to 90 ℃ and reacted under reflux for 6 hours. The reaction was cooled to room temperature, filtered and concentrated. Separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain brown solid N4- (4- (1H-pyrrolo [2,3-b ]]Pyridin-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzo-1, 2, 4-triamine (57E) (933 mg).
LC-MS(m/z):433.1[M+1]+。
The fifth step: n- (5- ((4- (1H-pyrrolo [2,3-b ] pyridin-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 57)
N-(5-((4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino )ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
Will N4- (4- (1H-pyrrolo [2,3-b ]]Pyridin-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzo-1, 2, 4-triamine (57E) (500mg, 1.16mmol) was dissolved in 15mL pyridine, and 1 was added- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (665mg, 3.48mmol) and acrylic acid (0.12mL, 1.74 mmol) were reacted at room temperature for 6 hours. The pyridine was spin-dried, 100mL of water and 100mL of dichloromethane were added, and the layers were separated. The organic phase was washed with a 4mol/L aqueous solution of sodium hydroxide (100mL) and dried over anhydrous sodium sulfate. Separating and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-10: 1) to obtain white solid N- (5- ((4- (1H-pyrrolo [2, 3-b))]Pyridin-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 57) (330mg, 58.5% yield).
LC-MS(m/z):487.1[M+1]+。
1H NMR(400MHz,DMSO-d6)δ10.07(s,1H),9.03(s,1H),8.88(s,1H),8.37– 8.32(m,1H),8.31(d,1H),8.01(dd,1.7Hz,1H),7.18(dd,4.7Hz,1H),7.01(s,1H),6.76 (s,1H),6.64(d,1H),6.43(dd,10.1Hz,1H),6.25(dd,1.9Hz,1H),5.80–5.71(m,1H), 3.87(d,3H),2.88(t,2H),2.75–2.67(m,3H),2.32(t,2H),2.19(d,6H)。
Example 58
N- (3- ((4- (1H-pyrrolo [2,3-b ] pyridin-3-yl) pyridin-2-yl) amino) -4-methoxyphenyl) acrylamide (Compound 58)
N-(3-((4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acr ylamide
The first step is as follows: n- (2-methoxy-5-nitrophenyl) -4- (1H-pyrrolo [2,3-b ] pyridin-3-yl) pyrimidin-2-amine (58A)
N-(2-methoxy-5-nitrophenyl)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
3- (2-Chloropyrimidin-4-yl) -1H-pyrrolo [2,3-B ] pyridine (57B) (2g, 8.7mmol) was dissolved in 2-pentanol (30mL), the compound 2-methoxy-5-nitroaniline (1.46g, 8.7mmol) and p-toluenesulfonic acid (2g, 10.44 mmol) were added, and the reaction was heated to 120 ℃ for 18 hours under reflux. The reaction was cooled to room temperature, 50mL of aqueous ammonia was added, filtered, and the filter cake was washed with 100mL of water and dried to give N- (2-methoxy-5-nitrophenyl) -4- (1H-pyrrolo [2,3-b ] pyridin-3-yl) pyrimidin-2-amine (58A) (2.5g, 80.6% yield) as a yellow solid.
LC-MS(m/z):363.1[M+1]+。
The second step is that: n is a radical of1- (4- (1H-pyrrolo [2,3-b ]]Pyridin-3-yl) pyrimidin-2-yl) -6-methoxybenzo-1, 3-triamine (58B)
N1-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)-6-methoxybenzene-1,3-diamine
Reacting N- (2-methoxy-5-nitrophenyl) -4- (1H-pyrrolo [2, 3-b)]Pyridin-3-yl) pyrimidin-2-amine (58A) (0.5g, 1.38mmol) was dissolved in 100mL of methanol, palladium on carbon (0.15g, 30%) was added, and the mixture was replaced with hydrogen atmosphere three times and reacted at room temperature for 8 hours. After completion of the reaction, the reaction mixture was filtered through celite, washed with dichloromethane (50mL) and methanol (50mL), and concentrated to give N as a red-brown solid1- (4- (1H-pyrrolo [2,3-b ]]Pyridin-3-yl) pyrimidin-2-yl) -6-methoxybenzo-1, 3-triamine (58B) (0.458 g).
The third step: n- (3- ((4- (1H-pyrrolo [2,3-b ] pyridin-3-yl) pyridin-2-yl) amino) -4-methoxyphenyl) propenamide (Compound 58)
N-(3-((4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acr ylamide
Will N1- (4- (1H-pyrrolo [2,3-b ]]Pyridin-3-yl) pyrimidin-2-yl) -6-methoxybenzo-1, 3-triamine (58B) (0.458mg, 1.38mmol) was dissolved in 15mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (527mg, 2.76mmol) and acrylic acid (0.14mL, 2.07mmol) were added to react at room temperature for 6 hours. The pyridine was spin-dried, 100mL of water and 100mL of dichloromethane were added, and the layers were separated. Washing the organic phase with 4mol/L sodium hydroxide aqueous solution (100mL), drying with anhydrous sodium sulfate, filtering, concentrating, separating and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-10: 1) to obtain white solid N- (3- ((4- (1H-pyrrolo [2,3-b ] of N- (3-methyl) pyrrole) ]Pyridin-3-yl) pyridin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 58) (230mg, 43.2% yield).
LC-MS(m/z):387.0[M+1]+。
1H NMR(400MHz,DMSO-d6)δ9.96(s,1H),9.11(s,1H),8.62(s,1H),8.38–8.32 (m,1H),8.27(d,1H),8.02(dd,1H),7.34(dd,1H),7.19(dd,1H),7.06(d,1H),6.84(d,, 1H),6.67(d,1H),6.46(dd,1H),6.26(dd,1H),5.75(dd,1H),3.85(s,3H)。
Example 59
N- (4-methoxy-3- ((4- (1-methyl-1H-pyrrolo [2,3-b ] pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 59)
N-(4-methoxy-3-((4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino) phenyl)acrylamide
The first step is as follows: n- (2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-pyrrolo [2,3-b ] pyridin-3-yl) pyrimidin-2-amine (59A)
N-(2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2 -amine
N- (2-methoxy-5-nitrophenyl) -4- (1H-pyrrolo [2,3-b ] pyridin-3-yl) pyrimidin-2-amine (58A) (0.4g, 1.1mmol) was dissolved in 20mL of tetrahydrofuran, cooled to 0 deg.C, sodium hydride (0.053g, 2.2mmol) was added, reacted for 30 minutes, iodomethane (0.2mL, 3.3mmol) was added, and reacted at room temperature for 4 hours. After the reaction, 60mL of water was added to precipitate a solid, which was washed with 100mL of water and 50mL of petroleum ether and dried to give N- (2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-pyrrolo [2,3-b ] pyridin-3-yl) pyrimidin-2-amine (59A) (0.413g) as a yellow solid.
The second step is that: n is a radical of1- (4- (1H-pyrrolo [2,3-b ]]Pyridin-3-yl) pyrimidin-2-yl) -6-methoxybenzo-1, 3-diamine (59B)
N1-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)-6-methoxybenzene-1,3-diamine
Reacting N- (2-methoxy-5-nitrophenyl) -4- (1-methyl-1H-pyrrolo [2, 3-b)]Pyridin-3-yl) pyrimidin-2-amine (59A) (0.5g,1.33mmol) was dissolved in 50mL of methanol, palladium on carbon (0.15g, 30%) was added, and the mixture was replaced with hydrogen atmosphere three times and reacted at room temperature for 1 day. After the reaction, the reaction mixture was washed with celite Filtration, washing with dichloromethane (100mL) and methanol (100mL), and concentration afforded N as a yellow solid1- (4- (1H-pyrrolo [2,3-b ]]Pyridin-3-yl) pyrimidin-2-yl) -6-methoxybenzo-1, 3-diamine (59B) (0.46 g).
LC-MS(m/z):347.1[M+1]+。
The third step: n- (4-methoxy-3- ((4- (1-methyl-1H-pyrrolo [2,3-b ] pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 59)
N-(4-methoxy-3-((4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino) phenyl)acrylamide
Will N1- (4- (1H-pyrrolo [2,3-b ]]Pyridin-3-yl) pyrimidin-2-yl) -6-methoxybenzo-1, 3-diamine (59B) (0.46mg, 1.33mmol) was dissolved in 15mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (762mg, 4mmol) and acrylic acid (0.14mL, 2mmol) were added to react at room temperature for 6 days. The pyridine was spin-dried, 100mL of water and 100mL of dichloromethane were added, and the layers were separated. Washing the organic phase with 4mol/L sodium hydroxide aqueous solution (100mL), drying with anhydrous sodium sulfate, filtering, concentrating, separating and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-10: 1) to obtain brown solid N- (4-methoxy-3- ((4- (1-methyl-1H-pyrrolo [2, 3-b): brown solid]Pyridin-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 59) (400mg, 75.2% yield).
LC-MS(m/z):401.1[M+1]+。
Example 60
N- (5- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl) acrylamide (compound 60)
N-(5-((4-(1-(difluoromethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(2-( 4-methylpiperazin-1-yl)ethoxy)phenyl)acrylamide
The first step is as follows: 4- (1- (difluoromethyl) -1H-indol-3-yl) -N- (2-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) -5-nitrophenyl) pyrimidin-2-amine (60A)
4-(1-(difluoromethyl)-1H-indol-3-yl)-N-(2-methoxy-4-(2-(4-methylpiperazin-1-yl)eth oxy)-5-nitrophenyl)pyrimidin-2-amine
4- (1- (difluoromethyl) -1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (30B) (1g, 2.33mmol) was dissolved in 30mL of tetrahydrofuran, sodium hydride (112mg, 4.66mmol) was slowly added, stirred for 30 minutes, 2- (4-methylpiperazin-1-yl) ethanol (672mg, 4.66mmol) was added, and the reaction was carried out at room temperature for 4 hours. After completion of the reaction, 150mL of water and 150mL of methylene chloride were added and the mixture was separated. The organic phase was dried over anhydrous sodium sulfate and concentrated to give 4- (1- (difluoromethyl) -1H-indol-3-yl) -N- (2-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) -5-nitrophenyl) pyrimidin-2-amine (60A) (1.2g, 93.0% yield) as a yellow solid.
LC-MS(m/z)=554.3[M+1]+。
The second step is that: n is a radical of1- (4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) benzo-1, 3-diamine (60B)
N1-(4-(1-(difluoromethyl)-1H-indol-3-yl)pyrimidin-2-yl)-6-methoxy-4-(2-(4-methylpi perazin-1-yl)ethoxy)benzene-1,3-diamine
4- (1- (difluoromethyl) -1H-indol-3-yl) -N- (2-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) -5-nitrophenyl) pyrimidin-2-amine (60A) (1.2g, 2.17mmol) was dissolved in 30mL of ethanol, 10mL of water, iron powder (727mg, 13mmol) and ammonium chloride (81.3mg, 1.52mmol) were added, and the mixture was heated to 90 ℃ for 4 hours under reflux. Concentrating the reaction solution, and separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain brown solid N 1- (4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) benzo-1, 3-diamine (60B) (740mg, 65.5% yield).
The third step: n- (5- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl) acrylamide (compound 60)
N-(5-((4-(1-(difluoromethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(2-( 4-methylpiperazin-1-yl)ethoxy)phenyl)acrylamide
Will N1- (4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- (2- (4-methylpiperazin-1-yl) ethoxy) benzo-1, 3-diamine (60B) (740mg, 1.4mmol) was dissolved in 20mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (802mg, 4.2mmol) and acrylic acid (0.146mL, 2.1mmol) were added and reacted at room temperature for 4 hours. The reaction mixture was spin-dried with 150mL of water and 150mL of dichloromethane, and the mixture was separated. The organic phase was washed with 4mol/L aqueous sodium hydroxide (100mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give N- (5- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (2- (4-methylpiperazin-1-yl) ethoxy) phenyl) acrylamide (compound 60) (200mg, yield 24.8%) as a white solid.
LC-MS(m/z)=578.3[M+1]+。
1H NMR(400MHz,CDCl3)δ9.68(s,1H),9.34(s,1H),8.59(s,1H),8.44(d,1H), 8.04(dd,1H),7.78(s,1H),7.67(s,1H),7.35(dd,2H),7.22(d,1H),6.62(s,1H),6.43(m, 2H),5.79(d,1H),4.19(t,2H),3.90(s,3H),2.80–2.74(m,2H),2.69(s,4H),2.62(s,4H), 2.38(s,3H)。
Example 61
N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((4- (7-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 61)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(7-methyl-1H-indol- 3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
The first step is as follows: 3- (2-Chloropyrimidin-4-yl) -7-methyl-1H-indole (61B)
3-(2-chloropyrimidin-4-yl)-7-methyl-1H-indole
7-methylindole (61A) (10g, 76.2mmol) was dissolved in 100mL 1, 2-dichloroethane, cooled to 0 ℃ under nitrogen, methylmagnesium bromide (25.4mL, 76.2mmol) was added dropwise, and stirring was continued for 0.5 h. 2, 4-dichloropyrimidine (11.4g, 76.2mmol) was added, the reaction was carried out at room temperature for 40 minutes, and the reaction was carried out at 60 ℃ for 8 hours. 20mL of methanol and 20mL of acetic acid were added and the reaction was carried out for 20 minutes, the solvent was evaporated, a solid was precipitated, the solid was washed with 200mL of water and 50mL of petroleum ether, and the cake was dried with an infrared lamp to give 3- (2-chloropyrimidin-4-yl) -7-methyl-1H-indole (61B) (12g, yield 64.9%) as a yellow solid.
LC-MS(m/z):244.0[M+1]+。
The second step is that: n- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (7-methyl-1H-indol-3-yl) pyrimidin-2-amine (61C)
N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(7-methyl-1H-indol-3-yl)pyrimidin-2-amine
3- (2-Chloropyrimidin-4-yl) -7-methyl-1H-indole (61B) (4.2g, 17.28mmol) was dissolved in 80mL 2-pentanol, 4-fluoro-2-methoxy-5-nitroaniline (4e) (3.2g, 17.28mmol) and p-toluenesulfonic acid monohydrate (3.98g, 20.7mmol) were added, and the reaction was heated to 120 ℃ for 3 days under reflux. Cooled to room temperature, 200mL of ammonia was added, the solid precipitated, filtered, and the filter cake washed with 200mL of water and 100mL of petroleum ether. Oven dried to give N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (7-methyl-1H-indol-3-yl) pyrimidin-2-amine (61C) as a dark green solid (4.5g, 66.3% yield).
LC-MS(m/z):394.1[M+1]+。
1H NMR(400MHz,DMSO-d6)δ11.85(s,1H),9.15(d,1H),8.39(d,1H),8.36(d, 1H),8.23(s,1H),8.19(d,1H),7.41(d,1H),7.38–7.32(m,1H),7.04–6.96(m,2H), 4.07–4.00(m,3H),3.31(s,3H),2.50(d,6H)。
The third step: n is a radical of1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (7-methyl-1H-indol-3-yl) pyrimidin-2-yl) -2-nitrobenzo-1, 4-diamine (61D)
N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(7-methyl-1H-indol-3-yl)p yrimidin-2-yl)-2-nitrobenzene-1,4-diamine
N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (7-methyl-1H-indol-3-yl) pyrimidin-2-amine (61C) (2.5g, 6.35mmol) was dissolved in N, N-dimethylacetamide (10mL), N, N-diisopropylethylamine (986mg, 7.63mmol) and N, N, N' -trimethylethylenediamine (18A) (780mg, 7.63mmol) were added, and the mixture was reacted at 120 ℃ for 1.5 hours under microwave. After the reaction is finished, concentrating, separating and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-10: 1) to obtain brown solid N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (7-methyl-1H-indol-3-yl) pyrimidin-2-yl) -2-nitrobenz-1, 4-diamine (61D) (2.1g, 70% yield).
LC-MS(m/z):476.3[M+1]+。
The fourth step: n is a radical of1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (7-methyl-1H-indol-3-yl) pyrimidin-2-yl) benzo-1, 2, 4-triamine (61E)
N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(7-methyl-1H-indol-3-yl)p yrimidin-2-yl)benzene-1,2,4-triamine
Will N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (7-methyl-1H-indol-3-yl) pyrimidin-2-yl) -2-nitrobenz-1, 4-diamine (61D) (1.3g, 2.74mmol) was dissolved in 30mL of ethanol, 10mL of water, iron powder (0.918g, 16.4mmol) and ammonium chloride (102.7mg, 1.92mmol) were added, and the mixture was heated to 90 ℃ and reacted under reflux for 4 hours. Concentrating the reaction solution, and separating and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-10: 1) to obtain brown solid N 1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (7-methyl-1H-indol-3-yl) pyrimidin-2-yl) benzo-1, 2, 4-triamine (61E) (0.8g, 66.7% yield).
LC-MS(m/z):446.1[M+1]+。
The fifth step: n- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((4- (7-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 61)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(7-methyl-1H-indol- 3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
Will N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (7-methyl-1H-indol-3-yl) pyrimidin-2-yl) benzo-1, 2, 4-triamine (61E) (0.8g, 1.mmol) was dissolved in 15mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (1.03g, 5.4mmol) and acrylic acid (0.19mL, 2.7mmol) were added in this order to react at room temperature for 4 hours. Pyridine was dried by spinning, 150mL of dichloromethane and 4mol/L aqueous sodium hydroxide solution (100mL) were added, the solution was separated, the aqueous phase was extracted once with 150mL of dichloromethane, the organic phases were combined, washed once with 200mL of saturated sodium chloride, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1:0 to 10:1) to give N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((4- (7-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 61) (400mg, yield 44.5%) as a yellow solid.
LC-MS(m/z):500.2[M+1]+。
1H NMR(400MHz,CDCl3)δ10.21(s,1H),9.81(s,1H),9.25(s,1H),8.89(s,1H), 8.37(d,1H),7.95(d,1H),7.69(s,1H),7.16(d,1H),7.14–7.08(m,1H),6.80(s,1H), 6.51(dd,1.4Hz,1H),6.37(s,1H),5.69(d,1H),3.88(d,3H),2.91(s,2H),2.84(s,2H), 2.71(s,3H),2.49(s,3H),2.26(s,6H),1.73(s,2H)。
Example 62
N- (5- ((4- (1, 7-dimethyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 62)
N-(5-((4-(1,7-dimethyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)et hyl)(methyl)amino)-4-methoxyphenyl)acrylamide
The first step is as follows: 3- (2-Chloropyrimidin-4-yl) -1, 7-dimethyl-1H-indole (62A)
3-(2-chloropyrimidin-4-yl)-1,7-dimethyl-1H-indole
3- (2-Chloropyrimidin-4-yl) -7-methyl-1H-indole (61B) (10g, 41.1mmol) was dissolved in 100mL of tetrahydrofuran, cooled to 0 deg.C, sodium hydride (3.3g, 82.2mmol) was added, the reaction was carried out at 0 deg.C for 30 minutes, methyl iodide (17.5g, 123.4mmol) was added, and the reaction was allowed to warm to room temperature for 1 hour. At the end of the reaction, the solvent was spun off, the solid was washed with 200mL of water and 50mL of petroleum ether and dried to give 3- (2-chloropyrimidin-4-yl) -1, 7-dimethyl-1H-indole (62A) (10g, 95.2% yield) as a reddish brown solid.
The second step is that: 4- (1, 7-dimethyl-1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (62B)
4-(1,7-dimethyl-1H-indol-3-yl)-N-(4-fluoro-2-methoxy-5-nitrophenyl)pyrimidin-2-a mine
3- (2-Chloropyrimidin-4-yl) -1, 7-dimethyl-1H-indole (62A) (5g, 19.4mmol) was dissolved in 100mL 2-pentanol, 4-fluoro-2-methoxy-5-nitroaniline (4e) (3.62g, 19.4mmol) and p-toluenesulfonic acid monohydrate (4.47g, 23.3mmol) were added, and the reaction was heated to 120 ℃ for 3 days under reflux. Cooled to room temperature, added with 200mL of ammonia, precipitated a solid, filtered, and the filter cake was washed with 200mL of water and 100mL of petroleum ether in that order and dried to give 4- (1, 7-dimethyl-1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (62B) (6g, 75.9% yield) as a yellow solid.
LC-MS(m/z):408.0[M+1]+。
1H NMR(400MHz,DMSO-d6)δ9.11(d,1H),8.38(d,1H),8.24(d,3H),7.34(d, 1H),7.27(d,1H),7.01–6.92(m,2H),4.14(s,3H),4.02(s,3H),2.76(s,3H)。
The third step: n is a radical of1- (4- (1, 7-dimethyl-1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenz-1, 4-amine (62C)
N1-(4-(1,7-dimethyl-1H-indol-3-yl)pyrimidin-2-yl)-N4-(2-(dimethylamino)ethyl)-2-m ethoxy-N4-methyl-5-nitrobenzene-1,4-diamine
4- (1, 7-dimethyl-1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (62B) (3g, 7.37mmol) was dissolved in 10mL of N, N-dimethylacetamide, and N, N-diisopropylethylamine (1.14g, 8.84mmol) and N, N, N' -trimethylethylenediamine (18A) (904mg, 8.84mmol) were added and reacted at 120 ℃ for 1.5 hours under microwave. After completion of the reaction, 150mL of water and 150mL of methylene chloride were added and the mixture was separated. The aqueous phase was extracted with 150mL of dichloromethane, and the organic phases were combined and washed with 200mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to give brown solid N1- (4- (1, 7-dimethyl-1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenz-1, 4-amine (62C) (3.6 g).
LC-MS(m/z):490.2[M+1]+。
The fourth step: n is a radical of4- (4- (1, 7-dimethyl-1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzo-1, 2, 4-triamine (62D)
N4-(4-(1,7-dimethyl-1H-indol-3-yl)pyrimidin-2-yl)-N1-(2-(dimethylamino)ethyl)-5-m ethoxy-N1-methylbenzene-1,2,4-triamine
Will N1- (4- (1, 7-dimethyl-1H-indol-3-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenz-1, 4-amine (62C) (3.6g, 7.36mmol) was dissolved in 30mL ethanol, 10mL water, iron powder (2.46 g, 44.1mmol) and ammonium chloride (273mg, 5.1mmol) were added, and the reaction was refluxed at 90 ℃ for 4 hours. Concentrating the reaction solution, and separating and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-10: 1) to obtain yellow solid N 4- (4- (1, 7-dimethyl-1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzo-1, 2, 4-triamine (62D) (2.3mg, 69.7% yield).
LC-MS(m/z):460.1[M+1]+。
The fifth step: n- (5- ((4- (1, 7-dimethyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 62)
N-(5-((4-(1,7-dimethyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)et hyl)(methyl)amino)-4-methoxyphenyl)acrylamide
Will N4- (4- (1, 7-dimethyl-1H-indol-3-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzo-1, 2, 4-triamine (62D) (1.66g, 3.62mmol) was dissolved in 30mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (2.07g, 10.85mmol) and acrylic acid (0.38mL, 5.43mmol) were added in this order to react at room temperature for 6 hours. After the pyridine was dried by spinning, a 4mol/L aqueous solution of sodium hydroxide (200mL) and 200mL of methylene chloride were added to separate the layers. The organic phase was washed once with 100mL of saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and purified by column chromatography on silica gel (dichloromethane/methanol (v/v) ═ 1:0 to 10:1) to give N- (5- ((4- (1, 7-dimethyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 62) (1g, yield 53.8%) as a brown solid.
LC-MS(m/z):514.2[M+1]+。
Example 63
N- (4-methoxy-3- ((4- (2-methyl-1H-benzo [ d ] imidazol-1-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 63)
N-(4-methoxy-3-((4-(2-methyl-1H-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phen yl)acrylamide
The first step is as follows: 1- (2-Chloropyrimidin-4-yl) -2-methyl-1H-benzo [ d ] imidazole (63B)
1-(2-chloropyrimidin-4-yl)-2-methyl-1H-benzo[d]imidazole
2-methylbenzimidazole (63A) (6.6g, 50mmol) was dissolved in 100mL of N, N-dimethylformamide, cooled to 0 ℃ under nitrogen, sodium hydride (2.4g, 60mmol) was added, stirring was continued for 0.5 h, 2, 4-dichloropyrimidine (7.5g, 50mmol) was added, and the reaction was allowed to proceed at room temperature for 10 h. 250mL of water was added to precipitate a solid, which was filtered, and the filter cake was washed with 200mL of water and 100mL of petroleum ether and dried to give 1- (2-chloropyrimidin-4-yl) -2-methyl-1H-benzo [ d ] imidazole (63B) (23g) as a white solid.
LC-MS(m/z):245.0[M+1]+。
1H NMR(400MHz,CDCl3)δ8.69(d,1H),8.36–8.27(m,1H),7.76–7.68(m,1H), 7.36–7.31(m,2H),7.26(s,1H),2.99(s,3H)。
The second step is that: n- (2-methoxy-5-nitrophenyl) -4- (2-methyl-1H-benzo [ d ] imidazol-1-yl) pyrimidin-2-amine (63C)
N-(2-methoxy-5-nitrophenyl)-4-(2-methyl-1H-benzo[d]imidazol-1-yl)pyrimidin-2-am ine
1- (2-Chloropyrimidin-4-yl) -2-methyl-1H-benzo [ d ] imidazole (63B) (2.44g, 10mmol) was dissolved in 30mL 2-pentanol, 2-methoxy-5-nitroaniline (1.68g, 10mmol) and p-toluenesulfonic acid (1.92g, 10mmol) were added, and the reaction was heated to 120 ℃ for 3 days under reflux. Cooled to room temperature, 100mL of aqueous ammonia was added, the solid precipitated, filtered, and the filter cake washed with 250mL of water and 100mL of petroleum ether and dried to give N- (2-methoxy-5-nitrophenyl) -4- (2-methyl-1H-benzo [ d ] imidazol-1-yl) pyrimidin-2-amine (63C) as a yellow solid (2.7g, 71.8% yield).
LC-MS(m/z):377.0[M+1]+。
The third step: n is a radical of1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (2-methyl-1H-benzo [ d ]]Imidazol-1-yl) pyrimidin-2-yl) -2-nitrobenzo-1, 4-diamine (63D)
N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(2-methyl-1H-benzo[d]imi dazol-1-yl)pyrimidin-2-yl)-2-nitrobenzene-1,4-diamine
Reacting N- (2-methoxy-5-nitrophenyl) -4- (2-methyl-1H-benzo [ d]Imidazol-1-yl) pyrimidin-2-amine (63C) (1g, 2.6mmol) was dissolved in 20mL of methanol, and palladium on carbon (0.334g, 30%) was added and the mixture was replaced with hydrogen atmosphere three times to conduct a reaction at room temperature for 3 hours. After the reaction was complete, the mixture was filtered through Celite and washed with 50mL of methanol. Concentrating the filtrateConcentrating, separating and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-50: 1), and obtaining yellow solid N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (2-methyl-1H-benzo [ d ]]Imidazol-1-yl) pyrimidin-2-yl) -2-nitrobenzo-1, 4-diamine (63D) (0.6g, 65.9% yield).
LC-MS(m/z):347.1[M+1]+。
The fourth step: n- (4-methoxy-3- ((4- (2-methyl-1H-benzo [ d ] imidazol-1-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 63)
N-(4-methoxy-3-((4-(2-methyl-1H-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phen yl)acrylamide
Will N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (2-methyl-1H-benzo [ d ]]Imidazol-1-yl) pyrimidin-2-yl) -2-nitrobenz-1, 4-diamine (63D) (0.6g, 1.73mmol) was dissolved in 15mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.993g, 5.2mmol) and acrylic acid (0.18mL, 2.6mmol) were added in that order and reacted at room temperature for 4 hours. Drying pyridine, adding 100mL ethyl acetate and 100mL 4mol/L sodium hydroxide aqueous solution, separating, drying the organic phase with anhydrous sodium sulfate, filtering, concentrating, and separating and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-50: 1) to obtain white solid N- (4-methoxy-3- ((4- (2-methyl-1H-benzo [ d ] b) ]Imidazol-1-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 63) (150mg, 21.7% yield).
LC-MS(m/z):401.1[M+1]+。
1H NMR(400MHz,CDCl3)δ8.39(d,1H),8.33(s,1H),8.18–8.14(m,1H),7.72 (dd,1H),7.66–7.59(m,1H),7.51(d,1H),7.40(d,1H),6.94–6.89(m,1H),6.73–6.66 (m,1H),6.40–6.32(m,1H),6.15(dd,1H),5.71(d,1H),3.92(s,3H),2.92(d,3H)。
Example 64
N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((4- (2-methyl-1H-benzo [ d ] imidazol-1-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (Compound 64)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(2-methyl-1H-benzo [d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
The first step is as follows: n- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (2-methyl-1H-benzo [ d ] imidazol-1-yl) pyrimidin-2-amine (64A)
N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(2-methyl-1H-benzo[d]imidazol-1-yl)pyrimi din-2-amine
1- (2-Chloropyrimidin-4-yl) -2-methyl-1H-benzo [ d ] imidazole (63B) (0.244g, 1mmol) was dissolved in 30mL 2-pentanol, 4-fluoro-2-methoxy-5-nitroaniline (4e) (0.186g, 1mmol) and p-toluenesulfonic acid monohydrate (0.192g, 1mmol) were added, and the reaction was heated to 120 ℃ for 1 day under reflux. The reaction mixture was cooled to room temperature, 200mL of aqueous ammonia was added to precipitate a solid, which was filtered, and the filter cake was washed with 250mL of water and 100mL of petroleum ether. Oven dried to give N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (2-methyl-1H-benzo [ d ] imidazol-1-yl) pyrimidin-2-amine (64A) (3.7g, 93.9% yield) as a brown solid.
LC-MS(m/z):395.1[M+1]+。
The second step is that: n is a radical of1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (2-methyl-1H-benzo [ d ]]Imidazol-1-yl) pyrimidin-2-yl) -2-nitrophenyl-1, 4-diamine (64B)
N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(2-methyl-1H-benzo[d]imi dazol-1-yl)pyrimidin-2-yl)-2-nitrobenzene-1,4-diamine
Reacting N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (2-methyl-1H-benzo [ d ]Imidazol-1-yl) pyrimidin-2-amine (64A) (2g, 5mmol) was dissolved in N, N-dimethylacetamide (12mL), N, N-diisopropylethylamine (0.775g, 6mmol) and N, N, N' -trimethylethylenediamine (18A) (613mg, 6mmol) were added, and the mixture was reacted at 120 ℃ for 2 hours under microwave. After the reaction is finished, the reaction solution is concentrated, and is separated and purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-20: 1), so that red brown solid N1- (2- (dimethylamino) ethyl ester is obtainedYl) -5-methoxy-N1-methyl-N4- (4- (2-methyl-1H-benzo [ d ]]Imidazol-1-yl) pyrimidin-2-yl) -2-nitrophenyl-1, 4-diamine (64B) (0.87g, 39.5% yield).
The third step: n is a radical of1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (2-methyl-1H-benzo [ d ]]Imidazol-1-yl) pyrimidin-2-yl) benzene-1, 2, 4-triamine (64C)
N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(2-methyl-1H-benzo[d]imi dazol-1-yl)pyrimidin-2-yl)benzene-1,2,4-triamine
Will N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (2-methyl-1H-benzo [ d ]]Imidazol-1-yl) pyrimidin-2-yl) -2-nitrobenzene-1, 4-diamine (64B) (0.87g, 1.95mmol) was dissolved in 30mL of ethanol, 10mL of water, iron powder (0.653g, 11.7mmol) and ammonium chloride (73mg, 1.37mmol) were added in this order, and the mixture was heated to 90 ℃ for reflux reaction for 4 hours. Concentrating the reaction solution, and separating and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-20: 1) to obtain brown solid N 1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (2-methyl-1H-benzo [ d ]]Imidazol-1-yl) pyrimidin-2-yl) benzene-1, 2, 4-triamine (64C) (0.6g, 73.6% yield).
The fourth step: n- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((4- (2-methyl-1H-benzo [ d ] imidazol-1-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (Compound 64)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(2-methyl-1H-benzo [d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
Will N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (2-methyl-1H-benzo [ d ]]Imidazol-1-yl) pyrimidin-2-yl) benzo-1, 2, 4-triamine (64C) (0.6g, 1.34mmol) was dissolved in 20mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.764g, 4mmol) and acrylic acid (0.14mL, 2mmol) were added in that order to react at room temperature for 3 hours. Removing pyridine by rotary drying, adding 150mL ethyl acetate and 4mol/L sodium hydroxide water solutionSeparating the solution (100mL), extracting the aqueous phase with 100mL ethyl acetate, combining the organic phases, washing with 150mL saturated sodium chloride, drying over anhydrous sodium sulfate, separating and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-20: 1) to obtain a light yellow solid N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((4- (2-methyl-1H-benzo [ d ] d)]Imidazol-1-yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 64) (300mg, 44.8% yield).
LC-MS(m/z):501.1[M+1]+。
1H NMR(400MHz,CDCl3)δ8.76(s,1H),8.44(d,1H),8.23–8.12(m,1H),7.74– 7.63(m,1H),7.28(d,1H),7.24(d,1H),7.07(s,1H),6.93(d,1H),6.83(s,1H),6.43(d, 1H),5.72(d,1H),3.87(s,3H),2.92(s,5H),2.75(s,3H),2.32(s,8H)。
Example 65
N- (3- ((5-chloro-4- (6- (2, 6-dimethyl-morpholine) -1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-phenyl) acrylamide (compound 65)
N-(3-((5-chloro-4-(6-(2,6-dimethylmorpholino)-1-methyl-1H-indol-3-yl)pyrimidin-2- yl)amino)-4-methoxyphenyl)acrylamide
The first step is as follows: 6-bromo-1- (triisopropylsilyl) -1H-indole (65B)
6-bromo-1-(triisopropylsilyl)-1H-indole
6-bromoindole (65A) (30g, 153.02mmol) was dissolved in 200mL of tetrahydrofuran, and sodium hydride (4.04g, 168.32mmol) was slowly added under ice-bath, followed by stirring for 30 minutes, and triisopropylchlorosilane (35.4g, 183.6mmol) was added dropwise, followed by reaction at room temperature for 1 hour. To the reaction solution was added 20mL of water to quench the reaction, 200mL of water and 500mL of ethyl acetate were added, the mixture was separated, and the aqueous phase was extracted with 500mL of ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, the solvent was dried by spinning, and the product was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 50:1 to 20:1) to give 6-bromo-1- (triisopropylsilyl) -1H-indole (65B) as a white solid (46g, 87.9% yield).
The second step is that: 2, 6-dimethyl-4- (1- (triisopropylsilyl) -1H-indol-6-yl) morpholine (65C)
2,6-dimethyl-4-(1-(triisopropylsilyl)-1H-indol-6-yl)morpholine
6-bromo-1- (triisopropylsilyl) -1H-indole (65B) (1g, 3mmol) was dissolved in 30mL of o-xylene, and 2, 6-dimethylmorpholine (518mg, 4.5mmol), sodium tert-butoxide (577mg, 6mmol), 4, 5-bis-diphenylphosphine-9, 9-dimethylxanthene (173.6mg, 0.3mmol) and palladium acetate (67.4mg, 0.3mmol) were added in this order, cooled to-20 ℃ and replaced with nitrogen for 30 minutes. The reaction was allowed to warm to 120 ℃ for 4 hours. After completion of the reaction, 10mL of water was added, the mixture was filtered through Celite, and the filtrate was washed with 100mL of ethyl acetate, and 100mL of water was added to the filtrate to separate the layers. The aqueous phase was extracted with 100mL ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to give 2, 6-dimethyl-4- (1- (triisopropylsilyl) -1H-indol-6-yl) morpholine (65C) (1.1g, 94.8% yield) as a brown solid.
LC-MS(m/z):387.1[M+1]+。
The third step: 4- (1H-indol-6-yl) -2, 6-dimethyl-morpholine (65D)
4-(1H-indol-6-yl)-2,6-dimethylmorpholine
2, 6-dimethyl-4- (1- (triisopropylsilyl) -1H-indol-6-yl) morpholine (65C) (1.1g, 2.8mmol) was dissolved in 20mL of tetrahydrofuran under ice-bath, tetrabutylammonium fluoride (2.8mL, 2.8mmol) was added, and the reaction was carried out at room temperature for 2 hours. After the reaction, 10mL of water was added to quench the reaction, and the reaction mixture was concentrated and purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 1:0 to 2:1) to give 4- (1H-indol-6-yl) -2, 6-dimethyl-morpholine (65D) (0.6g, 93.2% yield) as a yellow solid.
LC-MS(m/z):231.1[M+1]+。
The fourth step: 4- (3- (2, 5-dichloropyrimidin-4-yl) -1H-indol-6-yl) -2, 6-dimethyl-morpholine (65E)
4-(3-(2,5-dichloropyrimidin-4-yl)-1H-indol-6-yl)-2,6-dimethylmorpholine
4- (1H-indol-6-yl) -2, 6-dimethyl-morpholine (65D) (0.6g, 2.6mmol) was dissolved in 30mL of tetrahydrofuran, cooled to 0 ℃ under nitrogen, methylmagnesium bromide (0.87mL, 2.6mmol) was added dropwise and reacted for 30 minutes, 2,4, 5-trichloropyrimidine (0.477g, 2.6mmol) was added and reacted for 6 hours at 65 ℃. After completion of the reaction, 150mL of water and 150mL of ethyl acetate were added and the mixture was separated. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 1:0 to 2:1) to give 4- (3- (2, 5-dichloropyrimidin-4-yl) -1H-indol-6-yl) -2, 6-dimethyl-morpholine (65E) (0.64g, 65.5% yield) as a yellow solid.
LC-MS(m/z):377.0[M+1]+。
The fifth step: 4- (3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1H-indol-6-yl) -2, 6-dimethyl-morpholine (65F)
4-(3-(2,5-dichloropyrimidin-4-yl)-1-methyl-1H-indol-6-yl)-2,6-dimethylmorpholine
4- (3- (2, 5-dichloropyrimidin-4-yl) -1H-indol-6-yl) -2, 6-dimethyl-morpholine (65E) (1.44g, 3.8mmol) was dissolved in 30mL of tetrahydrofuran, and sodium hydride (306.5mg, 7.6mmol) was added thereto under ice-cooling, followed by stirring for 30 minutes, dropwise addition of methyl iodide (0.72mL, 11.5mmol), and reaction at room temperature for 1 hour. After the reaction was complete, the reaction was quenched by the addition of 20mL of water, the solvent was dried, the solid washed with 100mL of water and dried to give 4- (3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1H-indol-6-yl) -2, 6-dimethyl-morpholine (65F) as a yellow solid (1.3g, 87.8% yield).
And a sixth step: 5-chloro-4- (6- (2, 6-dimethyl-morpholine) -1-methyl-1H-indol-3-yl) -N- (2-methoxy-5-nitrophenyl) pyrimidin-2-amine (65G)
5-chloro-4-(6-(2,6-dimethylmorpholino)-1-methyl-1H-indol-3-yl)-N-(2-methoxy-5-ni trophenyl)pyrimidin-2-amine
4- (3- (2, 5-dichloropyrimidin-4-yl) -1-methyl-1H-indol-6-yl) -2, 6-dimethyl-morpholine (65F) (1.3g, 3.33mmol) was dissolved in 30mL 2-pentanol, 2-methoxy-5-nitroaniline (561mg, 3.33mmol) and p-toluenesulfonic acid (768mg, 4mmol) were added, and the reaction was heated to 120 ℃ for 3 days under reflux. The reaction solution was cooled to room temperature, 150mL of aqueous ammonia was added, a solid precipitated, filtered, and the filter cake was washed with 200mL of water and 100mL of petroleum ether and dried to give 5-chloro-4- (6- (2, 6-dimethyl-morpholine) -1-methyl-1H-indol-3-yl) -N- (2-methoxy-5-nitrophenyl) pyrimidin-2-amine (65G) (1G, 58.8% yield) as a brown solid.
LC-MS(m/z):523.0[M+1]+。
The seventh step: n1- (5-chloro-4- (6- (2, 6-dimethyl-morpholine) -1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxybenzo-1, 3-diamine (65H)
N1-(5-chloro-4-(6-(2,6-dimethylmorpholino)-1-methyl-1H-indol-3-yl)pyrimidin-2-yl) -6-methoxybenzene-1,3-diamine
Dissolving 5-chloro-4- (6- (2, 6-dimethyl-morpholine) -1-methyl-1H-indol-3-yl) -N- (2-methoxy-5-nitrophenyl) pyrimidin-2-amine (65G) (1G, 1.9mmol) in 30mL of ethanol, sequentially adding 10mL of water, iron powder (642mg, 11.5mmol) and ammonium chloride (71mg, 1.33mmol), heating to 90 ℃ for reflux reaction for 6 hours, cooling to room temperature, filtering, concentrating the filtrate, and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-50: 1) to obtain N1- (5-chloro-4- (6- (2, 6-dimethyl-morpholine) -1-methyl-1H-indol-3-yl) pyrimidine as a yellow solid -2-yl) -6-methoxybenzo-1, 3-diamine (65H) (800mg, 85.6% yield).
LC-MS(m/z):493.0[M+1]+。
Eighth step: n- (3- ((5-chloro-4- (6- (2, 6-dimethyl-morpholine) -1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-phenyl) acrylamide (compound 65)
N-(3-((5-chloro-4-(6-(2,6-dimethylmorpholino)-1-methyl-1H-indol-3-yl)pyrimidin-2- yl)amino)-4-methoxyphenyl)acrylamide
N1- (5-chloro-4- (6- (2, 6-dimethyl-morpholine) -1-methyl-1H-indol-3-yl) pyrimidin-2-yl) -6-methoxybenzo-1, 3-diamine (65H) (800mg, 1.6mmol) was dissolved in 15mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (917mg, 4.8mmol) and acrylic acid (0.17mL, 2.44mmol) were added in this order and reacted at room temperature for 4 hours. After the pyridine was dried by spinning, a 4mol/L aqueous solution of sodium hydroxide (150mL) and 150mL of ethyl acetate were added to separate the layers. The aqueous phase is extracted once with 1000mL of ethyl acetate, the organic phases are combined and washed once with 150mL of water. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1:0 to 20:1) to give N- (3- ((5-chloro-4- (6- (2, 6-dimethyl-morpholine) -1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-phenyl) acrylamide (compound 65) (400mg, yield 45.8%) as a white solid.
LC-MS(m/z):547.1[M+1]+。
Example 66
N- (5- ((4- (5, 6-dihydro-4H-pyrrolo [3,2,1-ij ] quinolin-1-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 66)
N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-2-yl)amino)-2-((2- (dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
The first step is as follows: 3- (2-Chloropyrimidin-4-yl) -7-methyl-1H-indole (66B)
3-(2-chloropyrimidin-4-yl)-7-methyl-1H-indole
5, 6-dihydro-4H-pyrrolo [3,2,1-IJ ] quinoline (66A) (0.78g, 5mmol) is dissolved in 10mL of 1, 2-dichloroethane, cooled to 0 ℃ under the protection of nitrogen, 2, 4-dichloropyrimidine (0.745g, 5mmol) is added, aluminum trichloride (0.667g, 5mmol) is added, the reaction is carried out at room temperature for 40 minutes, and the reaction is carried out at 80 ℃ for 6 hours. To the reaction solution was added 10mL of water, filtered, and the filter cake was washed with methanol (3 mL. times.3) and dried with an infrared lamp to give 3- (2-chloropyrimidin-4-yl) -7-methyl-1H-indole (66B) (1.0g, yield 75%) as a yellow solid.
1H NMR(400MHz,CDCl3)δ8.40(d,1H),7.99(m,2H),7.47(d,1H),7.22(t,1H), 7.03(d,1H),4.22(t,2H),3.02(t,2H),2.27(m,2H)。
The second step is that: 4- (5, 6-dihydro-4H-pyrrolo [3,2,1-ij ] quinolin-1-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (66C)
4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-N-(4-fluoro-2-methoxy-5-nitrophen yl)pyrimidin-2-amine
3- (2-Chloropyrimidin-4-yl) -7-methyl-1H-indole (66B) (0.54g, 2.0mmol) was dissolved in 8mL 2-pentanol, 4-fluoro-2-methoxy-5-nitroaniline (4e) (0.37g, 2.0mmol) and p-toluenesulfonic acid monohydrate (0.46g, 2.4mmol) were added, and the reaction was heated to 120 ℃ for 8 hours under reflux. After cooling to room temperature, 200mL of ammonia was added, the solid was precipitated, filtered, and the filter cake was washed with 200mL of water and 100mL of petroleum ether. Drying afforded 4- (5, 6-dihydro-4H-pyrrolo [3,2,1-ij ] quinolin-1-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (66C) as a pale yellow solid (0.6g, 71.6% yield).
LC-MS(m/z):420.1[M+1]+。
1H NMR(400MHz,CDCl3)δ9.85(d,1H),8.40(d,1H),8.29(s,1H),7.88(d,1H), 7.66(s,1H),7.18-7.26(m,1H),7.01(d,1H),6.74(d,1H),4.74(br,1H),4.31(t,2H),4.02 (s,3H),3.04(t,2H),2.29(t,2H)。
The third step: n is a radical of1- (4- (5, 6-dihydro-4H-pyrrolo [3,2, 1-ij)]Quinolin-1-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrobenzene-1, 4-diamine (66D)
N1-(4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-2-yl)-N4-(2-(dimethyl amino)ethyl)-2-methoxy-N4-methyl-5-nitrobenzene-1,4-diamine
4- (5, 6-dihydro-4H-pyrrolo [3,2, 1-ij)]Quinolin-1-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (66C) (0.6g, 1.43mmol) was dissolved in 10mL of N, N-dimethylacetamide, N, N-diisopropylethylamine (278mg, 2.15mmol) and N, N, N' -trimethylethylenediamine (18A) (219mg, 2.15mmol) were added, and the mixture was reacted at 130 ℃ for 1.5 hours by microwave. After the reaction, the reaction mixture was concentrated. Adding 100mL of water and 100mL of ethyl acetate, separating, extracting the aqueous phase with 100mL of ethyl acetate, combining the organic phases, washing with 100mL of saturated saline solution, drying with anhydrous sodium sulfate, filtering, and concentrating to obtain a red solid N1- (4- (5, 6-dihydro-4H-pyrrolo [3,2, 1-ij)]Quinolin-1-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrophenyl-1, 4-diamine (66D) (716 mg).
LC-MS(m/z):502.3[M+1]+。
The fourth step: n is a radical of4- (4- (5, 6-dihydro)-4H-pyrrolo [3,2,1-ij]Quinolin-1-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (66E)
N4-(4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-2-yl)-N1-(2-(dimethyl amino)ethyl)-5-methoxy-N1-methylbenzene-1,2,4-triamine
Will N1- (4- (5, 6-dihydro-4H-pyrrolo [3,2, 1-ij) ]Quinolin-1-yl) pyrimidin-2-yl) -N4- (2- (dimethylamino) ethyl) -2-methoxy-N4-methyl-5-nitrophenyl-1, 4-diamine (66D) (716mg, 1.43mmol) was dissolved in 15mL of ethanol, 5mL of water, iron powder (0.479g, 8.58mmol) and ammonium chloride (53.5mg, 1mmol) were added in this order, and the reaction was refluxed at 90 ℃ for 6 hours. After the reaction is finished, concentrating the reaction solution, and separating and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-10: 1) to obtain brown solid N4- (4- (5, 6-dihydro-4H-pyrrolo [3,2, 1-ij)]Quinolin-1-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (66E) (0.43g, 63.9% yield).
LC-MS(m/z):472.4[M+1]+。
1H NMR(400MHz,CDCl3)δ8.32(d,1H),8.17(s,1H),8.12(d,1H),7.87(s,1H),7.67 (s,1H),7.23–7.16(m,1H),7.06(d,1H),7.01(d,1H),6.66(s,1H),4.30–4.21(m,2H),3.85 (s,3H),3.48(s,2H),3.34(t,2H),3.11–2.99(m,4H),2.83(s,6H),2.72(s,3H),2.34–2.23 (m,2H)。
The fifth step: n- (5- ((4- (5, 6-dihydro-4H-pyrrolo [3,2,1-ij ] quinolin-1-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-phenyl) acrylamide (compound 66)
N-(5-((4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)pyrimidin-2-yl)amino)-2-((2- (dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
Will N4- (4- (5, 6-dihydro-4H-pyrrolo [3,2, 1-ij)]Quinolin-1-yl) pyrimidin-2-yl) -N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methylbenzene-1, 2, 4-triamine (66E) (430mg, 0.91)mmol) was dissolved in 15mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.523g, 2.74mmol) and acrylic acid (0.094mL, 1.37mmol) were added to react at room temperature for 4 hours. The pyridine was dried by spinning, 100mL of dichloromethane and 4mol/L aqueous sodium hydroxide (100mL) were added, the layers were separated, the aqueous layer was extracted with 100mL of dichloromethane, and the organic layers were combined and washed with 150mL of saturated sodium chloride. Drying the organic phase with anhydrous sodium sulfate, filtering, concentrating, and separating and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-10: 1) to obtain yellow solid N- (5- ((4- (5, 6-dihydro-4H-pyrrolo [3,2, 1-ij) ]Quinolin-1-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-phenyl) acrylamide (compound 66) (140mg, 29.3% yield).
LC-MS(m/z):526.3[M+1]+。
1H NMR(400MHz,CDCl3)δ10.21(s,1H),9.81(s,1H),9.25(s,1H),8.89(s,1H), 8.37(d,1H),7.95(d,1H),7.69(s,1H),7.16(d,1H),7.14–7.08(m,1H),6.80(s,1H), 6.51(dd,1H),6.37(s,1H),5.69(d,1H),3.88(d,3H),2.91(s,2H),2.84(s,2H),2.71(s, 3H),2.49(s,3H),2.26(s,6H),1.73(s,2H)。
Example 67
N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((4- (spiro [ cyclopropyl-1, 3 '-indol ] -1' -yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 67)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(spiro[cyclopropane -1,3'-indolin]-1'-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
The first step is as follows: 3- (2-hydroxyethyl) indol-2-one (67B)
3-(2-hydroxyethyl)indolin-2-one
2-Indolinone (67A) (5g, 37.6mmol) was dissolved in 100mL of 1.2-ethanediol, reacted at 200 ℃ in an autoclave for 10 hours, the reaction was completed, the reaction mixture was cooled to room temperature, filtered through celite, washed with 50mL of methanol, most of the solvent was removed by evaporation, 100mL of ethyl acetate and 100mL of water were added, and the mixture was separated. The aqueous phase was extracted with 100mL of ethyl acetate, and the combined organic phases were washed with 150mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give 3- (2-hydroxyethyl) indol-2-one (67B) as a yellow oil (4.5g, 68.2% yield).
LC-MS(m/z):178.1[M+1]+。
The second step is that: spiro [ cyclopropyl-1, 3 '-indol ] -2' -one (67C)
spiro[cyclopropane-1,3'-indolin]-2'-one
3- (2-hydroxyethyl) indol-2-one (67B) (3g, 16.9mmol) was dissolved in 60mL of dichloromethane, triethylamine (6.5mL, 46.8mmol) was added, the temperature was reduced to 0 deg.C, methanesulfonyl chloride (1.51mL, 82.2mmol) was added dropwise, and the reaction was continued overnight with warming to room temperature. After the reaction, 100mL of water and 60mL of dichloromethane were added, the mixture was separated, the aqueous phase was extracted with 100mL of dichloromethane, the organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was dried by spin-drying, and purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1:0 to 20:1) to obtain spiro [ cyclopropyl-1, 3 '-indol ] -2' -one (67C) (1.6g, yield 59.7%) as a red solid.
LC-MS(m/z):160.2[M+1]+。
The third step: spiro [ cyclopropyl-1, 3' -indole ] (67D)
spiro[cyclopropane-1,3'-indoline]
Spiro [ cyclopropyl-1, 3 '-indol ] -2' -one (67C) was dissolved in 50mL of tetrahydrofuran, and lithium aluminum hydride (1.25g, 33mmol) was slowly added thereto, reacted at room temperature for 30 minutes, and then heated to 65 ℃ for 4 hours. After the reaction, the mixture was poured into 100mL of an ice-water bath, the pH was adjusted to 8 with an aqueous solution of sodium hydroxide, and 100mL of ethyl acetate was added for liquid separation. The aqueous phase was extracted with 100mL of ethyl acetate, the organic phases were combined, washed with 200mL of saturated brine, dried over anhydrous sodium sulfate, and the solvent was dried and purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1:0 to 50:1) to give spiro [ cyclopropyl-1, 3' -indole ] (67D) (0.8g, yield 55.2%) as a brown oil.
LC-MS(m/z):146.2[M+1]+。
The fourth step: 1'- (2-Chloropyrimidin-4-yl) spiro [ cyclopropyl-1, 3' -indole ] (67E)
1'-(2-chloropyrimidin-4-yl)spiro[cyclopropane-1,3'-indoline]
Spiro [ cyclopropyl-1, 3' -indole ] (67D) (145.09mg, mmol) was dissolved in 10mL of dimethyl sulfoxide, potassium carbonate (276.4mg, 2mmol) and 2, 4-dichloropyrimidine (149mg, 1mmol) were added, and the mixture was raised to 80 ℃ and reacted for 1.5 hours. After completion of the reaction, 100mL of water and 100mL of ethyl acetate were added and the mixture was separated. The aqueous phase was extracted with 100mL of ethyl acetate, the organic phases were combined, washed with saturated brine (150mL), dried over anhydrous sodium sulfate, and the solvent was dried by rotary drying to give 1'- (2-chloropyrimidin-4-yl) spiro [ cyclopropyl-1, 3' -indole ] (67E) as a yellow solid (0.2g, 77.8% yield).
LC-MS(m/z):258.1[M+1]+。
The fifth step: n- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (spiro [ cyclopropyl-1, 3 '-indol ] -1' -yl) pyrimidin-2-amine (67F)
N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(spiro[cyclopropane-1,3'-indolin]-1'-yl)pyri midin-2-amine
1'- (2-Chloropyrimidin-4-yl) spiro [ cyclopropyl-1, 3' -indole ] (67E) (1g, 3.89mmol) was dissolved in 60mL 2-pentanol, 4-fluoro-2-methoxy-5-nitroaniline (4E) (724mg, 3.89mmol) and p-toluenesulfonic acid (0.887g, 4.67 mmol) were added, and the mixture was heated to 130 ℃ for reflux reaction for 6 hours. After the reaction, the solvent was dried by rotation, 150mL of water and 150mL of ethyl acetate were added, the mixture was separated, the aqueous phase was extracted with 150mL of ethyl acetate, the organic phases were combined, washed with saturated brine (200mL), dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 4:1 to dichloromethane/methanol ═ 10:1) to give N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (spiro [ cyclopropyl-1, 3 '-indol ] -1' -yl) pyrimidin-2-amine (67F) (1.2g, yield 95.2%) as a brown solid.
LC-MS(m/z):408.3[M+1]+。
And a sixth step: n is a radical of1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-2-nitro-N4- (4- (spiro [ cyclopropyl-1, 3' -indole)]-1' -yl) pyrimidin-2-yl) benzene-1, 4-diamine (67G)
N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-2-nitro-N4-(4-(spiro[cyclopropa ne-1,3'-indolin]-1'-yl)pyrimidin-2-yl)benzene-1,4-diamine
Reacting N- (4-fluoro-2-methoxy-5-nitrophenyl) -4- (spiro [ cyclopropyl-1, 3' -indole)]-1 '-yl) pyrimidin-2-amine (67F) (1.2g, 2.95mmol) was dissolved in 5mL of N, N-dimethylacetamide, N, N-diisopropylethylamine (0.571g, 4.42mmol) and N, N, N' -trimethylethylenediamine (18A) (452mg, 4.42mmol) were added, and the reaction was carried out by microwave at 130 ℃ for 1.5 hours. After completion of the reaction, 150mL of water and 150mL of methylene chloride were added and the mixture was separated. The aqueous phase was extracted with 150mL of dichloromethane, the combined organic phases were washed with saturated brine (200mL), dried over anhydrous sodium sulfate, and concentrated to give N as a brown solid 1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-2-nitro-N4- (4- (spiro [ cyclopropyl-1, 3' -indole)]-1' -yl) pyrimidin-2-yl) benzene-1, 4-diamine (67G) (1.2G, 85.7% yield).
LC-MS(m/z):490.3[M+1]+。
The seventh step: n is a radical of1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (spiro [ cyclopropyl-1, 3' -indole)]-1' -yl) pyrimidin-2-yl) benzene-1, 2,4-, triamine (67H)
N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(spiro[cyclopropane-1,3'-in dolin]-1'-yl)pyrimidin-2-yl)benzene-1,2,4-triamine
Will N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-2-nitro-N4- (4- (spiro [ cyclopropyl-1, 3' -indole)]-1' -yl) pyrimidin-2-yl) benzene-1, 4-diamine (67G) (1.2G, 2.45mmol) was dissolved in 24mL of ethanol, and 8mL of water, iron powder (0.822G, 14.7mmol) and ammonium chloride (92mg, 1.7mmol) were added in this order, and the mixture was heated to 90 ℃ and reacted for 4 hours under reflux. Concentrating the reaction solution, and separating and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-10: 1) to obtain brown solid N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (spiro [ cyclopropyl-1, 3' -indole)]-1' -yl) pyrimidin-2-yl) benzene-1, 2,4-, triamine (67H) (440mg, 40% yield).
LC-MS(m/z):460.4[M+1]+。
Eighth step: n- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((4- (spiro [ cyclopropyl-1, 3 '-indol ] -1' -yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 67)
N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(spiro[cyclopropane -1,3'-indolin]-1'-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
Will N1- (2- (dimethylamino) ethyl) -5-methoxy-N1-methyl-N4- (4- (spiro [ cyclopropyl-1, 3' -indole)]-1' -yl) pyrimidin-2-yl) benzene-1, 2,4-, triamine (67H) (0.44g, 0.96mmol) was dissolved in 15mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (0.55g, 2.88mmol) and acrylic acid (0.1mL, 1.44mmol) were added in that order to react at room temperature for 4 hours. Drying pyridine, adding 4mol/L aqueous solution of sodium hydroxide (100mL) and 100mL of dichloromethane, separating liquid, extracting aqueous phase with dichloromethane (100mL), combining organic phase, washing with saturated aqueous solution of sodium chloride (100mL), drying with anhydrous sodium sulfate, separating and purifying by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1: 0-10: 1) to obtain yellow solid N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-5- ((4- (spiro [ cyclopropyl-1, 3' -indole)]-1' -yl) pyrimidin-2-yl) amino) phenyl) acrylamide (compound 67) (100mg, 20.3% yield).
LC-MS(m/z):514.3[M+1]+。
1H NMR(400MHz,CDCl3)δ9.97(s,1H),9.45(s,1H),8.16(d,1H),7.80(s,1H),7.45(s, 1H),7.16–7.07(m,1H),6.89(t,1H),6.77(s,1H),6.70–6.65(m,1H),6.43(s,1H),6.37(d, 2H),5.71–5.62(m,1H),4.33(s,2H),3.87(s,3H),2.91(s,2H),2.70(s,3H),2.29(s,6H),1.58 (s,4H)。
Example 68
N- (5- ((4- (6-cyano-1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 68)
N-(5-((4-(6-cyano-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylami no)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
The first step is as follows: 1-methyl-1H-indole-6-carbonitrile (68B)
1-methyl-1H-indole-6-carbonitrile
6-cyano-indole (68A) (5g, 35.17mmol) was dissolved in 30mL of tetrahydrofuran, sodium hydride (1.69g, 70.34mmol) was slowly added, and the mixture was reacted at room temperature for 20 minutes, and iodomethane (14.97g, 105.5mmol) was added and the reaction was allowed to react at room temperature for 3 hours. After the reaction, 100mL of water was added to quench the reaction. Most of the solvent was removed, and 100mL of ethyl acetate and 100mL of water were added to separate the layers. The aqueous phase was extracted with 100mL of ethyl acetate, and the organic phases were combined, washed with saturated brine (150mL), dried over anhydrous sodium sulfate, and concentrated to give 1-methyl-1H-indole-6-carbonitrile (68B) (5.4g) as a yellow solid.
The second step is that: 3- (2-Chloropyrimidin-4-yl) -1-methyl-1H-indole-6-carbonitrile (68C)
3-(2-chloropyrimidin-4-yl)-1-methyl-1H-indole-6-carbonitrile
1-methyl-1H-indole-6-carbonitrile (68B) (5.4g, 34.6mmol) was dissolved in 40mL ethylene glycol dimethyl ether, 2, 4-dichloropyrimidine (5.15g, 34.6mmol) and aluminum trichloride (4.61g, 34.6mmol) were added, and the mixture was raised to 80 ℃ and reacted for 4 hours. After the reaction was complete, 100mL of water was added to precipitate a solid, which was filtered, the filter cake was washed with 150mL of water and dried by infrared lamp to give 3- (2-chloropyrimidin-4-yl) -1-methyl-1H-indole-6-carbonitrile (68C) as a yellow solid (9g, 97.8% yield).
LC-MS(m/z):269.1[M+1]+。
The third step: 3- (2- ((4-fluoro-2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1-methyl-1H-indole-6-carbonitrile (68D)
3-(2-((4-fluoro-2-methoxy-5-nitrophenyl)amino)pyrimidin-4-yl)-1-methyl-1H-indole- 6-carbonitrile
3- (2-Chloropyrimidin-4-yl) -1-methyl-1H-indole-6-carbonitrile (68C) (8g, 29.8mmol) was dissolved in 150mL 2-pentanol, 4-fluoro-2-methoxy-5-nitroaniline (4e) (5.55g, 29.8mmol) and p-toluenesulfonic acid monohydrate (6.82g, 35.9mmol) were added, and the reaction was heated to 120 ℃ for 2 days under reflux. Cooled to room temperature, 200mL of ammonia was added, the solid precipitated, filtered, and the filter cake washed with 200mL of water and 100mL of petroleum ether. Drying gave 3- (2- ((4-fluoro-2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1-methyl-1H-indole-6-carbonitrile (68D) as a brown solid (10g, 80.6% yield).
LC-MS(m/z):419.0[M+1]+。
The fourth step: 3- (2- ((4- ((2- (dimethylamino) ethyl) (methyl) amino) -2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1-methyl-1H-indole-6-carbonitrile (68E)
3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5-nitrophenyl)amino)p yrimidin-4-yl)-1-methyl-1H-indole-6-carbonitrile
3- (2- ((4-fluoro-2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1-methyl-1H-indole-6-carbonitrile (68D) (10g, 23.9mmol) was dissolved in 60mL of N, N-dimethylacetamide, and N, N-diisopropylethylamine (4.64g, 35.87mmol) and N, N, N' -trimethylethylenediamine (18A) (3.67g, 35.87mmol) were added and reacted at 130 ℃ for 1.5 hours under microwave. After the reaction, the mixture was concentrated. 200mL of water and 200mL of ethyl acetate were added, the layers were separated, the aqueous phase was extracted with 200mL of ethyl acetate, the organic phases were combined, washed with saturated brine (400mL), dried over anhydrous sodium sulfate, and concentrated to give 3- (2- ((4- ((2- (dimethylamino) ethyl) (methyl) amino) -2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1-methyl-1H-indole-6-carbonitrile (68E) (10g, 84% yield) as a yellow solid.
LC-MS(m/z):501.1[M+1]+。
The fifth step: 3- (2- ((5-amino-4- ((2- (dimethylamino) ethyl) (methyl) amino) -2-methoxyphenyl) amino) pyrimidin-4-yl) -1-methyl-1H-indole-6-carbonitrile (68F)
3-(2-((5-amino-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino) pyrimidin-4-yl)-1-methyl-1H-indole-6-carbonitrile
3- (2- ((4- ((2- (dimethylamino) ethyl) (methyl) amino) -2-methoxy-5-nitrophenyl) amino) pyrimidin-4-yl) -1-methyl-1H-indole-6-carbonitrile (68E) (11g, 22mmol) was dissolved in 100mL of ethanol, 33mL of water, iron powder (7.37g, 132mmol) and ammonium chloride (824mg, 15.4mmol) were added in this order, and the mixture was heated to 90 ℃ for 6 hours under reflux. After the reaction, the reaction mixture was concentrated, and purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 1:0 to 10:1) to obtain 3- (2- ((5-amino-4- ((2- (dimethylamino) ethyl) (methyl) amino) -2-methoxyphenyl) amino) pyrimidin-4-yl) -1-methyl-1H-indole-6-carbonitrile (68F) (6g, 58.3% yield) as a brown solid.
LC-MS(m/z):471.1[M+1]+。
And a sixth step: n- (5- ((4- (6-cyano-1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 68)
N-(5-((4-(6-cyano-1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylami no)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
3- (2- ((5-amino-4- ((2- (dimethylamino) ethyl) (methyl) amino) -2-methoxyphenyl) amino) pyrimidin-4-yl) -1-methyl-1H-indole-6-carbonitrile (68F) (6g, 12.7mmol) was dissolved in 50mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (7.3g, 38.2mmol) and acrylic acid (1.3mL, 19.1mmol) were added and reacted at room temperature for 4 hours. After the pyridine was dried by spinning, 200mL of methylene chloride and 4mol/L aqueous sodium hydroxide solution (200mL) were added to separate the solution. The aqueous phase was extracted with 200mL of dichloromethane, the organic phases were combined, washed with saturated sodium chloride (400mL), dried over anhydrous sodium sulfate, and purified by column chromatography on silica gel (dichloromethane/methanol (v/v) ═ 1:0 to 10:1) to give N- (5- ((4- (6-cyano-1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -2- ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxyphenyl) acrylamide (compound 68) (1.2g, 18.2% yield) as a yellow solid.
LC-MS(m/z):525.2[M+1]+。
Example 69
N- (5- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (2-morpholinoethoxy) phenyl) acrylamide (compound 69)
N-(5-((4-(1-(difluoromethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(2-m orpholinoethoxy)phenyl)acrylamide
The first step is as follows: 4- (1- (difluoromethyl) -1H-indol-3-yl) -N- (2-methoxy-4- (2-morpholinoethoxy) -5-nitrophenyl) pyrimidin-2-amine (69A)
4-(1-(difluoromethyl)-1H-indol-3-yl)-N-(2-methoxy-4-(2-morpholinoethoxy)-5-nitrop henyl)pyrimidin-2-amine
4- (1- (difluoromethyl) -1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (30B) (1g, 2.33mmol) was dissolved in 30mL of tetrahydrofuran, sodium hydride (112mg, 4.66mmol) was added slowly, the mixture was stirred for 30 minutes, 2-morpholinoethanol (611mg, 4.66mmol) was added, and the reaction was carried out at room temperature for 4 hours. After completion of the reaction, 150mL of water and 150mL of methylene chloride were added and the mixture was separated. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give 4- (1- (difluoromethyl) -1H-indol-3-yl) -N- (2-methoxy-4- (2-morpholinoethoxy) -5-nitrophenyl) pyrimidin-2-amine (69A) (1.1g, 88% yield) as a yellow solid.
LC-MS(m/z):541.3[M+1]+。
The second step is that: n is a radical of1- (4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- (2-morpholinoethoxy) benzene-1, 3-diamine (69B)
N1-(4-(1-(difluoromethyl)-1H-indol-3-yl)pyrimidin-2-yl)-6-methoxy-4-(2-morpholino ethoxy)benzene-1,3-diamine
4- (1- (difluoromethyl) -1H-indol-3-yl) -N- (2-methoxy-4- (2-morpholinoethoxy) -5-nitrophenyl) pyrimidin-2-amine (69A) (1.1g, 2.03mmol) was dissolved in 30mL of ethanol, 10mL of water was added, iron powder (682mg, 12.2mmol) and ammonium chloride (76mg, 1.42mmol) were added, the temperature was raised to 90 ℃, the reaction was refluxed for 4H, and concentrated. Separating and purifying by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1: 0-10: 1) to obtain brown solid N 1- (4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- (2-morpholinoethoxy) benzene-1, 3-diamine (69B) (1g, 97.1% yield)。
The third step: n- (5- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (2-morpholinoethoxy) phenyl) acrylamide (compound 69)
N-(5-((4-(1-(difluoromethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxy-2-(2-m orpholinoethoxy)phenyl)acrylamide
Will N1- (4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) -6-methoxy-4- (2-morpholinoethoxy) benzene-1, 3-diamine (69B) (1g, 1.96mmol) was dissolved in 30mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (1.12g, 5.88mmol) and acrylic acid (0.202mL, 2.94mmol) were added and the reaction was carried out at room temperature for 4 hours. The pyridine in the reaction solution was spin-dried, 150mL of water and 150mL of methylene chloride were added, and the mixture was separated. The organic phase was washed with 4mol/L aqueous sodium hydroxide (100mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography on silica gel (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give N- (5- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxy-2- (2-morpholinoethoxy) phenyl) acrylamide (compound 69) (400mg, yield 36.4%) as a white solid.
LC-MS(m/z):565.3[M+1]+。
Example 70
N- (2- ((1-Aminocyclopropyl) methoxy) -5- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 70)
N-(2-((1-aminocyclopropyl)methoxy)-5-((4-(1-(difluoromethyl)-1H-indol-3-yl)pyrimi din-2-yl)amino)-4-methoxyphenyl)acrylamide
The first step is as follows: (1- ((4- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxy-2-nitrophenoxy) methyl) cyclopropyl) carbamic acid tert-butyl ester (70A)
tert-butyl(1-((4-((4-(1-(difluoromethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-5-meth oxy-2-nitrophenoxy)methyl)cyclopropyl)carbamate
4- (1- (difluoromethyl) -1H-indol-3-yl) -N- (4-fluoro-2-methoxy-5-nitrophenyl) pyrimidin-2-amine (30B) (1g, 2.33mmol) was dissolved in 30mL of tetrahydrofuran, sodium hydride (112mg, 4.66mmol) was slowly added, stirred for 30 minutes, and (1-hydroxymethylcyclopropyl) -tert-butoxycarbonylamino (873mg, 4.66mmol) was added and reacted at room temperature for 4 hours. After completion of the reaction, 150mL of water and 150mL of methylene chloride were added and the mixture was separated. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give tert-butyl (1- ((4- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxy-2-nitrophenoxy) methyl) cyclopropyl) carbamate (70A) (1g, 72.5% yield) as a yellow solid.
LC-MS(m/z):597.3[M+1]+。
The second step is that: (1- ((2-amino-4- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenyl) methyl) cyclopropyl) carbamic acid tert-butyl ester (70B)
tert-butyl(1-((2-amino-4-((4-(1-(difluoromethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino )-5-methoxyphenoxy)methyl)cyclopropyl)carbamate
Tert-butyl (1- ((4- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxy-2-nitrophenoxy) methyl) cyclopropyl) carbamate (70A) (1g, 1.68mmol) was dissolved in 30mL of ethanol, 10 mL of water, iron powder (562mg, 10mmol) and ammonium chloride (63mg, 1.2mmol) were added, and the mixture was heated to 90 ℃ for 4 hours under reflux. The reaction solution was concentrated, and separated and purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give tert-butyl (1- ((2-amino-4- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxybenzyl) methyl) cyclopropyl) carbamate (70B) (951mg) as a brown solid.
LC-MS(m/z):567.3[M+1]+。
The third step: (1- ((2-acrylamido-4- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenyl) methyl) cyclopropyl) carbamic acid tert-butyl ester (70C)
tert-butyl(1-((2-acrylamido-4-((4-(1-(difluoromethyl)-1H-indol-3-yl)pyrimidin-2-yl)a mino)-5-methoxyphenoxy)methyl)cyclopropyl)carbamate
Tert-butyl (1- ((2-amino-4- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenyl) methyl) cyclopropyl) carbamate (70B) (951mg, 1.68mmol) was dissolved in 30mL of pyridine, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (963mg, 5.04mmol) and acrylic acid (0.173mL, 2.52mmol) were added and reacted at room temperature for 4 hours. The pyridine in the reaction solution was spin-dried, 150mL of water and 150mL of dichloromethane were added, and the mixture was separated. The organic phase was washed with 4mol/L aqueous sodium hydroxide (100mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give tert-butyl 1- ((2-acrylamido-4- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenyl) methyl) cyclopropyl) carbamate (70C) as a yellow solid (800mg, 76.9% yield).
LC-MS(m/z):621.3[M+1]+。
The fourth step: n- (2- ((1-Aminocyclopropyl) methoxy) -5- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 70)
N-(2-((1-aminocyclopropyl)methoxy)-5-((4-(1-(difluoromethyl)-1H-indol-3-yl)pyrimi din-2-yl)amino)-4-methoxyphenyl)acrylamide
Tert-butyl (1- ((2-acrylamido-4- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -5-methoxyphenyl) methyl) cyclopropyl) carbamate (70C) (0.8g, 1.29mmol) was dissolved in 50mL of dichloromethane, and 20mL of trifluoroacetic acid was added and reacted at room temperature for 4 hours. Most of the solvent was removed by rotation, 100mL of water was added, the pH was adjusted to 8 with a saturated aqueous sodium bicarbonate solution, 150mL of dichloromethane was added, and the layers were separated. The aqueous phase was extracted with 100mL of dichloromethane, and the organic phases were combined and washed with 150mL of saturated aqueous sodium chloride solution. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (dichloromethane: methanol (v/v) ═ 1:0 to 10:1) to give N- (2- ((1-aminocyclopropyl) methoxy) -5- ((4- (1- (difluoromethyl) -1H-indol-3-yl) pyrimidin-2-yl) amino) -4-methoxyphenyl) acrylamide (compound 70) as a white solid (370mg, 55.1% yield).
LC-MS(m/z):521.2[M+1]+。
1H NMR(400MHz,CDCl3)δ9.75(s,1H),9.37(s,1H),8.78(s,1H),8.44(d,1H), 8.05(dd,1H),7.82–7.75(m,1H),7.69(s,1H),7.35(dd,2H),7.22(d,1H),6.60(s,1H), 6.40(d,2H),5.77(t,1H),1.26(s,3H),0.88(s,2H),0.74(d,2H),0.68(t,2H)。
Test example 1: testing cancer cell growth inhibition
Serial passage tumor cells were trypsinized, suspended in culture medium, counted and plated into 96-well cell culture plates. Non-small cell lung cancer cell NCI-H1975 10000 cells per well, human epithelial cancer cell A431 cell line 10000 cells per well, 5% CO at 37 deg.C 2Incubate overnight. On the next day, 6 wells of each cell were fixed by adding 30. mu.l of 50% trichloroacetic acid; the test compound was added to each of the remaining wells. Test compounds were prepared as solutions in DMSO at a maximum concentration of 10 μ M, and diluted 5-fold for 10 test concentrations as described below. For the NCI-H1975, A431 cell line, the assay was diluted with a gradient of medium containing 0.1% FBS and brought to a final concentration of 2-fold. The culture medium of a 96-well cell culture plate seeded with NCI-H1975, A431 cells was changed to fresh medium containing 0.1% FBS (100 ul per well), and 100ul of the test compound at 2-fold final concentration was added. Each 96-well cell culture plate was incubated at 37 ℃ with 5% CO2The cell incubator was incubated for 72 hours. Then 50. mu.l of 50% trichloroacetic acid was added to each well and fixed in a refrigerator at 4 ℃ for 1 hour.
The trichloroacetic acid in each well was discarded and washed 5 times with 300. mu.l of double distilled water. After drying at room temperature, 50. mu.l of a 0.4% SRB (Sulforhodamine-B) dye solution (1% acetic acid/0.4% SRB) was added to each well and reacted for 15 min. The dye solution in each well was discarded, washed with 1% acetic acid 6-7 times, and dried at room temperature. To each well was added 200. mu.l of a 10mM Tris solution (pH 10.5), and the solution was dissolved with shaking. The absorbance at 490nm of each well was measured using a microplate reader. Calculation and analysis of the semi-effective Inhibitory Concentration (IC) of test compound using origin7.5, using readings from wells with test compound concentration of 0 as control 50)。
Anti-tumor cell proliferation of the Compounds of the inventionReproductive Activity measured by the above assay, IC50The values are shown in Table 1.
TABLE 1 test results of antitumor cell proliferation Activity
And (4) conclusion: the compound has obvious growth inhibition effect on non-small cell lung cancer cells NCI-H1975, and particularly the growth inhibition activity of the compound 20, the compound 33 and the like is less than 1 nM. The compound of the invention has obvious selectivity on the NCI-H1975 of the non-small cell lung cancer cells, and particularly, the growth inhibition activity of the compounds 16, 27, 30, 38, 40, 46, 47 and the like on the NCI-H1975 of the non-small cell lung cancer cells is more than 100 times of the growth inhibition activity on the A431 of the human epithelial cell cancer cells.
Claims (12)
1. A compound of formula (I) and optical isomers, pharmaceutically acceptable salts or co-crystals thereof, wherein:
b is selected from 6 to 15 membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O, S or P;
R1each independently selected from F, Cl, Br, I, hydroxy, cyano, C1-10Alkyl radical, C1-10Alkoxy, -NR1aR1b、-C(=O)C1-10Alkyl, -S (═ O)2-C1-10Alkyl, -C (═ O) -3 to 15 membered heterocycle, -C (═ O) -C3-15Carbocyclic ring, - (CH)2)n-3 to 15 membered heterocycle, - (CH)2)n-C3-15Carbocyclic ring, -O- (CH)2)n-C3-15Carbocyclic ring, -O- (CH)2)n-3 to 15 membered heterocycle, -O- (CH)2)n-C(=O)C1-6Alkyl, -O- (CH) 2)n-O-C(=O)C1-6Alkyl or-O- (CH)2)n-O-C1-10Alkyl, said CH2Alkyl, alkoxy, carbocycle or heterocycle is optionally further substituted by 0 to 5 groups selected from F, Cl, Br, I, ═ O, hydroxy, amino, cyano, nitro, C1-6Alkyl radical, C1-6Alkoxy, - (CH)2)n-OH、-(CH2)n-F、-C(=O)C1-6Alkoxy, -C (═ O) C1-6Alkyl, -C (═ O) C3-15Carbocyclic ring, -O-C (═ O) C1-6Alkyl, - (CH)2)n-C3-10Carbocyclic ring or- (CH)2)n-3 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from N, O, S or P;
R1aand R1bSelected from H or C1-10An alkyl group;
R2selected from H, F, Cl, Br, I, cyano, C1-10Alkyl or C1-10Alkoxy, said alkyl or alkoxy being optionally further substituted by 0 to 4 substituents selected from F, Cl, Br, I, C1-6Alkyl or C1-6Substituted by a substituent of alkoxy;
R3selected from H, C2-10Alkenyl radical, C3-15Cycloalkyl radical, C1-10Alkyl or C1-10Alkoxy, said alkenyl, cycloalkyl, alkyl or alkoxy being optionally further selected from 0 to 4 groups selected from F, Cl, Br, I, C1-6Alkyl or C1-6Substituted by a substituent of alkoxy;
R4selected from H, F, Cl, Br, I, nitro, amino, C1-10Alkyl, 5-to 15-membered spirocyclic, 4-to 15-membered fused cyclic, 3-to 10-membered heterocyclic, -NR4cR4d、-Z-(CH2)nR4a、-O-(CH2)nR4b、-Z-(CH2)nNR4cR4dor-O- (CH)2)nNR4cR4dSaid CH2Spiro, fused or heterocyclic ring optionally further substituted by 0 to 4 substituents selected from F, Cl, Br,I. Hydroxy, amino, C 1-6Alkyl radical, C1-6Alkoxy, - (CH)2)n-C(=O)-R4e、-(CH2)n-O-C(=O)-R4e、-NR4cR4dFrom 0 to 4R4cSubstituted C3-10Carbocyclic or substituted by 0 to 4R4cSubstituted with a substituent of a substituted 3-to 10-membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S;
z is selected from-NH-or-N (C)1-6Alkyl) -;
R4ais selected from C3-15A carbocycle or 3-to 15-membered heterocycle containing 1 to 4 heteroatoms selected from N, O or S, said carbocycle or heterocycle optionally further substituted with 0 to 4 heteroatoms selected from F, Cl, Br, I, amino, hydroxy, C1-6Alkoxy radical, C1-6Alkyl or by 1 to 2C1-6Substituted with a substituent of an alkyl-substituted amino group;
R4bis selected from-C (═ O) C1-6Alkyl, -O-C (═ O) C1-6Alkyl radical, C1-10Alkoxy radical, C3-15A carbocycle or a 3-to 15-membered heterocycle, said alkyl, alkoxy, carbocycle or heterocycle optionally being further substituted with 0 to 4 substituents selected from F, Cl, Br, I, amino, -NR4cR4dHydroxy, C1-6Alkyl radical, C1-6Alkoxy or halogen substituted C1-6Alkyl, said heterocycle containing 1 to 4 heteroatoms selected from N, O or S;
R4cand R4dSelected from H, C1-10Alkyl, -C (═ O) C1-6Alkyl or-C (═ O) C1-6An alkoxy group;
R4eselected from amino, hydroxy, C1-10Alkyl radical, C3-15A carbocycle or a 3-to 15-membered heterocycle, said amino, alkyl, carbocycle or heterocycle being optionally further substituted with 0 to 4 substituents selected from F, Cl, Br, I, amino, hydroxy, C 1-6Alkyl radical, C1-6Alkoxy, -C (═ O) C1-6Alkyl, -C (═ O) -NH2、-O-C(=O)C1-6Alkyl or halogen substituted C1-6Alkyl, said heterocycle containing 1 to 4 heteroatoms selected from N, O or S;
R5selected from H, F, Cl, Br, I or a 5 to 15 membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S, said heterocyclic ring optionally further substituted by 0 to 4 heteroatoms selected from F, Cl, Br, I, ═ O, -C (═ O) C1-6Alkyl radical, C1-6Alkyl or C1-6Substituted by a substituent of alkoxy;
f is selected from 0, 1, 2, 3, 4, 5 or 6;
n is selected from 0, 1, 2 or 3;
2. A compound according to claim 1, wherein:
b is selected from 6 to 15 membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S;
R1each independently selected from F, Cl, Br, I, hydroxy, cyano, C1-4Alkyl radical, C1-4Alkoxy, -NR1aR1b、-C(=O)C1-4Alkyl, -S (═ O)2-C1-4Alkyl, -C (═ O) -3 to 7 membered heterocycle, -C (═ O) -C3-7Carbocyclic ring, - (CH)2)n-C3-6Carbocyclic ring or- (CH)2)n-3 to 7 membered heterocycle, said CH2Alkyl, alkoxy, carbocyclic or The heterocycle is optionally further substituted by 0 to 4 substituents selected from F, Cl, Br, I, ═ O, hydroxy, C1-4Alkyl radical, C1-4Alkoxy, - (CH)2)n-OH、-(CH2)n-F、-C(=O)C1-4Alkoxy, -C (═ O) C3-6Carbocyclic ring, -C (═ O) C1-4Alkyl, - (CH)2)n-C3-6Carbocyclic ring or- (CH)2)n-a 3 to 6 membered heterocyclic substituent, said heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S;
R1aand R1bSelected from H or C1-4An alkyl group;
R2selected from H, F, Cl, Br, I, cyano, C1-4Alkyl or C1-4Alkoxy, said alkyl or alkoxy being optionally further substituted by 0 to 4 substituents selected from F, Cl, Br, I, C1-4Alkyl or C1-4Substituted by a substituent of alkoxy;
R3selected from H, C2-6Alkenyl radical, C3-6Cycloalkyl radical, C1-4Alkyl or C1-4Alkoxy, said alkenyl, cycloalkyl, alkyl or alkoxy being optionally further selected from 0 to 4 groups selected from F, Cl, Br, I, C1-4Alkyl or C1-4Substituted by a substituent of alkoxy;
R4selected from H, F, Cl, Br, I, 5-to 15-membered spirocyclic ring, 4-to 15-membered fused ring, 3-to 10-membered heterocyclic ring, -Z- (CH)2)nR4a、-O-(CH2)nR4b、-Z-(CH2)nNR4cR4dor-O- (CH)2)nNR4cR4dSaid heterocycle containing 1 to 4 heteroatoms selected from N, O or S, said CH2Spiro, fused or heterocyclic ring optionally further substituted by 0 to 4 groups selected from F, Cl, Br, I, amino, hydroxy, C1-4Alkyl, -NR4cR4d、-C(=O)-R4eOr C1-4Substituted by a substituent of alkoxy;
z is selected from-NH-or-N (C)1-4Alkyl) -;
R4aIs selected from C3-6A carbocyclic ring or a 3 to 7 membered heterocyclic ring containing 1 to 4 hetero atoms selected from N, O or SThe carbocycle or heterocycle is optionally further substituted by 0 to 4 atoms selected from F, Cl, Br, I, amino, hydroxy, C1-4Alkyl radical, by 1 to 2C1-4Substituted with a substituent of an alkyl-substituted amino group;
R4bis selected from C3-6A carbocycle or 3-to 7-membered heterocycle containing 1 to 4 heteroatoms selected from N, O, S, said carbocycle or heterocycle optionally further substituted with 0 to 4 heteroatoms selected from F, Cl, Br, I, amino, hydroxy, -NR4cR4d、C1-4Alkyl or C substituted by 1 to 2 halogens1-4Alkyl is substituted by a substituent;
R4cand R4dIs selected from H or C1-4An alkyl group;
R4eselected from amino, hydroxy, C1-4Alkyl radical, C3-6A carbocycle or a 3-to 7-membered heterocycle, said amino, alkyl, carbocycle or heterocycle being optionally further substituted with 0 to 4 substituents selected from F, Cl, Br, I, amino, hydroxy, C1-4Alkyl radical, C1-4Alkoxy or halogen substituted C1-4Alkyl, said heterocycle containing 1 to 4 heteroatoms selected from N, O or S;
R5selected from H, F, Cl, Br, I or a 5 to 6 membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O, S, said heterocyclic ring optionally further substituted with 0 to 4 heteroatoms selected from F, Cl, Br, I, ═ O, -C (═ O) C1-4Alkyl radical, C1-4Alkyl or C 1-4Substituted by a substituent of alkoxy;
f is selected from 0, 1, 2, 3 or 4;
each n is independently selected from 0, 1, 2 or 3.
3. A compound according to claim 2, wherein:
b is selected from an 8 to 13 membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S;
R1each independently selected from F, Cl, Br, I, hydroxy, cyano, -S (═ O)2-C1-4Alkyl radical, C1-4Alkyl, -C (═ O) -C3-6Carbocyclic ring, - (CH)2)n-C3-6Carbocyclic ring or- (CH)2)n-5 to 6 membered heterocycle, said CH2Alkyl, carbocycle or heterocycle is optionally further substituted by 0 to 4 substituents selected from F, Cl, Br, I, ═ O, hydroxy, C1-4Alkyl radical, C1-4Alkoxy, -CH2-cyclopropyl, -tert-butoxycarbonyl, - (CH)2)n-OH、-(CH2)n-F、-C(=O)C1-4Alkyl, - (CH)2)n-C3-6Carbocyclic ring or- (CH)2)n-a 3 to 6 membered heterocyclic ring, said heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S;
R2selected from H, F, Cl, C1-4Alkyl or C1-4An alkoxy group;
R3is H, C2-4Alkenyl radical, C3-4Cycloalkyl radical, C1-4Alkyl or C1-4Alkoxy, optionally further substituted with 0 to 4 substituents selected from F, Cl or Br;
R4selected from H, F, Cl, 7-to 11-membered spirocyclic ring, 6-to 10-membered fused ring, 3-to 6-membered heterocyclic ring, -Z- (CH)2)nR4a、-Z-(CH2)nNR4cR4d、-O-(CH2)nR4bor-O- (CH)2)nNR4cR4dSaid heterocycle containing 1 to 4 heteroatoms selected from N, O or S, said CH 2Spiro, fused or heterocyclic ring optionally further substituted by 0 to 4 groups selected from F, Cl, Br, I, amino, -NH (CH)3)、-N(CH3)2Methyl or ethyl;
z is selected from-NH-or-N (C)1-4Alkyl) -;
R4ais selected from C3-4A carbocycle or 5-membered heterocycle containing 1 to 4 heteroatoms selected from N, O, S, said carbocycle or heterocycle optionally further substituted with 0 to 4 heteroatoms selected from F, Cl, Br, I, amino, hydroxy, -NHCH3、-N(CH3)2Methyl or ethyl;
R4bis selected from C3-4Carbocyclic ring or 4 to 6 membered heterocyclic ring, said heterocyclic ringContaining 1 to 4 heteroatoms selected from N, O, S, said carbocyclic or heterocyclic ring being optionally further substituted by 0 to 4 heteroatoms selected from F, Cl, Br, I, amino, hydroxy, -NH (CH)3)、-N(CH3)2、-CH2CH2F. Methyl or ethyl;
R4cand R4dSelected from H, methyl or ethyl;
R5selected from H, F, Cl or a 5 to 6 membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O, S, said heterocyclic ring optionally further substituted by 0 to 4 heteroatoms selected from F, Cl, Br, I, ═ O, -C (═ O) C1-4Alkyl radical, C1-4Alkyl or C1-4Substituted by a substituent of alkoxy;
n is selected from 0, 1, 2 or 3.
4. A compound according to claim 3, wherein:
R1Each independently selected from F, Cl, Br, I, -S (═ O) 2CH3-C (═ O) -cyclopropyl, hydroxy, cyano, methyl, ethyl, isopropyl, cyclopropyl, -CH2-cyclopropyl, -CH (CH)3) -cyclopropyl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl, said methyl, ethyl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl being optionally further substituted by 0 to 4 substituents selected from F, Cl, Br, I, ═ O, hydroxy, methyl, ethyl, methoxy, isopropyl, cyclopropyl, -CH2-cyclopropyl, hydroxyethyl, 2-fluoroethyl, tert-butoxycarbonyl, oxetanyl, -C (═ O) CH3or-C (═ O) CH2CH3Substituted with the substituent(s);
R2selected from H, F, Cl, methyl or methoxy;
R3selected from H, methyl, ethyl, vinyl, cyclopropyl, methoxy, fluoromethoxy, difluoromethoxy or trifluoromethoxy;
R4selected from H, F, Cl, 7-to 11-membered spirocyclic ring, 3-to 6-membered heterocyclic ring, -Z- (CH)2)nR4a、-O-(CH2)nR4b、-Z-(CH2)nNR4cR4dor-O- (CH)2)nNR4cR4dSaid heterocycle containing 1 to 4 heteroatoms selected from N, O or S, said CH2Spiro or heterocycle optionally further substituted by 0 to 4 substituents selected from F, Cl, Br, I, methyl, ethyl or-N (CH)3)2Substituted with the substituent(s);
z is selected from-NH-or-N (CH)3)-;
R4aSelected from substituted or unsubstituted cyclopropyl or tetrahydropyrrolyl, when substituted, optionally further substituted by 1 to 4 substituents selected from F, Cl, Br, I, amino, hydroxy, -NHCH 3、-N(CH3)2Methyl or ethyl;
R4bselected from substituted or unsubstituted cyclopropyl,Tetrahydropyrrolyl, piperazinyl, piperidinyl or morpholinyl, when substituted, optionally further substituted by 1 to 4 substituents selected from F, Cl, Br, I, amino, hydroxy, -NHCH3、-N(CH3)2、-CH2CH2F. Methyl or ethyl;
R4cand R4dSelected from H, methyl or ethyl;
R5selected from H, F, Cl or morpholinyl;
n is selected from 0, 1, 2 or 3.
5. A compound according to claim 4, wherein:
R1Each independently selected from F, Cl, -S (═ O)2CH3Hydroxy, cyano, methyl, difluoromethyl, ethyl, -CH2CH2OH, isopropyl, cyclopropyl, -CH2-cyclopropyl group,
Morpholinyl, piperazinyl, piperidinyl or tetrahydropyrrolyl;
R2selected from H, F, Cl, methyl or methoxy;
R3selected from H, ethyl, methoxy or difluoromethoxy;
R4selected from H, F, Cl,
R5Selected from H, F, Cl or morpholinyl;
f is selected from 0, 1, 2 or 3.
7. the compound of any one of claims 1 to 6, and optical isomers, pharmaceutically acceptable salts or co-crystals thereof, wherein the salts are selected from hydrochloride, sulfate, phosphate, acetate, trifluoroacetate, fumarate, benzoate, benzenesulfonate, methanesulfonate, trifluoromethanesulfonate or combinations thereof.
8. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 6, or an optical isomer, a pharmaceutically acceptable salt or a co-crystal thereof, and a pharmaceutically acceptable carrier or excipient.
9. Use of a compound as claimed in any one of claims 1 to 7, and an optical isomer, a pharmaceutically acceptable salt or a co-crystal thereof, or a pharmaceutical composition as claimed in claim 8, in the preparation of a medicament for the treatment of cancer.
10. The use of claim 9, wherein the cancer comprises head and neck cancer, ovarian cancer, bladder cancer, cervical cancer, esophageal cancer, gastric cancer, breast cancer, intimal cancer, colon cancer, lung cancer, brain tumor, non-small cell lung cancer, pancreatic cancer, solid tumor, colorectal tumor, or glioblastoma.
11. A method of treating cancer, which comprises administering a compound according to any one of claims 1 to 7, or an optical isomer, a pharmaceutically acceptable salt or a co-crystal thereof, or a pharmaceutical composition according to claim 8.
12. The method of claim 11, wherein the cancer comprises head and neck cancer, ovarian cancer, bladder cancer, cervical cancer, esophageal cancer, gastric cancer, breast cancer, intimal cancer, colon cancer, lung cancer, brain tumor, non-small cell lung cancer, pancreatic cancer, solid tumor, colorectal tumor, or glioblastoma.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410421609 | 2014-08-25 | ||
CN2014104216096 | 2014-08-25 | ||
CN201510078497 | 2015-02-13 | ||
CN2015100784973 | 2015-02-13 | ||
CN201580023470.2A CN106458969A (en) | 2014-08-25 | 2015-08-25 | (substituted phenyl) (substituted pyrimidine) amino derivative, preparation method therefor, and medication use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580023470.2A Division CN106458969A (en) | 2014-08-25 | 2015-08-25 | (substituted phenyl) (substituted pyrimidine) amino derivative, preparation method therefor, and medication use |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113121575A true CN113121575A (en) | 2021-07-16 |
Family
ID=55398760
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110329149.4A Pending CN113121575A (en) | 2014-08-25 | 2015-08-25 | (substituted phenyl) (substituted pyrimidine) amino derivative and preparation method and pharmaceutical application thereof |
CN201580023470.2A Pending CN106458969A (en) | 2014-08-25 | 2015-08-25 | (substituted phenyl) (substituted pyrimidine) amino derivative, preparation method therefor, and medication use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580023470.2A Pending CN106458969A (en) | 2014-08-25 | 2015-08-25 | (substituted phenyl) (substituted pyrimidine) amino derivative, preparation method therefor, and medication use |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN113121575A (en) |
WO (1) | WO2016029839A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112375067A (en) * | 2014-12-11 | 2021-02-19 | 贝达医药公司 | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2959194A1 (en) * | 2014-10-11 | 2016-04-14 | Shanghai Hansoh Biomedical Co., Ltd. | 4-substituted-2-(n-(5-substituted allyl amide)phenyl)amino)pyrimidine compound, its use as an egfr inhibitor, and preparation and application thereof |
CN105085489B (en) * | 2014-11-05 | 2019-03-01 | 益方生物科技(上海)有限公司 | Pyrimidine or pyridine compounds and their, preparation method and medical usage |
CN106117185B (en) * | 2015-08-31 | 2017-11-07 | 广州必贝特医药技术有限公司 | 2,4 2 nitrogen-containing group substituted uracil compounds and its preparation method and application |
US10435388B2 (en) | 2016-01-07 | 2019-10-08 | Cs Pharmatech Limited | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase |
CN107344934B (en) * | 2016-05-04 | 2019-08-23 | 江苏正大丰海制药有限公司 | The solid form of pharmaceutically active substance |
EP3454860A4 (en) * | 2016-05-11 | 2020-01-15 | Beta Pharma, Inc. | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers |
RU2751341C2 (en) | 2016-05-26 | 2021-07-13 | РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС | Egfr inhibitor compounds |
CA3027732A1 (en) * | 2016-06-17 | 2017-12-21 | Beta Pharma, Inc. | Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof |
CN106432231B (en) * | 2016-09-09 | 2018-06-12 | 无锡佰翱得生物科学有限公司 | The pharmaceutical salts and its crystal form and preparation method of AZD9291 |
KR102245280B1 (en) * | 2016-09-19 | 2021-04-27 | 난징 추앙트어 파마슈티컬 테크놀로지 컴퍼니 리미티드 | Deuterated 3-(4,5-substituted aminopyrimidine) phenyl derivatives and applications thereof |
CN107840846B (en) * | 2016-09-19 | 2020-11-24 | 郑州泰基鸿诺医药股份有限公司 | Pyrimidine ring-containing compound, EGFR inhibitor and application thereof |
CN106674203A (en) * | 2016-11-25 | 2017-05-17 | 山东轩德医药科技有限公司 | Preparation method of 3-(2-chloro-pyrimidine-4-yl)-1-methylindole |
KR102011356B1 (en) * | 2017-01-19 | 2019-08-16 | 부산대학교 산학협력단 | Novel Derivatives of 2-Anilinopyrimidine and Composition Comprising the Same |
AR110778A1 (en) | 2017-01-26 | 2019-05-02 | Hanmi Pharm Ind Co Ltd | PIRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE |
US10633367B2 (en) * | 2017-10-03 | 2020-04-28 | X-Cutag Therapeutics, Inc. | Fluorine- and/or deuterium-containing compounds for treating non-small cell lung cancer and related diseases |
CN111825658A (en) * | 2019-04-18 | 2020-10-27 | 华东理工大学 | Novel EGFR (epidermal growth factor receptor) triple-mutation inhibitor and application thereof |
CN110684016A (en) * | 2019-09-27 | 2020-01-14 | 上海应用技术大学 | Fluorine-containing AZD9291 derivative and preparation method and application thereof |
WO2021104305A1 (en) * | 2019-11-26 | 2021-06-03 | 上海翰森生物医药科技有限公司 | Nitrogen-containing polycyclic derivative inhibitor, preparation method therefor and application thereof |
CN111303123B (en) * | 2020-03-31 | 2021-08-31 | 南京雷正医药科技有限公司 | 2- (2,4, 5-substituted anilino) pyrimidine compound and application thereof |
CN112159392B (en) * | 2020-09-15 | 2021-11-23 | 南京雷正医药科技有限公司 | Substituted pyrimidine compound, pharmaceutical composition thereof and application of compound |
CN115867539A (en) * | 2020-12-02 | 2023-03-28 | 上海和誉生物医药科技有限公司 | 2, 3-dihydro-1H-pyrrolo [3,2-b ] pyridine derivatives, preparation method and application thereof |
KR20240015688A (en) * | 2021-08-06 | 2024-02-05 | 아비스코 테라퓨틱스 컴퍼니 리미티드 | Pyrimidine or pyridine derivative and its preparation method and pharmaceutical application |
CN115785134B (en) * | 2022-10-28 | 2023-08-29 | 浙大城市学院 | Nitrogen-containing heterocyclic boric acid compound, and preparation method and application thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2920996A1 (en) * | 2007-10-19 | 2009-04-23 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
CN101503402A (en) * | 2009-03-10 | 2009-08-12 | 沈阳药科大学 | 2-aniline pyrimidine derivative, as well as preparation and uses thereof |
US20110065734A1 (en) * | 2007-11-16 | 2011-03-17 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
CN102083800A (en) * | 2008-06-27 | 2011-06-01 | 阿维拉制药公司 | Heteroaryl compounds and uses thereof |
CN102264745A (en) * | 2008-11-10 | 2011-11-30 | 财团法人卫生研究院 | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors |
CN103702990A (en) * | 2011-07-27 | 2014-04-02 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
CN104761585A (en) * | 2014-01-03 | 2015-07-08 | 南京波尔泰药业科技有限公司 | Substituted aminopyrimidine working as inhibitor of EGFR epidermal growth factor receptor |
CN104860941A (en) * | 2014-02-25 | 2015-08-26 | 上海海雁医药科技有限公司 | 2,4-disubstituted phenyl-1,5-diamine derivatives and use thereof, and pharmaceutical composition and medicinal composition prepared from 2,4-disubstituted phenyl-1,5-diamine derivative |
CN105085489A (en) * | 2014-11-05 | 2015-11-25 | 上海页岩科技有限公司 | Pyrimidine or pyridine compound, and preparation method and pharmaceutical application thereof |
CN106559991A (en) * | 2014-06-19 | 2017-04-05 | 阿里亚德医药股份有限公司 | For the heteroaryl compound of kinase inhibition |
-
2015
- 2015-08-25 CN CN202110329149.4A patent/CN113121575A/en active Pending
- 2015-08-25 WO PCT/CN2015/088015 patent/WO2016029839A1/en active Application Filing
- 2015-08-25 CN CN201580023470.2A patent/CN106458969A/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2920996A1 (en) * | 2007-10-19 | 2009-04-23 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US20110065734A1 (en) * | 2007-11-16 | 2011-03-17 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
CN102083800A (en) * | 2008-06-27 | 2011-06-01 | 阿维拉制药公司 | Heteroaryl compounds and uses thereof |
CN102264745A (en) * | 2008-11-10 | 2011-11-30 | 财团法人卫生研究院 | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors |
CN101503402A (en) * | 2009-03-10 | 2009-08-12 | 沈阳药科大学 | 2-aniline pyrimidine derivative, as well as preparation and uses thereof |
CN103702990A (en) * | 2011-07-27 | 2014-04-02 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
CN104761585A (en) * | 2014-01-03 | 2015-07-08 | 南京波尔泰药业科技有限公司 | Substituted aminopyrimidine working as inhibitor of EGFR epidermal growth factor receptor |
CN104860941A (en) * | 2014-02-25 | 2015-08-26 | 上海海雁医药科技有限公司 | 2,4-disubstituted phenyl-1,5-diamine derivatives and use thereof, and pharmaceutical composition and medicinal composition prepared from 2,4-disubstituted phenyl-1,5-diamine derivative |
CN106559991A (en) * | 2014-06-19 | 2017-04-05 | 阿里亚德医药股份有限公司 | For the heteroaryl compound of kinase inhibition |
CN105085489A (en) * | 2014-11-05 | 2015-11-25 | 上海页岩科技有限公司 | Pyrimidine or pyridine compound, and preparation method and pharmaceutical application thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112375067A (en) * | 2014-12-11 | 2021-02-19 | 贝达医药公司 | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators |
CN112375067B (en) * | 2014-12-11 | 2024-03-15 | 贝达医药公司 | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators |
Also Published As
Publication number | Publication date |
---|---|
CN106458969A (en) | 2017-02-22 |
WO2016029839A1 (en) | 2016-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113121575A (en) | (substituted phenyl) (substituted pyrimidine) amino derivative and preparation method and pharmaceutical application thereof | |
CN113396147B (en) | Aromatic heterocyclic derivative regulator, preparation method and application thereof | |
CA2853367C (en) | New naphthyridine derivative compounds | |
KR101914720B1 (en) | Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases | |
JP6054406B2 (en) | Anti-cancer benzopyrazine via FGFR kinase inhibition | |
JP6208223B2 (en) | New compounds | |
CA2900748C (en) | Novel pyrimidine and pyridine compounds and their usage | |
KR102564533B1 (en) | Heteroaryl derivatives, preparation method the same, and pharmaceutical composition comprising the same as an active ingredient | |
WO2019042409A1 (en) | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application | |
CN105384694B (en) | Substituted aminopyrimidine derivative and preparation method and pharmaceutical application thereof | |
CA3107365A1 (en) | Pyrazine compounds and uses thereof | |
BR112012007747B1 (en) | heterocyclic compounds useful as pdk1 inhibitors, their pharmaceutical composition and uses | |
AU2013269316A1 (en) | Pteridines as FGFR inhibitors | |
EP2762476A1 (en) | 1,2,4-triazine-6-carboxamide derivative | |
JP2016531127A (en) | Alkynyl alcohol and method of use | |
WO2019034128A1 (en) | Pyrrolotriazine derivative, preparation method and use thereof | |
CN113166110B (en) | 2-aminopyrimidine compound and application thereof | |
WO2019141202A9 (en) | Tam family kinase /and csf1r kinase inhibitor and use thereof | |
CA2990583A1 (en) | 1,4-disubstituted imidazole derivative | |
TW201934546A (en) | Pyrimidine compound, preparation method and medical use thereof | |
CN110520416B (en) | Polysubstituted pyridone derivative, preparation method and medical application thereof | |
WO2020233669A1 (en) | Indole derivative-containing inhibitor, preparation method therefor and application thereof | |
TW201315733A (en) | Imidazo quinoline derivatives and salts thereof, preparation process and pharmaceutical use thereof | |
CN115697993A (en) | Pyrimidines as AXL inhibitors | |
WO2023025320A1 (en) | Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210716 |